SEARCH

Search Details

KIYOTA Naomi
University Hospital / Cancer Center
Associate Professor

Researcher basic information

■ Research Keyword
  • patient reported outcome
  • Thyroid cancer
  • Head abd Neck Cancer
  • clinical trial
  • clinical oncology
■ Research Areas
  • Life sciences / Hematology and oncology
■ Committee History
  • May 2025 - Present, Japan Association of Endocrine Surgey, Board of directors
  • Jan. 2024 - Present, 日本内科学会, 近畿支部評議員
  • Jun. 2018 - Present, 日本頭頸部癌学会, 代議員
  • Aug. 2013 - Present, 日本臨床腫瘍学会, 協議員
  • Jun. 2020 - May 2024, 日本頭頸部癌学会, 幹事

Research activity information

■ Award
  • 2022 神戸大学医学部附属病院臨床研究推進センター, 優秀論文賞
    清田 尚臣

  • Dec. 2020 Japan Clinical Oncology Group (JCOG), JCOG Shimoyama Masanori Award, JCOG1008研究
    Naomi Kiyota

  • Dec. 2014 JCOGデータセンター, Best Study Coordinator賞, JCOG研究者
    Kiyota Naomi
    Others

■ Paper
  • Naruto Taira, Naomi Kiyota, Yuichiro Kikawa, Eiki Ichihara, Kyoko Kato, Kaoru Kubota, Ryosuke Tateishi, Akinobu Nakata, Keiichiro Nakamura, Yukiya Narita, Katsuyuki Hotta, Hiroji Iwata, Akihiko Gemma, Kojiro Shimozuma, Kei Muro, Tetsuya Iwamoto, Yuki Takumoto, Takeru Shiroiwa, Takashi Fukuda, Takuhiro Yamaguchi, Yasuhiro Hagiwara, Hironobu Minami
    Apr. 2025, Japanese Journal of Clinical Oncology, English
    [Refereed]
    Scientific journal

  • Matthias Büttner, Gerasimos Sykiotis, Akram Al-Ibraheem, Monica Pinto, Ioannis Iakovou, Arild Andre Østhus, Eva Hammerlid, Laura Deborah Locati, Eva Maria Gamper, Juan Ignacio Arraras, Susan J Jordan, Naomi Kiyota, Deborah Engesser, Katherine Taylor, Rita Canotilho, Georgios Ioannidis, Olga Husson, Ricardo Ribeiro Gama, Giuseppe Fanetti, Laura Moss, Johanna Inhestern, Guy Andry, Harald Rimmele, Susanne Singer
    PURPOSE: Hypoparathyroidism (HypoPT) is one of the most common complications of surgical treatment for thyroid cancer and afflicated patients often report symptoms or impairments in quality of life (QoL). We aimed to investigate differences in various QoL domains between thyroid cancer survivors with and without permanent hypoparathyroidism. METHODS: Thyroid cancer survivors with a minimum of 1.5 years post-diagnosis completed the EORTC core questionnaire (EORTC QLQ-C30) and the EORTC thyroid module (QLQ-THY34). Sociodemographic and clinical information were obtained from the patients themselves and their medical charts. Analysis of covariance was used to compare QoL between survivors with and without hypoparathyroidism (adjusting for age, gender, time since diagnosis, and comorbidity). RESULTS: Of the 126 participants, 21 (17%) were diagnosed with permanent HypoPT. There was no evidence of differences regarding any QoL domain between survivors due to hypoparathyroidism. The symptoms with the highest burden for both groups were fatigue (hypoPT: 24.9; non-hypoPT: 32.8; p = 0.151) and insomnia (hypoPT: 22.2; non-hypoPT: 30.8; p = 0.213). Thyroid cancer specific impairments were observed for joint pain (hypoPT: 28.6; non-hypoPT: 34.0; p = 0.480), worry about important others (hypoPT: 25.8; non-hypoPT: 27.9; p = 0.765), exhaustion (hypoPT: 23.8; non-hypoPT: 27.9; p = 0.482), and lacking social support (hypoPT: 36.5; no-hypoPT: 23.0; p = 0.070). CONCLUSION: The present study appears to show that QoL in thyroid cancer survivors may be unrelated to hypoparathyroidism, further suggesting a more complex relationship between these two aspects.
    Apr. 2025, Hormones (Athens, Greece), English, International magazine
    [Refereed]
    Scientific journal

  • Naomi Kiyota, Taiji Koyama, Iwao Sugitani
    Mar. 2025, European Thyroid Journal, English
    [Refereed][Invited]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takane Watanabe, Hiroki Oka, Kengo Nagashima, Hideaki Nishi, Yoshihiko Kumai, Hiroaki Iijima, Kenji Okami, Yasushi Shimizu, Satoshi Kano, Kazue Ito, Tomoko Yamazaki, Hideaki Takahashi, Nobuhiko Oridate, Tomoya Yokota, Taiji Koyama, Naomi Kiyota, Yasuyoshi Sato, Shunji Takahashi, Kyoko Kato, Shigenori Kadowaki, Yoshitaka Honma
    BACKGROUND: Platinum and anti-PD-1 antibodies are the front-line systemic therapy for recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). However, limited data are available on clinical outcomes and appropriate regimens for patients with RM-HNSCC following treatment failure with these agents. PATIENTS AND METHODS: We retrospectively analyzed the clinical data of patients with RM-HNSCC from 10 Japanese institutions in whom platinum and nivolumab treatment failed. RESULTS: Of the 480 patients included in the study, 236 were treated with the best supportive care and had a median overall survival of 3.1 months. The remaining 244 patients received salvage-line chemotherapy, which was paclitaxel + cetuximab in 72 (30%), paclitaxel or docetaxel in 89 (36%), and tegafur/gimeracil/oteracil in 48 (20%); the respective objective response rates were 54.9%, 27.9%, and 25.5%, with median progression-free survival of 5.4 months and median overall survival of 13.0 months. Multivariable analysis identified disease stabilization or response on prior nivolumab and paclitaxel + cetuximab as salvage-line chemotherapy to be associated with encouraging progression-free and overall survival. CONCLUSION: This study sheds light on clinical outcomes and prognostic factors in patients with RM-HNSCC after failure of platinum and anti-PD-1 antibody therapy. The findings provide essential baseline data for future therapeutic development in salvage-line settings.
    Mar. 2025, The oncologist, 30(3) (3), English, International magazine
    [Refereed]
    Scientific journal

  • Iwao Sugitani, Naomi Kiyota, Yasuhiro Ito, Naoyoshi Onoda, Tomo Hiromasa, Kiyomi Horiuchi, Seigo Kinuya, Tetsuo Kondo, Sueyoshi Moritani, Kiminori Sugino, Hisato Hara
    2025, Endocrine Journal, English
    [Refereed]
    Scientific journal

  • Yoshiaki Nagatani, Naomi Kiyota, Yoshinori Imamura, Taiji Koyama, Yohei Funakoshi, Masato Komatsu, Tomoo Itoh, Masanori Teshima, Ken-Ichi Nibu, Kazuko Sakai, Kazuto Nishio, Manami Shimomura, Tetsuya Nakatsura, Daiki Ikarashi, Takayuki Nakayama, Shigehisa Kitano, Hironobu Minami
    AIM: Although immune checkpoint inhibitors (ICPi) for salivary gland cancer (SGC) have been investigated in clinical trials, details of the tumor immune microenvironment (TIME) remain unclear. This research aimed to elucidate the TIME of SGC and its relationship with tumor mutation burden (TMB) and to explore the rationale for the applicability of ICPi. MATERIALS AND METHODS: We selected five pathological types, namely adenoid cystic carcinoma (ACC); adenocarcinoma, not otherwise specified (ANOS); salivary duct carcinoma (SDC); and low/high-grade mucoepidermoid carcinoma (MEClow/high). We investigated the TIME and TMB of each pathological type. TIME was evaluated by multiplexed fluorescent immunohistochemistry. TMB was measured by next-generation sequencing. RESULTS: ACC and MEChigh showed the lowest and highest infiltration of immune effector and suppressor cells in both tumor and stroma. ANOS, SDC, and MEClow showed modest infiltration of immune effector cells in tumors. Correlation analysis showed a positive correlation between CD3+CD8+ T cells in tumor and TMB (r = 0.647). CD3+CD8+ T cells in tumors showed a positive correlation with programmed cell death-ligand 1 expression in tumor cells (r = 0.513) and a weak positive correlation with CD3+CD4+Foxp3+ cells in tumors (r = 0.399). However, no correlation was observed between CD3+CD8+ T cells and CD204+ cells in tumors (r = -0.049). CONCLUSION: The TIME of ACC was the so-called immune desert type, which may explain the mechanisms of the poor response to ICPi in previous clinical trials. On the other hand, MEChigh was the immune-inflamed type, and this may support the rationale of ICPi for this pathological subtype.
    Corresponding, Dec. 2024, Asia-Pacific journal of clinical oncology, 20(6) (6), 779 - 788, English, International magazine
    [Refereed]
    Scientific journal

  • Naomi Kiyota
    Nov. 2024, The Lancet. Oncology, 25(12) (12), 1513 - 1514, English, International magazine
    [Refereed][Invited]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Micha J Pilz, Simone Seyringer, Susanne Singer, Georgios Ioannidis, Gerasimos P Sykiotis, Juan I Arraras, Olga Husson, Ioannis Iakovou, Giuseppe Fanetti, Dagmar Führer, Johanna Inhestern, Naomi Kiyota, Laura Deborah Locati, Monica Pinto, Ricardo Ribeiro Gama, Madeleine T King, Richard Norman, Eva M Gamper
    Background: Health economic appraisals often rely on the assessment of health utilities using preference-based measures (PBM). The cancer-specific PBM, European Organisation for Research and Treatment of Cancer Quality of Life Utility - Core 10 Dimensions (EORTC QLU-C10D), was developed recently, and now needs to be validated in various clinical populations. Methods: In a multicenter, multinational prospective cohort study, we longitudinally collected EORTC QLQ-C30 and EQ-5D-5L data from patients with thyroid cancer. We applied seven country-specific value sets to the QLQ-C30 data to derive country-specific utility values and used the EQ-5D-5L as a comparator PBM. Criterion validity was assessed by correlating index scores and Bland-Altman plots. Construct validity was investigated by correlating domain scores. Known-group comparisons and responsiveness were assessed using external clinical criteria. Results: A total of 181 patients with thyroid cancer from nine countries (three continents) provided analyzable data. Patients were included if they had differentiated, medullary, or anaplastic thyroid cancer. Mean utility values of both instruments were generally lower compared to general population norms. No floor or ceiling effects were present for the QLU-C10D. The intra-class correlation for EQ-5D-5L and QLU-C10D index values ranged from 0.761 to 0.901 across the measurement timepoints, supporting criterion validity. Spearman's correlation coefficients ranged from 0.289 to 0.716 for theoretically corresponding domain pairs. The QLU-C10D detected differences in 9 of 15 known-group comparisons, supporting sensitivity. Clinically important changes were detected by all QLU-C10D country specific value sets, supporting responsiveness. Further, the QLU-C10D had higher statistical efficiency than the EQ-5D-5L in 74.7% of comparisons. Conclusions: The QLU-C10D is a valid PBM for health economic evaluations in thyroid cancer studies. We recommend its use to estimate health utilities in economic evaluations of thyroid cancer therapies.
    Nov. 2024, Thyroid : official journal of the American Thyroid Association, 34(11) (11), 1356 - 1370, English, International magazine
    [Refereed]
    Scientific journal

  • Susanne Singer, Eva Hammerlid, Iwona M Tomaszewska, Cecilie D Amdal, Bente B Herlofson, Marcos Santos, Joaquim Castro Silva, Hisham Mehanna, Amy Fullerton, Teresa Young, Loreto Fernandez Gonzalez, Johanna Inhestern, Monica Pinto, Juan I Arraras, Noam Yarom, Pierluigi Bonomo, Ingo Baumann, Razvan Galalae, Ourania Nicolatou-Galitis, Naomi Kiyota, Judith Raber-Durlacher, Dina Salem, Alexander Fabian, Andreas Boehm, Sanja Krejovic-Trivic, Wei-Chu Chie, Katherine J Taylor, Allen C Sherman, Lisa Licitra, Jean-Pascal Machiels, Kristin Bjordal
    INTRODUCTION: Minimal important change estimates (MIC) are useful for interpreting results of clinical research with quality of life (QoL) as an endpoint. For the European Organisation for Research and Treatment of Cancer head and neck cancer module, the EORTC QLQ-HN43, no such thresholds are established. METHODS: Head and neck cancer patients under active treatment (n = 503) from 15 countries completed the EORTC QLQ-HN43 three times (t1: before treatment, t2: three months after t1, t3: six months after t1). A subgroup completed a Subjective Significance Questionnaire (SSQ), indicating experienced change from the previous time point in four QoL domains. QoL was assumed to deteriorate after t1 and improve again until t3. The MIC was established using the average of mean differences in SSQ groups (MICmean) and estimates based on logistic regressions (MICpredict). Additionally, minimal detectable changes (MDC) were computed using 0.5 standard deviation and standard error of the mean. RESULTS: For swallowing, speech, dry mouth, and global QoL, the MIC for deterioration were 13, 14, 26, and 10 respectively. The MIC for improvement were 8 (swallowing), 6 (dry mouth), and 5 (global QoL); no MIC for speech improvement can be presented because of insufficient correlation between change score and anchor. The MDC estimates for deterioration were 15, 14, 15, and 11. For improvement, the MDC estimates were 13, 14, 14, and 11. CONCLUSIONS: Our results underline that no single MIC or MDC can be applied to all EORTC QLQ-HN43 scales, and that the MIC for deterioration seems larger than those for improvement.
    Nov. 2024, European journal of cancer (Oxford, England : 1990), 212, 115062 - 115062, English, International magazine
    [Refereed]
    Scientific journal

  • Kazuki Yokoyama, Koichiro Wasano, Keita Sasaki, Ryunosuke Machida, Mitsuhiko Nakahira, Koji Kitamura, Tomofumi Sakagami, Naohiro Takeshita, Akira Ohkoshi, Motoyuki Suzuki, Ichiro Tateya, Yohei Morishita, Mariko Sekimizu, Masahiro Nakayama, Taiji Koyama, Hirofumi Shibata, Satoru Miyamaru, Naomi Kiyota, Nobuhiro Hanai, Akihiro Homma
    Abstract Background Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan. Methods From July 2021 to June 2022 in 54 healthcare facilities, we gathered data of patients diagnosed with RM-SCCHN and who had started first-line palliative chemotherapy with one of eight commonly used regimens. Patients with nasopharyngeal carcinomas were excluded. The number of patients receiving each regimen and the costs of each regimen for the first month and per year were tallied. Results The sample comprised 907 patients (674 were < 75 years old, 233 were ≥ 75 years old). 330 (36.4%) received Pembrolizumab monotherapy, and 202 (22.3%) received Nivolumab monotherapy. Over 90% of patients were treated with immune checkpoint inhibitors as monotherapy or in combination with chemotherapy. Treatment regimens’ first-month costs were 612 851–849 241 Japanese yen (JPY). The cost of standard palliative chemotherapy until 2012 was about 20 000 JPY per month. The incremental cost over the past decade is approximately 600 000–800 000 JPY per month, a 30- to 40-fold increase in the cost of palliative chemotherapy for RM-SCCHN. Conclusion First-line palliative chemotherapy for RM-SCCHN exceeds 600 000 JPY monthly. Over the last decade, the prognosis for RM-SCCHN has improved, but the costs of palliative chemotherapy have surged, placing a heavy burden on patients and society.
    Oxford University Press (OUP), Oct. 2024, Japanese journal of clinical oncology, 54(10) (10), 1115 - 1122, English, International magazine
    [Refereed]
    Scientific journal

  • Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Hirokazu Uemura, Kiyoto Shiga, Mitsuhiko Nakahira, Takahiro Asakage, Yuki Saito, Keita Sasaki, Ryo Kitabayashi, Satoshi Ishikura, Yasumasa Nishimura, Makoto Tahara
    BACKGROUND AND PURPOSE: Hypothyroidism is a recognized late adverse event following radiotherapy for head and neck cancer (HNC). In the JCOG1008 trial, we treated patients with high-risk HNC with postoperative chemoradiotherapy. We aimed to elucidate factors associated with hypothyroidism by analyzing the JCOG1008 data. MATERIALS AND METHODS: In 2012-2018, 261 patients from 28 institutions were enrolled in JCOG1008. Thyroid function tests were conducted to assess hypothyroidism, including free thyroxine (FT4) and thyroid-stimulating hormone assays. Hypothyroidism was defined as Grade 2 or higher in CTCAE v4.0. Various clinical and dosimetric parameters were analyzed. In radiotherapy, there were no dose constraints for the thyroid. Multivariable analysis was conducted on these variables to identify predictive factors for hypothyroidism. RESULTS: The analysis included 162 patients (57 with 3D-CRT and 105 with IMRT), with a median follow-up of 4.7 years (0.3-9.3 years). Among these, 27 (16.7 %) developed hypothyroidism within 2 years after radiotherapy. In a multivariable analysis, the weekly cisplatin [OR=7.700 (CI: 1.632-36.343, p = 0.010)] and baseline FT4 [OR=0.009 (CI: <0.001-0.313, p = 0.010)] were significantly associated with hypothyroidism in the IMRT group. Regarding dosimetric characteristics, V60Gy [OR=1.069 (CI: 0.999-1.143, p = 0.054)] was potentially associated with the development of hypothyroidism. CONCLUSION: The study revealed that the incidence of hypothyroidism within 2 years after postoperative chemoradiotherapy for high-risk HNC was 16.7 % based on analytical results from prospective clinical trials.
    Oct. 2024, Oral oncology, 157, 106976 - 106976, English, International magazine
    [Refereed]
    Scientific journal

  • Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma
    BACKGROUND: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m2) was non-inferior to 3-weekly cisplatin (100 mg/m2) for postoperative high-risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose-limiting toxicity effect of cisplatin, affects overall survival (OS). METHODS: We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy. AKI was defined based on AKI Network criteria (serum creatinine increase of ≥0.3 mg/dL or ≥1.5-fold [≥ stage I]) within 30 days after completing chemoradiotherapy. OS in the two arms was compared according to AKI development using the log-rank test. RESULTS: The total incidence of AKI was lower in the weekly arm than in the 3-weekly arm (38/122 [31.1%] vs. 56/129 [43.4%]). Additionally, stage II/III AKI occurred less frequently in the weekly arm than in the 3-weekly arm (8/122 [6.6%] vs. 19/129 [14.7%]). Cisplatin doses were similar in the weekly arm for patients with and without AKI (median, 238.6 mg/m2 vs. 239.2 mg/m2; p = 0.94), but lower in the 3-weekly arm for those who developed AKI (median, 276.3 mg/m2 vs. 297.4 mg/m2; p = 0.007). In the weekly arm, there was no difference in OS between patients with and without AKI (hazard ratio [HR], 1.06; 95% confidence interval [CI], 0.53 to 2.10). However, in the 3-weekly arm, patients with AKI had poorer OS than those without AKI (HR, 1.83; 95% CI, 1.04 to 3.21). CONCLUSIONS: In this supplementary analysis of JCOG1008 data, AKI impacted the OS of patients with head and neck cancer undergoing postoperative chemoradiotherapy in the 3-weekly arm but not in the weekly arm. Our results further endorse the utilization of weekly cisplatin at 40 mg/m2 in this setting.
    Corresponding, Sep. 2024, Cancer medicine, 13(18) (18), e70235, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Kazuhiko Doi, Hironori Sakai, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami
    Monovalent Omicron XBB.1.5 mRNA vaccines were newly developed and approved by the FDA in Autumn 2023 for preventing COVID-19. However, clinical efficacy for these vaccines is currently lacking. We previously established the quantification of antigen-specific antibody sequence (QASAS) method to assess the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the coronavirus antibody database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of monovalent XBB.1.5 vaccines. We analyzed repeated blood samples of healthy volunteers before and after monovalent XBB.1.5 vaccination (BNT162b2 XBB.1.5 or mRNA-1273.815) for the BCR repertoire to assess BCR/antibody sequences that matched SARS-CoV-2-specific sequences in the database. The number of matched unique sequences and their total reads quickly increased 1 week after vaccination. Matched sequences included those bound to the Omicron strain and Omicron XBB sublineage. The antibody sequences that can bind to the Omicron strain and XBB sublineage revealed that the monovalent XBB.1.5 vaccines showed a stronger response than previous vaccines or SARS-CoV-2 infection before the emergence of XBB sublineage. The QASAS method was able to demonstrate the immunogenic effect of monovalent XBB.1.5 vaccines for the 2023-2024 COVID-19 vaccination campaign.
    Aug. 2024, EJHaem, 5(4) (4), 661 - 668, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • T. Koyama, N. Kiyota, S. Boku, Y. Imamura, N. Shibata, H. Satake, K. Tanaka, H. Hayashi, T. Onoe, Y. Asada, T. Yamazaki, T. Nose, S. Ohata, Y. Nagatani, S. Kimbara, Y. Funakoshi, M. Teshima, H. Shinomiya, H. Minami
    Aug. 2024, ESMO Open, 9(8) (8)
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 【周術期薬物療法の成果と今後の課題】頭頸部がんに対する周術期治療
    小山 泰司, 清田 尚臣
    (有)科学評論社, Jul. 2024, 腫瘍内科, 34(1) (1), 59 - 66, Japanese

  • Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma
    OBJECTIVES: Acute kidney injury (AKI) represents a major toxicity associated with cisplatin. We developed a risk prediction model for cisplatin-induced AKI in patients with postoperative high-risk head and neck cancer who received chemoradiotherapy during a randomized phase II/III trial, JCOG1008. MATERIALS AND METHODS: Two hundred and fifty-one patients received radiotherapy with weekly cisplatin at 40 mg/m2 (weekly arm) or 3-weekly cisplatin at 100 mg/m2 (3-weekly arm). AKI was defined using the AKI Network classification/staging system as increased serum creatinine of ≥0.3 mg/dL or a ≥1.5-fold increase from baseline 30 days after completing chemoradiotherapy. The Akaike information criterion was used to explore the optimal model by combining explanatory variables at registration. RESULTS: Among the 251 patients (210 men and 41 women (median age; 62 years)), 94 (37.5 %) developed cisplatin-induced AKI. The optimal cisplatin-induced AKI risk prediction model comprised four factors, including a primary site of hypopharynx/larynx (vs. oral cavity/oropharynx), 3-weekly arm (vs. weekly arm), serum albumin of ≤3.5 g/dL (vs. >3.5 g/dL) and creatinine clearance (CCr) of <90 mL/min (vs. ≥90 mL/min). The incidence of cisplatin-induced AKI rose with cumulative count of the four factors. When the cumulative count was ≥2, the positive predictive value for cisplatin-induced AKI was 50.3 %. CONCLUSIONS: We developed a risk prediction model for cisplatin-induced AKI in patients with head and neck cancer who received postoperative chemoradiotherapy using primary site, cisplatin administration method, serum albumin, and CCr. Patients with risk factors unrelated to the cisplatin administration method should adopt a weekly cisplatin regimen.
    Corresponding, Jul. 2024, Oral oncology, 154, 106868 - 106868, English, International magazine
    [Refereed]
    Scientific journal

  • 清田 尚臣, 小山 泰司, 高野 悠子, 山崎 知子
    (一社)日本内分泌外科学会, Jun. 2024, 日本内分泌外科学会雑誌, 41(2) (2), 100 - 104, Japanese

  • T. Koyama, N. Kiyota, S. Boku, Y. Imamura, N. Shibata, H. Satake, K. Tanaka, H. Hayashi, T. Onoe, Y. Asada, T. Yamazaki, T. Nose, S. Ohata, Y. Nagatani, S. Kimbara, Y. Funakoshi, M. Teshima, H. Shinomiya, H. Minami
    Corresponding, Jun. 2024, ESMO Open, 9(6) (6)
    [Refereed]
    Scientific journal

  • Mitsuko Yui, Yoshihisa Matsuno, Tatsuya Furukawa, Masanori Teshima, Hirotaka Shinomiya, Naomi Kiyota, Tadashi Nomura, Daisuke Miyawaki, Ryohei Sasaki, Ken-Ichi Nibu
    Background Since the larynx and pharynx are vital for respiration, swallowing, and speech, chemoradiotherapy (CRT) has been widely applied for T3 hypopharyngeal cancer (HPC) as an organ-preserving treatment. However, CRT can lead to severe late adverse events such as dysphagia and aspiration pneumonia, especially in patients who have difficulty swallowing and/or aspiration at the time of initial diagnosis. Patients and methods Between 2012 and 2020, 86 patients with T3 HPC treated with curative intent at Kobe University Hospital were included in this study. The average age was 69 years old, ranging from 43 to 89. Diseases were classified as Stage III in 29 patients, Stage IVA in 52 patients, and Stage IVB in five patients. Thirty-five (41%) patients were treated by CRT, and 51 (59%) patients were treated by surgery. Patients were followed up for at least two years, and the follow-up period ranged from four to 128 months (median: 45 months). Results Three-year progression-free survival (PFS) rates of patients treated by CRT and patients treated by surgery were 56.2% and 60.3%, respectively. Three-year disease-specific survival (DSS) rates of patients treated by CRT and surgically treated patients were 79.0% vs. 70.8%, respectively. Three-year overall survival (OS) rates of patients treated by CRT and surgically treated patients were 64.5% and 69.0%, respectively. Of note, a significant difference was observed between three-year DSS and three-year PFS (79.0% vs. 56.2%, p = 0.0014) in the patients treated by CRT but not in the patients treated by surgery. Conclusions No significant differences were observed between the PFS, DSS, and OS rates of patients treated by CRT and those of surgically treated patients. Locoregional recurrences after CRT were significantly successfully salvaged by surgical intervention. These results suggest that CRT can be applied as an alternative to surgery without reducing survival, especially for patients without severe clinical symptoms. Meticulous follow-up is mandatory for early detection of recurrence to salvage by surgery and for the management of late adverse events.
    Jun. 2024, Cureus, 16(6) (6), e62553, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Katherine J Taylor, Cecilie D Amdal, Kristin Bjordal, Guro L Astrup, Bente B Herlofson, Fréderic Duprez, Ricardo R Gama, Alexandre Jacinto, Eva Hammerlid, Melissa Scricciolo, Femke Jansen, Irma M Verdonck-de Leeuw, Giuseppe Fanetti, Orlando Guntinas-Lichius, Johanna Inhestern, Tatiana Dragan, Alexander Fabian, Andreas Boehm, Ulrike Wöhner, Naomi Kiyota, Maximilian Krüger, Pierluigi Bonomo, Monica Pinto, Sandra Nuyts, Joaquim Castro Silva, Carmen Stromberger, Pol Specenier, Francesco Tramacere, Ayman Bushnak, Pietro Perotti, Michaela Plath, Alberto Paderno, Noa Stempler, Maria Kouri, Vincent Grégoire, Susanne Singer
    Head and neck cancer (HNC) patients suffer from a range of health-related quality of life (HRQoL) issues, but little is known about their long-term HRQoL. This study explored associations between treatment group and HRQoL at least 5 years' post-diagnosis in HNC survivors. In an international cross-sectional study, HNC survivors completed the European Organization for Research and Treatment of Cancer (EORTC) quality of life core questionnaire (EORTC-QLQ-C30) and its HNC module (EORTC-QLQ-H&N35). Meaningful HRQoL differences were examined between five treatment groups: (a) surgery, (b) radiotherapy, (c) chemo-radiotherapy, (d) radiotherapy ± chemotherapy and neck dissection and (e) any other surgery (meaning any tumour surgery that is not a neck dissection) and radiotherapy ± chemotherapy. Twenty-six sites in 11 countries enrolled 1105 survivors. They had a median time since diagnosis of 8 years, a mean age of 66 years and 71% were male. After adjusting for age, sex, tumour site and UICC stage, there was evidence for meaningful differences (10 points or more) in HRQoL between treatment groups in seven domains (Fatigue, Mouth Pain, Swallowing, Senses, Opening Mouth, Dry Mouth and Sticky Saliva). Survivors who had single-modality treatment had better or equal HRQoL in every domain compared to survivors with multimodal treatment, with the largest differences for Dry Mouth and Sticky Saliva. For Global Quality of Life, Physical and Social Functioning, Constipation, Dyspnoea and Financial Difficulties, at least some treatment groups had better outcomes compared to a general population. Our data suggest that multimodal treatment is associated with worse HRQoL in the long-term compared to single modality.
    May 2024, International journal of cancer, 154(10) (10), 1772 - 1785, English, International magazine
    [Refereed]
    Scientific journal

  • Satoshi Seno, Kazuma Iwashita, Akifumi Kajiwara, Rie Sasaki, Tatsuya Furukawa, Masanori Teshima, Hirotaka Shinomiya, Kiyota N, Rod Lynch, Kenji Yoshida, Takeaki Ishihara, Daisuke Miyawaki, Ken-ichi Nibu, Ryohei Sasaki
    May 2024, Cancers
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Junki Mizusawa, Gakuto Ogawa, Mitsumi Terada, Hiroto Ishiki, Yuichiro Kikawa, Naomi Kiyota
    The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative was established in 2016 to assess the quality and standardization of patient-reported outcomes (PRO) data analysis in randomized controlled trials (RCTs) on advanced breast cancer. The initiative identified deficiencies in PRO data reporting, including nonstandardized methods for handling missing data. This study evaluated the reporting of health-related quality of life (HRQOL) in Japanese cancer RCTs to provide insights into the state of PRO reporting in Japan. The study reviewed PubMed articles published from 2010 to 2018. Eligible studies included Japanese cancer RCTs with ≥50 adult patients (≥50% were Japanese) with solid tumors receiving anticancer treatments. The evaluation criteria included clarity of the HRQOL hypotheses, multiplicity testing, primary analysis methods, and reporting of clinically meaningful differences. Twenty-seven HRQOL trials were identified. Only 15% provided a clear HRQOL hypothesis, and 63% examined multiple HRQOL domains without adjusting for multiplicity. Model-based methods were the most common statistical methods for the primary HRQOL analysis. Only 22% of the trials explicitly reported clinically meaningful differences in HRQOL. Baseline assessments were reported in most trials, but only 26% reported comparisons between the treatment groups. HRQOL analysis was based on the intention-to-treat population in 19% of the trials, and 74% reported compliance at follow-up; however, 41% did not specify how missing values were handled. Although the rates of reporting clinical hypotheses and clinically meaningful differences were relatively low, the current state of HRQOL evaluation in the Japanese cancer RCT appears comparable to that of previous studies.
    Last, May 2024, Cureus, 16(5) (5), e60804, English, International magazine
    [Refereed]
    Scientific journal

  • Makoto Tahara, Naomi Kiyota, Hiroo Imai, Shunji Takahashi, Akihiro Nishiyama, Shingo Tamura, Yasushi Shimizu, Shigenori Kadowaki, Ken-Ichi Ito, Masahiro Toyoshima, Yoshinori Hirashima, Shinji Ueno, Iwao Sugitani
    Background: Driver mutations at BRAF V600 are frequently identified in papillary thyroid cancer and anaplastic thyroid cancer (ATC), in which BRAF inhibitors have shown clinical effectiveness. This Japanese phase 2 study evaluated the efficacy and safety of a BRAF inhibitor, encorafenib, combined with an MEK inhibitor, binimetinib, in patients with BRAF V600-mutated thyroid cancer. Methods: This phase 2, open-label, uncontrolled study was conducted at 10 institutions targeted patients with BRAF V600-mutated locally advanced or distant metastatic thyroid cancer not amenable to curative treatment who became refractory/intolerant to ≥1 previous vascular endothelial growth factor receptor-targeted regimen(s) or were considered ineligible for those. The primary endpoint was centrally assessed objective response rate (ORR). The secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. Results: We enrolled 22 patients with BRAFV600E-mutated thyroid cancer: 17 had differentiated thyroid cancer (DTC), and 5 had ATC. At data cutoff (October 26, 2022), the median follow-up was 11.5 (range = 3.4-19.0) months. The primary endpoint of centrally assessed ORR was 54.5% (95% confidence interval [CI] 32.2-75.6; partial response in 12 patients and stable disease in 10). The ORRs in patients with DTC and ATC were 47.1% (8 of 17) and 80.0% (4 of 5), respectively. The medians for DOR and PFS by central assessment and for OS were not reached in the overall population, the DTC subgroup, or the ATC subgroup. At 12 months, the rate of ongoing response was 90.9%, and the PFS and OS rates were 78.8% and 81.8%, respectively. All patients developed ≥1 adverse events (AEs): grade 3 AEs in 6 patients (27.3%). No patients developed grade 4-5 AEs. The most common grade 3 AE was lipase increased (4 patients [18.2%]). Those toxicities were mostly manageable with appropriate monitoring and dose adjustment. Conclusions: Treatment with encorafenib plus binimetinib met the primary endpoint criteria and demonstrated clinical benefit in patients with BRAFV600E-mutated thyroid cancer regardless of its histological type, such as DTC or ATC, with no new safety concerns identified. Encorafenib plus binimetinib could thus be a new treatment option for BRAF V600-mutated thyroid cancer. Clinical Trial Registration number: Japan Registry of Clinical Trials: jRCT2011200018.
    Corresponding, Mar. 2024, Thyroid : official journal of the American Thyroid Association, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naomi Kiyota, Makoto Tahara, Akihiro Homma
    Surgery remains a foundation of treatment for locally advanced squamous cell carcinoma of the head and neck. For postoperative patients at high risk of recurrence, however, surgery by itself is not enough, and improvement in survival requires postoperative treatment. Unlike the case with most other malignancies, the standard postoperative treatment for locally advanced squamous cell carcinoma of the head and neck patients with high-risk factors for recurrence is radiotherapy or chemoradiotherapy with cisplatin. However, chemoradiotherapy with cisplatin at a dose of 100 mg/m2 once every 3 weeks has raised discussion over insufficient cisplatin delivery due to high-dose-related toxicity. As a possible solution, a recent randomized trial of the JCOG1008 has proved the non-inferiority of postoperative chemoradiotherapy with weekly cisplatin at a dose of 40 mg/m2 to 3-weekly cisplatin in terms of overall survival. Here, this review article focuses on current evidence and future perspectives of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.
    Mar. 2024, Japanese Journal of Clinical Oncology, English, International magazine
    [Refereed][Invited]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yasuyuki Kajimoto, Hirotaka Shinomiya, Natsumi Uehara, Masanori Teshima, Takeshi Fujita, Akinobu Kakigi, Yoshinori Imamura, Naomi Kiyota, Daisuke Miyawaki, Ryohei Sasaki, Hidehito Kimura, Ken-Ichi Nibu
    The expression of EGFR and p16 in the external auditory canal squamous cell carcinoma (EACSCC) and their impacts on oncological outcomes were not well studied. Seventeen-one consecutive patients who were treated for EACSCC at Kobe University Hospital from 1995 to 2018 were enrolled in this study. The expression of EGFR, and p16 were evaluated and their impacts on oncological outcomes were statistically analyzed. Positive expression of EGFR was observed in 62 patients (87%). Strong positive expression of p16 were observed in 18 patients (32.4%), and weakly positive expression in 30 patients (42.3%), respectively. While the number of the patients with negative EGFR expression were limited, all the surgically treated patients with negative EGFR expression have been alive without disease. In the patients with T3 & T4a EACSCC, prognosis of the patients with positive p16 expression EACSCC tended to be better than those with negative p16 expression. These results suggest the clinical significance of EGFR and p16 expressions in the patients with advanced EACSCC to predict oncological outcomes.
    Jan. 2024, The Kobe journal of medical sciences, 69(4) (4), E144-E150, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Koichi Yasuda, Naomi Kiyota, Kazuto Matsuura, Satoshi Saito, Yoshitaka Honma, Yoshinori Imamura, Kaoru Tanaka, Sadamoto Zenda, Takuma Onoe, Takeshi Kodaira, Satoshi Kobayashi, Hidefumi Aoyama, Nobuhiro Hanai, Akihiro Homma
    INTRODUCTION: Chemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications. METHODS: In April and May 2023, a questionnaire survey was emailed to all institutions belonging to the JCOG-HNCSG, consisting of 37 institutions. RESULTS: The major factors influencing the indications for high-dose CDDP were renal function and performance status (PS). The majority agreed that the treatment is administered to patients aged 65-74 years with PS 0-1 and 65-74 years with eGFR ≥60 (ml/ min/1.73m2), and not in patients aged ≥75 years with PS 2, ≥80 years with PS 1, and ≥65 years with eGFR <60. Regarding weekly CDDP, the majority agreed that the treatment is not conducted in patients aged ≥75 years with PS 2, ≥65 years with eGFR <40, and ≥70 years with eGFR <50. DISCUSSION: In Japan, where CRT is actively performed even among older people, a survey was conducted to determine its indications. Renal function and PS were considered important, and comorbidities, such as heart failure, were considered while determining the indication. These results will help define the eligibility criteria for prospective studies on CRT in older patients.
    2024, Frontiers in oncology, 14, 1441056 - 1441056, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Goh Ohji, Yohei Funakoshi, Kimikazu Yakushijin, Takaji Matsutani, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Naomi Kiyota, Hironobu Minami
    A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.
    2024, Frontiers in immunology, 15, 1468760 - 1468760, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Susanne Singer, Gerasimos Sykiotis, Akram Al-Ibraheem, Monica Pinto, Ioannis Iakovou, Arild Andre Østhus, Eva Hammerlid, Laura Deborah Locati, Eva Maria Gamper, Juan Ignacio Arraras, Susan Jordan, Matthias Buettner, Deborah Engesser, Katherine Taylor, Rita Canotilho, Georgios Ioannidis, Olga Husson, Ricardo Ribeiro Gama, Giuseppe Fanetti, Laura Moss, Johanna Inhestern, Guy Andry, Harald Rimmele, Naomi Kiyota
    PURPOSE: The purpose of this study was to investigate the impact of the type of data capture on the time and help needed for collecting patient-reported outcomes as well as on the proportion of missing scores. METHODS: In a multinational prospective study, thyroid cancer patients from 17 countries completed a validated questionnaire measuring quality of life. Electronic data capture was compared to the paper-based approach using multivariate logistic regression. RESULTS: A total of 437 patients were included, of whom 13% used electronic data capture. The relation between data capture and time needed was modified by the emotional functioning of the patients. Those with clinical impairments in that respect needed more time to complete the questionnaire when they used electronic data capture compared to paper and pencil (ORadj 24.0; p = 0.006). This was not the case when patients had sub-threshold emotional problems (ORadj 1.9; p = 0.48). The odds of having the researcher reading the questions out (instead of the patient doing this themselves) (ORadj 0.1; p = 0.01) and of needing any help (ORadj 0.1; p = 0.01) were lower when electronic data capture was used. The proportion of missing scores was equivalent in both groups (ORadj 0.4, p = 0.42). CONCLUSIONS: The advantages of electronic data capture, such as real-time assessment and fewer data entry errors, may come at the price of more time required for data collection when the patients have mental health problems. As this is not uncommon in thyroid cancer, researchers need to choose the type of data capture wisely for their particular research question.
    Last, Dec. 2023, Endocrine, English, International magazine
    [Refereed]
    Scientific journal

  • Yosuke Ariizumi, Nobuhiro Hanai, Takahiro Asakage, Akira Seto, Toshifumi Tomioka, Junji Miyabe, Hisashi Kessoku, Takashi Mukaigawa, Go Omura, Masanori Teshima, Daisuke Nishikawa, Yuki Saito, Yukinori Asada, Takuo Fujisawa, Takuma Makino, Hiroshi Nishino, Daisuke Sano, Mitsuhiko Nakahira, Kunihiko Tokashiki, Hirokazu Uemura, Tsutomu Ueda, Akihiro Sakai, Muneyuki Masuda, Takahiro Tsujikawa, Yusuke Hiei, Naoki Nishio, Hidetoshi Matsui, Naomi Kiyota, Akihiro Homma
    BACKGROUND: Total pharyngolaryngectomy (TPL) is standard treatment for hypopharyngeal cancer. However, extensive thyroidectomy and paratracheal nodal dissection (PTND) can cause hypoparathyroidism. We sought to determine the optimum extent of resection. METHODS: We analyzed the clinicopathological information of 161 pyriform sinus cancer patients undergoing TPL from 25 Japanese institutions. Rates of recurrence and risk factors for hypoparathyroidism, as well as incidence of pathological contralateral level VI nodal metastasis and stomal recurrence, were investigated. RESULTS: The extent of thyroidectomy and nodal dissection were not independent risk factors for recurrence. Incidences of contralateral level VI nodal involvement and stomal recurrence were 1.8% and 1.2%, respectively. Patients undergoing hemithyroidectomy/ipsilateral PTND did not develop stomal recurrence and had the lowest incidence of hypoparathyroidism. Prognosis in patients without tracheostomy prior to hemithyroidectomy/ipsilateral PTND was comparable to that with more extensive resections. CONCLUSIONS: Hemithyroidectomy/ipsilateral PTND may be sufficient for pyriform sinus cancer cases without tracheostomy.
    Nov. 2023, Head & neck, 46(2) (2), 269 - 281, English, International magazine
    Scientific journal

  • Tomoya Yokota, Sadamoto Zenda, Takeshi Kodaira, Naomi Kiyota, Yasushi Fujimoto, Koichiro Wasano, Ryo Takahashi, Takashi Mizowaki, Akihiro Homma, Keita Sasaki, Ryunosuke Machida, Yuta Sekino, Haruhiko Fukuda
    BACKGROUND: Chemoradiotherapy (CRT) with concurrent cisplatin is the standard of care as a nonsurgical definitive treatment for patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). However, CRT is associated with increased severe late adverse events, including swallowing dysfunction, xerostomia, ototoxicity, and hypothyroidism. Few strategies aimed at less invasive CRT without compromising treatment outcomes have been successful. The purpose of this study is to confirm the non-inferiority of reduced dose prophylactic radiation with 40 Gy compared to standard dose prophylactic radiation with 56 Gy in terms of the time to treatment failure (TTF) among patients with clinical stage III-IVB LA-SCCHN. METHODS: This study is a multicenter, two-arm, open-label, randomized phase III trial. Patients with LA-SCCHN excluding p16 positive oropharynx cancer are randomized to the standard arm or experimental arm. A total dose of 70 Gy for tumors with concurrent cisplatin at 100 mg/m2 are administered in both arms. For prophylactic field, patients in the standard arm receive a total dose of 56 Gy in 35 fractions for 7 weeks using simultaneous integrated boost (SIB56) and those in the experimental arm receive 40 Gy in 20 fractions using two-step methods for 4 weeks (2-step40). A total of 400 patients will be enrolled from 52 Japanese institutions within 5 years. The primary endpoint is TTF, and the secondary endpoints are overall survival, complete response rate, progression-free survival, locoregional relapse-free survival, acute and late adverse events, quality of life score, and swallowing function score. DISCUSSION: If the experimental arm is non-inferior to the standard arm in terms of TTF and superior on the safety endpoints, the 2-step40 procedure is the more useful treatment than SIB56 for definitive CRT. TRIAL REGISTRATION: This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031210100 ( https://jrct.niph.go.jp/latest-detail/jRCTs031210100 ). Date of Registration: May 2021.
    Nov. 2023, BMC cancer, 23(1) (1), 1068 - 1068, English, International magazine
    [Refereed]
    Scientific journal

  • 【各臓器がんに対する周術期(手術・放射線治療)薬物療法のState of the art】頭頸部がん
    小山 泰司, 清田 尚臣
    (有)科学評論社, Sep. 2023, 腫瘍内科, 32(3) (3), 223 - 229, Japanese

  • Akihiro Yamada, Hirotaka Shinomiya, Natsumi Uehara, Keisuke Iritani, Shun Tatehara, Tatsuya Furukawa, Masanori Teshima, Daisuke Miyawaki, Takeshi Fujita, Akinobu Kakigi, Naomi Kiyota, Ryohei Sasaki, Ken-Ichi Nibu
    BACKGROUND: Squamous cell carcinoma of the external auditory canal (EACSCC) is a rare condition. However, a standard treatment has not yet been established. We retrospectively evaluated the efficacy, adverse events, and feasibility of TPF-CCRT (concomitant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced EACSCC. METHODS: Thirty-five consecutive patients with advanced EACSCC (T3, T4) initially treated with TPF-CCRT at Kobe University Hospital were included. T4 diseases with invasion of the brain, internal carotid artery, or internal jugular vein were classified as T4b, and those without these features were classified as T4a. RESULTS: Five-year overall survival rates for T3 and T4 were 100% and 64.2%, respectively. A significant difference was observed between T4a and T4b (82.4% vs. 30%, p = 0.007). Five-year progression-free survival rates of T3, T4a, and T4b were 100%, 68%, and 20% (p = 0.022), respectively. CONCLUSIONS: TPF-CCRT should be considered as a plausible treatment option for advanced EACSCC.
    Jul. 2023, Head & neck, English, International magazine
    Scientific journal

  • Akihiro Homma, Mizuo Ando, Nobuhiro Hanai, Hiroyuki Harada, Yoshitaka Honma, Tomonori Kanda, Satoshi Kano, Daisuke Kawakita, Naomi Kiyota, Yoshiyuki Kizawa, Masahiro Nakagawa, Takenori Ogawa, Hirotaka Shinomiya, Takeshi Shinozaki, Motoyuki Suzuki, Tetsuya Tsuji, Koichi Yasuda, Sadamoto Zenda, Takeshi Kodaira, Tadaaki Kirita, Ken-Ichi Nibu
    The aim of the "Japanese Clinical Practice Guidelines for Head and Neck Cancer - 2022 Update" is to review the latest evidence regarding head and neck cancer and to present the current standard approaches for diagnosis and treatment. These evidence-based recommendations were created with the consensus of the Guideline Committee, which is composed of otorhinolaryngologists and head and neck surgeons, together with radiologists, radiation oncologists, medical oncologists, plastic surgeons, dentists, palliative care physicians, and rehabilitation physicians. These guidelines were created by the Clinical Practice Guideline Committee of the Japan Society for Head and Neck Cancer based on the "Head and Neck Cancer Treatment Guidelines 2018 Edition," and the revised draft was compiled after evaluation by the Assessment Committee and public comments. The 'Clinical questions and recommendations' section consists of 13 categories, and 59 clinical questions are described in total. Here we describe 6 clinical questions specific to other sets of guidelines with recommendations and comments.
    Jul. 2023, Auris, nasus, larynx, English, International magazine
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Wataru Hojo, Hironori Sakai, Sakuya Matsumoto, Marika Watanabe, Akihito Kitao, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami
    The use of anti-SARS-CoV-2 antibody products like tixagevimab/cilgavimab represents an important strategy to protect immunocompromised patients with haematological malignancies from COVID-19. Although patients who receive these agents should still be vaccinated, the use of tixagevimab/cilgavimab can mask the production of anti-spike antibody after vaccination, making it hard to assess vaccine response. We have newly established a quantification method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assay and the Coronavirus Antibody Database (CoV-AbDab). Repeated blood samples before and after vaccination were analysed for the BCR repertoire, and BCR sequences were searched in the database. We analysed the number and percentage frequency of matched sequences. We found that the number of matched sequences increased 2 weeks after the first vaccination and quickly decreased. Meanwhile, the number of matched sequences more rapidly increased after the second vaccination. These results show that the postvaccine immune response can be assessed at the mRNA level by analysing the fluctuation in matching sequences. Finally, BCR repertoire analysis with CoV-AbDab clearly demonstrated the response to mRNA SARS-CoV-2 vaccination even after tixagevimab/cilgavimab administration in haematological malignancy patients who underwent allogeneic haematopoietic stem cell transplantation.
    Jun. 2023, British journal of haematology, 202(3) (3), 504 - 516, English, International magazine
    Scientific journal

  • QOL/PRO研究に関する国際的取り組みに参画するための国内体制整備
    石木 寛人, 荒川 さやか, 天野 晃滋, 里見 絵理子, 小林 智美, 小川 祐子, 平山 貴敏, 松岡 弘道, 内藤 立暁, 下村 昭彦, 黒澤 彩子, 木川 雄一郎, 寺田 参省, 水澤 純基, 清田 尚臣
    (NPO)日本緩和医療学会, Jun. 2023, Palliative Care Research, 18(Suppl.) (Suppl.), S209 - S209, Japanese

  • QOL/PRO研究に関する国際的取り組みに参画するための国内体制整備
    石木 寛人, 荒川 さやか, 天野 晃滋, 里見 絵理子, 小林 智美, 小川 祐子, 平山 貴敏, 松岡 弘道, 内藤 立暁, 下村 昭彦, 黒澤 彩子, 木川 雄一郎, 寺田 参省, 水澤 純基, 清田 尚臣
    (NPO)日本緩和医療学会, Jun. 2023, Palliative Care Research, 18(Suppl.) (Suppl.), S209 - S209, Japanese

  • 進行・再発・転移の未治療固形がん患者における静脈血栓塞栓症の前向き観察研究の統合解析
    今村 善宣, 能勢 拓, 大幡 真也, 森 健太, 乙井 一典, 宮田 吉晴, 金原 史朗, 長谷 善明, 小山 泰司, 船越 洋平, 清田 尚臣, 南 博信
    (一社)日本血栓止血学会, May 2023, 日本血栓止血学会誌, 34(2) (2), 195 - 195, Japanese

  • 白金製剤・ニボルマブ不応・不耐後の再発・転移頭頸部扁平上皮癌の臨床転帰に関する後方視的多施設共同研究
    門脇 重憲, 岡 弘毅, 長島 健悟, 西 秀昭, 熊井 良彦, 飯島 宏章, 大上 研二, 清水 康, 加納 里志, 伊東 和恵, 山崎 知子, 高橋 秀聡, 折舘 伸彦, 横田 知哉, 小山 泰司, 清田 尚臣, 佐藤 靖祥, 高橋 俊二, 加藤 恭子, 本間 義崇
    (一社)日本頭頸部癌学会, May 2023, 頭頸部癌, 49(2) (2), 137 - 137, Japanese

  • 当院における甲状腺がんに対するがん遺伝子パネル検査の現状と課題
    小山 泰司, 清田 尚臣, 今村 善宣, 長谷 善明, 下田 光, 手島 直則, 四宮 弘隆, 宮脇 大輔, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2023, 頭頸部癌, 49(2) (2), 132 - 132, Japanese

  • 進行頭頸部扁平上皮がん患者における静脈血栓塞栓症 前向き観察研究サブ解析
    今村 善宣, 小山 泰司, 長谷 善明, 手島 直則, 四宮 弘隆, 宮脇 大輔, 佐々木 良平, 丹生 健一, 清田 尚臣
    (一社)日本頭頸部癌学会, May 2023, 頭頸部癌, 49(2) (2), 152 - 152, Japanese

  • Katherine J Taylor, Cecilie D Amdal, Kristin Bjordal, Guro L Astrup, Bente B Herlofson, Fréderic Duprez, Ricardo R Gama, Alexandre Jacinto, Eva Hammerlid, Melissa Scricciolo, Femke Jansen, Irma M Verdonck-de Leeuw, Giuseppe Fanetti, Orlando Guntinas-Lichius, Johanna Inhestern, Tatiana Dragan, Alexander Fabian, Andreas Boehm, Ulrike Wöhner, Naomi Kiyota, Maximilian Krüger, Pierluigi Bonomo, Monica Pinto, Sandra Nuyts, Joaquim C Silva, Carmen Stromberger, Francesco Tramacere, Ayman Bushnak, Pietro Perotti, Michaela Plath, Alberto Paderno, Noa Stempler, Maria Kouri, Susanne Singer
    The long-term problems of head and neck cancer survivors (HNCS) are not well known. In a cross-sectional international study aimed at exploring the long-term quality of life in this population, 1114 HNCS were asked to state their two most serious long-term effects. A clinician recorded the responses during face-to-face appointments. A list of 15 example problems was provided, but a free text field was also available. A total of 1033 survivors responded to the question. The most frequent problems were 'dry mouth' (DM) (n = 476; 46%), 'difficulty swallowing/eating' (DSE) (n = 408; 40%), 'hoarseness/difficulty speaking' (HDS) (n = 169; 16%), and 'pain in the head and neck' (PHN) (n = 142; 14%). A total of 5% reported no problems. Logistic regression adjusted for age, gender, treatment, and tumor stage and site showed increased odds of reporting DM and DSE for chemo-radiotherapy (CRT) alone compared to surgery alone (odds ratio (OR): 4.7, 95% confidence interval (CI): 2.5-9.0; OR: 2.1, CI: 1.1-3.9), but decreased odds for HDS and PHN (OR: 0.3, CI: 0.1-0.6; OR: 0.2, CI: 0.1-0.5). Survivors with UICC stage IV at diagnosis compared to stage I had increased odds of reporting HDS (OR: 1.9, CI: 1.2-3.0). Laryngeal cancer survivors had reduced odds compared to oropharynx cancer survivors of reporting DM (OR: 0.4, CI: 0.3-0.6) but increased odds of HDS (OR: 7.2, CI: 4.3-12.3). This study provides evidence of the serious long-term problems among HNCS.
    Mar. 2023, Healthcare (Basel, Switzerland), 11(6) (6), English, No password, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • Hiroto Ishiki, Yuichiro Kikawa, Mitsumi Terada, Junki Mizusawa, Michitaka Honda, Tsuguo Iwatani, Tomonori Mizutani, Keita Mori, Naoki Nakamura, Tempei Miyaji, Takuhiro Yamaguchi, Masahiko Ando, Kenichi Nakamura, Haruhiko Fukuda, Naomi Kiyota
    Assessments of patient-reported outcomes and health-related quality of life in cancer clinical trials have been increasingly emphasized recently because patient and public involvement in cancer treatment development has been promoted by regulatory authorities and academic societies. To assess patient experiences during and after cancer treatment, there is interest in implementing patient-reported outcome and health-related quality of life assessments into cancer clinical trials. The Japan Clinical Oncology Group quality of life ad hoc committee previously created a version of the Quality of Life Assessment Policy in 2006. Recently, there has been increasing demand from Japan Clinical Oncology Group researchers to assess patient-reported outcome/health-related quality of life in clinical trials. Although guidelines are available regarding planning and reporting clinical trials that include patient-reported outcome/health-related quality of life as an endpoint, there are still issues regarding the lack of consensus on standardized methods for analysing and interpreting the results. Hence, it was considered necessary to reorganize the Japan Clinical Oncology Group patient-reported outcome/quality of life research committee and to revise the former patient-reported outcome/quality of life research policy to promote patient-reported outcome/health-related quality of life research in future Japan Clinical Oncology Group trials. The purpose of this Japan Clinical Oncology Group patient-reported outcome/quality of life research policy is to define patient-reported outcome/health-related quality of life research and provide guidelines for including patient-reported outcome/health-related quality of life as an endpoint in Japan Clinical Oncology Group trials.
    Mar. 2023, Japanese journal of clinical oncology, 53(3) (3), 195 - 202, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • 【ゲノム医療時代の甲状腺癌治療】遺伝子異常に基づく薬物療法時代の検体処理
    小松 正人, 清田 尚臣
    (一社)日本内分泌外科学会, Mar. 2023, 日本内分泌外科学会雑誌, 40(1) (1), 29 - 32, Japanese

  • がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測 多施設共同第2相臨床試験副次的解析
    今村 善宣, 能勢 拓, 宮田 吉晴, 小山 泰司, 長谷 善明, 金原 史朗, 船越 洋平, 清田 尚臣, 藥師神 公和, 南 博信
    (一社)日本内科学会, Feb. 2023, 日本内科学会雑誌, 112(臨増) (臨増), 163 - 163, Japanese

  • Yasunori Fujita, Fumika Kamitani, Masaaki Yamamoto, Hidenori Fukuoka, Yushi Hirota, Nobuharu Nishiyama, Naho Goda, Yuko Okada, Yuiko Inaba, Hiroki Nakajima, Yukako Kurematsu, Keitaro Kanie, Hiroki Shichi, Shin Urai, Masaki Suzuki, Naoki Yamamoto, Hironori Bando, Genzo Iguchi, Hirotaka Suto, Yohei Funakoshi, Naomi Kiyota, Yutaka Takahashi, Wataru Ogawa
    CONTEXT: The occurrence of multiple endocrinopathies due to immune checkpoint inhibitors (ICIs) is a relatively common adverse event. However, the occurrence of a combination of hypophysitis and type 1 diabetes mellitus (T1DM) is extremely rare, and its clinical features are unclear. OBJECTIVE: We comparatively analyzed the clinical features of this combination and each individual ICI-induced endocrinopathy. METHODS: We reported 3 cases that we encountered and reviewed previously reported cases of patients with combined hypophysitis and T1DM due to ICIs. RESULTS: Anti-programmed cell death-1 (anti-PD-1) antibodies were prescribed to all 3 cases. The duration from ICI initiation to the onset of endocrine disease was 12 to 48 weeks. Several human leukocyte antigen (HLA) haplotypes that have disease susceptibility to hypophysitis were detected in all 3 patients. With the 17 previously reported cases, combined endocrinopathies were more common in men (85%). The onset age was in the 60s for both combined and single endocrinopathies. Anti-PD-1 antibodies were used in most of the cases (90%). The time from ICI initiation to the onset of endocrinopathies was 24 (8-76) weeks for hypophysitis and 32 (8-76) weeks for T1DM in patients with combined endocrinopathies, which was not significantly different from that for each single endocrinopathy. CONCLUSION: We presented 3 cases of patients with combined endocrinopathies of hypophysitis and T1DM that may have been caused by anti-PD-1 antibodies. There was no difference in the time from ICI initiation to the onset of endocrinopathies between combined and single endocrinopathies. Further case accumulation and pathogenic investigations are required.
    Jan. 2023, Journal of the Endocrine Society, 7(3) (3), bvad002, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Satoshi Okumura, Mikiya Ishihara, Naomi Kiyota, Kimikazu Yakushijin, Kohichi Takada, Shinichiro Kobayashi, Hiroaki Ikeda, Makoto Endo, Koji Kato, Shigehisa Kitano, Akihiko Matsumine, Yasuhiro Nagata, Shinichi Kageyama, Taizo Shiraishi, Tomomi Yamada, Keizo Horibe, Kazuto Takesako, Hiroshi Miwa, Takashi Watanabe, Yoshihiro Miyahara, Hiroshi Shiku
    INTRODUCTION: Adoptive cell transfer of genetically engineered T cells is a promising treatment for malignancies; however, there are few ideal cancer antigens expressed on the cell surface, and the development of chimeric antigen receptor T cells (CAR-T cells) for solid tumour treatment has been slow. CAR-T cells, which recognise major histocompatibility complex and peptide complexes presented on the cell surface, can be used to target not only cell surface antigens but also intracellular antigens. We have developed a CAR-T-cell product that recognises the complex of HLA-A*02:01 and an epitope of the MAGE-A4 antigen equipped with a novel signalling domain of human GITR (investigational product code: MU-MA402C) based on preclinical studies. METHODS AND ANALYSIS: This is a dose-escalation, multi-institutional, phase 1 study to evaluate the tolerability and safety of MU-MA402C for patients with MAGE A4-positive and HLA-A*02:01-positive unresectable advanced or recurrent solid cancer. Two dose cohorts are planned: cohort 1, MU-MA402C 2×108/person; cohort 2, MU-MA402C 2×109/person. Prior to CAR-T-cell infusion, cyclophosphamide (CPA) and fludarabine (FLU) will be administered as preconditioning chemotherapy. Three evaluable subjects per cohort, for a total of 6 subjects (maximum of 12 subjects), will be recruited for this clinical trial. The primary endpoints are safety and tolerability. The severity of each adverse event will be evaluated in accordance with Common Terminology Criteria for Adverse Events V.5.0. The secondary endpoint is efficacy. Antitumour response will be evaluated according to Response Evaluation Criteria in Solid Tumours V.1.1. ETHICS AND DISSEMINATION: This clinical trial will be conducted in accordance with the current version of Good Clinical Practice. The protocol was approved by the Clinical Research Ethics Review Committee of Mie University Hospital (approval number F-2021-017). The trial results will be published in peer-reviewed journals and/or disseminated through international conferences. TRIAL REGISTRATION NUMBER: jRCT2043210077.
    Nov. 2022, BMJ open, 12(11) (11), e065109, English, International magazine
    Scientific journal

  • 切除不能進行/転移・再発固形癌に対するePROモニタリングの有用性を検証する比較試験
    平 成人, 南 博信, 岩田 広治, 弦間 昭彦, 室 圭, 市原 英基, 加藤 恭子, 木川 雄一郎, 清田 尚臣, 久保田 馨, 建石 良介, 中田 晃暢, 中村 圭一郎, 成田 有季哉, 堀田 勝幸
    (一社)日本癌治療学会, Oct. 2022, 日本癌治療学会学術集会抄録集, 60回, O48 - 3, English

  • Naomi Kiyota, Makoto Tahara
    Sep. 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(26) (26), 3096 - 3097, English, No password, International magazine
    Scientific journal
    添付ファイルのURL

  • Takuya Higashiyama, Kiminori Sugino, Hisato Hara, Ken-Ichi Ito, Noriaki Nakashima, Naoyoshi Onoda, Masayuki Tori, Hiroshi Katoh, Naomi Kiyota, Ichiro Ota, Nobuyasu Suganuma, Yatsuka Hibi, Toshimitsu Nemoto, Shunji Takahashi, Katsunari Yane, Tetsuya Ioji, Shinsuke Kojima, Hideaki Kaneda, Iwao Sugitani, Makoto Tahara
    PURPOSE: Anaplastic thyroid cancer (ATC) is a rare and highly aggressive cancer for which effective systemic therapy has long been sought. Here, we assessed the efficacy and safety of lenvatinib in patients with unresectable ATC. PATIENTS AND METHODS: The study was investigator-initiated and conducted under a multicenter, open-label, nonrandomized, phase II design. Eligibility criteria included pathologically proven ATC; unresectable measurable lesion as defined by RECIST 1.1; age 20 years or older; ECOG PS 0-2; and adequate organ function. The primary end-point was overall survival. Secondary end-points were progression-free survival, objective response rate, disease control rate, clinical benefit rate, and safety. RESULTS: Of 52 patients enrolled from 17 institutions, 42 patients who were confirmed to have ATC were included for efficacy analysis, and 50 patients were included for safety analysis. The estimated 1-year overall survival rate was 11.9% (95% CI, 4.4%-23.6%). One patient (2.4%) achieved complete response, four patients (9.5%) partial response, and 26 patients (61.9%) stable disease, including nine patients (21.4%) who demonstrated durable stable disease, giving an objective response rate of 11.9%, disease control rate of 73.8%, and clinical benefit rate of 33.3%. Adverse events of any grade were observed in 45 patients (90.0%), the most common of which of any grade included loss of appetite (48.0%), fatigue (48.0%), hypertension (44.0%), and palmar-plantar erythrodysesthesia syndrome (26.0%). CONCLUSION: Lenvatinib treatment resulted in disappointing survival for unresectable ATC patients. Although the number of responders was small, responses were durable, indicating that lenvatinib may be beneficial for selected patients. Further investigation to identify suitable candidates for lenvatinib monotherapy is needed.
    Elsevier BV, Sep. 2022, European journal of cancer (Oxford, England : 1990), 173, 210 - 218, English, International magazine
    Scientific journal

  • Yuki Saito, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Tomoya Yokota, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi
    It was not until around 2000 that human papillomavirus-related oropharyngeal carcinoma was recognized as carcinoma with clinical presentations different from nonrelated head and neck carcinoma. Twenty years after and with the revision of the tumor-node-metastasis classification in 2017, various clinical trials focused on human papillomavirus-related oropharyngeal carcinoma to improve the prognosis and quality of life of patients with this disease. However, the incidence of human papillomavirus-related cancers is increasing, which is expected to be particularly prominent in Japan, where human papillomavirus vaccination is not widely available. In this review, we describe the current status of clinical trials (mainly focused on initial surgery and radiation dose reduction) for, primary and secondary prevention of, and the present status of human papillomavirus-related oropharyngeal carcinoma in Japan.
    Jul. 2022, Japanese journal of clinical oncology, 52(7) (7), 700 - 706, English, International magazine
    Scientific journal

  • Naomi Kiyota, Makoto Tahara, Junki Mizusawa, Takeshi Kodaira, Hirofumi Fujii, Tomoko Yamazaki, Hiroki Mitani, Shigemichi Iwae, Yasushi Fujimoto, Yusuke Onozawa, Nobuhiro Hanai, Takenori Ogawa, Hiroki Hara, Nobuya Monden, Eiji Shimura, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Akihiro Homma, Seiichi Yoshimoto, Nobuhiko Oridate, Koichi Omori, Tsutomu Ueda, Kenji Okami, Ichiro Ota, Kiyoto Shiga, Masashi Sugasawa, Takahiro Asakage, Yuki Saito, Shigeyuki Murono, Yasumasa Nishimura, Kenichi Nakamura, Ryuichi Hayashi
    PURPOSE: The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m2). However, whether chemoradiotherapy with weekly cisplatin (40 mg/m2) yields comparable efficacy with 3-weekly cisplatin in postoperative high-risk LA-SCCHN is unknown. PATIENTS AND METHODS: In this multi-institutional open-label phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin (100 mg/m2) or with weekly cisplatin (40 mg/m2) to confirm the noninferiority of weekly cisplatin. The primary end point of phase II was the proportion of treatment completion, and that of phase III was overall survival. A noninferiority margin of hazard ratio was set at 1.32. RESULTS: Between October 2012 and December 2018, a total of 261 patients were enrolled (3-weekly cisplatin, 132 patients; weekly cisplatin, 129 patients). At the planned third interim analysis in the phase III part, after a median follow-up of 2.2 (interquartile range 1.19-3.56) years, chemoradiotherapy with weekly cisplatin was noninferior to 3-weekly cisplatin in terms of overall survival, with a hazard ratio of 0.69 (99.1% CI, 0.374 to 1.273 [< 1.32], one-sided P for noninferiority = .0027 < .0043). Grade 3 or more neutropenia and infection were less frequent in the weekly arm (3-weekly v weekly, 49% v 35% and 12% v 7%, respectively), as were renal impairment and hearing impairment. No treatment-related death was reported in the 3-weekly arm, and two (1.6%) in the weekly arm. CONCLUSION: Chemoradiotherapy with weekly cisplatin is noninferior to 3-weekly cisplatin for patients with postoperative high-risk LA-SCCHN. These findings suggest that chemoradiotherapy with weekly cisplatin can be a possible treatment option for these patients.
    Lead, Jun. 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(18) (18), 1980 - 1990, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Taiji Koyama, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami
    Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells, but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for the S1 protein after a third vaccination in 22 patients treated with the anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving the seroconversion rate in patients treated with the anti-CD20 antibody who failed standard two-dose vaccination.
    Jun. 2022, Vaccines, 10(6) (6), English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Haruhiko Otsuka, Takeshi Fukumoto, Naomi Kiyota, Chihiro Takemori, Haruki Jimbo, Chikako Nishigori
    Regorafenib is an oral multikinase inhibitor targeting several tyrosine kinase receptors including BRAF and epidermal growth factor receptor (EGFR) and is approved as a third-line treatment for metastatic gastrointestinal stromal tumor (GIST). While acneiform eruptions have been observed in patients receiving other BRAF and EGFR inhibitors, the commonly reported adverse reactions to regorafenib are fatigue and palmar-plantar erythrodysesthesia. Herein, we report, to the best of our knowledge, the first case who presented with a severe acneiform eruption 24 months after beginning regorafenib for the treatment of GIST. A 61-year-old woman developed GIST with multiple liver metastases, and she was treated with imatinib and sunitinib. However, these therapies were discontinued, and regorafenib was administered. Twenty-four months after beginning regorafenib, she developed an acneiform eruption on her back. Histopathologic analysis of a skin biopsy from the back revealed neutrophilic suppurative folliculitis. Therefore, she postponed regorafenib administration for 2 months and was treated with topical application of clindamycin phosphate hydrate, which was effective. Consistent with reported evidence that the presence of acneiform eruption and the efficacy of EGFR inhibitors are positively associated, regorafenib had good anticancer activity in our patient. Ultimately, we found that although regorafenib-associated skin toxicities usually appear within 1 month of treatment, patients potentially can present with delayed-onset acneiform eruptions even 24 months later.
    PAGEPress Publications, Jun. 2022, Dermatology reports, 14(2) (2), 9303 - 9303, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Naomi Kiyota, Makoto Tahara, Bruce Robinson, Martin Schlumberger, Steven I Sherman, Sophie Leboulleux, Eun Kyung Lee, Takuya Suzuki, Min Ren, Kazuma Fushimi, Lori J Wirth
    BACKGROUND: Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) is an aggressive form of thyroid cancer. Lenvatinib is a multikinase inhibitor approved for treatment of RAI-R DTC. The impact of tumor response and tumor burden on overall survival (OS) after lenvatinib treatment in patients with RAI-R DTC was assessed. METHODS: Data from patients treated with lenvatinib (N = 261) in SELECT were retrospectively analyzed. Patients were divided into lenvatinib responder or nonresponder subgroups and into low (≤40 mm) or high (>40 mm) tumor burden subgroups based on baseline sums of diameters of target lesions using Response Evaluation Criteria in Solid Tumors, version 1.1 (cutoff values were determined by receiver-operating characteristic analyses). Associations of tumor response and tumor burden with OS were assessed. RESULTS: Median OS was prolonged in lenvatinib responders versus nonresponders (52.2 vs 19.0 months; hazard ratio [HR], 0.32; 95% CI, 0.23-0.46). Patients with a lower tumor burden who received lenvatinib had prolonged OS versus those with a higher tumor burden (median OS, not reached vs 29.1 months, respectively; HR, 0.42; 95% CI, 0.28-0.63). Baseline tumor burden was associated with OS by multivariate analysis (HR, 0.56; 95% CI, 0.35-0.89; P = .0138). CONCLUSIONS: Patients with a lower tumor burden receiving lenvatinib had prolonged OS compared with those with a higher tumor burden receiving lenvatinib. Baseline tumor burden may be a prognostic factor for OS in patients with RAI-R DTC treated with lenvatinib.
    Jun. 2022, Cancer, 128(12) (12), 2281 - 2287, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • 小山 泰司, 清田 尚臣, 今村 善宣, 土井 久容, 丹田 雅明, 四宮 弘隆, 宮脇 大輔, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2022, 頭頸部癌, 48(2) (2), 182 - 182, Japanese

  • Taku Nose, Yohei Funakoshi, Hirotaka Suto, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Hironobu Minami
    Although nivolumab is administered every two or four weeks, high programmed cell death-1 (PD-1) binding of nivolumab on T cells lasting for several months has been reported. A relationship between the PD-1 occupancy rate on T-cells and the efficacy of nivolumab is not yet fully understood. The present study used flow cytometric analyses to determine the time-dependence of PD-1 occupancy in five patients who discontinued nivolumab. The relationship between PD-1 occupancy at relapse and the efficacy of re-challenge was also studied. Occupancies after discontinuation were measured at a total of 32 points. The data indicated that it took 32.4 and 48.9 weeks to decrease occupancy by 50 and 70%, respectively. Subsequently, two patients had recurrence and were re-challenged with nivolumab. At that time, one patient had 70.8% occupancy while the other had 6.6%. Treatment was effective only for the patient with lower occupancy. Overall, the present study suggests that re-challenge with nivolumab may be efficacious in patients with low occupancy at recurrence.
    May 2022, Molecular and clinical oncology, 16(5) (5), 104 - 104, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ryo Ishii, Akira Ohkoshi, Naomi Kiyota, Kazuto Matsuura, Koichi Yasuda, Yoshinori Imamura, Yuki Saito, Akihiro Homma
    There are no established guidelines for managing older patients with head and neck cancer. Most clinical trials that define current standard therapy included few elderly patients. On the other hand, there is great variability in patients' comorbidities, physical functions, cognitive function, familial and financial background and values. The key point appears to be appropriate geriatric assessment, clarifying the patients' outcomes and a multidisciplinary team approach, including the treatment decision-making policy. Although these processes should be scientific in nature, the evidence for the treatment of elderly head and neck patients is very limited. This review summarizes the evidence available regarding the management of geriatric assessment, each treatment modality and the multidisciplinary team approach for older patients with head and neck cancers.
    Apr. 2022, Japanese journal of clinical oncology, 52(4) (4), 313 - 321, English, International magazine
    [Refereed][Invited]
    Scientific journal

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Ryo Takai, Taku Nose, Shinya Ohata, Yoshiaki Nagatani, Taiji Koyama, Akihito Kitao, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Kenichi Harada, Yugo Tanaka, Yasuko Mori, Hironobu Minami
    BACKGROUND: Although COVID-19 severity in cancer patients is high, the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients undergoing chemotherapy for solid cancers in Japan have not been reported. METHODS: We investigated the safety and immunogenicity of BNT162b2 in 41 patients undergoing chemotherapy for solid cancers and in healthy volunteers who received 2 doses of BNT162b2. We evaluated serum IgG antibody titers for S1 protein by ELISA at pre-vaccination, prior to the second dose and 14 days after the second vaccination in 24 cancer patients undergoing cytotoxic chemotherapy (CC group), 17 cancer patients undergoing immune checkpoint inhibitor therapy (ICI group) and 12 age-matched healthy volunteers (HV group). Additionally, inflammatory cytokine levels were compared between the HV and ICI groups at pre and the next day of each vaccination. RESULTS: Anti-S1 antibody levels were significantly lower in the ICI and CC groups than in the HV group after the second dose (median optimal density: 0.241 [0.063-1.205] and 0.161 [0.07-0.857] vs 0.644 [0.259-1.498], p = 0.0024 and p < 0.0001, respectively). Adverse effect profile did not differ among the three groups, and no serious adverse event occurred. There were no differences in vaccine-induced inflammatory cytokines between the HV and ICI groups. CONCLUSION: Although there were no significant differences in adverse events in three groups, antibody titers were significantly lower in the ICI and CC groups than in the HV group. Further protection strategies should be considered in cancer patients undergoing CC or ICI.
    Apr. 2022, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 28(4) (4), 516 - 520, English, International magazine
    Scientific journal

  • Maura L Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Vijayvel Jayaprakash, Li Wei, Robert L Ferris
    In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy. Nivolumab versus IC as first-line treatment also improved OS among patients with R/M SCCHN who progressed on platinum therapy for locally advanced disease in the adjuvant or primary setting at 1-year follow-up. In the present long-term follow-up analysis of patients receiving first-line treatment, OS benefit with nivolumab (n = 50) versus IC (n = 26) was maintained (median: 7.7 months versus 3.3 months; hazard ratio: 0.56; 95% confidence interval, 0.34-0.94) at 2 years. No new safety signals were identified. In summary, this long-term 2-year analysis of CheckMate 141 supports the use of nivolumab as a first-line treatment for patients with platinum-refractory R/M SCCHN.
    Mar. 2022, The oncologist, 27(2) (2), e194-e198, English, International magazine
    Scientific journal

  • Aoi Okamoto, Yohei Funakoshi, Masahiro Oe, Ryo Takai, Hirotaka Suto, Yoshiaki Nagatani, Meiko Nishimura, Yoshinori Imamura, Tomonari Kunihisa, Naomi Kiyota, Koji Miki, Kouichi Ohe, Hirokazu Tanino, Hironobu Minami
    BACKGROUND/AIM: Aldehyde dehydrogenase (ALDH) 1A1 is a well-known marker for cancer stem cells (CSCs), characterized by self-renewal capacity and multidrug resistance in breast cancer. We developed a near-infrared turn-on fluorescence probe for ALDH1A1, C5S-A, which is suitable for observing and analyzing viable cells. Here, we demonstrated the utility of C5S-A in CSC research using breast cancer cell lines. MATERIALS AND METHODS: To evaluate concordance between C5S-A and conventional stem cell markers, breast cancer cells sorted for ALDEFLUOR-positive cells and for CD44+/CD24- cell populations were stained with C5S-A. Tumorigenicity of C5S-A-positive cells was examined by mammosphere formation assay and subcutaneous transplantation to immunodeficient mice. Additionally, to determine how long fluorescence from a single staining remained observable, we cultured breast cancer cells for 5 days after C5S-A staining. We then evaluated whether C5S-A-positive cells possessed resistance to cytotoxic drugs by chronological imaging. RESULTS: C5S-A staining showed good concordance with conventional breast CSC markers, and good utility for research into CSC characteristics in breast cancer cell lines, including tumorigenesis. Additionally, C5S-A was observable for more than 3 days with a single staining. Using this property, we then confirmed that C5S-A-positive cells possessed resistance to cytotoxic drugs, which is one of the characteristics of CSCs. CONCLUSION: We showed that C5S-A is suitable for CSC research using breast cancer cell lines, and confirmed its utility in observing cells over time.
    Mar. 2022, Anticancer research, 42(3) (3), 1199 - 1205, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Susanne Singer, Eva Hammerlid, Iwona M Tomaszewska, Cecilie Delphin Amdal, Kristin Bjordal, Bente Brokstad Herlofson, Marcos Santos, Joaquim Castro Silva, Hisham Mehanna, Amy Fullerton, Christine Brannan, Loreto Fernandez Gonzalez, Johanna Inhestern, Monica Pinto, Juan I Arraras, Noam Yarom, Pierluigi Bonomo, Ingo Baumann, Razvan Galalae, Ourania Nicolatou-Galitis, Naomi Kiyota, Judith Raber-Durlacher, Dina Salem, Alexander Fabian, Andreas Boehm, Sanja Krejovic-Trivic, Wei-Chu Chie, Katherine Taylor, Christian Simon, Lisa Licitra, Allen C Sherman
    PURPOSE: The aim of this study was to explore what methods should be used to determine the minimal important difference (MID) and minimal important change (MIC) in scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43. METHODS: In an international multi-centre study, patients with head and neck cancer completed the EORTC QLQ-HN43 before the onset of treatment (t1), three months after baseline (t2), and six months after baseline (t3). The methods explored for determining the MID were: (1) group comparisons based on performance status; (2) 0.5 and 0.3 standard deviation and standard error of the mean. The methods examined for the MIC were patients' subjective change ratings and receiver-operating characteristics (ROC) curves, predictive modelling, standard deviation, and standard error of the mean. The EORTC QLQ-HN43 Swallowing scale was used to investigate these methods. RESULTS: From 28 hospitals in 18 countries, 503 patients participated. Correlations with the performance status were |r|< 0.4 in 17 out of 19 scales; hence, performance status was regarded as an unsuitable anchor. The ROC approach yielded an implausible MIC and was also discarded. The remaining approaches worked well and delivered MID values ranging from 10 to 14; the MIC for deterioration ranged from 8 to 16 and the MIC for improvement from - 3 to - 14. CONCLUSIONS: For determining MIDs of the remaining scales of the EORTC QLQ-HN43, we will omit comparisons of groups based on the Karnofsky Performance Score. Other external anchors are needed instead. Distribution-based methods worked well and will be applied as a starting strategy for analyses. For the calculation of MICs, subjective change ratings, predictive modelling, and standard-deviation based approaches are suitable methods whereas ROC analyses seem to be inappropriate.
    Mar. 2022, Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 31(3) (3), 841 - 853, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Tomoya Yokota, Susumu Okano, Kaoru Tanaka, Takuma Onoe, Yosuke Ariizumi, Akihiro Homma
    Salivary gland malignancies are rare neoplasms that have a broad histological spectrum and a variety of biologic behaviors. Salivary gland malignancies are known as chemo-resistant tumors, which render optimal treatment challenging. This review summarizes the role of systemic therapy for salivary gland malignancies. To date, the advantage of adding concurrent chemotherapy has remained undefined for both postoperative and inoperable locally advanced salivary gland malignancy patients undergoing radiotherapy. For recurrent/metastatic disease, local and/or systemic treatment options should be discussed in a multidisciplinary setting with consideration to both patient needs and tumor factors. For symptomatic patients or those who may compromise organ function, palliative systemic therapy can be a reasonable option based on the results of phase II studies. Platinum combination regimens as first-line therapy have been widely accepted. Personalized therapies have become established options, particularly for androgen receptor-positive, HER2-positive and NTRK fusion-positive salivary gland malignancies (i.e. androgen receptor and HER2 in salivary duct carcinoma and NTRK3 in secretory carcinoma). For patients with adenoid cystic carcinoma, multi-targeted tyrosine kinase inhibitors have also been developed. Anti-PD1 checkpoint inhibitors have shown limited activity to date. Investigation of active systemic treatments for salivary gland malignancy remains a significant unmet need. Future directions might include a more comprehensive genomic screening approach (usually next-generation sequencing-based) and combination strategies using immune checkpoint inhibitors. These are rare malignancies that require ongoing effort in the conduct of high-quality clinical trials.
    Feb. 2022, Japanese journal of clinical oncology, 52(4) (4), 293 - 302, English, No password, International magazine
    [Refereed][Invited]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • cT3N0M0声門癌に対する根治的放射線治療の成績
    岩下 和真, 石原 武明, 妹尾 悟史, 窪田 光, 川口 弘毅, 小林 加奈, 宮脇 大輔, 佐々木 良平, 手島 直則, 丹生 健一, 今村 善宣, 清田 尚臣
    (公社)日本医学放射線学会, Feb. 2022, Japanese Journal of Radiology, 40(Suppl.) (Suppl.), 36 - 36, Japanese

  • Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Wataru Hojo, Hironori Sakai, Marika Watanabe, Miki Saeki, Yuri Hirakawa, Rina Sakai, Sakuya Matsumoto, Yu Mizutani, Akihito Kitao, Yoshiharu Miyata, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Mitsuhiro Ito, Meiko Nishimura, Yoshinori Imamura, Naomi Kiyota, Hiroshi Matsuoka, Yasuko Mori, Hironobu Minami
    We investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with B-cell malignancies treated with anti-CD20 antibody. Although T-cell-mediated immune responses were detected even in patients receiving R-CHOP treatment, the S1 antibody titer following BNT162b2 vaccination remained only marginally increased for more than 3 years after the final dose of anti-CD20 antibody. We found no relationship between the percent of B-cells and S1 antibody titer. The duration of this suppression was much longer than we anticipated. Further protection and treatment strategies against COVID-19 for these patients are warranted.
    Jan. 2022, International journal of hematology, 115(1) (1), 7 - 10, English, Domestic magazine
    Scientific journal

  • Masanori Teshima, Hirotaka Shinomiya, Hidehito Kimura, Kazunobu Hashikawa, Naomi Kiyota, Daisuke Miyawaki, Ryohei Sasaki, Eiji Kohmura, Ken-Ichi Nibu
    Purpose: To investigate the oncological outcomes of orbital malignant tumors invading the skull base. Methods: A retrospective analysis was conducted on 16 patients with orbital malignant tumors invading the skull base. Eleven patients were treated with skull base surgery, four patients were treated with particle therapies, and one patient was treated with chemoradiotherapy (CRT) as initial treatment. Results: The most frequent histological type was adenoid cystic carcinoma in seven patients, followed by squamous cell carcinoma in two patients. Local recurrence occurred in two of the six surgically treated patients who did not receive postoperative radiotherapy (RT) or CRT. One of them was successfully salvaged by RT, and the other died of disease. With a median follow-up of 24 months, the 2-year overall, local control, and disease-free survival rates of all patients were 82.5%, 87.5%, and 59%, respectively. Conclusions: Patients with positive surgical margins were at risk of local recurrence. Postoperative RT should be considered for all surgically treated patients.Level of Evidence: 4.
    Dec. 2021, Laryngoscope investigative otolaryngology, 6(6) (6), 1347 - 1352, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hirokazu Komatsu, Tatsuya Furukawa, Keisuke Iritani, Shun Tatehara, Miki Takahashi, Shinobu Iwaki, Yasumasa Kakei, Takumi Hasegawa, Masanori Teshima, Hirotaka Shinomiya, Naoki Otsuki, Kazunobu Hashikawa, Naomi Kiyota, Ryohei Sasaki, Masaya Akashi, Ken-Ichi Nibu
    OBJECTIVE: The blowing time ratio, which is the ratio of the blowing time when the nostrils are open and closed, is significantly correlated with velopharyngeal pressure, not only during speech but also during swallowing. This study aimed to further evaluate the usefulness of the blowing time ratio as a screening tool to evaluate the swallowing pressure of patients treated for oral and oropharyngeal cancers using high-resolution manometery (HRM). METHODS: Ten patients treated for oral or oropharyngeal cancer were recruited for this study. Swallowing pressures at the velopharynx, oropharynx, and upper esophageal sphincter (UES) were measured using HRM. Their correlations with the blowing time ratio were analyzed. RESULTS: The blowing time ratio was significantly correlated with the swallowing pressures of the oropharynx (CC = 0.815, p = 0.004) and the velopharynx (CC = 0.657, p = 0.039), but not of the UES. CONCLUSIONS: The present results further support our previous finding that the blowing time ratio is a useful screening tool to evaluate velopharyngeal and oropharyngeal swallowing pressures in patients treated for oral and oropharyngeal cancer.
    Nov. 2021, Auris, nasus, larynx, 49(3) (3), 477 - 483, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kiyoto Shiga, Ken-Ichi Nibu, Yasushi Fujimoto, Takahiro Asakage, Akihiro Homma, Hiroki Mitani, Takenori Ogawa, Kenji Okami, Shigeyuki Murono, Shigeru Hirano, Tsutomu Ueda, Nobuhiro Hanai, Kiyoaki Tsukahara, Ichiro Ota, Seiichi Yoshimoto, Takeshi Shinozaki, Shigemichi Iwae, Katsunori Katagiri, Daisuke Saito, Naomi Kiyota, Makoto Tahara, Fumiaki Takahashi, Ryuichi Hayashi
    BACKGROUND: This study aimed to reveal the influence of the invasion site of external auditory canal (EAC) cancer by analyzing the outcome of patients with advanced tumor. METHODS: A total of 111 patients with T4 EAC cancer were enrolled in this study. Of these patients, 79 underwent chemoradiotherapy and 32 underwent surgery under curative intent. Univariate and multivariate analyses and the Kaplan-Meier method were used to focus on the tumor invasion sites and overall survival of the patients. RESULTS: The 3-year overall survival rate of all patients was 55.0%. In multivariate analysis, the only significant invasion site for overall survival was the facial nerve, with the dura mater being the next most influential site. When Kaplan-Meier survival curve was calculated, facial nerve and dura mater were the significant factors resulting in poor patient outcomes. CONCLUSION: The facial nerve and dura mater are crucial sites of EAC cancer for patient outcomes.
    Oct. 2021, Head & neck, 43(10) (10), 3097 - 3105, English, International magazine
    Scientific journal

  • Yoshinori Imamura, Kaoru Tanaka, Naomi Kiyota, Hidetoshi Hayashi, Ichiro Ota, Akihito Arai, Shigemichi Iwae, Shujiro Minami, Katsunari Yane, Tomoko Yamazaki, Yoshiaki Nagatani, Masanori Toyoda, Takayuki Takahama, Kazuko Sakai, Kazuto Nishio, Naoki Otsuki, Ken-Ichi Nibu, Hironobu Minami
    The clinical utility of systemic therapy and genomic profiling in non-squamous-cell head and neck cancer (NSCHNC) has not been fully elucidated. This phase II trial evaluated the efficacy and safety of docetaxel and cisplatin combination in the first-line setting. Eligibility criteria were recurrent and/or metastatic NSCHNC; progressive disease within the last 6 months; no prior systemic therapy; and ECOG performance status of 0-1. Patients received docetaxel (75 mg/m2 on day 1) and cisplatin (75 mg/m2 on day 1), repeated every 21 days for 6 cycles. The primary endpoint was confirmed objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and adverse events. Next-generation sequencing (NGS) was performed using the Ion AmpliSeq Cancer Hotspot Panel v2. Twenty-three patients were enrolled from November 2012 to October 2016, of whom 8 were male. Median age was 57 years. Ninety-six percent of cases were metastatic. Among 22 evaluable patients, confirmed ORR was 45% (95% confidential interval 24-68%). With a median follow-up period of 18.8 months, median PFS and OS were 6.7 and 20.1 months, respectively. Grade 3/4 adverse events included febrile neutropenia (39%) and anemia (22%). No treatment-related deaths were observed. NGS analysis revealed potential treatment targets, including ERBB2, KIT, and ALK. The docetaxel and cisplatin combination regimen can be considered a new treatment option in recurrent and/or metastatic NSCHNC, although primary prophylaxis for febrile neutropenia should be considered. Diverse genomic alterations may lead novel treatment options.This trial was registered with the UMIN Clinical Trials Registry as UMIN000008333 on [September 1st, 2012].
    Corresponding, Sep. 2021, Medical oncology (Northwood, London, England), 38(11) (11), 128 - 128, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • 木川 雄一郎, 石木 寛人, 寺田 参省, 水澤 純基, 清田 尚臣
    (有)科学評論社, Sep. 2021, 腫瘍内科, 28(3) (3), 291 - 295, Japanese

  • Taku Nose, Yoshinori Imamura, Shinya Ohata, Shiro Kimbara, Yoshiharu Miyata, Yasuko Hyogo, Yoshimi Fujishima, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hironobu Minami
    BACKGROUND: The incidence of cancer-associated venous thromboembolism (CA-VTE) in Japan has not been fully investigated. METHODS AND RESULTS: Clinicopathological information from patients with solid malignancies who first visited our department between November 2011 and March 2018 were retrospectively reviewed from medical records. The primary outcome was incidence of CA-VTE, defined as deep-vein thrombosis (DVT) and/or pulmonary embolism (PE). On median follow-up of 187 days, 91 of 2735 patients (3.3%) developed CA-VTE during their clinical course, giving an incidence rate of 40.7 per 1000 person-years. Of the 91 patients, 75 (82%) were diagnosed with DVT alone, 6 (7%) with PE alone, and 10 (11%) with both DVT and PE. CA-VTE was most frequent in non-small cell lung cancer (10.8%), followed by cancer of unknown origin (5.8%). Forty-four patients (48%) had one or more symptoms at the initial diagnosis of VTE. Five patients (6%) had a normal D-dimer level (≤ 1.0 µg/mL); of these, 2 were asymptomatic. CONCLUSIONS: In this retrospective study, the incidence of CA-VTE in Japanese patients with cancer was equivalent to that in Western populations. Approximately half of CA-VTE patients were asymptomatic and 6% had normal D-dimer levels, indicating the need for closer attention to occult CA-VTE.
    Sep. 2021, International journal of hematology, 114(3) (3), 319 - 324, English, Domestic magazine
    Scientific journal

  • Shunji Takahashi, Makoto Tahara, Koichi Ito, Masayuki Tori, Naomi Kiyota, Katsutoshi Yoshida, Yukinori Sakata, Akira Yoshida
    Sep. 2021, Advances in therapy, 38(9) (9), 4989 - 4993, English, International magazine

  • Hirotaka Shinomiya, Natsumi Uehara, Takeshi Fujita, Daisuke Miyawaki, Yoshinori Imamura, Masanori Teshima, Akinobu Kakigi, Naomi Kiyota, Ryohei Sasaki, Ken-Ichi Nibu
    PURPOSE: Chemoradiotherapy with docetaxel (DOC), cisplatin (CDDP), and 5-FU (TPF-CRT) for locally advanced external auditory canal cancer (EACC) has favorable oncological and functional outcomes. To establish TPF-CRT as a standard of care for advanced EACC, we conducted this study to determine the maximum tolerated (MTD) and recommended dose (RD) of DOC in TPF-CRT for locally advanced EACC. METHODS: To determine the recommended (RD) and maximum tolerated dose (MTD) of DOC in TPF-CRT for EACC, a phase I trial was conducted using the standard "3 + 3" design for maximum dose finding. DOC was administered twice every 4 weeks, CDDP at 70 mg/m2 and 5-FU at 700 mg/m2; patients were also receiving radiotherapy (66 Gy). Eight patients with T3 or T4 EACC were prospectively enrolled. RESULTS: Two patients treated with DOC, 50 mg/m2, and one out of six patients treated with DOC, 40 mg/m2, had dose-limiting toxicities. Prolonged febrile neutropenia was observed in three patients. Grade 3 non-hematological toxicities were observed in only three patients. At study completion, six patients survived, five of whom were disease free. CONCLUSION: The RD and MTD of DOC in TPF-CRT for locally advanced EACC are 40 mg/m2 when doses of CDDP and 5-FU are 70 mg/m2 and 700 mg/m2, respectively.
    Jul. 2021, European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 279(6) (6), 2805 - 2810, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hironobu Minami, Naomi Kiyota, Takashi Omori
    Jul. 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 39(20) (20), 2317 - 2318, English, International magazine

  • Taiji Koyama, Yohei Funakoshi, Yoshinori Imamura, Sho Nishimura, Yoshimi Fujishima, Masanori Toyoda, Naomi Kiyota, Hirokazu Tanino, Hironobu Minami
    Treatment with anti-programmed cell death-1 (PD-1) antibodies improves the anti-cancer immune response and can provide a meaningful clinical benefit to cancer patients. However, this treatment can result in specific autoimmune toxicities, termed immune-related adverse events (irAEs). Although irAEs are well recognized, the development of infectious diseases due to this treatment is not often observed. Some recent reports have indicated that patients who receive anti-PD-1 antibodies are at a higher risk for tuberculosis than others. However, reports on nontuberculous mycobacterial infection during anti-PD-1 antibody treatment are still rare. We herein report the first case of Mycobacterium mageritense infection during anti-PD-1 antibody treatment.
    May 2021, Internal medicine (Tokyo, Japan), 60(21) (21), 3485 - 3488, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 高レニン、高アルドステロンを呈したDOC産生副腎皮質癌の一例
    福満 隼人, 山本 直希, 福岡 秀規, 山本 雅昭, 神澤 真紀, 清田 尚臣, 小松 昇平, 重村 克己, 廣田 勇士, 小川 渉, 高橋 裕
    (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 224 - 224, Japanese

  • H Shinomiya, N Uehara, T Fujita, K Yoshida, Y Imamura, M Teshima, H Kimura, D Miyawaki, A Kakigi, N Kiyota, N Otsuki, R Sasaki, E Kohmura, K Nibu
    AbstractBackgroundThe prognosis of patients with advanced squamous cell carcinoma of the external auditory canal and middle ear has been improved by advances in skull base surgery and multidrug chemoradiotherapy during the last two decades. MethodsNinety-five patients with squamous cell carcinoma of the external auditory canal and middle ear who were treated between 1998 and 2017 were enrolled. The number of patients with tumour stages T1, T2, T3 and T4 was 15, 22, 24 and 34, respectively. Oncological outcomes and prognostic factors were retrospectively investigated. ResultsAmong patients with T4 disease, invasion of the brain (p = 0.024), carotid artery (p = 0.049) and/or jugular vein (p = 0.040) were significant predictors of poor prognosis. The five-year overall survival rate of patients with at least one of these factors (T4b) was significantly lower than that of patients without these factors (T4a) (25.5 vs 65.5 per cent, p = 0.049). ConclusionIt is proposed that stage T4 be subclassified into T4a and T4b according to the prognostic factors.
    Cambridge University Press (CUP), Apr. 2021, The Journal of Laryngology & Otology, 135(4) (4), 297 - 303
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Hidetomo Takakura, Sakuya Matsumoto, Taiji Koyama, Yoshimi Fujishima, Yohei Funakoshi, Masanori Toyoda, Takanori Hirose, Maki Kanzawa, Teruya Kawamoto, Hitomi Hara, Hironobu Minami
    Capicua transcriptional repressor (CIC)-rearranged sarcoma is an Ewing-like sarcoma with an aggressive clinical course and poor prognosis. No standard treatment has been established. The present study describes a case of CIC-rearranged sarcoma with lung metastases developing in a 24-year-old woman as a therapy-associated malignancy following chemotherapy for anaplastic large cell lymphoma at nine years old. This was treated with palliative regimens used for Ewing sarcoma. The patient achieved disease control for one year. Of note, ifosfamide and etoposide (IE), which were used as a second line treatment lead to a partial response. The case described in the present study indicated that treatment with Ewing regimens is a reasonable option for patients with metastatic CIC-rearranged sarcoma, including those with a second malignant case.
    Apr. 2021, Molecular and clinical oncology, 14(4) (4), 68 - 68, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kiyoto Shiga, Ken-Ichi Nibu, Yasushi Fujimoto, Takahiro Asakage, Akihiro Homma, Hiroki Mitani, Takenori Ogawa, Kenji Okami, Shigeyuki Murono, Shigeru Hirano, Tsutomu Ueda, Nobuhiro Hanai, Kiyoaki Tsukahara, Ichiro Ota, Seiichi Yoshimoto, Takeshi Shinozaki, Shigemichi Iwae, Katsunori Katagiri, Daisuke Saito, Naomi Kiyota, Makoto Tahara, Fumiaki Takahashi, Ryuichi Hayashi
    OBJECTIVES: This study aimed to evaluate the efficacy of chemoradiotherapy (CRT) for patients with advanced cancer of the external auditory canal (EAC) by analyzing the outcome of the patients. METHODS: This is a multi-institutional retrospective survey, and we reviewed the medical records of the subjects. A total of 181 patients with tumor (T)3 or T4 tumor in 17 institutions were enrolled. Further analysis was performed for 74 patients who underwent CRT under curative intent. RESULTS: Overall 5-year survival rates of the patients who underwent CRT (n = 74) were 54.6%. Those of the patients who underwent CRT with modified TPF (docetaxel, cisplatin [CDDP], and 5-fluorouracil) regimen (n = 50) and CRT with CDDP regimens (n = 24) were 64.4% and 36.7%, respectively. Significant differences were observed between these two groups. CONCLUSION: Given the tendency that head and neck surgeons prefer CRT for advanced larger cancer of the EAC, CRT for advanced EAC cancer using the modified TPF regimen showed good clinical outcomes. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:E870-E874, 2021.
    Mar. 2021, The Laryngoscope, 131(3) (3), E870-E874, English, International magazine
    Scientific journal

  • Susumu Okano, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Tomoya Yokota, Yoshinori Imamura, Yosuke Ariizumi, Tetsuo Akimoto, Ryuichi Hayashi
    In order to maximize the benefit of induction chemotherapy, practice based on a comprehensive interpretation of a large number of clinical trials, as in this review, is essential. The standard treatment for locally advanced squamous cell carcinoma of the head and neck is surgery or chemoradiation. However, induction chemotherapy followed by (chemo) radiotherapy may be used in some circumstances. Although many clinical trials of induction chemotherapy have been conducted, a rationale other than to preserve the larynx is still controversial. Selection of this modality should therefore be made with care. The current standard regimen for induction chemotherapy is docetaxel, cisplatin and 5-FU, but concerns remain about toxicity, cost and the duration of treatment. Regarding treatment after induction chemotherapy, it is also unclear whether radiation alone or chemoradiation is the better option. Furthermore, there is no answer as to what drugs should be used in combination with radiation therapy after induction chemotherapy. Several new induction chemotherapy treatment developments are currently underway, and future developments are expected. This review article summarizes the current position of induction chemotherapy for head and neck squamous cell carcinoma, based on the evidence produced to date, and discusses the future prospects for this treatment.
    Feb. 2021, Japanese journal of clinical oncology, 51(2) (2), 173 - 179, English, International magazine
    Scientific journal

  • Hironobu Minami, Toshihiko Doi, Masanori Toyoda, Yoshinori Imamura, Naomi Kiyota, Ayako Mitsuma, Tomoya Shimokata, Yoichi Naito, Nobuaki Matsubara, Takeshi Tajima, Kota Tokushige, Kae Ishihara, Scott Cameron, Yuichi Ando
    Spartalizumab is a humanized IgG4/κ mAb directed against human programmed cell death-1 (PD-1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n = 18) with a range of tumor types received spartalizumab i.v. at doses of 1, 3, and 10 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or discontinuation at the discretion of the investigator or patient. Most patients (61%) had received five or more prior lines of therapy. No dose-limiting toxicities were reported and, hence, the maximum tolerated dose was 10 mg/kg or more. Pharmacokinetics in Japanese patients aligned with those reported in a global dose-escalation study. The safety profile was consistent with other approved anti-PD-1 mAbs; the most common drug-related adverse events were maculopapular rash (22%), followed by malaise and increased blood alkaline phosphatase (11% each). Partial responses were reported in two patients (11%), one with transitional cell carcinoma and the other with hepatocellular carcinoma. In conclusion, this study confirmed the safety of spartalizumab given at a dose of up to 10 mg/kg every 2 weeks in Japanese patients with cancers.
    Feb. 2021, Cancer science, 112(2) (2), 725 - 733, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yoichi Naito, Hiroyuki Aburatani, Toraji Amano, Eishi Baba, Toru Furukawa, Tetsu Hayashida, Eiso Hiyama, Sadakatsu Ikeda, Masashi Kanai, Motohiro Kato, Ichiro Kinoshita, Naomi Kiyota, Takashi Kohno, Shinji Kohsaka, Keigo Komine, Itaru Matsumura, Yuji Miura, Yoshiaki Nakamura, Atsushi Natsume, Kazuto Nishio, Katsutoshi Oda, Naoyuki Oda, Natsuko Okita, Kumiko Oseto, Kuniko Sunami, Hideaki Takahashi, Masayuki Takeda, Shimon Tashiro, Shinichi Toyooka, Hideki Ueno, Shinichi Yachida, Takayuki Yoshino, Katsuya Tsuchihara
    BACKGROUND: To promote precision oncology in clinical practice, the Japanese Society of Medical Oncology, the Japanese Society of Clinical Oncology, and the Japanese Cancer Association, jointly published "Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment" in 2017. Since new information on cancer genomic medicine has emerged since the 1st edition of the guidance was released, including reimbursement for NGS-based multiplex gene panel tests in 2019, the guidance revision was made. METHODS: A working group was organized with 33 researchers from cancer genomic medicine designated core hospitals and other academic institutions. For an impartial evaluation of the draft version, eight committee members from each society conducted an external evaluation. Public comments were also made on the draft. The finalized Japanese version was published on the websites of the three societies in March 2020. RESULTS: The revised edition consists of two parts: an explanation of the cancer genomic profiling test (General Discussion) and clinical questions (CQs) that are of concern in clinical practice. Particularly, patient selection should be based on the expectation that the patient's post-test general condition and organ function will be able to tolerate drug therapy, and the optimal timing of test should be considered in consideration of subsequent treatment plans, not limited to treatment lines. CONCLUSION: We expect that the revised version will be used by healthcare professionals and will also need to be continually reviewed in line with future developments in cancer genome medicine.
    Feb. 2021, International journal of clinical oncology, 26(2) (2), 233 - 283, English, Domestic magazine
    Scientific journal

  • Shiro Kimbara, Yoshinori Imamura, Kimikazu Yakushijin, Ako Higashime, Taiji Koyama, Yoshimi Fujishima, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Hiroshi Matsuoka, Hironobu Minami
    Regorafenib is an oral multi-kinase inhibitor which targets tumor angiogenesis, the tumor microenvironment and oncogenesis. Based on this mode of action, regorafenib has a broad spectrum of toxicities. However, at present, few reports have focused on autoimmune adverse events. We report a first case of regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission during treatment for the patients with heavily treated advanced colorectal cancer. This case report highlights the need for caution with regard to regorafenib treatment in patients with cancer with concomitant immune thrombocytopenic purpura.
    Feb. 2021, Molecular and clinical oncology, 14(2) (2), 30 - 30, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ryo Takai, Yohei Funakoshi, Hirotaka Suto, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Kimikazu Yakushijin, Naomi Kiyota, Ken-Ichi Harada, Kimihiro Yamashita, Yoshihiro Kakeji, Hironobu Minami
    BACKGROUND/AIM: Biomarkers for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) are required. We encountered a patient whose skin irAE fluctuated in parallel with serum soluble interleukin-2 receptor (sIL-2R). PATIENTS AND METHODS: We examined 15 patients with cancer who received ICIs. Serum sIL-2R levels before and during ICI treatment were measured. The sIL-2R levels of preserved serum samples from another five patients who developed grade 3 irAEs were measured. RESULTS: Twelve patients showed no significant changes in sIL-2R levels during ICI treatment. Baseline serum sIL-2R levels in three patients increased beyond the normal range before the second cycle. These three patients had grade ≥2 irAEs at the second cycle treatment visit, supporting our hypothesis. Furthermore, at diagnosis of irAEs, the sIL-2R levels of all preserved samples from patients with grade 3 irAEs were significantly elevated. CONCLUSION: Serum sIL-2R is a promising biomarker for the diagnosis of irAEs.
    Feb. 2021, Anticancer research, 41(2) (2), 1021 - 1026, English, International magazine
    Scientific journal

  • Hikaru Kubota, Daisuke Miyawaki, Naritoshi Mukumoto, Takeaki Ishihara, Megumi Matsumura, Takumi Hasegawa, Masaya Akashi, Naomi Kiyota, Hirotaka Shinomiya, Masanori Teshima, Ken-Ichi Nibu, Ryohei Sasaki
    BACKGROUND: To evaluate factors associated with osteoradionecrosis of the jaw (ORNJ) in patients with head and neck squamous cell carcinoma (HNSCC), focusing on jaw-related dose-volume histogram (DVH) parameters. METHODS: We retrospectively reviewed the medical records of 616 patients with HNSCC treated with curative-intent or postoperative radiation therapy (RT) during 2008-2018. Patient-related (age, sex, history of smoking or alcohol use, diabetes mellitus, performance status, pre-RT dental evaluation, pre- or post-RT tooth extraction), tumor-related (primary tumor site, T-stage, nodal status), and treatment-related (pre-RT surgery, pre-RT mandible surgery, induction or concurrent chemotherapy, RT technique) variables and DVH parameters (relative volumes of the jaw exposed to doses of 10 Gy-70 Gy [V10-70]) were investigated and compared between patients with and without ORNJ. The Mann-Whitney U test was used to compare RT dose parameters. Univariate and multivariate Cox regression analyses were used to assess factors associated with ORNJ development. Kaplan-Meier analyses were performed for cumulative ORNJ incidence estimation. RESULTS: Forty-six patients (7.5%) developed ORNJ. The median follow-up duration was 40 (range 3-145) months. The median time to ORNJ development was 27 (range 2-127) months. DVH analysis revealed that V30-V70 values were significantly higher in patients with than in those without ORNJ. In univariate analyses, primary tumor site, pre-RT mandible surgery, post-RT tooth extraction, and V60 > 14% were identified as important factors. In multivariate analyses, V60 > 14% (p = 0.0065) and primary tumor site (p = 0.0059) remained significant. The 3-year cumulative ORNJ incidence rates were 2.5% and 8.6% in patients with V60 ≤ 14% and > 14%, respectively (p < 0.0001), and 9.3% and 1.4% in patients with oropharyngeal or oral cancer and other cancers, respectively (p < 0.0001). CONCLUSIONS: V60 > 14% and oropharyngeal or oral cancer were found to be independent risk factors for ORNJ. These findings might be useful to minimize ORNJ incidence in HNSCC treated with curative RT.
    Jan. 2021, Radiation oncology (London, England), 16(1) (1), 1 - 1, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kiyota N
    2021, ESMO Open
    Scientific journal

  • Yoshiaki Nagatani, Yohei Funakoshi, Hirotaka Suto, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Kimihiro Yamashita, Hironobu Minami
    CONTEXT: Myeloid-derived suppressor cells (MDSC) are a heterogeneous population of immune cells of myeloid lineage. Recent reports have suggested that human MDSC are divided into three subsets: monocytic MDSC (M-MDSC), granulocytic MDSC (G-MDSC), and immature MDSC (I-MDSC). However, the characteristics of each human MDSC subset still remain unclear. MATERIALS AND METHODS: To evaluate the immunosuppressive effects and mechanisms, we first performed a T-cell suppression assay using cells obtained from healthy donor peripheral blood samples. The levels of immune inhibitory molecules in the culture supernatant of each MDSC subset were measured to reveal the T-cell suppressive mechanisms. Then, we compared these results with the results from cells obtained from cancer patient blood samples. Finally, we investigated the difference in the frequency of each MDSC subset between the healthy donors and the cancer patients. RESULTS: Although M-MDSC and G-MDSC suppressed T-cell activation, I-MDSC had no T-cell suppressive effect. We found that the culture supernatant of M-MDSC and G-MDSC contained high levels of interleukin-1 receptor antagonist (IL-1RA) and arginase, respectively, in both healthy donors and cancer patients. No inhibitory molecules were detected in the culture supernatant of I-MDSC. The population of functional MDSC (M-MDSC and G-MDSC) in the total MDSC was significantly increased in cancer patients compared with that in healthy donors. CONCLUSIONS: Although M-MDSC and G-MDSC, which released IL-1RA and arginase, respectively, suppressed T-cell activation, I-MDSC did not have an immunosuppressive effect. The population of functional MDSC was increased in cancer patients compared with that in healthy donors.
    2021, Journal of cancer research and therapeutics, 17(4) (4), 1093 - 1100, English, International magazine
    Scientific journal

  • Hirotaka Suto, Yohei Funakoshi, Yoshiaki Nagatani, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Hisayuki Matsumoto, Shinwa Tanaka, Ryo Takai, Hiroshi Hasegawa, Kimihiro Yamashita, Takeru Matsuda, Yoshihiro Kakeji, Hironobu Minami
    CONTEXT: There is an increasing demand for appropriate preclinical mice models for evaluating the efficacy of cancer immunotherapies. AIMS: Therefore, we established a humanized patient-derived xenograft (PDX) model using microsatellite instability-high (MSI-H) colorectal cancer (CRC) tissues and patient-derived peripheral blood mononuclear cells (PBMCs). SUBJECTS AND METHODS: The CRC tissues of patients scheduled for surgery were tested for MSI status, and CRC tumors were transplanted into NOD/LtSz-scid/IL-2Rg-/-(NSG) mice to establish MSI-H PDX models. PDX tumors were compared to the original patient tumors in terms of histological and genetic characteristics. To humanize the immune system of MSI-H PDX models, patient PBMCs were injected through the tail vein. RESULTS: PDX models were established from two patients with MSI-H CRC; one patient had a germline mutation in MLH1 (c.1990-2A > G), and the other patient had MLH1 promoter hypermethylation. PDX with the germline mutation was histologically similar to the patient tumor, and retained the genetic characteristics, including MSI-H, deficient mismatch repair (dMMR), and MLH1 mutation. In contrast, the histological features of the other PDX from a tumor with MLH1 promoter hypermethylation were clearly different from those of the original tumor, and MLH1 promoter hypermethylation and MSI-H/dMMR were lost in the PDX. When T cells from the same patient with MLH1 mutation were injected into the PDX through the tail vein, they were detected in the PDX tumor. CONCLUSIONS: The MSI-H tumor with an MMR mutation is suitable for MSI-H PDX model generation. The PBMC humanized MSI-H PDX has the potential to be used as an efficient model for cancer immunotherapy research.
    2021, Journal of cancer research and therapeutics, 17(6) (6), 1358 - 1369, English, International magazine
    Scientific journal

  • Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Hideaki Goto, Hirotaka Suto, Naoko Chayahara, Masanori Toyoda, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Masanori Teshima, Naoki Otsuki, Ken-Ichi Nibu, Hironobu Minami
    Background: We previously reported that a high tumor burden is a prognostic factor based on an analysis of 26 patients with radioactive iodine-refractory differentiated thyroid cancer (RR-DTC) who were treated with lenvatinib. However, the optimal tumor burden for starting lenvatinib still remains to be defined. The aim of this retrospective study was to further explore in the same patient cohort the optimal timing for the start of lenvatinib by focusing on the pre- and post-treatment tumor burden. Methods: The 26 patients were treated with lenvatinib from 2012 to 2017. We explored the optimal timing for the start of lenvatinib by comparing the characteristics of long-term responders who were defined as patients with progression-free survival ≥ 30 months and non-long-term responders. Results: Long-term responders had a smaller post-treatment tumor burden at maximum shrinkage than non-long-term responders. Further, post-treatment tumor burden had a strong linear correlation with baseline tumor burden. We created an estimation formula for baseline tumor burden related to prognosis, using these regression lines. Patients with a sum of diameters of target lesions < 60 mm or maximum tumor diameter < 34 mm at baseline were estimated to have significantly better survival outcomes. Conclusions: We found a strong linear correlation between pre- and post-treatment tumor burden. Our results suggested a cut-off value for baseline tumor burden for long-term prognosis among patients treated with lenvatinib.
    Corresponding, 2021, Frontiers in oncology, 11, 638123 - 638123, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • Satoshi Sai, Masanori Toyoda, Kazutoshi Tobimatsu, Hironaga Satake, Hisateru Yasui, Shiro Kimbara, Taiji Koyama, Yoshimi Fujishima, Yoshinori Imamura, Yohei Funakoshi, Naomi Kiyota, Hirochika Toyama, Yuzo Kodama, Hironobu Minami
    PURPOSE: We conducted a phase 1 study to determine the maximum tolerated dose and the recommended dose of gemcitabine/nab-paclitaxel/S-1 combination chemotherapy in patients with unresectable pancreatic cancer. METHODS: We enrolled patients aged 20 years or older with unresectable pancreatic cancer and who had not been treated with chemotherapy or radiation therapy. Gemcitabine and nab-paclitaxel were administered on days 1 and 8, and S-1 was administered orally twice daily for 2 weeks, repeated every 3 weeks. The starting dose was level 0 [gemcitabine 700 mg/m2, nab-paclitaxel 90 mg/m2, S-1 60/80/100 mg/day (< 1.25 m2/1.25-1.50 m2/ > 1.5 m2)]. Dose-limiting toxicities were determined during the first course, and a classical 3 + 3 dose finding design was planned. RESULTS: From March 2018 to October 2019, 20 patients were enrolled. At dose level 0, three of six patients experienced dose-limiting toxicities; one grade 3 skin rash on day 8, and two grade 3 or 4 neutropenia on day 8. At dose level-1 (gemcitabine 600 mg/m2, nab-paclitaxel 90 mg/m2, and S-1 50/70/80 mg/day), two of twelve patients experienced dose-limiting toxicities, all of which were grade 3 neutropenia on day 8. The most frequently observed toxicity during eight courses was neutropenia. Other treatment-related adverse events were mild. Eleven out of 19 (58%) patients achieved partial response. CONCLUSION: We defined the maximum tolerated dose and the recommended dose for combination therapy with gemcitabine/nab-paclitaxel/S-1 as dose level-1. Considering the observed response rate, further studies are warranted in order to determine the efficacy of this regimen (UMIN-CTR 000030007).
    Jan. 2021, Cancer chemotherapy and pharmacology, 87(1) (1), 65 - 71, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Satoshi Sai, Yoshinori Imamura, Naomi Kiyota, Naoe Jimbo, Masanori Toyoda, Yohei Funakoshi, Naoko Chayahara, Yasuko Hyogo, Kei Takenaka, Hirotaka Suto, Hironobu Minami
    Intimal sarcoma of the pulmonary artery (PAIS) is a rare disease with a poor prognosis. Pazopanib, which has been indicated in metastatic non-adipocytic soft-tissue sarcomas and is expected to be active in PAIS, is a multi-kinase inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor. The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR-α and -β presented a long-term stable disease when treated with pazopanib (progression-free survival, 5.8 months). In a second case with a weak expression of PDGFR-α and -β, the disease progressed rapidly on pazopanib (progression-free survival, 1.1 months). VEGFR-2 was not expressed in the tumors of both cases. The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy.
    Jan. 2021, Molecular and clinical oncology, 14(1) (1), 6 - 6, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Matthias Büttner, Laura D Locati, Monica Pinto, Cláudia Araújo, Iwona M Tomaszewska, Naomi Kiyota, E Vidhubala, Christine Brannan, Eva Hammerlid, Olga Husson, Dina Salem, Georgios Ioannidis, Eva Gamper, Juan Ignacio Arraras, Guy Andry, Johanna Inhestern, Juliane Theurer, Katherine Taylor, Susanne Singer
    PURPOSE: Surgical complications such as hypoparathyroidism (HPT) or vocal cord palsy are seldom assessed when the quality of life (QOL) in thyroid cancer patients is investigated. The aim of this study was to measure the QOL difference in thyroid cancer survivors with and without HPT. METHODS: Participants for this analysis were enrolled in 13 countries from a study that pilot-tested a thyroid cancer-specific QOL instrument. They were included if they had been diagnosed with thyroid cancer at least 9 months previously. QOL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) and some items on HPT symptoms (eg, tingling in fingers or toes). HPT status and other clinical data were extracted from the patients' medical charts. Comparisons of QOL domains between patients with and without HPT were performed using Mann-Whitney U test. The occurrence of HPT-related symptoms was compared using chi-square tests. Multiple ordinal regression analysis was performed to evaluate factors that might affect QOL. RESULTS: Eighty-nine patients participated in this study, 17 of whom were considered to have HPT. Patients in the HPT group reported significantly reduced QOL in 9 of the 15 scales of the EORTC QLQ-C30 compared to patients without HPT. Regression analysis showed that HPT was independently negatively associated with various scales of the QLQ-C30. Both groups showed a high prevalence of typical HPT symptoms. CONCLUSION: Thyroid cancer patients with HPT report significantly impaired QOL compared to thyroid cancer survivors without HPT. The assessment of HPT should be considered when measuring QOL in thyroid cancer patients.
    Dec. 2020, The Journal of clinical endocrinology and metabolism, 105(12) (12), English, International magazine, Co-authored internationally
    Scientific journal

  • Mitsumi Terada, Kenichi Nakamura, Francesca Martinelli, Madeline Pe, Junki Mizusawa, Junko Eba, Haruhiko Fukuda, Naomi Kiyota, Laureline Gatellier, Yoshiyuki Majima, Galina Velikova, Andrew Bottomley
    This report summarizes the presentations and discussion in the first Japan Clinical Oncology Group-European Organisation for Research and Treatment of Cancer Quality of Life/Patient-Reported Outcome workshop funded by the National Cancer Center Hospital that was held on Saturday, 1 September 2018 in Tokyo, Japan. The infrastructure and understanding regarding the Quality of Life/Patient-Reported Outcome assessment of cancer patients in Japan is still immature, in spite of the increased demand for oncological Patient-Reported Outcome research felt not only by researchers but also by patients or other stakeholders of cancer drug development. The workshop aimed to share each perspective, common issues to be considered and future perspectives regarding the strong alliance between the European Organisation for Research and Treatment of Cancer Quality of Life Group and the Japan Clinical Oncology Group for Quality of Life/Patient-Reported Outcome research as well as explore the possibility of conducting collaborative research. European Organisation for Research and Treatment of Cancer is a leading international cancer clinical trials organization, and its Quality of Life Group is a global leader in the implementation of Quality of Life research in cancer patients. The three invited speakers from the European Organisation for Research and Treatment of Cancer Quality of Life Group presented their perspective, latest methodology and ongoing projects. The three speakers from the Japan Clinical Oncology Group presented their current status, experience and some issues regarding data management or interpretation of the Patient-Reported Outcome data. The two patient advocates also shared their expectations in terms of advances in cancer research based on the Patient-Reported Outcome assessment. As the next steps after this workshop, the Japan Clinical Oncology Group and European Organisation for Research and Treatment of Cancer have decided to cooperate more closely to facilitate Patient-Reported Outcome research in both the groups, and the Japan Clinical Oncology Group has approved the establishment of a new committee for Quality of Life/Patient-Reported Outcome research in Japan.
    Oct. 2020, Japanese journal of clinical oncology, 50(11) (11), 1333 - 1341, English, No password, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • 局所進行頭頸部癌術後補助化学放射線療法の第II/III相試験(JCOG1008)
    山崎 知子, 清田 尚臣, 田原 信, 藤井 博文, 三谷 浩樹, 岩江 信法, 丸尾 貴志, 小野澤 祐輔, 花井 信広, 小川 武則, 門田 伸也, 古平 毅, 水澤 純基, 中村 健一, 林 隆一
    (一社)日本癌治療学会, Oct. 2020, 日本癌治療学会学術集会抄録集, 58回, O1 - 1, English

  • Chia-Jui Yen, Naomi Kiyota, Nobuhiro Hanai, Shunji Takahashi, Tomoya Yokota, Shigemichi Iwae, Yasushi Shimizu, Ruey-Long Hong, Masahiro Goto, Jin-Hyoung Kang, Wing Sum Kenneth Li, Robert L Ferris, Maura Gillison, Toshimitsu Endo, Vijayvel Jayaprakash, Makoto Tahara
    BACKGROUND: The present study evaluated the 2-year survival of the Asian population in the CheckMate 141 trial. METHODS: The CheckMate 141 trial included patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). In the present study, 34 Asian patients (nivolumab group: 23 patients; investigator's choice of therapy [IC] group: 11 patients) were analyzed. RESULTS: The median overall survival (OS) was 12.1 and 6.2 months for the nivolumab and IC groups, respectively. The estimated 2-year OS rates were 22.7% and 0% for the nivolumab and IC groups, respectively. In the nivolumab group, the patients with any treatment-related adverse events (TRAEs), including skin-related disorders, showed better OS than the patients without any TRAEs. CONCLUSIONS: Nivolumab demonstrated prolonged OS benefits in the Asian population with platinum-refractory R/M SCCHN and a favorable safety profile. TRAEs, including skin-related disorders, may be favorable prognostic factors for nivolumab efficacy. CLINICAL TRIAL REGISTRATION: NCT02105636.
    Corresponding, Oct. 2020, Head & neck, 42(10) (10), 2852 - 2862, English, No password, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • Tomoya Yokota, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi
    Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. A breakthrough in cancer immunotherapy employing immune checkpoint inhibitors has evolved into a number of clinical trials with antibodies against programmed cell death 1 (PD-1), its ligand PD-L1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for patients with squamous cell carcinoma of the head and neck. CheckMate141 and KEYNOTE-048 were practice-changing randomized phase 3 trials for patients with platinum-refractory and platinum-sensitive recurrent or metastatic squamous cell carcinoma of the head and neck, respectively. Furthermore, many combination therapies using anti-CTLA-4 inhibitors, tyrosine kinase inhibitors and immune accelerators are currently under investigation. Thus, the treatment strategy of recurrent or metastatic squamous cell carcinoma of the head and neck is becoming more heterogeneous and complicated in the new era of individualized medicine. Ongoing trials are investigating immunotherapeutic approaches in the curative setting for locoregionally advanced disease. This review article summarizes knowledge of the role of the immune system in the development and progression of squamous cell carcinoma of the head and neck, and provides a comprehensive overview on the development of immunotherapeutic approaches in both recurrent/metastatic and locoregionally advanced diseases.
    Sep. 2020, Japanese journal of clinical oncology, 50(10) (10), 1089 - 1096, English, International magazine
    [Refereed]
    Scientific journal

  • Shunji Takahashi, Makoto Tahara, Koichi Ito, Masayuki Tori, Naomi Kiyota, Katsutoshi Yoshida, Yukinori Sakata, Akira Yoshida
    INTRODUCTION: Lenvatinib is approved in Japan for treating patients with all histological subtypes of unresectable thyroid cancer, including differentiated thyroid cancer (DTC), medullary thyroid cancer (MTC), and anaplastic thyroid cancer (ATC). However, safety and effectiveness data are limited in Japanese patients. Therefore, this prospective, post-marketing observational study evaluated, in daily clinical practice, the safety and effectiveness of lenvatinib in Japanese patients with unresectable thyroid cancer. METHODS: All patients with unresectable thyroid cancer first treated with lenvatinib between May and November 2015 were registered. Patients were orally administered lenvatinib and followed up for 12 months. The endpoints included adverse drug reactions (ADRs), overall survival (OS), overall response rate (ORR), and time-to-treatment failure. Post hoc Cox multivariate analyses were performed to assess prognostic factors associated with the 12-month OS rate. RESULTS: Of 629 registered patients, 594 were included in the analysis. A total of 442 patients (74.4%) had DTC, 28 (4.7%) had MTC, and 124 (20.9%) had ATC. Hypertension, proteinuria, and palmar-plantar erythrodysesthesia syndrome were the most frequently reported ADRs across all histological subtypes. The median OS was 101.0 days in patients with ATC which was not reached in patients with DTC and patients with MTC, with 12-month OS rates of 15.6%, 75.7%, and 83.0%, respectively. The ORRs were 59.2%, 45.0%, and 43.8% among 368 patients with DTC, 20 with MTC, and 105 with ATC, respectively. Multivariate analyses revealed that Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size, the presence of tumor invasion, and body weight were baseline prognostic factors affecting OS in patients with DTC, while ECOG PS and the presence of liver metastasis were prognostic factors in patients with ATC. CONCLUSION: Lenvatinib demonstrated an acceptable safety profile for patients with thyroid cancer in a real-world setting in Japan. The safety profile and effectiveness findings for lenvatinib in this study were consistent with those from previous clinical trials, irrespective of histological subtype.
    Sep. 2020, Advances in therapy, 37(9) (9), 3850 - 3862, English, International magazine
    Scientific journal

  • Mori Kenta, Otsui Kazunori, Imamura Yoshinori, Kitagawa Koichi, Okada Hideaki, Hata Akito, Hayashi Hidetoshi, Nose Taku, Ohata Shinya, Miyata Yoshiharu, Funakoshi Yohei, Toyoda Masanori, Kiyota Naomi, Yakushijin Kimikazu, Matsuoka Hiroshi, Minami Hironobu
    (一社)日本循環器学会, Jul. 2020, 日本循環器学会学術集会抄録集, 84回(4) (4), PE52 - 6, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 小児・若年の上咽頭癌3例の治療経験
    宮脇 大輔, 妹尾 悟史, 窪田 光, 川口 弘毅, 石原 武明, 植村 優, 山本 暢之, 今村 善宣, 清田 尚臣, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, Jul. 2020, 頭頸部癌, 46(2) (2), 168 - 168, Japanese

  • 頭頸部癌における免疫チェックポイント阻害薬後の救済化学療法についての後方視的検討
    小山 泰司, 清田 尚臣, 今村 善宣, 長谷 善明, 高倉 嗣丈, 蓼原 瞬, 入谷 啓介, 古川 竜也, 手島 直則, 四宮 弘隆, 宮脇 大輔, 明石 昌也, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, Jul. 2020, 頭頸部癌, 46(2) (2), 174 - 174, Japanese

  • 当院における頭頸部がんに対する高用量シスプラチン併用化学放射線療法による急性腎障害の後方視的検討
    高倉 嗣丈, 今村 善宣, 小山 泰司, 長谷 善明, 四宮 弘隆, 手島 直則, 古川 竜也, 入谷 啓介, 蓼原 瞬, 宮脇 大輔, 明石 昌也, 佐々木 良平, 丹生 健一, 清田 尚臣
    (一社)日本頭頸部癌学会, Jul. 2020, 頭頸部癌, 46(2) (2), 185 - 185, Japanese

  • C. Suzuki, N. Kiyota, Y. Imamura, J. Rikitake, S. Sai, T. Koyama, Y. Hyogo, Y. Nagatani, Y. Funakoshi, M. Toyoda, N. Otsuki, KI. Nibu, H. Minami
    BACKGROUND: Nivolumab improves overall survival (OS) in patients with platinum-refractory recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). In one study, however, Kaplan-Meier OS and progression-free survival (PFS) curves for the nivolumab and cytotoxic agent arms crossed at 3-6 months, suggesting that patients with initial resistance to immunotherapy might have better outcomes with cytotoxic treatment. Here, we explored the conditions and candidates which are predictive of nivolumab outcomes in R/M HNSCC. METHODS: We retrospectively reviewed the clinical records of 27 consecutive R/M HNSCC patients treated with nivolumab from 2014 to 2018. Tumor size was evaluated by RECIST ver.1.1. Tumor growth rate (Gr) was defined as 3log(D0/Dpre)/t, where D0 and Dpre are the sum of the diameters of the target lesions (SumTLs) at baseline and pre-baseline, and t is time, with 1t defined as 4 weeks. RESULTS: Twenty-five patients were enrolled. Survival was significantly worse in patients with disease progression within 3 months. Outcomes appeared poorer in patients with higher pre-treatment Gr and bigger SumTLs at baseline. We therefore explored the association between prognosis, Gr and SumTLs. Recursive partitioning analysis showed that the characteristics of patients with disease progression after 3 months were Gr < 0.76 and SumTLs < 31.0 mm. Further, Gr < 0.76 and SumTLs < 31.0 mm was associated with significantly longer PFS (p = 0.01) and OS (p < 0.01). CONCLUSIONS: These results suggest that Gr and SumTLs at baseline are significantly associated with OS and PFS in R/M HNSCC patients treated with nivolumab.
    Corresponding, Springer Science and Business Media LLC, Jul. 2020, International Journal of Clinical Oncology, 25(7) (7), 1270 - 1277, English, No password, Domestic magazine
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • Naomi Kiyota, Yoshinori Imamura
    AME Publishing Company, Jun. 2020, Therapeutic Radiology and Oncology, 4, 5 - 5, English, No password
    [Refereed][Invited]
    Scientific journal
    添付ファイルのURL

  • HER2陽性再発・転移唾液腺癌患者に対するトラスツズマブ・ドセタキセル併用療法の第II相試験
    木下 一郎, 加納 里志, 清田 尚臣, 多田 雄一郎, 伊地知 圭, 山崎 知子, 西本 尚樹, 畑中 豊, 松野 吉弘, 秋田 弘俊
    (一社)日本内科学会, Feb. 2020, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 230 - 230, Japanese

  • がん免疫療法時代の再発・転移頭頸部扁平上皮癌における全身性炎症スコアの予後予測性
    今村 善宣, 清田 尚臣, 小山 泰司, 金原 史朗, 長谷 善明, 須藤 洋崇, 能勢 拓, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2020, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 186 - 186, Japanese

  • 2735人を対象とした悪性腫瘍関連静脈血栓塞栓症の合併率に関する後ろ向きコホート研究 甲状腺癌に対するチロシンキナーゼ阻害薬と血栓の関係
    能勢 拓, 今村 善宣, 清田 尚臣, 大幡 真也, 金原 史朗, 宮田 吉晴, 小山 泰司, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2020, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 226 - 226, Japanese

  • 当院における頭頸部がんに対する3-weekly高用量シスプラチン併用化学放射線療法の臨床的忍容性の検討
    高倉 嗣丈, 今村 善宣, 清田 尚臣, 金原 史朗, 小山 泰司, 藤島 佳未, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2020, 日本内科学会雑誌, 109(Suppl.) (Suppl.), 259 - 259, Japanese

  • Takeshi Ioroi, Naomi Kiyota, Yoshinori Imamura, Masaaki Tanda, Shiori Aoki, Mamoru Okuno, Kazuhiro Yamamoto, Ryohei Sasaki, Ken-Ichi Nibu, Hironobu Minami, Midori Hirai, Ikuko Yano
    Background: Oral mucositis frequently occurs in cancer patients treated with chemotherapy and chemoradiotherapy (CRT). This study examined the safety and efficacy of ibuprofen gargle in healthy volunteers and patients with chemotherapy- and concomitant CRT-induced oral mucositis. Methods: We enrolled healthy volunteers and patients with chemotherapy- and CRT-induced oral mucositis. In cohort I, single and multiple doses of ibuprofen gargle (0.6% or 1.0%) were administered to healthy volunteers on day 1 and days 4-10. In cohort II, multiple doses of ibuprofen gargle (0.6%) were administered to patients with complicated grade 2-3 oral mucositis based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The primary endpoint of cohort I was the treatment-related adverse events (TRAEs) as defined by CTCAE version 4.0. The primary endpoint of cohort II was the change in the visual analogue scale (VAS) pain score from before to 15 min after gargle use on day 3. The incidence and severity of TRAEs were assessed based on the CTCAE version 4.0 and a subjective rating scale completed by healthy volunteers and patients. Results: In cohort I, 9 of 10 healthy volunteers were evaluable for safety. All 9 healthy volunteers reported the TRAE of oral irritation with single or multiple use of the gargle. In cohort II, 10 patients were enrolled and evaluable for safety and 7 of 10 patients were evaluable for efficacy. The mean change in the VAS pain score from before to 15 min after using the gargle on day 3 was - 1.28 (95% confidence interval: - 2.06, - 0.51), and all patients experienced some degree of pain relief (range: - 0.2 to - 2.5). All 10 patients reported the TRAE of oral irritation. No other TRAEs of ibuprofen gargle were observed in the healthy volunteers and patients. Conclusion: Despite oral irritation, the ibuprofen gargle appeared to be safe and effective for the pain related to chemo- or CRT-induced oral mucositis. However, ibuprofen-related oral irritation warrants further formulation improvement. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000014433).
    2020, Journal of pharmaceutical health care and sciences, 6, 12 - 12, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yoshinori Imamura, Naomi Kiyota, Gakuto Ogawa, Tetsuo Akimoto, Masato Fujii, Nobuhiro Hanai, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Yusuke Onozawa, Ryuichi Hayashi, Makoto Tahara
    OBJECTIVES: To explore the risk factors of laryngo-esophageal dysfunction-free survival and nutritional support dependence over 12 months in patients with unresectable locally advanced head and neck carcinomas who received chemoradiotherapy in a phase II trial of JCOG0706 (UMIN000001272). METHODS: Forty-five patients received radiation therapy for a total of 70 Gy/35fr concurrently with S-1 and cisplatin. Risk factors of laryngo-esophageal dysfunction-free survival and nutritional support dependence over 12 months were analyzed using Cox regression models and logistic regression models, respectively, with consideration to patient laboratory data just before chemoradiotherapy. Radiation fields were reviewed to analyze the relationship between the extent of the irradiated field and functional outcome. RESULTS: With a median follow-up period of 3.5 years, 3-year laryngo-esophageal dysfunction-free survival was 48.9%. For laryngo-esophageal dysfunction-free survival, hazards ratio of 2.35 in patients with nutritional support at registration (vs. without nutritional support; 95% confidence interval 0.96-5.76). For nutritional support dependence over 12 months, odds ratio was 6.77 in patients with hemoglobin less than the median of 13.4 g/dl (vs. higher than or equal to the median; 95% confidence interval 1.24-36.85) and was 6.00 in patients with albumin less than the median of 3.9 g/dl (vs. higher than or equal to the median; 95% confidence interval 1.11-32.54). Primary sites in disease-free patients with nutritional support dependence over 12 months were the oropharynx (N = 2) or hypopharynx (N = 1), and all pharyngeal constrictor muscles were included in irradiated fields with a curative dose. CONCLUSIONS: This supplementary analysis showed that pretreatment severe dysphagia requiring nutritional support, anemia and hypoalbuminemia might have a negative prognostic impact on long-term functional outcomes after curative chemoradiotherapy in head and neck cancer.
    Dec. 2019, Japanese journal of clinical oncology, 49(11) (11), 1009 - 1015, English, International magazine
    [Refereed]
    Scientific journal

  • Nagatani Yoshiaki, Imamura Yoshinori, Nakamura Tsutomu, Yamashita Kazuhiko, Okuno Mamoru, Yasui Hiroyuki, Hiraoka Jun, Niigata Riho, Kono Keiji, Hyogo Yasuko, Suto Hirotaka, Takenaka Kei, Funakoshi Yohei, Toyoda Masanori, Kiyota Naomi, Minami Hironobu
    {ClinMed} International Library, Sep. 2019, International Journal of Oncology Research, 2(2) (2)
    Scientific journal

  • 小山 泰司, 清田 尚臣
    (有)科学評論社, Sep. 2019, 腫瘍内科, 24(3) (3), 232 - 236, Japanese

  • Nabil F Saba, George Blumenschein Jr, Joel Guigay, Lisa Licitra, Jerome Fayette, Kevin J Harrington, Naomi Kiyota, Maura L Gillison, Robert L Ferris, Vijayvel Jayaprakash, Li Li, Peter Brossart
    OBJECTIVES: Many patients with squamous cell carcinoma of the head and neck (SCCHN) are ≥65 years old; comorbidities and other age-related factors may affect their ability to tolerate traditional chemotherapy. Nivolumab is the only immunotherapy to significantly improve overall survival (OS) versus investigator's choice (IC) of single-agent chemotherapy at primary analysis in a phase 3 trial (CheckMate 141) in patients with recurrent/metastatic SCCHN post-platinum therapy. In this post hoc analysis, we report efficacy and safety by age. PATIENTS AND METHODS: Eligible patients were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks (n = 240) or IC (methotrexate, docetaxel, or cetuximab n = 121). The primary endpoint of the trial was OS. For this analysis, outcomes were analyzed by age < 65 and ≥65 years. The data cut-off date was September 2017 (minimum follow-up 24.2 months). RESULTS: At baseline, 68 patients (28.3%) receiving nivolumab and 45 patients (37.2%) receiving IC were ≥65 years. Baseline characteristics were generally similar across age groups. OS and tumor response benefits with nivolumab versus IC were maintained regardless of age. The 30-month OS rates of 11.2% (<65 years) and 13.0% (≥65 years) with nivolumab were more than tripled versus corresponding IC rates of 1.4% and 3.3%, respectively. The nivolumab arm had a lower rate of treatment-related adverse events versus IC regardless of age, consistent with the overall patient population. CONCLUSION: In CheckMate 141, nivolumab resulted in a higher survival versus IC in patients <65 and ≥65 years, with a manageable safety profile in both age groups. ClinicalTrials.gov: NCT02105636.
    Sep. 2019, Oral oncology, 96, 7 - 14, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Hideaki Goto, Hirotaka Suto, Naoko Chayahara, Masanori Toyoda, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Naoki Otsuki, Ken-Ichi Nibu, Hironobu Minami
    BACKGROUND: Multitarget kinase inhibitors (m-TKI), including lenvatinib, are now available as treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC). However, the optimal timing of treatment initiation with m-TKI in these patients remains to be defined. METHODS: We retrospectively reviewed the clinical records of 30 consecutive patients with RR-DTC. The relationship between clinical characteristics was evaluated, including tumor growth parameters at pretreatment/post-treatment and efficacy of lenvatinib. RESULTS: A total of 26 patients with RR-DTC treated with lenvatinib were evaluable for response and eligible for analysis. From the results of multivariate analysis, baseline tumor size and tumor-related symptoms were independent negative prognostic factors for overall survival (OS) and progression-free survival (PFS). Pretreatment tumor growth parameters were not prognostic for either PFS or OS. CONCLUSIONS: Patients with RR-DTC with a high tumor burden and tumor-related symptoms had significantly worse prognosis. Greater tumor reduction after starting lenvatinib may lead to better prognosis, irrespective of pretreatment high tumor growth rate.
    Corresponding, Sep. 2019, Head & neck, 41(9) (9), 3023 - 3032, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • 【逸脱症例から学ぶ がん薬物療法 標準治療の実践!】(第1章)がん薬物治療 頭頸部がん
    今村 善宣, 清田 尚臣
    (株)じほう, Jul. 2019, 薬事, 61(10) (10), 1710 - 1714, Japanese
    [Refereed]

  • Naoko Chayahara, Toru Mukohara, Motoko Tachihara, Yoshimi Fujishima, Atsushi Fukunaga, Ken Washio, Masatsugu Yamamoto, Kyosuke Nakata, Kazuyuki Kobayashi, Kei Takenaka, Masanori Toyoda, Naomi Kiyota, Kazutoshi Tobimatsu, Hisayo Doi, Naomi Mizuta, Naho Marugami, Atsushi Kawaguchi, Chikako Nishigori, Yoshihiro Nishimura, Hironobu Minami
    LESSONS LEARNED: The results of the APPEARANCE trial indicate that adapalene does not prevent acne-like rash over placebo when added to topical moisturizer and oral minocycline but instead may have a detrimental effect. Therefore, adapalene is not recommended as prophylaxis against acne-like rash induced by anti-epidermal growth factor receptor therapies.Given that acne-like rash was completely controlled with placebo in approximately half of patients, predictive measures to identify patients needing intensive prophylaxis are required. BACKGROUND: Anti-epidermal growth factor receptor (EGFR) therapies are frequently associated with acne-like rash. To evaluate the prophylactic efficacy of adapalene, a topical retinoid used as first-line therapy for acne vulgaris, we conducted a randomized, placebo-controlled, evaluator-blinded, left-right comparative trial. METHODS: Patients with non-small cell lung, colorectal, or head and neck cancer scheduled to receive anti-EGFR therapies were randomly assigned to once-daily adapalene application on one side of the face, with placebo on the other side. All patients had topical moisturizer coapplied to both sides of the face, and received oral minocycline. The primary endpoint was the difference in total facial lesion count of acne-like rash at 4 weeks. Secondary endpoints included complete control rate (CCR) of acne-like rash (≤5 facial lesions) and global skin assessment (Investigator's Global Assessment [IGA] scale, grade 0-4) at 4 weeks. Two blinded dermatologists independently evaluated the endpoints from photographs. RESULTS: A total of 36 patients were enrolled, of whom 26 were evaluable. Adapalene treatment was associated with a greater lesion count than placebo at 4 weeks, although the difference was not statistically significant (mean, 12.6 vs. 9.8, p = .12). All four patients with a difference >10 in lesion count between face sides had a greater count on the adapalene-treated side. No significant differences were observed in CCR of acne-like rash (54% vs. 50%) or IGA scale (mean grade, 1.9 vs. 1.7) between the adapalene and placebo sides. CONCLUSION: Adapalene is not recommended as prophylaxis against acne-like rash induced by anti-EGFR therapies.
    Jul. 2019, The oncologist, 24(7) (7), 885-e413, English, International magazine
    [Refereed]
    Scientific journal

  • Nobuya Monden, Takahiro Asakage, Naomi Kiyota, Akihiro Homma, Kazuto Matsuura, Nobuhiro Hanai, Takeshi Kodaira, Sadamoto Zenda, Hirofumi Fujii, Makoto Tahara, Tomoya Yokota, Tetsuo Akimoto, Shigemichi Iwae, Tetsuro Onitsuka, Takenori Ogawa, Susumu Okano, Shunji Takahashi, Yasushi Shimizu, Koichiro Yonezawa, Ryuichi Hayashi
    A number of major modifications were made to the classification of head and neck carcinomas in the eighth edition of the American Joint Committee on Cancer, Cancer Staging Manual and Union for International Cancer Control TNM classification of Malignant Tumors. These modifications were aimed at improving the prognosis prediction accuracy of the system. In this article, we review the new edition of the TNM classification system. Among the several changes in the new system, a separate algorithm for p16-positive oropharyngeal carcinoma was included, as were new chapters on 'Head and Neck Skin Carcinoma' and 'Unknown Primary Carcinoma-Cervical Nodes.' Changes to Tumor (T) classification were made by introducing the depth of invasion of oral carcinoma, whereas changes to Node (N) classification were made by adding extra-nodal extension. It is believed that these changes will help improve the accuracy of the system in the prediction of prognosis. However, it is necessary to verify their validity through further clinical research.
    Oxford University Press (OUP), Jul. 2019, Japanese journal of clinical oncology, 49(7) (7), 589 - 595, English, International magazine
    [Refereed]
    Scientific journal

  • Barbara Burtness, Robert Haddad, José Dinis, José Trigo, Tomoya Yokota, Luciano de Souza Viana, Ilya Romanov, Jan Vermorken, Jean Bourhis, Makoto Tahara, José Getulio Martins Segalla, Amanda Psyrri, Irina Vasilevskaya, Chaitali Singh Nangia, Manuel Chaves-Conde, Naomi Kiyota, Akihiro Homma, Petra Holeckova, Josep Maria Del Campo, Nirav Asarawala, Ulisses Ribaldo Nicolau, Daniel Rauch, Caroline Even, Bushi Wang, Neil Gibson, Eva Ehrnrooth, Kevin Harrington, Ezra E W Cohen
    Importance: Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC. Objective: To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in patients with HNSCC. Design, Setting, and Participants: This multicenter, phase 3, double-blind randomized clinical trial (LUX-Head & Neck 2) studied 617 patients from November 2, 2011, to July 4, 2016. Patients who had complete response after CRT, comprising radiotherapy with cisplatin or carboplatin, with or without resection of residual disease, for locoregionally advanced high- or intermediate-risk HNSCC of the oral cavity, hypopharynx, larynx, or oropharynx were included in the study. Data analysis was of the intention-to-treat population. Interventions: Patients were randomized (2:1) to treatment with afatinib (40 mg/d) or placebo, stratified by nodal status (N0-2a or N2b-3) and Eastern Cooperative Oncology Group performance status (0 or 1). Treatment continued for 18 months or until disease recurrence, unacceptable adverse events, or patient withdrawal. Main Outcomes and Measures: The primary end point was DFS, defined as time from the date of randomization to the date of tumor recurrence or secondary primary tumor or death from any cause. Secondary end points were DFS at 2 years, overall survival (defined as time from the date of randomization to death), and health-related quality of life. Results: A total of 617 patients were studied (mean [SD] age, 58 [8.4] years; 528 male [85.6%]). Recruitment was stopped after a preplanned interim futility analysis on July 4, 2016, on recommendation from an independent data monitoring committee. Treatment was discontinued. Median DFS was 43.4 months (95% CI, 37.4 months to not estimable) in the afatinib group and not estimable (95% CI, 40.1 months to not estimable) in the placebo group (hazard ratio, 1.13; 95% CI, 0.81-1.57; stratified log-rank test P = .48). The most common grade 3 and 4 drug-related adverse effects were acneiform rash (61 [14.8%] of 411 patients in the afatinib group vs 1 [0.5%] of 206 patients in the placebo group), stomatitis (55 [13.4%] in the afatinib group vs 1 [0.5%] in the placebo group), and diarrhea (32 [7.8%] in the afatinib group vs 1 [0.5%] in the placebo group). Conclusions and Relevance: This study's findings indicate that treatment with afatinib after CRT did not improve DFS and was associated with more adverse events than placebo in patients with primary, unresected, clinically high- to intermediate-risk HNSCC. The use of adjuvant afatinib after CRT is not recommended. Trial Registration: ClinicalTrials.gov identifier: NCT01345669.
    Jun. 2019, JAMA oncology, 5(8) (8), 1170 - 1180, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal

  • 小山 泰司, 清田 尚臣
    (株)医学書院, Jun. 2019, 耳鼻咽喉科・頭頸部外科, 91(7) (7), 572 - 578, Japanese

  • Susanne Singer, Cecilie Delphin Amdal, Eva Hammerlid, Iwona M Tomaszewska, Joaquim Castro Silva, Hisham Mehanna, Marcos Santos, Johanna Inhestern, Christine Brannan, Noam Yarom, Amy Fullerton, Monica Pinto, Juan I Arraras, Naomi Kiyota, Pierluigi Bonomo, Allen C Sherman, Ingo Baumann, Razvan Galalae, Loreto Fernandez Gonzalez, Ourania Nicolatou-Galitis, Zeinab Abdel-Hafeez, Judith Raber-Durlacher, Claudia Schmalz, Paola Zotti, Andreas Boehm, Dirk Hofmeister, Sanja Krejovic Trivic, Suat Loo, Wei-Chu Chie, Kristin Bjordal, Bente Brokstad Herlofson, Vincent Grégoire, Lisa Licitra
    BACKGROUND: We validated the new European Organisation for Research and Treatment of Cancer Quality of Life Head and Neck Module (EORTC QLQ-HN43). METHODS: We enrolled 812 patients with head and neck cancer from 18 countries. Group 1 completed the questionnaire before therapy, and 3 and 6 months later. In group 2 (survivors), we determined test-retest reliability using intraclass correlation coefficients (ICC). Internal consistency was assessed using Cronbach's Alpha, the scale structure with confirmatory factor analysis, and discriminant validity with known-group comparisons. RESULTS: Cronbach's alpha was >0.70 in 10 of the 12 multi-item scales. All standardized factor loadings exceeded 0.40. The ICC was >0.70 in all but two scales. Differences in scale scores between known-groups were >10 points in 17 of the 19 scales. Sensitivity to change was found to be sufficient in 18 scales. CONCLUSIONS: Evidence supports the reliability and validity of the EORTC QLQ-HN43 as a measure of quality of life.
    Jun. 2019, Head & neck, 41(6) (6), 1725 - 1737, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal

  • Masanori Teshima, Naoki Otsuki, Hirotaka Shinomiya, Naruhiko Morita, Tatsuya Furukawa, Koichi Morimoto, Tetsu Nakamura, Kazunobu Hashikawa, Naomi Kiyota, Ryohei Sasaki, Ken-Ichi Nibu
    OBJECTIVES: To evaluate the impact of retropharyngeal lymph node (RPLN) dissection in the surgical treatment of hypopharyngeal cancer. METHODS: Between 2007 and 2016, 98 previously untreated patients with pathological diagnosed hypopharyngeal squamous cell carcinoma underwent total pharyngolaryngectomy and bilateral neck dissection at Kobe University Hospital. Bilateral dissection of RPLN was simultaneously performed in all patients. Pharynx was reconstructed with free jejunal transfer in 94 patients and primarily closed in 4 patients. Postoperative chemoradiotherapy was performed in patients with high risk factors including metastasis to RPLN, multiple lymph node metastasis, extranodal invasion, and/or positive/close surgical margins. RESULTS: The median follow-up period was 25 months ranging from 1 to 105 months. RPLN adenopathy was preoperatively identified in 9 patients in FDG-positron emission tomography. All of them had pathologically diagnosed RPLN metastases, which had been controlled in all patients during the observation periods. Among the other 89 patients, 7 patients had RPLN metastasis. The 2-year overall survival rates of the patients with and without RPLN metastasis were 65.7% and 69.8% (P = .61), respectively. CONCLUSIONS: In the present study, patients with RPLN metastasis showed equally favorable oncological outcome compared with patients without RPLN metastasis. At least, ipsilateral RPLN dissection should be considered in the surgical treatment of advanced hypopharyngeal cancer and multiple neck lymph node metastasis regardless of primary subsite.
    Jun. 2019, Head & neck, 41(6) (6), 1738 - 1744, English, International magazine
    [Refereed]
    Scientific journal

  • Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, Hironobu Minami
    Wiley, May 2019, Cancer Science, 110(6) (6), 1987 - 1994
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 田原 信, 清田 尚臣, 本間 明宏
    (株)メディカルレビュー社, May 2019, がん免疫療法, 3(1) (1), 12 - 19, Japanese

  • 再発・転移性頭頸部扁平上皮癌に対するニボルマブ第III相試験(CheckMate141)のアジア人2年フォローアップ
    横田 知哉, 清田 尚臣, 長谷川 泰久, 高橋 俊二, 岩江 信法, 清水 康, Ferris Robert L., 遠藤 俊充, Jayaprakash Vijayvel, 田原 信
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 131 - 131, Japanese

  • 免疫関連有害事象に対する支援体制の構築と運用
    土井 久容, 丹田 雅明, 今村 善宣, 金原 史朗, 清田 尚臣
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 218 - 218, Japanese
    [Refereed]

  • Nobuhiro Hanai, Takahiro Asakage, Naomi Kiyota, Akihiro Homma, Ryuichi Hayashi
    The standard local treatment for early-stage tongue cancer with no clinical lymph node metastases is partial glossectomy. The frequency of occult lymph node metastasis is ~20-30%. Thus, whether prophylactic neck dissection with glossectomy or glossectomy alone should be performed has been a controversial issue since the 1980s. Both treatments have advantages and disadvantages; however, especially in cases involving prophylactic neck dissection, surgical invasion and complications including the cosmetic disadvantage caused by neck skin incision, accessory nerve paralysis or facial nerve (mandibular marginal branch) paralysis, stiffness of the shoulder or neck and a feeling of neck tightness have been considered issues that could be solved by providing less-invasive treatment to the 70-80% of patients without occult lymph node metastasis. A more accurate preoperative diagnosis and strict follow-up are required to provide minimally invasive treatment while ensuring the therapeutic effect. It is also necessary to narrow down the target based on the risk-benefit balance. The depth of invasion should be considered in cases involving oral cavity malignancies. This was also taken into account in recent revisions of eighth edition of the TNM Classification of Malignant Tumors and it is an important factor for N0 neck management. This review article summarizes previous and recent reports on neck management, focusing on the risk-benefit and future perspectives of the diagnosis and treatment of early-stage oral tongue cancer. This effort is an attempt to establish treatment from the patient's point of view, with the patient's quality of life taken into account.
    Apr. 2019, Japanese journal of clinical oncology, 49(4) (4), 297 - 305, English, International magazine
    [Refereed]
    Scientific journal

  • Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Naoki Fukuda, Tatsuya Sasaki, Takuya Suzuki, Hiroki Ikezawa, Corina E Dutcus, Makoto Tahara
    AIM: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer. PATIENTS/METHODS: In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC) received once-daily lenvatinib 24 mg. The primary end point was safety. RESULTS: All patients experienced ≥1 adverse event (AE); only one patient experienced an AE leading to discontinuation. The most common any-grade AEs were hypertension, decreased appetite, palmar-plantar erythrodysesthesia, fatigue and proteinuria. Response rates for RR-DTC: 68%; MTC: 22%; ATC: 24%. Median progression-free survival for RR-DTC: 25.8 months; MTC: 9.2 months; ATC: 7.4 months. CONCLUSION: Lenvatinib demonstrated a manageable safety profile, proven antitumor activity in RR-DTC and promising efficacy in MTC and ATC. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov NCT01728623.
    Mar. 2019, Future oncology (London, England), 15(7) (7), 717 - 726, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 甲状腺癌に対するレンバチニブ治療中の観血的処置の安全性・予後への影響に関する遡及的検討
    金原 史朗, 清田 尚臣, 小山 泰司, 藤島 佳未, 今村 善宣, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2019, 日本内科学会雑誌, 108(Suppl.) (Suppl.), 284 - 284, Japanese
    [Refereed]

  • Hideaki Goto, Yohei Shimono, Yohei Funakoshi, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Seishi Kono, Shintaro Takao, Toru Mukohara, Hironobu Minami
    Tumor microenvironment plays a key role for tumor development and progression. Although adipose tissue is a predominant component of stroma in mammary tissues and secretes various cytokines, chemokines and growth factors, roles of adipocytes in breast cancers remain to be elucidated. In this study, we found that adipsin, an adipokine secreted from mammary adipose tissues, enhanced proliferation and cancer stem cell (CSC)-like properties of human breast cancer patient-derived xenograft (PDX) cells. Adipsin was predominantly expressed in both adipose tissues of the surgical specimens of breast cancer patients and adipose-derived stem cells (ADSCs) isolated from them, and its expression level was significantly higher in obese patients. ADSCs significantly enhanced the sphere-forming ability of breast cancer PDX cells derived from both estrogen receptor-positive and -negative breast cancer PDX cells. Suppression of adipsin-mediated signaling by a specific inhibitor or adipsin knockdown in ADSCs significantly decreased the sphere-forming ability and the expression of CSC markers in co-cultured breast cancer PDX cells. Growth of breast cancer PDX tumors was significantly enhanced by co-transplantation with ADSCs in vivo, and it was weakened when co-transplanted with the adipsin knocked-down ADSCs. These results suggest that adipsin is an important adipokine secreted from mammary adipose tissue that functions as a component of tumor microenvironment and a CSC niche in breast cancers.
    Feb. 2019, Oncogene, 38(6) (6), 767 - 779, English, International magazine
    [Refereed]
    Scientific journal

  • Ito, Y., Ishikawa, H., Kihara, M., Hirokawa, M., Kiyota, N., Kasahara, T., Miyauchi, A.
    2019, Thyroid, 29(10) (10)
    Scientific journal

  • Koyama, T., Kiyota, N.
    2019, Otolaryngology - Head and Neck Surgery (Japan), 91(7) (7)
    Scientific journal

  • 生活支援における効果的な多職種連携 経口抗がん薬服用患者への介入
    土井 久容, 今西 優子, 木下 実里, 丹田 雅明, 豊田 昌徳, 船越 洋平, 今村 善宣, 西野 聖子, 清田 尚臣
    (一社)日本がん看護学会, Jan. 2019, 日本がん看護学会誌, 33(Suppl.) (Suppl.), 214 - 214, Japanese
    [Refereed]

  • Takashi Matsuzuka, Naomi Kiyota, Junki Mizusawa, Tetsuo Akimoto, Masato Fujii, Yasuhisa Hasegawa, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Yusuke Onozawa, Ryuichi Hayashi, Makoto Tahara
    Objectives: To evaluate the clinical impact of cachexia, defined by the combination of albumin and C-reactive protein levels, in patients with unresectable locally advanced head and neck squamous cell carcinomas who received chemoradiotherapy in a phase II trial of JCOG0706. Methods: Forty-five patients received radiation for a total of 70 Gy/35fr concurrently with S-1 and cisplatin. The present analysis was conducted in 44 patients with available data. The association between treatment efficacy and cachexia was investigated. Pretreatment cachexia was defined as a serum albumin level of less than 3.5 mg/dl and C-reactive protein level of more than 0.5 mg/dl. Results: Among the 44 patients, 5 patients had cachexia. On comparison with the cachexic and non-cachexic patients, the percentage of clinical complete remission (20% vs 72%), time to treatment failure at 3 years, (20% vs 53%) and proportion of treatment completion (20% vs 79%) were statistically worse in the cachexic patients, while overall survival, progression-free survival and local progression-free survival at 3 years tended to be worse in cachexic patients. Conclusions: This supplementary analysis from a prospective study suggests that a pretreatment status of cancer cachexia is a prognostic factor for treatment outcomes and compliance in patients with locally advanced head and neck squamous cell carcinomas treated with chemoradiotherapy, and a candidate stratification factor in future prospective trials in this population.
    Jan. 2019, Japanese journal of clinical oncology, 49(1) (1), 37 - 41, English, International magazine
    [Refereed]
    Scientific journal

  • Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara
    Background: Induction chemotherapy (IC) is a treatment option for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). However, treatment with docetaxel, cisplatin, and 5-FU (TPF) followed by cisplatin and radiotherapy is controversial because of toxicity concerns. The aim of this phase II study was to assess the feasibility of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for LA SCCHN. Patients and Methods: We enrolled patients with histological evidence of squamous cell carcinoma of the oropharynx, hypopharynx, or larynx without distant metastases. IC comprised cisplatin (75 mg/m2) and docetaxel (75 mg/m2) on day 1, repeated every 3 weeks for up to three courses. Cetuximab was initiated at 400 mg/m2, followed by 250 mg/m2 doses weekly until the end of radiotherapy. Radiotherapy (70 Gy/35 fr/7 w) was initiated after the last docetaxel administration. The primary endpoint was the rate of treatment completion. Results: We enrolled 54 patients (median age, 58 years) between August 2013 and October 2015. Our patients were 49 males and 5 females with hypopharyngeal (n = 28), oropharyngeal (n = 19), or laryngeal (n = 7) cancers, and 48 of them had stage IV disease. The overall response rate was 72.2% with a median follow-up of 36.1 months and a 3-year overall survival of 90.7%. The treatment completion rate was 76%; 50 patients (93%) received ≥2 courses of IC, and 41 (76%) completed radiotherapy. The frequencies of grade ≥3 febrile neutropenia or allergy/infusion reactions were 39% and 11%, respectively. There was one treatment-related death. Conclusions: IC with TPEx followed by cetuximab with concurrent radiotherapy showed acceptable compliance for the treatment of LA SCCHN. However, high frequency of febrile neutropenia remains a challenge and further improvement in the management of TPEx is necessary. Trial Registration: UMIN000009928.
    2019, Frontiers in oncology, 9, 6 - 6, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Petr Szturz, Kristien Wouters, Naomi Kiyota, Makoto Tahara, Kumar Prabhash, Vanita Noronha, David Adelstein, Dirk Van Gestel, Jan B Vermorken
    In locally advanced squamous cell carcinomas of the head and neck (LA-SCCHN), concurrent chemoradiotherapy is an integral part of multimodality management both in the adjuvant and in the definitive settings. Although de-intensification strategies have been propelled to the forefront of clinical research in human papillomavirus (HPV) positive oropharyngeal cancer, three cycles of 100 mg/m2 cisplatin given every 3 weeks concurrently with conventionally fractionated external beam radiotherapy represent a cost-effective and globally accessible treatment option for the majority of LA-SCCHN cases. Based on four large randomized trials, this regimen has become the non-surgical standard of care for cisplatin-eligible patients. Nevertheless, the outcomes in terms of efficacy, toxicity, and compliance have been rather disappointing. Therefore, there is an unmet need to find a better alternative. With limited support from randomized trials, weekly low-dose cisplatin regimens have replaced the standard high-dose schedule at some institutions. Four prospective trials exploring radiotherapy with and without weekly low-dose cisplatin have been published. Two of them were conducted in the 1980s, one of which had a negative outcome, the third study provided insufficient information on toxicity, and the fourth trial had to be prematurely terminated due to poor accrual. Moreover, the findings of two phase III trials comparing the two concurrent cisplatin regimens favored the high-dose protocol. We performed a composite meta-analysis of 59 prospective trials enrolling a total of 5,582 patients. The primary endpoint was overall survival. Reflecting different radiotherapy fractionation schemes and treatment intents, three meta-analyses were carried out, one for postoperative conventional chemoradiotherapy, one for definitive conventional chemoradiotherapy, and one for definitive altered fractionation chemoradiotherapy. In the former two settings, both high- and low-dose regimens yielded similar survival outcomes, thus, the primary objective was not met. When given concurrently with altered fractionation radiotherapy, patients treated with high-dose cisplatin had significantly longer overall survival than those who received low-dose cisplatin. In this article we provide a synthetic view of the results, discuss the issue of cumulative dose, compare two vs. three cycles of high-dose cisplatin, and present our three-step recommendations for use of the current standard of care, high-dose cisplatin, in clinical practice.
    2019, Frontiers in oncology, 9, 86 - 86, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 頭頸部がんに対する免疫チェックポイント阻害薬
    Kiyota Naomi
    (一社)日本頭頸部癌学会, Dec. 2018, 頭頸部癌, 44(4号) (4号), 336 - 341, Japanese
    [Invited]
    Scientific journal

  • 口腔癌に対する免疫チェックポイント阻害剤投与の実際と腫瘍内科医との連携 頭頸部がんに対する免疫チェックポイント阻害薬と頭頸部がん診療連携プログラム
    Kiyota Naomi
    (一社)日本口腔腫瘍学会, Dec. 2018, 日本口腔腫瘍学会誌, 30(4号) (4号), 144 - 150, Japanese
    [Invited]
    Scientific journal

  • Kiyo Tanaka, Nobuhiro Hanai, Junko Eba, Junki Mizusawa, Takahiro Asakage, Akihiro Homma, Naomi Kiyota, Haruhiko Fukuda, Ryuichi Hayashi
    For stage I/II tongue cancer patients, it is controversial whether prophylactic neck dissection should be performed with partial glossectomy. Based on the evidence of the primary tumor's depth of invasion as a predictive factor of occult lymph node metastases and a prognostic factor of disease-free survival, randomized phase III trial was initiated in November 2017 to evaluate the omission value for prophylactic neck dissection for stage I/II tongue cancer with 3-10 mm of depth of invasion. In 5 years, 440 patients will be accrued from 28 institutions. The primary end point of the study is the overall survival, whereas the secondary end points are relapse-free survival, local relapse-free survival, proportion of unresectable relapse and of cervical lymph node relapse, post-operative function (paralysis of the accessory and facial nerves and subjective symptoms) and adverse events. This trial has been registered with the UMIN Clinical Trials Registry (registration number: UMIN000030098; http://www.umin.ac.jp/ctr/index.htm).
    Dec. 2018, Japanese journal of clinical oncology, 48(12) (12), 1105 - 1108, English, International magazine
    [Refereed]
    Scientific journal

  • Hideaki Goto, Naomi Kiyota, Naoki Otsuki, Yoshinori Imamura, Naoko Chayahara, Hirotaka Suto, Yoshiaki Nagatani, Masanori Toyoda, Toru Mukohara, Ken-Ichi Nibu, Toshihiko Kasahara, Yasuhiro Ito, Akihiro Miya, Mitsuyoshi Hirokawa, Akira Miyauchi, Hironobu Minami
    Sorafenib and lenvatinib showed efficacy for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) in pivotal phase 3 clinical trials. Although the efficacy of lenvatinib in patients who received previous treatment with multi-target kinase inhibitors (m-TKIs), including sorafenib, was reported, the efficacy of sorafenib in patients who previously received lenvatinib remains unknown. A 75-year-old woman diagnosed as RAI-refractory poorly differentiated carcinoma with multiple lung metastases and started treatment with lenvatinib. She continued to receive lenvatinib but with repeated dose interruptions and reductions due to continuous proteinuria. Because of severe and persistent proteinuria as well as newly developed renal impairment, lenvatinib was suspended after two years of treatment. After the 7-month suspension, her proteinuria and renal impairment were partially improved, but her lung metastases progressed. Because she was unable to tolerate previous treatment with lenvatinib, sorafenib was started. At 7 months of treatment with sorafenib, her lung metastases shrank and she could continue sorafenib without exacerbation of proteinuria or renal impairment. This case may suggest that sorafenib does not exacerbate the proteinuria or renal impairment induced by lenvatinib, and may be an effective treatment option for RAI-refractory DTC patients who are unable to tolerate lenvatinib.
    Corresponding, Dec. 2018, Auris, nasus, larynx, 45(6) (6), 1249 - 1252, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • Miki Takahashi, Nana Kosaka, Emi Wakui, Shinobu Iwaki, Mika Nishii, Masanori Teshima, Hirotaka Shinomiya, Koichi Morimoto, Naomi Kiyota, Ryohei Sasaki, Makoto Usami, Naoki Otsuki, Ken-Ichi Nibu
    BACKGROUND: Concomitant chemoradiotherapy (CCRT) produces severe mucositis and swallowing dysfunction, often resulting in malnutrition. Intensive nutrition support (INS) in addition to percutaneous endoscopic gastrostomy (PEG) is reported to decrease adverse effects during CCRT. PATIENTS AND METHODS: Fifty-eight patients with oropharyngeal cancer treated by CDDP-based CCRT were retrospectively analyzed. Twenty-nine patients treated with INS in addition to PEG were classified as INS group, and other 29 patients treated with PEG but without INS were classified as control group. RESULTS: INS in addition to PEG significantly increased calorie intake in the second half of CCRT and reduced adverse events including mucositis (p = 0.0019), leukopenia (p = 0.04), and renal function (p = 0.006). Moreover, 21 out of 29 patients had successfully administration of 200 mg/m2 or more of CDDP, while only 10 out of 29 patients had enough amount of CDDP in control group. CONCLUSIONS: These results suggest that INS in addition to prophylactic PEG not only decreases adverse effects but also may potentially improve oncological outcome of the patients with oropharyngeal cancer treated by CCRT.
    Dec. 2018, International journal of clinical oncology, 23(6) (6), 1023 - 1028, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kakiuchi S, Yakushijin Kimikazu, Sakai R, Kawaguchi K, Higashime A, Kurata K, Ichikawa H, Nagao S, Rikitake J, Kiyota Naomi, Matsuoka Hiroshi, Minami Hironobu
    A 69-year-old woman who had been diagnosed with unresectable papillary thyroid cancer was referred to our hospital. We initially treated her with sorafenib, but she subsequently developed erythema multiforme, which was suspected to be a drug rush due to sorafenib; therefore, sorafenib was discontinued. At the time of discontinuation, immature blast cells were detected in her peripheral blood. Approximately two weeks later, her skin rash improved substantially, but the proportion of blasts in the peripheral blood increased. We performed a bone marrow examination, and she was diagnosed with FLT3-ITD-positive acute myeloid leukemia. FLT3-ITD expression is found in 20-25% of AML and is a known independent poor prognostic factor. To overcome the poor prognosis associated with FLT3-ITD, molecular drugs targeting FLT3-ITD are attracting much attention. Sorafenib, a multi-kinase inhibitor, also has an effect on FLT3-ITD. Although primary disease flares after tyrosine kinase inhibitor discontinuation have been reported, this is the first report to describe discontinuation of sorafenib treatment as a potential trigger of FLT3-ITD-positive acute myeloid leukemia in papillary thyroid cancer.
    Dec. 2018, J Oncol Pharm Pract, 25(8) (8), 2010 - 2015, English, International magazine
    [Refereed]
    Scientific journal

  • Hyogo Y, Kiyota Naomi, Ohtsuki Naoki, Goto Shunsuke, Imamura Yoshinori, Chayahara N, Toyoda Masanori, Nibu Ken-ichi, Hyodo T, Hara S, Masuoka H, Kasahara T, Ito Y, Miya A, Hirokawa M, Miyauchi A, Minami Hironobu
    Corresponding, Nov. 2018, Case Rep Oncol, 11(3) (3), 735 - 741, English, No password
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • 【頭頸部がん・甲状腺がん・希少がん】 甲状腺がん BRAF遺伝子変異陽性甲状腺未分化がんに対するdabrafenib trametinib併用療法
    Kiyota Naomi
    (有)科学評論社, Oct. 2018, 腫瘍内科, 22(4号) (4号), 399 - 403, Japanese
    [Invited]

  • sorafenib投薬を中断することで顕在化したFLT3-ITD陽性急性骨髄性白血病の一例(Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia)
    垣内 誠司, 坂井 里奈, 川口 晃司, 東目 亜湖, 倉田 啓史, 市川 大哉, 長尾 茂輝, 力武 隼平, 清田 尚臣, 藥師神 公和, 松岡 広, 南 博信
    (一社)日本血液学会-東京事務局, Sep. 2018, 臨床血液, 59(9) (9), 1641 - 1641, English

  • Kiyota Naomi
    Sep. 2018, Ther Radiol Oncol, 2(39) (39), English, No password
    [Refereed][Invited]
    Scientific journal
    添付ファイルのURL

  • Maura L Gillison, George Blumenschein Jr, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, Li Li, Robert L Ferris
    Nivolumab significantly improved overall survival (OS) vs investigator's choice (IC) of chemotherapy at the primary analysis of randomized, open-label, phase 3 CheckMate 141 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Here, we report that OS benefit with nivolumab was maintained at a minimum follow-up of 11.4 months. Further, OS benefit with nivolumab vs IC was also noted among patients who received first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting.
    Sep. 2018, The oncologist, 23(9) (9), 1079 - 1082, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal

  • 【どこが変わった頭頸部癌診療ガイドライン】 がん薬物療法
    Kiyota Naomi
    (株)医学書院, Sep. 2018, 耳鼻咽喉科・頭頸部外科, 90(10号) (10号), 855 - 860, Japanese

  • 【ちょっと気になる頭頸部癌化学療法】 術後再発高リスク患者に対する治療の現状とエビデンス
    力武隼平, Kiyota Naomi
    (株)東京医学社, Aug. 2018, JOHNS, 34(8号) (8号), 983 - 985, Japanese
    [Invited]
    Scientific journal

  • Lori J Wirth, Makoto Tahara, Bruce Robinson, Sanjeev Francis, Marcia S Brose, Mouhammed Amir Habra, Kate Newbold, Naomi Kiyota, Corina E Dutcus, Elton Mathias, Matthew Guo, Steven I Sherman, Martin Schlumberger
    BACKGROUND: Hypertension (HTN) is an established class effect of vascular endothelial growth factor receptor (VEGFR) inhibition. In the phase 3 Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) trial, HTN was the most frequent adverse event of lenvatinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, fibroblast growth factor receptor 1 (FGFR1), FGFR2, FGFR3, FGFR4, platelet-derived growth factor receptor α (PDGFRα), ret proto-oncogene (RET), and stem cell factor receptor (KIT). This exploratory analysis examined treatment-emergent hypertension (TE-HTN) and its relation with lenvatinib efficacy and safety in SELECT. METHODS: In the multicenter, double-blind SELECT trial, 392 patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC) were randomized 2:1 to lenvatinib (24 mg/d on a 28-day cycle) or placebo. Survival endpoints were assessed with Kaplan-Meier estimates and log-rank tests. The influence of TE-HTN on progression-free survival (PFS) and overall survival (OS) was analyzed with univariate and multivariate Cox proportional hazards models. RESULTS: Overall, 73% of lenvatinib-treated patients and 15% of placebo-treated patients experienced TE-HTN. The median PFS for lenvatinib-treated patients with (n = 190) and without TE-HTN (n = 71) was 18.8 and 12.9 months, respectively (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.39-0.88; P = .0085). For lenvatinib-treated patients, the objective response rate was 69% with TE-HTN and 56% without TE-HTN (odds ratio, 1.72; 95% CI, 0.98-3.01). The median change in tumor size for patients with and without TE-HTN was -45% and -40%, respectively (P = .2). The median OS was not reached for patients with TE-HTN; for those without TE-HTN, it was 21.7 months (HR, 0.43; 95% CI, 0.27-0.69; P = .0003). CONCLUSIONS: Although HTN is a clinically significant adverse event that warrants monitoring and management, TE-HTN was significantly correlated with improved outcomes in patients with RR-DTC, indicating that HTN may be predictive for lenvatinib efficacy in this population. Cancer 2018;124:2365-72. © 2018 American Cancer Society.
    Jun. 2018, Cancer, 124(11) (11), 2365 - 2372, English, International magazine
    [Refereed]
    Scientific journal

  • Robert L Ferris, George Blumenschein Jr, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Even, Francis Worden, Nabil F Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Vijayvel Jayaprakash, Li Li, Maura L Gillison
    OBJECTIVES: We report 2-year results from CheckMate 141 to establish the long-term efficacy and safety profile of nivolumab and outcomes by tumor PD-L1 expression in patients with recurrent or metastatic (R/M),platinum-refractory squamous cell carcinoma of the head and neck (SCCHN). METHODS: Patients with R/M SCCHN with tumor progression/recurrence within 6 months of platinum therapy were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks or investigator's choice (IC). Primary endpoint: overall survival (OS). Data cutoff: September 2017. RESULTS: With 24.2 months' minimum follow-up, nivolumab (n = 240) continued to improve OS vs IC (n = 121), hazard ratio (HR) = 0.68 (95% CI 0.54-0.86). Nivolumab nearly tripled the estimated 24-month OS rate (16.9%) vs IC (6.0%), and demonstrated OS benefit across patients with tumor PD-L1 expression ≥1% (HR [95% CI] = 0.55 [0.39-0.78]) and  < 1% (HR [95% CI] = 0.73 [0.49-1.09]), and regardless of tumor HPV status. Estimated OS rates at 18, 24, and 30 months with nivolumab were consistent irrespective of PD-L1 expression (<1%/≥1%). In the nivolumab arm, there were no observed differences in baseline characteristics or safety profile between long-term survivors and the overall population. Grade 3-4 treatment-related adverse event rates were 15.3% and 36.9% for nivolumab and IC, respectively. CONCLUSION: Nivolumab significantly improved OS at the primary analysis and demonstrated prolonged OS benefit vs IC and maintenance of a manageable and consistent safety profile with 2-year follow-up. OS benefit was observed with nivolumab irrespective of PD-L1 expression and HPV status. (Clinicaltrials.gov: NCT02105636).
    Jun. 2018, Oral oncology, 81, 45 - 51, English, International magazine
    [Refereed]
    Scientific journal

  • Takashi Tatara, Toru Mukohara, Yohei Shimono, Takashi Yamasaki, Yoshinori Imamura, Yohei Funakoshi, Masanori Toyoda, Naomi Kiyota, Shintaro Takao, Seishi Kono, Yoshihiro Kakeji, Hironobu Minami
    BACKGROUND AND OBJECTIVES: To explore whether lymphocytes in sentinel lymph nodes (SLNs) are highly exposed to tumor neoantigens and thus express high level of programmed death 1 (PD-1), we examined PD-1 expression in SLNs and non-sentinel regional lymph nodes (non-SLNs) in breast cancer. METHODS: We performed PD-1 immunohistochemistry in two cohorts: 40 metastasis-negative SLNs including 10 patients for each subtype (luminal A-like, luminal B-like, HER2, and triple negative breast cancer [TNBC]); and 25 pairs of metastasis-positive SLNs and non-SLNs (10 luminal A-like, 10 luminal B-like, and 5 TNBC). RESULTS: Among 40 metastasis-negative SLNs, 34 and 6 samples were PD-1 intensity grade 1 (low) and 2 (high), respectively. PD-1 intensity correlated with PD-1-positive lymphocyte numbers (P = 0.005); TNBC had the highest PD-1 lymphocyte numbers among all subtypes. The median PD-1-positive lymphocyte number was higher in SLNs than non-SLNs. In most cases, more lymphocytes in SLNs expressed PD-1 than those in non-SLNs (P < 0.0001). CONCLUSIONS: TNBC had the greatest PD-1 expression among all subtypes, and metastasis-positive SLNs had more PD-1-positive lymphocytes than downstream non-SLNs. These data suggested that lymphocytes in SLNs are activated following exposure to tumor neoantigens and thus tumor specific, and could be utilized as a biomarker platform.
    May 2018, Journal of surgical oncology, 117(6) (6), 1131 - 1136, English, International magazine
    [Refereed]
    Scientific journal

  • 3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Takashi Tatara, Toru Mukohara, Rina Tanaka, Yohei Shimono, Yohei Funakoshi, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Midori Hirai, Yoshihiro Kakeji, Hironobu Minami
    BACKGROUND: Our hypothesis was that three-dimensional (3D) culture better represents differential in vivo responses to trastuzumab between PIK3CA-wild-type (wt) and mutant (mt) cell lines than does two-dimensional (2D) culture. MATERIALS AND METHODS: Apoptosis and cell signaling proteins were evaluated in response to trastuzumab with and without BKM120, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, using western blot analysis of four breast cancer cell lines with human epidermal growth factor receptor 2 (HER2) amplification. RESULTS: Increased expression of cleaved poly (ADP-ribose) polymerase (PARP) was observed only in 3D-cultured PIK3CA-wt lines in response to trastuzumab, but not in 2D-cultured PIK3CA-wt or PIK3CA-mt lines. Decrease in the ratio of phosphorylated (p-)AKT to AKT in response to trastuzumab was more profound in PIK3CA-wt cells than in PIK3CA-mt cells in 3D culture, while the difference between PIK3CA genotypes was less apparent in 2D culture. Treatment with BKM120 and trastuzumab resulted in a stronger increase in cleaved PARP than either treatment alone. CONCLUSION: 3D Culture appears to better represent trastuzumab-induced apoptosis and resistance to trastuzumab associated with PIK3CA mutation.
    May 2018, Anticancer research, 38(5) (5), 2831 - 2839, English, International magazine
    [Refereed]
    Scientific journal

  • Modified TALK Score for Japanese Patients with Laryngeal and Hypopharyngeal Cancers to Predict the Possibility of Laryngeal Preservation by Concurrent Chemoradiotherapy.
    Naoki Otsuki, Mio Matsui, Miki Takahashi, Ryohei Sasaki, Naomi Kiyota, Makoto Usami, Ken-Ichi Nibu
    OBJECTIVE: TALK score has been developed as an index for predicting the possibility of larynx preservation and prognosis of the patients with advanced laryngeal and hypopharyngeal cancers treated by concurrent chemoradiotherapy (CCRT). In this study, we validated the original TALK score in our clinical setting and modified the score for Japanese population. METHODS: The subjects were 21 patients with laryngeal cancer and 50 patients with hypopharyngeal cancer who underwent CCRT at Kobe University Hospital between April 2007 and August 2012. Data regarding T stage, serum albumin level just before treatment, maximum alcohol use, Karnofsky Performance Status (KPS), 3-year overall survival rate and 3-year larynx-preservation rate were collected from medical records. In the revised TALK score (JTALK), the following scoring criteria were modified to adjust Japanese population: T stage of the primary tumor (≥T3), serum albumin level (<3.5 g/dl), maximum alcohol use (≥one 350-ml can of beer/day or an equivalent amount), and KPS (<80%). RESULTS: The original TALK score was not significantly associated with the larynx preservation rates or survival rates for laryngeal cancer or hypopharyngeal cancer. Instead, JTALK score was significantly associated with the 3-year larynx preservation rates and 3-year survival rates of the patients with hypopharyngeal and laryngeal cancer. CONCLUSION: These results indicate that JTALK score could be a useful index for predicting the possibility of larynx preservation and prognosis of Japanese patients with advanced laryngeal and hypopharyngeal cancer treated by CCRT.
    Apr. 2018, The Kobe journal of medical sciences, 63(4) (4), E113-E122 - E122, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Meiko Nishimura, Mitsuhiro Hayashi, Yu Mizutani, Kei Takenaka, Yoshinori Imamura, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Hiroaki Aikawa, Yasuhiro Fujiwara, Akinobu Hamada, Hironobu Minami
    Background: The development of skin rashes is the most common adverse event observed in cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors such as erlotinib. However, the pharmacological evidence has not been fully revealed. Results: Erlotinib distribution in the rashes was more heterogeneous than that in the normal skin, and the rashes contained statistically higher concentrations of erlotinib than adjacent normal skin in the superficial skin layer (229 ± 192 vs. 120 ± 103 ions/mm2; P = 0.009 in paired t-test). LC-MS/MS confirmed that the concentration of erlotinib in the skin rashes was higher than that in normal skin in the superficial skin layer (1946 ± 1258 vs. 1174 ± 662 ng/cm3; P = 0.028 in paired t-test). The results of MALDI-MSI and LC-MS/MS were well correlated (coefficient of correlation 0.879, P < 0.0001). Conclusions: Focal distribution of erlotinib in the skin tissue was visualized using non-labeled MALDI-MSI. Erlotinib concentration in the superficial layer of the skin rashes was higher than that in the adjacent normal skin. Methods: We examined patients with advanced pancreatic cancer who developed skin rashes after treatment with erlotinib and gemcitabine. We biopsied both the rash and adjacent normal skin tissues, and visualized and compared the distribution of erlotinib within the skin using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The tissue concentration of erlotinib was also measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with laser microdissection.
    Apr. 2018, Oncotarget, 9(26) (26), 18540 - 18547, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 次世代シークエンサーを用いた唾液腺導管癌・腺癌NOSの新規治療標的遺伝子の同定
    今村 善宣, 清田 尚臣, 長谷 善明, 鈴木 千晶, 兵庫 寧子, 崔 諭司, 力武 隼平, 船越 洋平, 豊田 昌徳, 南 博信
    (一社)日本内科学会, Feb. 2018, 日本内科学会雑誌, 107(Suppl.) (Suppl.), 189 - 189, Japanese
    [Refereed]

  • がんクリニカルシークエンスと遺伝性腫瘍の関係
    豊田 昌徳, 味木 徹夫, 今村 善宣, 船越 洋平, 清田 尚臣, 南 博信
    (一社)日本内科学会, Feb. 2018, 日本内科学会雑誌, 107(Suppl.) (Suppl.), 189 - 189, Japanese
    [Refereed]

  • TaharaM, Kiyota Naomi, YokotaT, HasegawaY, MuroK, TakahashiS, OnoeT, HommaA, TaguchiJ, SuzukiM, MinatoK, YaneK, UedaS, HaraH, SaijoK, YamanakaT
    BACKGROUND: The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with platinum, 5-FU and cetuximab (PFE). However, this regimen requires hospitalization to ensure proper hydration and continuous infusion of 5-FU, and causes severe nausea and anorexia. We evaluated the efficacy and safety of paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with R/M SCCHN. PATIENTS AND METHODS: Eligibility criteria included recurrent and/or metastatic, histologically proven SCC of the oropharynx, oral cavity, hypopharynx or larynx; PS 0-1; adequate organ function; no suitable local therapy for R/M SCCHN; and no prior systemic chemotherapy for R/M SCCHN. Chemotherapy consisted of paclitaxel 100 mg/m2 on days 1, 8; carboplatin area under the blood concentration-time curve 2.5 on days 1, 8, repeated every 3 weeks for up to 6 cycles; and cetuximab at an initial dose of 400 mg/m2, followed by 250 mg/m2 weekly until disease progression or unacceptable toxicities. Primary end point was overall response rate. Secondary end points were safety, treatment completion rate, progression-free survival, overall survival, and clinical benefit rate. Planned sample size was 45 patients. RESULTS: Forty-seven subjects were accrued from July 2013 to October 2014. Of 45 evaluable, 40 were male; median age was 63 years; Eastern Cooperative Oncology Group Performance Status was 0/1 in 23/22 cases; site was the hypopharynx/oropharynx/oral cavity/larynx in 17/11/10/7 cases; and 36/9 cases were smokers/nonsmokers, respectively. Overall response rate, the primary end point, was 40%. Median overall survival was 14.7 months and progression-free survival was 5.2 months. Grade 3/4 adverse events included neutropenia (68%), skin reaction (15%), fatigue (9%) and febrile neutropenia (9%). A potentially treatment-related death occurred in one patient with intestinal pneumonia. CONCLUSIONS: The PCE regimen shows promising activity with acceptable toxicity in the outpatient clinic. Further studies are needed to compare PCE with PFE in this population. REGISTERED CLINICAL TRIAL NUMBER: UMIN000010507.
    Feb. 2018, Ann Oncol, 29(4) (4), 1004 - 1009, English, International magazine
    [Refereed]
    Scientific journal

  • Kiyota, N.
    2018, Otolaryngology - Head and Neck Surgery (Japan), 90(10) (10)
    Scientific journal

  • Petr Szturz, Kristien Wouters, Naomi Kiyota, Makoto Tahara, Kumar Prabhash, Vanita Noronha, David Adelstein, Jan B Vermorken
    OBJECTIVES: Altered fractionation radiotherapy and concomitant chemoradiotherapy represent commonly used intensification strategies in the management of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This meta-analysis compares compliance, safety, and efficacy between two single-agent cisplatin schedules given concurrently with altered fractionation radiotherapy. METHODS: We systematically searched for prospective trials of patients with LA-SCCHN who received post-operative or definitive altered fractionation concurrent chemoradiotherapy. High-dose cisplatin once every three to four weeks (100 mg/m2, 2 doses) was compared with a weekly low-dose protocol (≤50 mg/m2, ≥4 doses). The primary outcome was overall survival. The secondary endpoints comprised treatment adherence, acute and late toxicities, and objective response rate. RESULTS: Twelve studies with 1373 patients treated with definitive chemoradiotherapy were included. Compared to the weekly low-dose cisplatin regimen, the three- to four-weekly high-dose cisplatin regimen improved overall survival (p=.0185), was more compliant with respect to receiving all planned cycles of cisplatin (71% versus 95%, p=.0353), and demonstrated less complications in terms of severe (grade 3-4) acute mucositis and/or stomatitis (75% versus 40%, p=.0202) and constipation (8% versus 1%, p=.0066), toxic deaths (4%, versus 1%, p=.0168), 30-day mortality (8% versus 3%, p=.0154), and severe late subcutaneous fibrosis (21% versus 2%, p<.0001). Overall and complete response rates were similar between both chemotherapy schedules. CONCLUSION: In chemoradiotherapy incorporating altered fractionation, two cycles of high-dose cisplatin with a three to four week interval are superior to weekly low-dose schedules. Further studies should identify those who might derive the greatest benefit from this intensified approach.
    Jan. 2018, Oral oncology, 76, 52 - 60, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal

  • 長谷 善明, 清田 尚臣
    (株)日本臨床社, Dec. 2017, 日本臨床, 75(増刊9 がん転移学(下)) (増刊9 がん転移学(下)), 159 - 163, Japanese

  • Hirotaka Shinomiya, Hitomi Shinomiya, Mie Kubo, Yuki Saito, Masafumi Yoshida, Mizuo Ando, Masanori Teshima, Naoki Otsuki, Naomi Kiyota, Ryohei Sasaki, Kenichi Nibu
    Dec. 2017, PLOS ONE, 12(12) (12), e0187992, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 根治切除不能な頭頸部扁平上皮癌における悪液質と予後の検討 JCOG0706副次的解析
    松塚 崇, 清田 尚臣, 水澤 純基, 秋元 哲夫, 長谷川 泰久, 岩江 信法, 門田 伸也, 松浦 一登, 小野澤 祐輔, 本間 明宏, 藤井 博文, 福田 治彦, 林 隆一, 田原 信
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P108 - 3, Japanese

  • 根治切除不能な頭頸部扁平上皮癌における悪液質と予後の検討 JCOG0706副次的解析
    松塚 崇, 清田 尚臣, 水澤 純基, 秋元 哲夫, 長谷川 泰久, 岩江 信法, 門田 伸也, 松浦 一登, 小野澤 祐輔, 本間 明宏, 藤井 博文, 福田 治彦, 林 隆一, 田原 信
    (一社)日本癌治療学会, Oct. 2017, 日本癌治療学会学術集会抄録集, 55回, P108 - 3, Japanese

  • Kenichiro Kakutani, Yoshitada Sakai, Koichiro Maeno, Toru Takada, Takashi Yurube, Takuto Kurakawa, Shingo Miyazaki, Yoshiki Terashima, Masaaki Ito, Hitomi Hara, Teruya Kawamoto, Yasuo Ejima, Akihiro Sakashita, Naomi Kiyota, Yoshiyuki Kizawa, Ryohei Sasaki, Toshihro Akisue, Hironobu Minami, Ryosuke Kuroda, Masahiro Kurosaka, Kotaro Nishida
    STUDY DESIGN: A prospective cohort study of performance status (PS) and activities of daily living (ADL) in patients with spinal metastasis. OBJECTIVE: To identify the effect of spinal surgery on PS and ADL in patients with spinal metastasis. SUMMARY OF BACKGROUND DATA: Spinal metastasis causes severe neurological deficits, resulting in drastic loss of patients' PS and ADL. However, the effect of spine surgery on PS and ADL is not well known. MATERIALS AND METHODS: Seventy patients with spinal metastasis were enrolled in this study. Forty-six patients desired and underwent spine surgery ("surgery" group) and 24 patients did not desire surgery ("nonsurgery" group). Both groups received optimal treatments, including radiation, chemotherapy, and palliative care services. Evaluation was performed at 1, 3, and 6 months after study enrollment using the Eastern Cooperative Oncology Group PS, the Barthel index (BI) for ADL, and Frankel classification for neurological status. RESULTS: There was no significant difference in baseline PS, the BI, or Frankel classification between the groups. The surgery group showed significant improvement in PS, maintaining grade 2 or less throughout the duration of the study, as well as in ADL, exceeding 70 points of the BI, compared with the nonsurgery group (P<0.05). Significantly improved neurological condition was also observed in the surgery group over the following 6 months. More than 95% of patients who underwent surgery improved their PS, the BI, and neurological status. Furthermore, >80% of these patients maintained improvement in PS, the BI, and neurological status for at least 6 months. In contrast, PS, the BI, and neurological status of patients in the "nonsurgery" group deteriorated throughout the study period. CONCLUSIONS: Spine surgery improves PS, ADL, and neurological status in patients with spinal metastasis for a minimum 6 months. This indicates that these patients can acquire an independent daily life.
    Oct. 2017, Clinical spine surgery, 30(8) (8), E1026-E1032, English, International magazine
    [Refereed]
    Scientific journal

  • Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi, Tomoya Yokota, Chia-Jui Yen, Shigemichi Iwae, Yasushi Shimizu, Ruey-Long Hong, Masahiro Goto, Jin-Hyoung Kang, Wing Sum Kenneth Li, Robert L. Ferris, Maura Gillison, Yoshinobu Namba, Manish Monga, Mark Lynch, Makoto Tahara
    Oct. 2017, ORAL ONCOLOGY, 73, 138 - 146, English, No password, Co-authored internationally
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • Petr Szturz, Kristien Wouters, Naomi Kiyota, Makoto Tahara, Kumar Prabhash, Vanita Noronha, Ana Castro, Lisa Licitra, David Adelstein, Jan B. Vermorken
    AlphaMed Press, Sep. 2017, Oncologist, 22(9) (9), 1056 - 1066, English, Co-authored internationally
    [Refereed]
    Scientific journal

  • Naomi Kiyota, Bruce Robinson, Manisha Shah, Ana O. Hoff, Matthew H. Taylor, Di Li, Corina E. Dutcus, Eun Kyung Lee, Sung-Bae Kim, Makoto Tahara
    Sep. 2017, THYROID, 27(9) (9), 1135 - 1141, English, No password, Co-authored internationally
    [Refereed]
    Scientific journal
    添付ファイルのURLLink to Kobe Univ. Repository (Kernel)

  • Kevin J. Harrington, Robert L. Ferris, George Blumenschein, A. Dimitrios Colevas, Jerome Fayette, Lisa Licitra, Stefan Kasper, Caroline Even, Everett E. Vokes, Francis Worden, Nabil F. Saba, Naomi Kiyota, Robert Haddad, Makoto Tahara, Viktor Gruenwald, James W. Shaw, Manish Monga, Mark Lynch, Fiona Taylor, Michael DeRosa, Laura Morrissey, Kim Cocks, Maura L. Gillison, Joel Guigay
    Aug. 2017, LANCET ONCOLOGY, 18(8) (8), 1104 - 1115, English, Co-authored internationally
    [Refereed]
    Scientific journal

  • Ken-ichi Nibu, Ryuichi Hayashi, Takahiro Asakage, Hiroya Ojiri, Yoshihiro Kimata, Takeshi Kodaira, Toshitaka Nagao, Torahiko Nakashima, Takashi Fujii, Hirofumi Fujii, Akihiro Homma, Kazuto Matsuura, Nobuya Monden, Takeshi Beppu, Nobuhiro Hanai, Tadaaki Kirita, Yuzuru Kamei, Naoki Otsuki, Naomi Kiyota, Sadamoto Zenda, Ken Omura, Koichi Omori, Tetsuo Akimoto, Kazuyoshi Kawabata, Seiji Kishimoto, Hiroya Kitano, Iwai Tohnai, Takashi Nakatsuka
    Aug. 2017, AURIS NASUS LARYNX, 44(4) (4), 375 - 380, English
    [Refereed]
    Scientific journal

  • Non-surgical treatment strategy for locally advanced laryngeal and hypopharyngeal cancer
    Naomi Kiyota
    Japanese Journal of Cancer and Chemotherapy Publishers Inc., Jul. 2017, Japanese Journal of Cancer and Chemotherapy, 44(7) (7), 575 - 578, Japanese
    [Refereed]
    Scientific journal

  • Shingo Miyazaki, Kenichiro Kakutani, Yoshitada Sakai, Yasuo Ejima, Koichiro Maeno, Toru Takada, Takashi Yurube, Yoshiki Terashima, Masaaki Ito, Yuji Kakiuchi, Yoshiki Takeoka, Hitomi Hara, Teruya Kawamoto, Akihiro Sakashita, Takuya Okada, Naomi Kiyota, Yoshiyuki Kizawa, Ryohei Sasaki, Toshihiro Akisue, Hironobu Minami, Ryosuke Kuroda, Kotaro Nishida
    Jun. 2017, INTERNATIONAL ORTHOPAEDICS, 41(6) (6), 1265 - 1271, English
    [Refereed]
    Scientific journal

  • Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara
    May 2017, JOURNAL OF CLINICAL ONCOLOGY, 35, English
    [Refereed]

  • 当院における嗅神経芽細胞腫症例の検討
    古川竜也, 大月直樹, 四宮弘隆, 森田成彦, 井之口豪, 古閑紀雄, Kiyota Naomi, 佐々木良平, 甲村英二, 丹生健一
    May 2017, 頭頸部癌, 43(2号) (2号), 205, Japanese
    [Refereed]

  • 個別化治療を目指した頭頸部癌診療ガイドライン 頭頸部がんに対する放射線治療の個別化 治療効果予測からの検討
    佐々木良平, 宮脇大輔, Kiyota Naomi, 大月直樹, 丹生健一
    (一社)日本頭頸部癌学会, May 2017, 頭頸部癌, 43(2号) (2号), 144 - 144, Japanese
    [Refereed][Invited]

  • 局所進行頭頸部扁平上皮癌における導入化学療法TPFの安全性と有効性の検討
    長谷善明, Kiyota Naomi, 今村善宜, 宮脇大輔, 佐々木良平, 四宮弘隆, 大月直樹, 丹生健一
    (一社)日本頭頸部癌学会, May 2017, 頭頸部癌, 43(2号) (2号), 177 - 177, Japanese
    [Refereed]

  • Susanne Singer, Susan Jordan, Laura D Locati, Monica Pinto, Iwona M Tomaszewska, Cláudia Araújo, Eva Hammerlid, E Vidhubala, Olga Husson, Naomi Kiyota, Christine Brannan, Dina Salem, Eva M Gamper, Juan Ignacio Arraras, Georgios Ioannidis, Guy Andry, Johanna Inhestern, Vincent Grégoire, Lisa Licitra
    Apr. 2017, Endocrine-related cancer, 24(4) (4), 197 - 207, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal

  • 高齢社会の癌薬物療法 高齢頭頸部癌患者に対する癌薬物療法
    Kiyota Naomi
    日本気管食道科学会, Apr. 2017, 日本気管食道科学会会報, 68(2号) (2号), 202 - 203, Japanese
    [Refereed][Invited]
    Scientific journal

  • Makoto Tahara, Martin Schlumberger, Rossella Elisei, Mouhammed Amir Habra, Naomi Kiyota, Ralf Paschke, Corina E. Dutcus, Taro Hihara, Shannon McGrath, Mark Matijevic, Tadashi Kadowaki, Yasuhiro Funahashi, Steven I. Sherman
    Apr. 2017, EUROPEAN JOURNAL OF CANCER, 75, 213 - 221, English, Co-authored internationally
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 転移・再発甲状腺がんに対する薬物療法
    Kiyota Naomi
    Apr. 2017, 日本内分泌・甲状腺外科学会雑誌, 34(Suppl.1) (Suppl.1), S45, Japanese
    [Invited]

  • 秋末敏宏, 酒井良忠, 松原伸晃, 中村直樹, 角谷賢一朗, 原仁美, 河本旭哉, 深瀬直政, 黒田良祐, Kiyota Naomi, Minami Hironobu
    (公社)日本整形外科学会, Mar. 2017, 日本整形外科学会雑誌, 91(3) (3), S1058 - S1058, Japanese
    [Invited]

  • Takeaki Ishihara, Kazuhiro Kitajima, Yuko Suenaga, Yasuo Ejima, Hirokazu Komatsu, Naoki Otsuki, Ken-Ichi Nibu, Naomi Kiyota, Satoru Takahashi, Ryohei Sasaki
    This study evaluated the prognostic significance of the maximum standardized uptake value of the primary site (pSUVmax) in 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scans of patients with oropharyngeal or hypopharyngeal cancer who were treated using definitive radiotherapy. The study included 86 patients who were primarily treated with radiotherapy for oropharyngeal or hypopharyngeal cancer. Sixty-nine patients underwent concurrent chemotherapy. The associations between pre-treatment pSUVmax and treatment outcomes were evaluated. The most appropriate pSUVmax cut-off value for predicting disease-free survival (DFS) and local control (LC) was selected using receiver operating characteristic (ROC) curves. The median follow-up time for surviving patients was 60 months, while the median survival time in the entire patient cohort was 55 months. A pSUVmax cut-off value of 9.0 showed the best discriminative performance. Five-year OS and DFS rates were 65.9% and 60.0%, respectively. In univariate analyses, pSUVmax (p = 0.009), T-stage (p = 0.001), N-stage (p = 0.039), and clinical stage (p = 0.017) were identified as significant prognostic predictors for DFS. The multivariate analysis did not identify any statistically significant factors, but the association between pSUVmax and DFS was borderline significant (p = 0.055). Interestingly, pSUVmax was predictive of local controllability in T1-T2 disease (p = 0.024), but there was no significant association for T3-T4 disease (p = 0.735). In this study, pSUVmax was predictive of DFS and LC in patients with oropharyngeal or hypopharyngeal cancer that was treated with definitive radiotherapy. pSUVmax was strongly associated with LC in T1-T2 disease.
    Feb. 2017, Nagoya journal of medical science, 79(1) (1), 27 - 36, English, Domestic magazine
    [Refereed]

  • 【頭頸部癌学-診断と治療の最新研究動向-】 頭頸部癌の治療 放射線治療・薬物治療 口腔・咽頭・喉頭癌 局所進行頭頸部癌に対する薬物療法 術後治療
    長谷善明, Kiyota Naomi
    Feb. 2017, 日本臨床, 75(増刊2 頭頸部癌学) (増刊2 頭頸部癌学), 451 - 456, Japanese
    [Refereed][Invited]
    Scientific journal

  • 当院におけるT3N0M0喉頭癌の放射線治療成績
    石原武明, 松尾圭朗, 西川遼, 宮脇大輔, 吉田賢史, 江島泰生, 佐々木良平, Kiyota Naomi, 森本浩一, 斉藤幹, 大月直樹, 丹生健一
    (公社)日本医学放射線学会, Feb. 2017, Japanese Journal of Radiology, 35(Suppl.) (Suppl.), 46 - 46, Japanese
    [Refereed]

  • Takeshi Fukumoto, Susumu Fujiwara, Masanobu Sakaguchi, Masahiro Oka, Naomi Kiyota, Yasuo Ejima, Koichi Nakajima, Chikako Nishigori
    John Libbey Eurotext, 2017, European Journal of Dermatology, 27(2) (2), 177 - 178, English
    [Refereed]
    Scientific journal

  • Makoto Tahara, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina E Dutcus, Shunji Takahashi
    BACKGROUND: Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic thyroid cancer (ATC), the subtype associated with the highest lethality. Effective therapy for ATC is an unmet need. PATIENTS AND METHODS: This phase 2, single-arm, open-label study in patients with thyroid cancer, including ATC, RR-DTC, and medullary thyroid cancer was conducted from 3 September 2012 to 9 July 2015. Patients received lenvatinib 24 mg daily until disease progression or development of unacceptable toxicity. The primary endpoint was safety, and the secondary endpoint was efficacy, as assessed by progression-free survival (PFS), overall survival (OS), and objective response rate. RESULTS: At data cutoff, 17 patients with ATC were enrolled. All experienced ≥1 treatment-emergent adverse event (TEAE). The most frequent TEAEs were decreased appetite (82%), hypertension (82%), fatigue (59%), nausea (59%), and proteinuria (59%). Of note, only one patient required lenvatinib withdrawal because of a TEAE, and this TEAE was considered unrelated to lenvatinib. The median PFS was 7.4 months [95% confidence interval (CI): 1.7-12.9], the median OS was 10.6 months (95% CI: 3.8-19.8), and the objective response rate was 24%. CONCLUSION: In this study, lenvatinib demonstrated manageable toxicities with dose adjustments and clinical activity in patients with ATC. This clinical activity of lenvatinib warrants further investigation in ATC. CLINICALTRIALSGOV: NCT01728623.
    2017, Frontiers in oncology, 7, 25 - 25, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Shunji Takahashi, Naomi Kiyota, Makoto Tahara
    The development of orally active, multitargeted kinase inhibitors (MKIs) represents a significant advance in the treatment of progressive, metastatic thyroid cancer. Lenvatinib, an MKI targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor, c-Kit, and RET, has shown efficacy in stabilizing previously progressive disease, with emerging evidence of a possible benefit in terms of overall survival. However, lenvatinib is associated with a side-effect profile similar to those of other MKIs that might affect the outcome of therapy. The aim of this review is to summarize the clinical efficacy and safety of MKIs in the treatment of advanced thyroid cancer in pivotal phase III trials. Common adverse events that may occur during lenvatinib therapy and their management are discussed, including conditions in which its administration should be temporarily withdrawn and resumed pending resolution of adverse events. We focus on data from a subanalysis of Japanese patients in the SELECT trial and in a post-marketing study in Japan. We suggest that lenvatinib is a valuable treatment option for advanced differentiated thyroid cancer. Monitoring and careful management of adverse events including supportive care are required to ensure continuation of therapy.
    2017, Cancers of the head & neck, 2(7) (7), 7 - 7, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 今村善宣, 清田尚臣, 大月直樹, 森本浩一, 四宮弘隆, 江島泰生, 南川勉, Sasaki Ryohei, 丹生健一
    (一社)日本頭頸部癌学会, Dec. 2016, 頭頸部癌, 42(4号) (4号), 432 - 437, Japanese
    [Refereed]
    Scientific journal

  • Tomoko Kataoka, Naomi Kiyota, Takanobu Shimada, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Yutaka Fujiwara, Ken-Ichi Nibu, Takahide Komori, Ryohei Sasaki, Toru Mukohara, Hironobu Minami
    OBJECTIVE: Radiation-induced mucositis (RIM) in chemoradiotherapy (CRT) for head and neck cancer (HNC) causes severe pain and worsens CRT compliance, QOL and outcome. Following retrospective reports, we conducted a randomized trial of the safety and efficacy of gabapentin for RIM-associated pain during CRT. METHODS: HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G). Gabapentin was maintained at 900mg/day for 4 weeks after CRT. Primary endpoint was maximum visual analogue scale (VAS) score during CRT, and secondary endpoints were total opioid dose, changes in QOL (EORTC QLQ-C30 and QLQ-HN 35) from baseline to 4 weeks after CRT, and adverse events. RESULTS: Twenty-two eligible Stage III or IV pts were randomly assigned to SPC or SPC+G (n=11 each). Twelve were treated in a locally advanced setting and 10 in a postoperative setting. Median maximum VAS scores, median total dose of opioids at maximum VAS and total dose of opioids at 4 weeks after CRT tended to be higher in the SPC+G arm (47 in SPC vs. 74 in SPC+G, p=0.517; 215mg vs. 745.3mg, p=0.880; and 1260mg vs. 1537.5mg, p=0.9438, respectively), without significance. QOL analysis showed significantly worse scores in the SPC+G arm for weight gain (p=0.005). Adverse events related to gabapentin were manageable. CONCLUSIONS: This pilot study is the first prospective randomized trial of gabapentin for RIM-related pain. Gabapentin had no apparent beneficial effect. Further research into agents for RIM-related pain is warranted.
    Corresponding, Dec. 2016, Auris, nasus, larynx, 43(6) (6), 677 - 84, English, No password, International magazine
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • Sadamoto Zenda, Takashi Kojima, Ken Kato, Sachiko Izumi, Taijiro Ozawa, Naomi Kiyota, Chikatoshi Katada, Takahiro Tsushima, Yoshinori Ito, Tetsuo Akimoto, Yasuhisa Hasegawa, Miyuki Kanamaru, Hiroyuki Daiko
    Dec. 2016, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 96(5) (5), 976 - 984, English
    [Refereed]
    Scientific journal

  • Susanne Singer, Olga Husson, Iwona M Tomaszewska, Laura D Locati, Naomi Kiyota, Ulrike Scheidemann-Wesp, Dirk Hofmeister, Melanie Winterbotham, Christine Brannan, Cláudia Araújo, Eva M Gamper, Dagmara Kulis, Harald Rimmele, Guy Andry, Lisa Licitra
    Nov. 2016, Thyroid : official journal of the American Thyroid Association, 26(11) (11), 1605 - 1613, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal

  • R. L. Ferris, G. Blumenschein, J. Fayette, J. Guigay, A. D. Colevas, L. Licitra, K. Harrington, S. Kasper, E. E. Vokes, C. Even, F. Worden, N. F. Saba, L. C. Iglesias Docampo, R. Haddad, T. Rordorf, N. Kiyota, M. Tahara, M. Monga, M. Lynch, W. J. Geese, J. Kopit, J. W. Shaw, M. L. Gillison
    Nov. 2016, NEW ENGLAND JOURNAL OF MEDICINE, 375(19) (19), 1856 - 1867, English, Co-authored internationally
    [Refereed]
    Scientific journal

  • 頭頸・口腔 頭頸部がんに対する治療戦略 再発性または転移性(R/M)頭頸部扁平上皮癌(HNSCC)に対するnivolumab療法と検査者選択療法の比較(Nivolumab vs investigator's choice for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC))
    高橋 俊二, 清田 尚臣, 長谷川 泰久, 横田 知哉, 岩江 信法, 清水 康, 後藤 昌弘, 灘波 良信, Ferris Robert L., Monga Manish, 田原 信
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, MS29 - 1, English

  • 頭頸・口腔 頭頸部がんに対する治療戦略 再発・転移頭頸部癌に対するPaclitaxel+Carboplatin+Cetuximab療法の第II相試験
    清田 尚臣, 横田 知哉, 長谷川 泰久, 室 圭, 高橋 俊二, 尾上 琢磨, 本間 明宏, 鈴木 政美, 家根 旦有, 原 浩樹, 西條 憲, 山中 竹春, 田原 信
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, WS80 - 1, Japanese

  • Phase 2 Trial of Bi-weekly Cetuximab for Recurrent or Metastatic Colorectal Cancer (BIC-K Trial)
    Naoko Chayahara, Naomi Kiyota, Masanori Toyoda, Toru Mukohara, Yoshimi Fujishima, Akihito Tsuji, Hironaga Satake, Sahchiko Kimura, Masahito Kotaka, Hironobu Minami
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    [Refereed]

  • Hironaga Satake, Makoto Tahara, Satoshi Mochizuki, Ken Kato, Hiroki Hara, Tomoya Yokota, Naomi Kiyota, Takayuki Kii, Keisho Chin, Sadamoto Zenda, Takashi Kojima, Hideaki Bando, Tomoko Yamazaki, Satoru Iwasa, Yoshitaka Honma, Satoru Hamauchi, Takahiro Tsushima, Atsushi Ohtsu
    Jul. 2016, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 78(1) (1), 91 - 99, English
    [Refereed]
    Scientific journal

  • Meiko Nishimura, Masanori Toyoda, Kei Takenaka, Yoshinori Imamura, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Takeshi Kotake, Akihito Tsuji, Kosuke Saito, Yoshiro Saito, Hironobu Minami
    Jun. 2016, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 77(6) (6), 1165 - 1170, English
    [Refereed]
    Scientific journal

  • 同時併用化学放射線療法を施行した進行期喉頭癌、下咽頭癌症例におけるTalk Scoreの検討
    高橋美貴, 松井美緒, 涌井絵美, 清田尚臣, Sasaki Ryohei, 大月直樹, 宇佐美眞, 丹生健一
    May 2016, 頭頸部癌, 42(2号) (2号), 181, Japanese
    Research society

  • 当科で放射線治療を施行した下咽頭癌T1・T2症例の検討
    古川竜也, 大月直樹, 四宮弘隆, 小松弘和, 森本浩一, 清田尚臣, Sasaki Ryohei, 丹生健一
    May 2016, 頭頸部癌, 42(2号) (2号), 181, Japanese
    Research society

  • 舌癌術後再発症例に対する放射線治療成績
    Miyawaki Daisuke, 江島泰生, 吉田賢史, 石原武明, 西川遼, 清田尚臣, 南川勉, 大月直樹, 丹生健一, Sasaki Ryohei
    (一社)日本頭頸部癌学会, May 2016, 頭頸部癌, 42(2号) (2号), 207 - 207, Japanese
    [Refereed]
    Research society

  • セツキシマブ追加の有無による、再発性/転移性頭頸部癌の第一選択治療の比較(First-line Treatment of Recurrent/Metastatic Head and Neck Cancer with or without Cetuximab)(英語)
    今村善宣, 清田尚臣, 大月直樹, 森本浩一, 四宮弘隆, 江島泰生, 吉田賢史, 南川勉, Sasaki Ryohei, 丹生健一
    May 2016, 頭頸部癌, 42(2号) (2号), 211, Japanese
    Research society

  • Yuko Suenaga, Kazuhiro Kitajima, Takeaki Ishihara, Ryohei Sasaki, Naoki Otsuki, Ken-ichi Nibu, Tsutomu Minamikawa, Naomi Kiyota, Kazuro Sugimura
    Springer Verlag, Apr. 2016, European Radiology, 26(4) (4), 1018 - 1030, English
    [Refereed]
    Scientific journal

  • Hirotaka Shinomiya, Shingo Hasegawa, Daisuke Yamashita, Yasuo Ejima, Yoshida Kenji, Naoki Otsuki, Naomi Kiyota, Shunsuke Sakakibara, Tadashi Nomura, Kazunobu Hashikawa, Eiji Kohmura, Ryohei Sasaki, Ken-Ichi Nibu
    BACKGROUND: The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF). METHODS: Between 2006 and 2011, 34 patients with squamous cell carcinoma of the temporal bone were treated at Kobe University Hospital. Medical records were retrospectively reviewed to obtain information concerning patient characteristics, extent of disease, treatment, adverse events, and oncologic results. RESULTS: Ten patients were treated with CCRT using TPF regimen. The 5-year overall survival rate and disease-free survival rate were both 60%. Of special interest is that even for patients with unresectable T4 disease, the 5-year overall survival rate was 56%. CONCLUSION: The results of our study indicate that CCRT with TPF for locally advanced temporal bone cancer is an effective and promising regimen. © 2015 Wiley Periodicals, Inc. Head Neck 38: E949-E953, 2016.
    Apr. 2016, Head & neck, 38 Suppl 1, E949-53, English, International magazine
    [Refereed]
    Scientific journal

  • Shinomiya Hitomi, Ohtsuki Naoki, 山下大介, 四宮弘隆, 手島直則, Ejima Yasuo, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    (一社)日本頭頸部癌学会, Apr. 2016, 頭頸部癌, 42(1号) (1号), 51 - 56, Japanese
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Yutaka Fujiwara, Naomi Kiyota, Toru Mukohara, Takanobu Shimada, Masanori Toyoda, Yoshinori Imamura, Naoko Chayahara, Hideo Tomioka, Michio Umezu, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
    Feb. 2016, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 77(2) (2), 281 - 288, English
    [Refereed]
    Scientific journal

  • Kiyota, N.
    2016, Otolaryngology - Head and Neck Surgery (Japan), 88(2) (2)
    Scientific journal

  • Yoshinori Imamura, Naomi Kiyota, Naoki Otsuki, Koichi Morimoto, Hirotaka Shinomiya, Yasuo Ejima, Tsutomu Minamikawa, Ryohei Sasaki, Ken-Ichi Nibu
    Japan Society for Head and Neck Cancer, 2016, Japanese Journal of Head and Neck Cancer, 42(4) (4), 432 - 437, Japanese
    [Refereed]
    Scientific journal

  • Hitomi Shinomiya, Naoki Otsuki, Daisuke Yamashita, Hirotaka Shinomiya, Masanori Teshima, Yasuo Ejima, Naomi Kiyota, Ryohei Sasaki, Ken-Ichi Nibu
    Japan Society for Head and Neck Cancer, 2016, Japanese Journal of Head and Neck Cancer, 42(1) (1), 51 - 56, Japanese
    [Refereed]
    Scientific journal

  • Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    Oxford University Press, 2016, Japanese Journal of Clinical Oncology, 46(5) (5), 448 - 452, English
    [Refereed]
    Scientific journal

  • Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara
    Dec. 2015, CANCER SCIENCE, 106(12) (12), 1714 - 1721, English, No password, Co-authored internationally
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • Susanne Singer, Cláudia Araújo, Juan Ignacio Arraras, Ingo Baumann, Andreas Boehm, Bente Brokstad Herlofson, Joaquim Castro Silva, Wei-Chu Chie, Sheila Fisher, Orlando Guntinas-Lichius, Eva Hammerlid, María Elisa Irarrázaval, Marianne Jensen Hjermstad, Kenneth Jensen, Naomi Kiyota, Lisa Licitra, Ourania Nicolatou-Galitis, Monica Pinto, Marcos Santos, Claudia Schmalz, Allen C Sherman, Iwona M Tomaszewska, Irma Verdonck de Leeuw, Noam Yarom, Paola Zotti, Dirk Hofmeister
    John Wiley and Sons Inc., Sep. 2015, Head & neck, 37(9) (9), 1358 - 67, English, International magazine, Co-authored internationally
    [Refereed]
    Scientific journal

  • TakenakaK, Mukohara Toru, HiraiC, FunakoshiY, NakamuraY, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, ItohT, Yokozaki Hiroshi, MinamiH
    We report a mediastinal germ cell tumor (GCT) that exhibited a discrepancy between the time course of serum human chorionic gonadotropin (hCG) levels and clinical consequences. An otherwise healthy man, aged 34 years, was diagnosed with a nonseminomatous GCT, most likely embryonal carcinoma (EC), based on a mediastinal tumor biopsy. Standard chemotherapy resulted in an optimal decrease in serum hCG levels. However, multiple lesions in the liver continued to enlarge, which led to his death. Autopsy revealed few viable tumor cells in the liver, with the great majority of the tumor cells appearing to have undergone necrosis, suggesting that they responded to the chemotherapy. The residual tumor cells in the mediastinum and the liver were similar to syncytiotrophoblast cells, suggesting a choriocarcinoma (CC). On immunohistochemical analysis, the mediastinal tumor cells in the diagnostic biopsy specimen expressed both CD30 and hCG, whereas residual mediastinal and hepatic tumor cells in the autopsy specimen after chemotherapy also expressed hCG, but not CD30. These findings suggested that the patient suffered from a primary mixed GCT consisting of an EC and a CC. Both pre- and postchemotherapy tumors strongly expressed matrix metalloproteinase-2, supporting the aggressive and invasive features of the tumor phenotype. We speculate that the extremely invasive tumor destroyed normal liver structure, whereas chemotherapy and central necrosis reduced the number of viable cells themselves, causing a discordant decrease in serum hCG levels.
    S. Karger AG, Aug. 2015, Case Rep Oncol, 8(2) (2), 323 - 31, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • III. Molecular targeting treatment for thyroid cancer
    Naomi Kiyota
    Japanese Journal of Cancer and Chemotherapy Publishers Inc., Jul. 2015, Japanese Journal of Cancer and Chemotherapy, 42(7) (7), 806 - 809, Japanese
    [Refereed]
    Scientific journal

  • Makoto Tahara, Naomi Kiyota, Junki Mizusawa, Kenichi Nakamura, Ryuichi Hayashi, Tetsuo Akimoto, Yasuhisa Hasegawa, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Hirofumi Fujii, Yusuke Onozawa, Akira Homma, Akira Kubota, Haruhiko Fukuda, Masato Fujii
    Blackwell Publishing Ltd, Jun. 2015, Cancer Science, 106(6) (6), 726 - 733, English
    [Refereed]
    Scientific journal

  • Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette, Lisa F. Licitra, Makoto Tahara, Jan B. Vermorken, Paul M. Clement, Thomas Gauler, Didier Cupissol, Juan José Grau, Joël Guigay, Francesco Caponigro, Gilberto de Castro, Luciano de Souza Viana, Ulrich Keilholz, Joseph M. del Campo, Xiuyu Julie Cong, Eva Ehrnrooth, Ezra E. W. Cohen, for the LUX-H&N 1 investigators
    Lancet Publishing Group, May 2015, The Lancet. Oncology, 16(5) (5), 583 - 594, English
    Scientific journal

  • 甲状腺がん 2015年の甲状腺がんの治療 甲状腺がんに対する分子標的療法(Thyroid Cancer: Treatment of Thyroid Cancer 2015 Molecular Targeted Treatment for Thyroid Cancer)
    Kiyota Naomi, Otsuki Naoki, Imamura Yoshinori, Sasaki Ryohei, Nibu Ken-ichi, Minami Hironobu
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 98 - 98, English

  • プラチナ薬剤抵抗性の頭頸部がんに関する炎症スコアの予後的な意義(Prognostic Value of the Inflammation Scores for Platinum Refractory Head and Neck Cancer)
    Imamura Yoshinori, Kiyota Naomi, Otsuki Naoki, Saito Miki, Morimoto Koichi, Komatsu Hirokazu, Ejima Yasuo, Yoshida Kenji, Miyawaki Daisuke, Uezono Haruka, Ishihara Takeaki, Minamikawa Tsutomu, Sasaki Ryohei, Nibu Ken-ichi
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 136 - 136, English

  • Yoshinori Imamura, Toru Mukohara, Yohei Shimono, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Shintaro Takao, Seishi Kono, Tetsuya Nakatsura, Hironobu Minami
    Apr. 2015, ONCOLOGY REPORTS, 33(4) (4), 1837 - 1843, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
    西村 明子, 清田 尚臣, 豊田 昌徳, 茶屋原 菜穂子, 竹中 圭, 瓜生 恭章, 今村 善宣, 船越 洋平, 向原 徹, 南 博信
    (一社)日本内科学会, Feb. 2015, 日本内科学会雑誌, 104(臨増) (臨増), 282 - 282, Japanese

  • [Concurrent chemoradiotherapy with cisplatin for locally advanced squamous cell carcinoma of head and neck].
    Kiyota N
    Feb. 2015, Nihon rinsho. Japanese journal of clinical medicine
    Scientific journal

  • Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew H. Taylor, Sung-Bae Kim, Monika K. Krzyzanowska, Corina E. Dutcus, Begona de las Heras, Junming Zhu, Steven I. Sherman
    Feb. 2015, NEW ENGLAND JOURNAL OF MEDICINE, 372(7) (7), 621 - 630, English, Co-authored internationally
    [Refereed]
    Scientific journal

  • Takanobu Shimada, Naomi Kiyota, Yosinori Imamura, Koichi Morimoto, Miki Saito, Hideki Nishimura, Naoki Otsuki, Ryohei Sasaki, Ken-Ichi Nibu
    Japan Society for Head and Neck Cancer, Jan. 2015, Japanese Journal of Head and Neck Cancer, 40(4) (4), 490 - 496, Japanese
    [Refereed]
    Scientific journal

  • Naoki Otsuki, Hirotaka Shinomiya, Hirokazu Komatsu, Koichi Morimoto, Miki Saito, Naomi Kiyota, Ryohe Sasaki, Ken-Ichi Nibu
    Japan Society for Head and Neck Cancer, Jan. 2015, Japanese Journal of Head and Neck Cancer, 40(4) (4), 406 - 411, Japanese
    [Refereed]
    Scientific journal

  • Kiyota, N.
    2015, Nihon rinsho. Japanese journal of clinical medicine, 73
    Scientific journal

  • Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette, Lisa F. Licitra, Makoto Tahara, Jan B. Vermorken, Paul M. Clement, Thomas Gauler, Didier Cupissol, Juan José Grau, Joël Guigay, Francesco Caponigro, Gilberto de Castro, Luciano de Souza Viana, Ulrich Keilholz, Joseph M. del Campo, Xiuyu Julie Cong, Eva Ehrnrooth, Ezra E. W. Cohen, for the LUX-H&N 1 investigators
    Lancet Publishing Group, 2015, The Lancet. Oncology, 16(5) (5), 583 - 594, English
    Scientific journal

  • Naomi Kiyota, Makoto Tahara, Masato Fujii
    Jan. 2015, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45(1) (1), 2 - 6, English, No password
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • 頭頸部進行がんに対する治療戦略 進行期(Stage III/IV)喉頭癌・下咽頭癌の治療戦略
    大月 直樹, 四宮 弘隆, 小松 弘和, Morimoto Koichi, 齋藤 幹, Kiyota Naomi, 佐々木 良平, Nibu Ken-ichi
    Dec. 2014, 頭頸部癌, 40(4号) (4号), 406 - 411, Japanese
    [Refereed]
    Scientific journal

  • 当院における再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用(DC)療法の遡及的解析
    島田 貴信, Kiyota Naomi, 今村 善宣, Morimoto Koichi, 斉藤 幹, 西村 英輝, 大月 直樹, 佐々木 良平, Nibu Ken-ichi
    Dec. 2014, 頭頸部癌, 40(4号) (4号), 490 - 496, Japanese
    [Refereed]
    Scientific journal

  • Yutaka Fujiwara, Takashi Kobayashi, Naoko Chayahara, Yoshinori Imamura, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Shin Nishiumi, Takeshi Azuma, Masaru Yoshida, Hironobu Minami, Antonio Gonzalez-Bulnes
    Public Library of Science ({PLoS}), Nov. 2014, PLoS ONE, 9(11) (11), e113259, English
    [Refereed]
    Scientific journal

  • Naomi Kiyota
    Japan Society for Head and Neck Cancer, Oct. 2014, Japanese Journal of Head and Neck Cancer, 40(3) (3), 294 - 296, Japanese
    [Refereed]
    Scientific journal

  • 頭頸部がん治療医の養成の現状と今後の方向について 腫瘍内科医の立場から
    Kiyota Naomi
    Oct. 2014, 頭頸部癌, 40(3号) (3号), 294 - 296, Japanese
    [Refereed][Invited]
    Scientific journal

  • S. Takahashi, M. Tahara, N. Kiyota, T. Yamazaki, N. Chayahara, K. Nakano, R. Inagaki, K. Toda, T. Enokida, H. Minami, Y. Imamura, T. Sasaki, T. Suzuki, K. Fujino, C. Dutcus
    Elsevier BV, Sep. 2014, Annals of Oncology, 25, iv343 - iv343
    Scientific journal

  • 進行甲状腺癌の治療戦略 進行性甲状腺癌(放射性ヨウ素治療抵抗性の分化癌、髄様癌、未分化癌)に対するレンバチニブの第2相試験
    Kiyota Naomi, 田原 信, 高橋 俊二, Chayahara Naoko, 山崎 知子, Minami Hironobu, 今村 善宣, 榎田 智弘, 仲野 兼司, 稲垣 里奈, 戸田 和寿, 佐々木 達哉, 鈴木 拓也, 藤野 克樹, Dutcus Corina E
    日本内分泌外科学会・日本甲状腺外科学会, Sep. 2014, 日本内分泌・甲状腺外科学会雑誌, 31(Suppl.2) (Suppl.2), S217 - S217, Japanese

  • 治療前FDG-PETによる喉頭癌の再発予測
    北島 一宏, 末永 裕子, 奥永 崇志, 久保 和広, 佐々木 良平, 丹生 健一, Kiyota Naomi, 杉村 和朗
    Sep. 2014, 核医学, 51(3号) (3号), 265, Japanese

  • 甲状腺がんに対する分子標的薬の適正使用と副作用管理について
    Kiyota Naomi
    Sep. 2014, 日本内分泌・甲状腺外科学会雑誌, 31(Suppl.2) (Suppl.2), S192, Japanese

  • Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Takanobu Shimada, Yoshinori Imamura, Toru Mukohara, Hironobu Minami
    Aug. 2014, PLOS ONE, 9(8) (8), e104215, English
    [Refereed]
    Scientific journal

  • TYRO3 as a Potential Therapeutic Target in Breast Cancer
    Roudy Chiminch Ekyalongo, Toru Mukohara, Yohei Funakoshi, Hideo Tomioka, Yu Kataoka, Yohei Shimono, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Hironobu Minami
    Jul. 2014, ANTICANCER RESEARCH, 34(7) (7), 3337 - 3345, English
    [Refereed]
    Scientific journal

  • Kazuhiro Kitajima, Yuko Suenaga, Tomonori Kanda, Daisuke Miyawaki, Kenji Yoshida, Yasuo Ejima, Ryohei Sasaki, Hirokazu Komatsu, Miki Saito, Naoki Otsuki, Ken-ichi Nibu, Naomi Kiyota, Tsutomu Minamikawa, Kazuro Sugimura
    May 2014, PLOS ONE, 9(5) (5), e96999, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 免疫組織化学染色による唾液腺導管癌15例の検討
    今村 善宣, Kiyota Naomi, 大月 直樹, 山下 大介, 佐々木 良平, 丹生 健一
    May 2014, 頭頸部癌, 40(2号) (2号), 186, Japanese

  • 頭頸部進行がんに対する治療戦略 進行期喉頭癌・下咽頭癌に対する治療戦略
    大月 直樹, 四宮 弘隆, 小松 弘和, 森本 浩一, 齋藤 幹, Kiyota Naomi, 佐々木 良平, 丹生 健一
    May 2014, 頭頸部癌, 40(2号) (2号), 148, Japanese

  • 頭頸部癌に対するセツキシマブ併用放射線治療の初期経験
    上薗 玄, Ejima Yasuo, Miyawaki Daisuke, 四宮 弘隆, 小松 弘和, 藤尾 久美, 森本 浩一, 今村 善宣, 斉藤 幹, 大月 直樹, Kiyota Naomi, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2014, 頭頸部癌, 40(2号) (2号), 265 - 265, Japanese

  • 頭頸部がん治療医の養成の現状と今後の方向について_腫瘍内科医の立場から
    Kiyota Naomi
    May 2014, 頭頸部癌, 40(2号) (2号), 136, Japanese

  • 中咽頭癌に対する化学放射線療法におけるPEG留置患者の栄養投与量と有害事象
    高橋 美貴, 小坂 奈々, 宇佐美 眞, 中川 絵美, 齋藤 幹, 大月 直樹, Ejima Yasuo, Miyawaki Daisuke, 佐々木 良平, Kiyota Naomi, 丹生 健一
    (一社)日本頭頸部癌学会, May 2014, 頭頸部癌, 40(2号) (2号), 238 - 238, Japanese

  • T3N0-1声門癌に対する喉頭温存を目的とした根治的化学放射線治療の検討
    佐々木 良平, 松尾 圭朗, Ejima Yasuo, Miyawaki Daisuke, 上薗 玄, 今村 善宣, Kiyota Naomi, 四宮 弘隆, 小松 弘和, 森本 浩一, 斉藤 幹, 大月 直樹, 丹生 健一
    (一社)日本頭頸部癌学会, May 2014, 頭頸部癌, 40(2号) (2号), 155 - 155, Japanese

  • 当院における唾液腺導管癌15例の臨床病理学的検討
    今村 善宣, Kiyota Naomi, 大月 直樹, 平井 千浦子, Toyoda Masanori, Chayahara Naoko, 船越 洋平, 向原 徹, 丹生 健一, Minami Hironobu
    Feb. 2014, 日本内科学会雑誌, 103(Suppl.) (Suppl.), 253, Japanese

  • Shiro Kimbara, Yutaka Fujiwara, Masanori Toyoda, Naoko Chayahara, Yoshinori Imamura, Naomi Kiyota, Toru Mukohara, Atsushi Fukunaga, Masahiro Oka, Chikako Nishigori, Hironobu Minami
    Springer-Verlag Tokyo, 2014, Clinical Journal of Gastroenterology, 7(3) (3), 255 - 259, English
    [Refereed]
    Scientific journal

  • Yasuhide Yamada, Naomi Kiyota, Nozomu Fuse, Ken Kato, Hironobu Minami, Kensei Hashizume, Yoshihiro Kuroki, Yuichiro Ito, Atsushi Ohtsu
    Jan. 2014, GASTRIC CANCER, 17(1) (1), 161 - 172, English
    [Refereed]
    Scientific journal

  • Futoshi Kunieda, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Satoshi Ishikura, Junki Mizusawa, Kenichi Nakamura, Haruhiko Fukuda, Masato Fujii
    Oxford University Press, 2014, Japanese Journal of Clinical Oncology, 44(8) (8), 770 - 774, English
    [Refereed]
    Scientific journal

  • 乳癌における新規治療標的としてのTyro3(Tyro3 as a potential therapeutic target in breast cancer)
    エキャロンゴ・ルーディ・チミンチ, 向原 徹, 船越 洋平, 富岡 秀夫, 片岡 優, 豊田 昌徳, 清田 尚臣, 南 博信
    (一社)日本癌学会, Oct. 2013, 日本癌学会総会記事, 72回, 484 - 484, English

  • Yutaka Fujiwara, Naoko Chayahara, Toru Mukohara, Naomi Kiyota, Hideo Tomioka, Yohei Funakoshi, Hironobu Minami
    Oct. 2013, Oncology Reports, 30(4) (4), 1802 - 1806, English
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Toru Mukohara, Hideo Tomioka, Roudy Chiminch Ekyalongo, Yu Kataoka, Yumiko Inui, Yuriko Kawamori, Masanori Toyoda, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
    Oct. 2013, INVESTIGATIONAL NEW DRUGS, 31(5) (5), 1158 - 1168, English
    [Refereed]
    Scientific journal

  • 進行喉頭癌に対する喉頭温存療法の後ろ向き多施設共同研究
    藤井 正人, 本間 明宏, 藤本 保志, 太田 一郎, 林 隆一, 田原 信, 大上 研二, 岩江 信法, 大月 直樹, 清田 尚臣, 西野 宏, 鬼塚 哲郎
    (一社)日本癌治療学会, Sep. 2013, 日本癌治療学会誌, 48(3) (3), 2164 - 2164, Japanese

  • 当院における唾液腺導管癌15例の臨床病理学的特徴
    今村 善宣, Kiyota Naomi, 大月 直樹, 島田 貴信, 山下 大介, Sasaki Ryohei, 丹生 健一
    May 2013, 頭頸部癌, 39(2号) (2号), 233, Japanese
    Research society

  • 再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用(DC)療法
    島田 貴信, Kiyota Naomi, 今村 善宣, Morimoto Koichi, 斎藤 幹, 西村 英輝, Sasaki Ryohei, 大月 直樹, 丹生 健一
    May 2013, 頭頸部癌, 39(2号) (2号), 194, Japanese

  • 頸部リンパ節転移を認めた原発不明悪性黒色腫の2例
    米澤 宏一郎, Morimoto Koichi, 山下 大介, 谷本 均, 齋藤 幹, Ohtsuki Naoki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    Apr. 2013, 頭頸部癌, 39(1号) (1号), 72 - 76, Japanese
    [Refereed]
    Scientific journal

  • Roudy Chiminch Ekyalongo, Toru Mukohara, Yu Kataoka, Yohei Funakoshi, Hideo Tomioka, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
    Apr. 2013, INVESTIGATIONAL NEW DRUGS, 31(2) (2), 293 - 303, English
    [Refereed]
    Scientific journal

  • Yutaka Fujiwara, Yuichi Ando, Toru Mukohara, Naomi Kiyota, Naoko Chayahara, Ayako Mitsuma, Megumi Inada-Inoue, Masataka Sawaki, Robert Ilaria, P. Kellie Turner, Jumpei Funai, Kaijiro Maeda, Hironobu Minami
    Apr. 2013, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 71(4) (4), 991 - 998, English
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Yutaka Fujiwara, Naomi Kiyota, Toru Mukohara, Takanobu Shimada, Masanori Toyoda, Yoshinori Imamura, Naoko Chayahara, Michio Umezu, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
    Mar. 2013, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 43(3) (3), 271 - 277, English
    [Refereed]
    Scientific journal

  • 局所進行食道癌に対する化学放射線治療
    小田 麻生, 西村 英輝, 吉田 賢史, Miyawaki Daisuke, 村岡 修, 原田 文, ノル・シャズリナ・ビンティ・スライマン, Sasaki Ryohei, 奥野 達哉, Kiyota Naomi
    (公社)日本医学放射線学会, Feb. 2013, Japanese Journal of Radiology, 31(Suppl.I) (Suppl.I), 51 - 51, Japanese
    [Refereed]

  • Kiyota, N.
    2013, Otolaryngology - Head and Neck Surgery (Japan), 85(7) (7)
    Scientific journal

  • Koichiro Yonezawa, Koichi Morimoto, Daisuke Yamashita, Hitoshi Tanimoto, Miki Saito, Naoki Otsuki, Naomi Kiyota, Ryohei Sasaki, Ken-ichi Nibu
    Japan Society for Head and Neck Cancer, 2013, Japanese Journal of Head and Neck Cancer, 39(1) (1), 72 - 76, Japanese
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Toru Mukohara, Roudy Chiminch Ekyalongo, Hideo Tomioka, Yu Kataoka, Yohei Shimono, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
    Cognizant Communication Corporation, 2013, Oncology Research, 21(6) (6), 287 - 293, English
    [Refereed]
    Scientific journal

  • Hideki Nishimura, Ryohei Sasaki, Kenji Yoshida, Daisuke Miyawaki, Yoshiaki Okamoto, Naomi Kiyota, Miki Saito, Naoki Otsuki, Ken-ichi Nibu
    Nov. 2012, JOURNAL OF RADIATION RESEARCH, 53(6) (6), 892 - 899, English
    [Refereed]
    Scientific journal

  • Sachi Morita, Satoshi Oizumi, Hironobu Minami, Koichi Kitagawa, Yoshito Komatsu, Yutaka Fujiwara, Megumi Inada, Satoshi Yuki, Naomi Kiyota, Ayako Mitsuma, Masataka Sawaki, Hiromi Tanii, Junko Kimura, Yuichi Ando
    Oct. 2012, INVESTIGATIONAL NEW DRUGS, 30(5) (5), 1950 - 1957, English
    Scientific journal

  • 嗄声を発症した横行結腸がん同時性肝転移術後の1例
    Kiyota Naomi
    科学評論社, Oct. 2012, 腫瘍内科, 10(4号) (4号), 372 - 377, Japanese
    [Refereed][Invited]
    Scientific journal

  • 切除不能頭頸部癌に対するSequential therapyの安全性に関する後向き研究
    Kiyota Naomi, Ohtsuki Naoki, Sasaki Ryohei, Nibu Ken-ichi
    Oct. 2012, 頭頸部癌, 38(3号) (3号), 374 - 379, Japanese
    [Refereed]
    Scientific journal

  • Naomi Kiyota, Makoto Tahara, Susumu Okano, Mitsuhiko Kawashima, Kazuto Matsuura, Yuske Onozawa, Kenichi Nibu, Ryuichi Hayashi, Kenichi Yoshimura, Atsushi Ohtsu
    Lead, Oct. 2012, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 42(10) (10), 927 - 933, English, No password
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • 頭頸部がん治療の過去と未来 頭頸部がんの分子標的治療について
    Kiyota Naomi
    Oct. 2012, 日本癌治療学会誌, 47(3号) (3号), 723, Japanese

  • Yu Kataoka, Toru Mukohara, Hideo Tomioka, Yohei Funakoshi, Naomi Kiyota, Yutaka Fujiwara, Masakazu Yashiro, Kosei Hirakawa, Midori Hirai, Hironobu Minami
    Aug. 2012, Investigational New Drugs, 30(4) (4), 1352 - 1360, English
    [Refereed]
    Scientific journal

  • MCF-7乳癌細胞株におけるinsulin-like growth factor 1 receptor阻害薬に対する獲得耐性機構(Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line)(英語)
    エキャロンゴ・ルーディー・チミンチ, 向原 徹, 片岡 優, 船越 洋平, 富岡 秀夫, Kiyota Naomi, 藤原 豊, 南 博信
    Aug. 2012, 日本癌学会総会記事, (71回) (71回), 335, Japanese
    Research society

  • Hideo Tomioka, Toru Mukohara, Yu Kataoka, Roudy Chiminch Ekyalongo, Yohei Funakoshi, Yasuo Imai, Naomi Kiyota, Yutaka Fujiwara, Hironobu Minami
    Aug. 2012, INTERNATIONAL JOURNAL OF ONCOLOGY, 41(2) (2), 551 - 558, English
    [Refereed]
    Scientific journal

  • Yutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, Akiyuki Suzuki, Yoshiko Umeyama, Toru Mukohara, Hironobu Minami
    Jun. 2012, INVESTIGATIONAL NEW DRUGS, 30(3) (3), 1055 - 1064, English
    [Refereed]
    Scientific journal

  • 抗がん薬投与におけるeGFRの有用性の検討
    Fujiwara Yutaka, Toyoda Masanori, Chayahara Naoko, Kiyota Naomi, Umezu Michio, Mukohara Toru, Minami Hironobu
    Feb. 2012, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 192, Japanese
    [Refereed]
    Research society

  • Naomi Kiyota
    Japan Society for Head and Neck Cancer, 2012, Japanese Journal of Head and Neck Cancer, 38(4) (4), 399 - 402, Japanese
    [Refereed]
    Scientific journal

  • Takanobu Shimada, Naomi Kiyota, Hideki Nishimura, Naoki Otsuki, Ryohei Sasaki, Ken-ichi Nibu
    2012, Japanese Journal of Head and Neck Cancer, 38(3) (3), 374 - 379, Japanese
    [Refereed]
    Scientific journal

  • Atsuo Okamura, Kimikazu Yakushijin, Yumiko Inui, Yohei Funakoshi, Yuriko Kawamori, Takanobu Shimada, Masanori Toyoda, Naoko Chayahara, Naomi Kiyota, Yutaka Fujiwara, Toru Mukohara, Hiroshi Matsuoka, Katsuya Yamamoto, Hironobu Minami
    Jun. 2011, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(6) (6), 765 - 770, English
    [Refereed]
    Scientific journal

  • Nishimura Hideki, Miyawaki Daisuke, Ohtsuki Naoki, Kiyota Naomi
    (一社)日本頭頸部癌学会, Apr. 2011, 頭頸部癌, 37巻, 1号, pp. 62-66(1) (1), 62 - 66, Japanese
    [Refereed]
    Scientific journal

  • Hideki Nishimura, Ryohei Sasaki, Takeshi Yoshida, Daisuke Miyawaki, Naki Otsuki, Miki Sitou, Naomi Kiyota, Synsuke Soejima, Kajurou Sugimura, Ken-ichi Nibu
    2011, Japanese Journal of Head and Neck Cancer, 37(1) (1), 62 - 66, Japanese
    [Refereed]
    Scientific journal

  • Naomi Kiyota
    2011, Japanese Journal of Head and Neck Cancer, 37(3) (3), 362 - 365, Japanese
    [Refereed]
    Scientific journal

  • M. Tahara, K. Araki, S. Okano, N. Kiyota, N. Fuse, K. Minashi, T. Yoshino, T. Doi, S. Zenda, M. Kawashima, T. Ogino, R. Hayashi, H. Minami, A. Ohtsu
    Jan. 2011, ANNALS OF ONCOLOGY, 22(1) (1), 175 - 180, English
    [Refereed]
    Scientific journal

  • 下咽頭癌に対する術後放射線治療の遡及的検討
    Nishimura Hideki, Miyawaki Daisuke, Sasaki Ryohei
    (一社)日本頭頸部癌学会, May 2010, 頭頸部癌, 36(2) (2), 211 - 211, Japanese
    [Refereed]

  • 原発不明癌頸部リンパ節転移に対する治療経験
    吉田 賢史, 西村 英輝, 宮脇 大輔, 河辺 哲也, 佐々木 良平, 斎藤 幹, 大月 直樹, 丹生 健一, 清田 尚臣, 岡本 欣晃
    (一社)日本頭頸部癌学会, May 2010, 頭頸部癌, 36(2) (2), 179 - 179, Japanese

  • 局所進行頭頸部扁平上皮癌術後再発High-Risk群に対するHigh-dose CDDP+RTの実施可能性試験
    清田 尚臣, 田原 信, 門脇 重憲, 岡野 晋, 河島 光彦, 松浦 一登, 小野澤 祐輔, 丹生 健一, 林 隆一
    (一社)日本頭頸部癌学会, May 2010, 頭頸部癌, 36(2) (2), 206 - 206, Japanese

  • 結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価
    藤原 豊, 茶屋原 菜穂子, 向原 徹, 清田 尚臣, 富岡 秀夫, 船越 洋平, 南 博信
    (一社)日本内科学会, Feb. 2010, 日本内科学会雑誌, 99(Suppl.) (Suppl.), 162 - 162, Japanese

  • Naomi Kiyota
    2010, Toukeibu Gan, 36(3) (3), 278 - 281, English
    [Refereed]
    Scientific journal

  • Yohei Funakoshi, Toru Mukohara, Tomoko Kataoka, Hideo Tomioka, Naoko Chayahara, Yutaka Fujiwara, Naomi Kiyota, Tomonori Shirasaka, Takanori Oka, Kenji Okada, Yutaka Okita, Shigeo Hara, Tomoo Itoh, Soichi Fumita, Kazuhiko Nakagawa, Hironobu Minami
    2010, Rare Tumors, 2(3) (3), 151 - 153, English
    [Refereed]
    Scientific journal

  • 中咽頭癌同時併用化学放射線療法における経皮内視鏡的胃瘻造設術の有用性
    Tanimoto Hitoshi, Sasaki Ryohei, Kiyota Naomi
    Oct. 2009, 頭頸部癌, 35巻, 3号, pp. 287-292, Japanese
    [Refereed]
    Scientific journal

  • Kenichi Nakamura, Makoto Tahara, Naomi Kiyota, Ryuichi Hayashi, Tetsuo Akimoto, Haruhiko Fukuda, Masato Fujii, Narikazu Boku
    Jul. 2009, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 39(7) (7), 460 - 463, English
    Scientific journal

  • Kiyota Naomi
    (一社)日本消化器内視鏡学会, Jun. 2009, Gastroenterological Endoscopy, 51巻, 6号, pp. 1423-1430(6) (6), 1423 - 1430, Japanese
    [Refereed]
    Scientific journal

  • 頭頸部がん治療における多職種医療普及のためのサテライト講演会 その成果と課題
    全田 貞幹, 大田 洋二郎, 本間 明宏, 丹生 健一, 神田 亨, 妻木 浩美, 清田 尚臣, 浅井 昌大
    (一社)日本頭頸部癌学会, May 2009, 頭頸部癌, 35(2) (2), 173 - 173, Japanese

  • Naomi Kiyota, Makoto Tahara, Shigenori Kadowaki, Nozomu Fuse, Toshihiko Doi, Hironobu Minami, Atsushi Ohtsu
    Lead, Apr. 2009, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 39(4) (4), 225 - 230, English, No password
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • Tsuruta, S., Yano, T., Muto, M., Minashi, K., Tahara, M., Kiyota, N., Kaneko, K., Fujii, S., Ohtsu, A.
    2009, Gastroenterological Endoscopy, 51(6) (6), 1423 - 1430, English
    [Refereed]
    Scientific journal

  • Masanori Teshima, Hitoshi Tanimoto, Miki Saito, Naoki Otsuki, Ken-ichi Nibu, Ryohei Sasaki, Naomi Kiyota, Shinya Okuno
    2009, Toukeibu Gan, 35(3) (3), 287 - 292, English
    [Refereed]
    Scientific journal

  • 頭頸部癌における集学的治療 当院における切除不能局所進行頭頸部扁平上皮癌に対する5-FUとCisplatinを同時併用した化学放射線療法の治療成績
    門脇 重憲, 田原 信, 清田 尚臣, 三梨 桂子, 矢野 友規, 布施 望, 吉野 孝之, 土井 俊彦, 河島 光彦, 林 隆一, 大津 敦
    (一社)日本癌治療学会, Oct. 2008, 日本癌治療学会誌, 43(2) (2), 283 - 283, Japanese

  • 化学放射線療法の多角的治療戦略 頭頸部扁平上皮癌に対するInduction chemotherapy
    田原 信, 清田 尚臣, 全田 貞幹, 河島 光彦, 林 隆一
    (一社)日本頭頸部癌学会, May 2008, 頭頸部癌, 34(2) (2), 92 - 92, Japanese

  • 化学放射線療法の多角的治療戦略 手術後の化学放射線療法 Adjuvant chemoradiotherapyの適応と位置づけ
    林 隆一, 清田 尚臣, 田原 信, 全田 貞幹, 河島 光彦
    (一社)日本頭頸部癌学会, May 2008, 頭頸部癌, 34(2) (2), 93 - 93, Japanese

  • 喉頭がん(T2,T3)治療法の選択 切除・再建か放射線・化学療法か 喉頭がんT2,T3に対する治療 手術治療の立場から
    宮崎 眞和, 林 隆一, 河島 光彦, 全田 貞幹, 荒平 聡子, 田原 信, 清田 尚臣, 海老原 敏
    (一社)日本頭頸部癌学会, May 2008, 頭頸部癌, 34(2) (2), 115 - 115, Japanese

  • 切除不能中下咽頭喉頭扁平上皮癌に対するプラチナ同時併用化学放射線療法の検討
    河島 光彦, 林 隆一, 田原 信, 荒平 聡子, 清田 尚臣, 全田 貞幹, 荻野 尚
    (一社)日本頭頸部癌学会, May 2008, 頭頸部癌, 34(2) (2), 151 - 151, Japanese

  • 当院における転移・再発頭頸部扁平上皮癌に対するシスプラチン+5FU(PF)療法の治療成績
    清田 尚臣, 田原 信, 門脇 重憲, 林 隆一, 荒平 聡子, 全田 貞幹, 河島 光彦, 荻野 尚, 大津 敦
    (一社)日本頭頸部癌学会, May 2008, 頭頸部癌, 34(2) (2), 170 - 170, Japanese

  • Kazuhiro Kaneko, Tomonori Yano, Keiko Minashi, Hiroaki Ikematsu, Toshihiko Doi, Takayuki Yoshino, Nozomu Fuse, Naomi Kiyota, Takahiro Horimatsu, Etsuko Warita, Shinya Tsuruta, Yuki Asada, Daisuke Fukuda, Satoshi Mochizuki, Hiroki Hara, Atsushi Ohtsu, Atsushi Katagiri, Kazuo Konishi, Michio Imawari
    Apr. 2008, GASTROINTESTINAL ENDOSCOPY, 67(5) (5), AB187 - AB187, English
    [Refereed]

  • Naomi Kiyota, Makoto Tahara, Satoshi Fujii, Mitsuhiko Kawashima, Takashi Ogino, Hironobu Minami, Ryuichi Hayashi, Atsushi Ohtsu
    Feb. 2008, CANCER, 112(4) (4), 885 - 891, English, No password
    [Refereed]
    Scientific journal
    添付ファイルのURL

  • Santa Hattori, Manabu Muto, Tomonori Yano, Keiko Minashi, Makoto Tahara, Takashi Kojima, Naomi Kiyota, Satoshi Takeuchi, Yasumasa Ezoe, Fumio Ito, Atsushi Ohtsu, Shigeaki Yoshida
    Apr. 2007, GASTROINTESTINAL ENDOSCOPY, 65(5) (5), AB170 - AB170, English
    [Refereed]

  • Kuwayama, H., Asaka, K., Sugiyama, T., Fukuda, Y., Aoyama, N., Hirai, Y., Fujioka, T., Karasawa, G., Uyama, R., Kato, M., Shimizu, Y., Nakagawa, S., Nishi, K., Ozasa, S., Kudo, M., Kamata, T., Saito, M., Kawamura, N., Tsuyuguchi, M., Ooizumi, H., Kobayashi, T., Iijima, A., Yabana, T., Yamashita, K., Harada, Y., Niido, T., Yasuda, Y., Iga, Y., Kuwayama, H., Takahashi, M., Takada, H., Takada, H., Oka, S., Ichimura, H., Makino, E., Miki, K., Miwa, J., Matsubara, Y., Tomita, T., Koyama, S., Sakaki, N., Takahashi, M., Yokoyama, H., Koike, Y., To, T., Satake, Y., Machida, M., Kawai, T., Taira, S., Nukaga, K., Uemura, N., Akiyama, J., Hiraga, Y., Koizuka, H., Yasaka, S., Tajiri, R., Kobayakawa, M., Takahara, A., Shimamoto, M., Murata, H., Okada, T., Fujiyama, Y., Koyama, S., Sasaki, M., Tsujikawa, T., Ishizuka, I., Ashida, K., Takahashi, H., Fukuchi, T., Kiyota, N., Yamashita, H., Tsukamoto, R., Ito, H., Nishide, T., Kato, H., Ando, T., Terao, K., Aoyama, N., Shirasaka, D., Tamura, T., Yoshida, S., Hirano, S., Fukuda, Y., Hori, K., Tomita, T., Sakagami, T., Inoue, K., Hananoki, M., Miyashima, N., Okuda, H., Harada, K., Honda, T., Takeda, M., Haruma, K., Hidaka, T., Oogoshi, H., Nagata, S., Tari, A., Tani, H., Mieno, H., Mihara, M., Wada, Y., Shimatani, T., Inoue, M., Kobayashi, T., Yamauchi, K., Tsugita, M., Kuniyoshi, N., Fujimoto, K., Iwakiri, R., Sakata, H., Tsunada, S., Ootani, A., Kikkawa, A., Eriguchi, Y., Fukuyama, K., Hattori, M., Tanaka, T., Hasuda, K., Goto, H., Fujioka, T., Sato, R., Murakami, K., Kodama, M., Okimoto, T., Miyajima, H., Ono, M., Arita, T., Sato, S., Abe, H.
    2007, Alimentary Pharmacology and Therapeutics, 25(9) (9)
    Scientific journal

  • 清田 尚臣, 田原 信
    (株)メジカルビュー社, Nov. 2006, Mebio Oncology, 3(4) (4), 50 - 57, Japanese

  • FOLFOX投与中に間質性肺炎を発症した大腸癌2例の検討
    藤島 佳未, 小島 隆嗣, 土井 俊彦, 大津 敦, 三梨 桂子, 目良 清美, 竹内 啓, 清田 尚臣, 田原 信
    (一社)日本癌治療学会, Sep. 2006, 日本癌治療学会誌, 41(2) (2), 522 - 522, Japanese

  • Kiyota N
    Apr. 2005, Journal of gastroenterology
    Scientific journal

  • Kiyota N
    2005, Journal of gastroenterology
    Scientific journal

  • Fukuchi, T., Ashida, K., Yamashita, H., Kiyota, N., Tsukamoto, R., Takahashi, H., Ito, D., Nagamatsu, R.
    2005, Journal of gastroenterology, 40(4) (4)
    Scientific journal

■ MISC
  • 進行・再発・転移の固形腫瘍における血栓塞栓症と出血リスク:PROVE-emboli試験post-hoc解析
    今村善宣, 能勢拓, 大幡真也, 乙井一典, 乙井一典, 森健太, 辻高寛, 宮田吉晴, 金原史朗, 長谷善明, 小山泰司, 船越洋平, 清田尚臣, 清田尚臣, 南博信, 南博信
    2024, 日本血栓止血学会誌, 35(2) (2)

  • 花房 宏昭, 田中 敬子, 濱 真奈美, 金原 史朗, 益子 尚久, 坊 亮輔, 國久 智成, 粟野 宏之, 清田 尚臣, 久保 亮治, 南 博信, 野津 寛大
    (一社)日本遺伝カウンセリング学会, Jun. 2023, 日本遺伝カウンセリング学会誌, 44(2) (2), 139 - 139, Japanese

  • がん関連静脈血栓塞栓症に対するアピキサバン療法の出血リスク予測:多施設共同第2相臨床試験副次的解析
    今村善宣, 能勢拓, 宮田吉晴, 小山泰司, 長谷善明, 金原史朗, 船越洋平, 清田尚臣, 藥師神公和, 南博信
    2023, 日本内科学会雑誌, 112

  • 進行・再発・転移の未治療固形がん患者における静脈血栓塞栓症の前向き観察研究の統合解析
    今村善宣, 能勢拓, 大幡真也, 森健太, 乙井一典, 宮田吉晴, 金原史朗, 長谷善明, 小山泰司, 船越洋平, 清田尚臣, 清田尚臣, 南博信, 南博信
    2023, 日本血栓止血学会誌, 34(2) (2)

  • 小児がん経験者の移行期医療の現状およびがん治療歴と心機能に関する解析
    平川結梨, 藥師神公和, 松本咲耶, 坂井里奈, 倉田啓史, 今村善宜, 北尾章人, 船越洋平, 田中秀和, 清田尚臣, 南博信
    2023, 日本腫瘍循環器学会学術集会抄録集(Web), 6th

  • がん治療前の悪性腫瘍関連下肢静脈血栓塞栓症のリスク因子に関する検討:PROVE-emboli study
    能勢拓, 今村善宣, 大幡真也, 森健太, 乙井一典, 小山泰司, 長谷義明, 金原史朗, 船越洋平, 清田尚臣, 清田尚臣, 南博信, 南博信
    2023, 日本腫瘍循環器学会学術集会抄録集(Web), 6th

  • 【肺がん・頭頸部がん】頭頸部がんに対する化学放射線療法
    能勢 拓, 清田 尚臣
    (有)科学評論社, Dec. 2022, 腫瘍内科, 30(6) (6), 671 - 676, Japanese

  • 清田 尚臣
    (株)文光堂, Oct. 2022, Medical Practice, 39(10) (10), 1457 - 1461, Japanese

  • がんゲノム医療時代と生物学的製剤・分子標的治療薬
    金原 史朗, 清田 尚臣
    (有)科学評論社, Sep. 2022, 耳鼻咽喉科, 2(3) (3), 372 - 376, Japanese

  • 清田 尚臣
    (株)東京医学社, Dec. 2021, JOHNS, 37(12) (12), 1551 - 1553, Japanese

  • 能勢 拓, 清田 尚臣
    (有)科学評論社, Nov. 2021, 腫瘍内科, 28(5) (5), 519 - 525, Japanese

  • 【10年後の乳がん診療】乳がん薬物療法におけるQOL評価
    木川 雄一郎, 石木 寛人, 寺田 参省, 水澤 純基, 清田 尚臣
    (有)科学評論社, Sep. 2021, 腫瘍内科, 28(3) (3), 291 - 295, Japanese

  • 臨床試験と倫理 倫理的な臨床試験とは?
    清田 尚臣
    耳鼻咽喉科臨床学会, Jun. 2021, 耳鼻咽喉科臨床 補冊, (補冊157) (補冊157), 50 - 50, Japanese

  • 再発・転移頭頸部扁平上皮癌に対するニボルマブ療法治療の予後予測における好酸球数変化の有用性
    小山 泰司, 清田 尚臣, 今村 善宣, 長谷 善明, 蓼原 瞬, 手島 直則, 四宮 弘隆, 宮脇 大輔, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2021, 頭頸部癌, 47(2) (2), 208 - 208, Japanese

  • T3N0M0声門癌に対する根治的放射線治療の成績
    岩下 和真, 石原 武明, 妹尾 悟史, 窪田 光, 川口 弘毅, 小林 加奈, 宮脇 大輔, 佐々木 良平, 蓼原 瞬, 手島 直則, 四宮 弘隆, 丹生 健一, 今村 善宣, 清田 尚臣
    (一社)日本頭頸部癌学会, May 2021, 頭頸部癌, 47(2) (2), 239 - 239, Japanese

  • 福満 隼人, 山本 直希, 福岡 秀規, 山本 雅昭, 神澤 真紀, 清田 尚臣, 小松 昇平, 重村 克己, 廣田 勇士, 小川 渉, 高橋 裕
    (一社)日本内分泌学会, Apr. 2021, 日本内分泌学会雑誌, 97(1) (1), 224 - 224, Japanese

  • 渡部 まりか, 清田 尚臣
    (有)科学評論社, Mar. 2021, 腫瘍内科, 27(3) (3), 326 - 331, Japanese

  • 須藤 洋崇, 清田 尚臣
    医歯薬出版(株), Feb. 2021, 医学のあゆみ, 276(8) (8), 765 - 769, Japanese

  • Risk Benefit Balanceを考慮した分子標的薬の使用法
    清田 尚臣
    (一社)日本内分泌外科学会, Nov. 2020, 日本内分泌外科学会雑誌, 37(Suppl.2) (Suppl.2), S250 - S250, Japanese

  • がんゲノム医療時代における甲状腺がんに対するがん薬物療法
    清田 尚臣
    (一社)日本内分泌外科学会, Nov. 2020, 日本内分泌外科学会雑誌, 37(Suppl.2) (Suppl.2), S297 - S297, Japanese

  • 山本 直希, 山本 雅昭, 稲葉 惟子, 清田 尚臣, 西山 信晴, 西影 星二, 福田 いずみ, 福岡 秀規, 小川 渉
    (一社)日本内分泌学会, Oct. 2020, 日本内分泌学会雑誌, 96(2) (2), 564 - 564, Japanese

  • 笠原 俊彦, 伊藤 康弘, 清田 尚臣, 舛岡 裕雄, 宮 章博, 中村 友彦, 吉岡 和佳, 西原 永潤, 伊藤 充, 宮内 昭
    (一社)日本甲状腺学会, Oct. 2020, 日本甲状腺学会雑誌, 11(2) (2), 68 - 76, Japanese

  • 松本 咲耶, 清田 尚臣
    (株)日本臨床社, Sep. 2020, 日本臨床, 78(増刊4 内分泌腺腫瘍) (増刊4 内分泌腺腫瘍), 423 - 428, Japanese

  • 藤田 泰功, 合田 菜穂, 浦井 伸, 志智 大城, 蟹江 慶太郎, 山本 雅昭, 岡田 裕子, 廣田 勇士, 福岡 秀規, 井口 元三, 清田 尚臣, 小川 渉, 高橋 裕
    (一社)日本内分泌学会, Aug. 2020, 日本内分泌学会雑誌, 96(1) (1), 307 - 307, Japanese

  • Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Yukari Tsubata, Takamasa Hotta, Kenji Tamura, Noboru Yamamoto, Hironobu Minami
    Apr. 2020, CANCER SCIENCE, 111(4) (4), 1437 - 1437, English
    Others

  • Updated Evidence and Proper Management of Immune Check Point Inhibitors for Head and Neck Cancer
    清田尚臣, 清田尚臣, 今村善宣
    2020, Quintessence

  • 日本人悪性腫瘍関連静脈血栓塞栓症に対するapixaban療法の第II相臨床試験
    今村善宣, 乙井一典, 森健太, 喜多川浩一, 岡田秀明, 秦明登, 林秀敏, 能勢拓, 大幡真也, 宮田吉晴, 船越洋平, 豊田昌徳, 藥師神公和, 清田尚臣, 清田尚臣, 松岡広, 南博信, 南博信
    2020, 日本血液学会学術集会抄録(Web), 82nd

  • 患者満足度を評価するQOL尺度(EORTC IN-PATSAT9)の日本語版翻訳のパイロットスタディ
    石木 寛人, 久保 絵美, 木川 雄一郎, 清水 正樹, 木内 大佑, 里見 絵理子, 寺田 参省, Niculae Alena, Kulis Dagmara, Bredart Anne, 清田 尚臣
    (一社)日本癌治療学会, Oct. 2019, 日本癌治療学会学術集会抄録集, 57回, O17 - 5, English

  • Ichiro Kinoshita, Satoshi Kano, Yasushi Shimizu, Naomi Kiyota, Yuichiro Tada, Kei Ijichi, Tmoko Yamazaki, Akihiro Homma, Yoichi M. Ito, Kota Ono, Keiko Kobayashi, Toshiyuki Isoe, Yutaka Hatanaka, Hitoshi Tsuda, Shojiroh Morinaga, Yoshihiro Matsuno, Hirotoshi Dosaka-Akita
    Jul. 2019, CANCER RESEARCH, 79(13) (13), English
    Summary international conference

  • 再発又は遠隔転移を有する頭頸部がんの患者を対象としたニボルマブの安全性及び有効性の検討
    田原信, 清田尚臣, 丹生健一, 星野智洋, 飯田修, 林隆一
    (一社)日本頭頸部癌学会, 13 May 2019, 頭頸部癌, 45(2) (2), 143 - 143, Japanese

  • 再発転移頭頸部扁平上皮癌 ニボルマブ投与例におけるmodified Glasgow Prognostic Scoreの予後予測性
    今村 善宣, 清田 尚臣, 金原 史朗, 小山 泰司, 大月 直樹, 四宮 弘隆, 蓼原 瞬, 入谷 啓介, 宮脇 大輔, 南川 勉, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 132 - 132, Japanese

  • 下咽頭癌外側咽頭後リンパ節転移症例の検討
    手島 直則, 古川 竜也, 森田 成彦, 四宮 弘隆, 森本 浩一, 大月 直樹, 清田 尚臣, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 149 - 149, Japanese

  • 再発転移鼻副鼻腔原発粘膜悪性黒色腫に対するニボルマブの後方視的検討
    小山 泰司, 清田 尚臣, 金原 史朗, 今村 善宣, 蓼原 瞬, 入谷 啓介, 四宮 弘隆, 大月 直樹, 南川 勉, 宮脇 大輔, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 162 - 162, Japanese

  • 頭頸部扁平上皮癌術後の再発高リスク症例に対する放射線療法の治療成績の検討
    妹尾 悟史, 吉田 賢史, 宮脇 大輔, 石原 武明, 今村 善宣, 清田 尚臣, 四宮 弘隆, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 168 - 168, Japanese

  • 中咽頭癌に対する化学放射線療法による摂食・嚥下に関するQOLの変化
    高橋 美貴, 岩城 忍, 涌井 絵美, 古川 竜也, 四宮 弘隆, 大月 直樹, 清田 尚臣, 宮脇 大輔, 佐々木 良平, 喜多川 浩一, 西村 英輝, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 169 - 169, Japanese

  • T4下咽頭癌に対する根治的(化学)放射線療法の後方視的検討
    宮脇 大輔, 石原 武明, 吉田 賢史, 今村 善宣, 四宮 弘隆, 清田 尚臣, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 201 - 201, Japanese

  • 再発転移頭頸部扁平上皮癌 ニボルマブ投与例におけるmodified Glasgow Prognostic Scoreの予後予測性
    今村 善宣, 清田 尚臣, 金原 史朗, 小山 泰司, 大月 直樹, 四宮 弘隆, 蓼原 瞬, 入谷 啓介, 宮脇 大輔, 南川 勉, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 132 - 132, Japanese

  • 下咽頭癌外側咽頭後リンパ節転移症例の検討
    手島 直則, 古川 竜也, 森田 成彦, 四宮 弘隆, 森本 浩一, 大月 直樹, 清田 尚臣, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 149 - 149, Japanese

  • 再発転移鼻副鼻腔原発粘膜悪性黒色腫に対するニボルマブの後方視的検討
    小山 泰司, 清田 尚臣, 金原 史朗, 今村 善宣, 蓼原 瞬, 入谷 啓介, 四宮 弘隆, 大月 直樹, 南川 勉, 宮脇 大輔, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 162 - 162, Japanese

  • 頭頸部扁平上皮癌術後の再発高リスク症例に対する放射線療法の治療成績の検討
    妹尾 悟史, 吉田 賢史, 宮脇 大輔, 石原 武明, 今村 善宣, 清田 尚臣, 四宮 弘隆, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 168 - 168, Japanese

  • 中咽頭癌に対する化学放射線療法による摂食・嚥下に関するQOLの変化
    高橋 美貴, 岩城 忍, 涌井 絵美, 古川 竜也, 四宮 弘隆, 大月 直樹, 清田 尚臣, 宮脇 大輔, 佐々木 良平, 喜多川 浩一, 西村 英輝, 丹生 健一
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 169 - 169, Japanese

  • T4下咽頭癌に対する根治的(化学)放射線療法の後方視的検討
    宮脇 大輔, 石原 武明, 吉田 賢史, 今村 善宣, 四宮 弘隆, 清田 尚臣, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2019, 頭頸部癌, 45(2) (2), 201 - 201, Japanese

  • 生活支援における効果的な多職種連携~経口抗がん薬服用患者への介入~
    土井久容, 土井久容, 今西優子, 木下実里, 木下実里, 丹田雅明, 丹田雅明, 豊田昌徳, 船越洋平, 今村善宣, 西野聖子, 西野聖子, 清田尚臣, 清田尚臣
    2019, 日本がん看護学会誌(Web), 33

  • がん薬物治療 1 頭頸部がん
    今村善宣, 清田尚臣
    2019, 月刊薬事, 61(10) (10)

  • 当院における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討
    高井亮, 山下公大, 須藤洋崇, 豊田昌徳, 船越洋平, 今村善宣, 清田尚臣, 清田尚臣, 井上潤, 田中心和, 松田武, 児玉裕三, 南博信, 南博信, 掛地吉弘
    2019, 日本消化器癌発生学会総会プログラム・抄録集, 30th

  • 本邦における高頻度マイクロサテライト不安定性大腸癌のスクリーニング方法の検討
    須藤洋崇, 豊田昌徳, 船越洋平, 今村善宣, 清田尚臣, 清田尚臣, 井上潤, 田中心和, 高瀬信尚, 長谷川寛, 山下公大, 松田武, 鈴木知志, 児玉裕三, 掛地吉弘, 南博信, 南博信
    2019, 日本家族性腫瘍学会学術集会プログラム・抄録集, 25th

  • EGFR阻害薬に伴うざ瘡様皮疹へのアダパレンゲル予防投与のプラセボ対照左右ランダム化比較試験
    土井 久容, 茶屋原 菜穂子, 清田 尚臣, 豊田 昌徳, 立原 素子, 山本 正嗣, 藤島 佳未, 飛松 和俊, 福永 淳, 川口 淳, 向原 徹, 南 博信
    (一社)日本がん看護学会, Jan. 2019, 日本がん看護学会誌, 33(Suppl.) (Suppl.), 173 - 173, Japanese

  • 甲状腺がんに対するレンバチニブ治療中の観血的処置の安全性に関する遡及的検討
    金原 史朗, 清田 尚臣, 今村 善宣, 大月 直樹, 丹生 健一, 南川 勉, 原 仁美, 角谷 賢一朗, 佐々木 良平, 南 博信
    日本内分泌外科学会・日本甲状腺外科学会, Oct. 2018, 日本内分泌・甲状腺外科学会雑誌, 35(Suppl.2) (Suppl.2), S319 - S319, Japanese

  • 頭頸部がんにおける免疫チェックポイント阻害薬の適正使用
    Kiyota Naomi
    (一社)日本耳鼻咽喉科学会, Jul. 2018, 日本耳鼻咽喉科学会会報, 121(7号) (7号), 941 - 943, Japanese
    [Invited]
    Introduction scientific journal

  • 頭頸部がんにおける免疫チェックポイント阻害薬の適応と実際
    Kiyota Naomi
    (一社)日本耳鼻咽喉科学会, Jun. 2018, 日本耳鼻咽喉科学会会報, 121(6号) (6号), 826 - 828, Japanese
    [Invited]
    Introduction scientific journal

  • 再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第II相臨床試録
    今村善宣, 清田尚臣, 田中薫, 林秀俊, 太田一郎, 平野滋, 岩江信法, 南修司郎, 家根且有, 山崎知子, 長谷善明, 豊田昌徳, 大月直樹, 丹生健一, 南博信
    (一社)日本頭頸部癌学会, 09 May 2018, 頭頸部癌, 44(2) (2), 126 - 126, Japanese

  • 甲状腺癌気道浸潤例に対する放射線外照射の有効性の検討
    鈴木 千晶, 清田 尚臣, 大月 直樹, 宮脇 大輔, 今村 善宣, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2018, 頭頸部癌, 44(2) (2), 176 - 176, Japanese

  • 【患者・家族への説明ガイド-正しく伝え,納得を引き出し,判断を促すために】腫瘍のこと (Question 90)最近の抗癌剤はとても高額だそうですが,医療費はいくらくらいですか?
    田中美香, Kiyota Naomi
    Apr. 2018, 耳鼻咽喉科・頭頸部外科, 90(5号) (5号), 282 - 283, Japanese
    [Invited]
    Introduction scientific journal

  • Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例
    崔諭司, 今村善宣, 清田尚臣, 清田尚臣, 重岡學, 豊田昌徳, 船越洋平, 兵庫寧子, 須藤洋崇, 金原史朗, 奥田祐亮, 吉田賢史, 南博信
    2018, 日本臨床腫瘍学会学術集会(CD-ROM), 16th

  • 局所進行頭頸部扁平上皮癌に対するTPE導入化学療法とセツキシマブ併用放射線療法の第II相試験(ECRIPS study)
    清田尚臣, 尾上琢磨, 岡野晋, 高橋俊二, 北村守正, 藤井正人, 妹尾直, 野上尚之, 山中竹春, 全田貞幹, 田原信
    2018, 日本臨床腫瘍学会学術集会(CD-ROM), 16th, ROMBUNNO.O1‐8‐3, Japanese

  • 【各臓器がんに対する免疫チェックポイント阻害薬】 各臓器がんに対する免疫チェックポイント阻害薬の現状について 頭頸部がん
    鈴木千晶, Kiyota Naomi
    Jan. 2018, がん分子標的治療, 15(4号) (4号), 379 - 382, Japanese
    [Invited]
    Introduction commerce magazine

  • Nivolumab Versus Investigator'S Choice (IC) for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; CHECKMATE 141): Outcomes in First-Line R/M Patients and Updated Safety and Efficacy
    Maura L. Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark Lynch, Justin Kopit, Robert L. Ferris
    Nov. 2017, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 13, 144 - 144, English
    Summary international conference

  • Remarkable response to cetuximab-containing chemotherapy for tongue cancer refractory to immune checkpoint inhibitors
    Hirotaka Suto, Naomi Kiyota, Yoshinori Imamura, Yasuko Hyogo, Kei Takenaka, Yoshiaki Nagatani, Meiko Nishimura, Masanori Toyoda, Toru Mukohara, Hironobu Minami
    Oct. 2017, ANNALS OF ONCOLOGY, 28, English
    Summary international conference

  • 【がん免疫療法の躍進】がん免疫療法の臨床 がん種別治療 頭頸部がんのがん免疫療法
    金原史朗, Kiyota Naomi
    Oct. 2017, 医学のあゆみ, 263(1号) (1号), 81 - 86, Japanese
    [Invited]
    Introduction commerce magazine

  • 【頭頸部悪性腫瘍の疑問に答える】 治療中の対応 抗がん薬減量の目安について教えてください
    須藤洋崇, Kiyota Naomi
    Sep. 2017, JOHNS, 33(9号) (9号), 1267 - 1270, Japanese
    Introduction commerce magazine

  • 【転移性脊椎腫瘍に対する最小侵襲脊椎安定術(MISt)】 転移性脊椎腫瘍に対する出張型骨転移Cancer Boardの取り組み
    Kakutani Kenichiro, Sakai Yoshitada, 伊藤雅明, Kawamoto Teruya, Hara Hitomi, 深瀬直政, Okada Takuya, Sugimoto Koji, Miyawaki Daisuke, Sasaki Ryohei, Kiyota Naomi, Minami Hironobu, 秋末敏宏, Kuroda Ryosuke, 西田康太郎
    (株)全日本病院出版会, Sep. 2017, 整形外科最小侵襲手術ジャーナル, (84) (84), 79 - 83, Japanese
    [Refereed]
    Introduction scientific journal

  • Cancer-Immunological Topics 免疫チェックポイント阻害薬 頭頸部がん
    須藤洋崇, Kiyota Naomi
    Sep. 2017, がん免疫療法, 1(2号) (2号), 135 - 137, Japanese
    [Invited]
    Introduction commerce magazine

  • Head and Neck Tumor 頭頸部腫瘍 局所進行喉頭・下咽頭癌における喉頭温存 局所進行喉頭・下咽頭癌における機能温存戦略 非外科的治療のエビデンス
    Kiyota Naomi
    Jul. 2017, 癌と化学療法, 44(7号) (7号), 575 - 578, Japanese
    [Invited]
    Introduction commerce magazine

  • Human papilloma virus associated head and neck cancer and immune check point inhibitors
    清田 尚臣
    科学評論社, Jun. 2017, 腫瘍内科 = Clinical oncology, 19(6) (6), 721 - 725, Japanese

  • 【中咽頭癌の新しい治療戦略/頭頸部癌に対する治療完遂のコツとチーム医療の実際/再発転移性頭頸部扁平上皮癌の最新治療戦略】 再発転移性頭頸部扁平上皮癌の最新治療戦略 生存延長最大化のための適正使用 プラチナ製剤抵抗性頭頸部扁平上皮癌に対する免疫チェックポイント阻害薬
    Kiyota Naomi
    Jun. 2017, 頭頸部癌Frontier, 5(1号) (1号), 34 - 39, Japanese
    Introduction commerce magazine

  • Maura L. Gillison, George R. Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert I. Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Mark John Lynch, Justin Kopit, Robert L. Ferris
    May 2017, JOURNAL OF CLINICAL ONCOLOGY, 35, English
    Summary international conference

  • 頭頸部癌治療にIMRTが与えた影響 腫瘍内科医からみた頭頸部がん臨床試験におけるIMRTの重要性と課題
    Kiyota Naomi
    May 2017, 頭頸部癌, 43(2号) (2号), 135, Japanese
    [Invited]
    Introduction other

  • 【免疫チェックポイント阻害薬の新しい展開】 頭頸部がんに対する免疫チェックポイント阻害薬
    Kiyota Naomi
    科学評論社, Jan. 2017, 腫瘍内科, 19(1号) (1号), 81 - 86, Japanese
    Introduction commerce magazine

  • 【症例から学ぶ頭頸部癌治療-化学療法/分子標的療法-】 症例から学ぶ分子標的療法 高齢頭頸部癌患者に対する抗EGFR抗体併用放射線療法 症例から考える
    Kiyota Naomi
    Jan. 2017, 頭頸部癌Frontier, 4(2号) (2号), 123 - 127, Japanese
    [Invited]
    Introduction commerce magazine

  • TPF導入化学療法の副作用対策と完遂のためのポイントを教えてください
    今村善宣, Kiyota Naomi
    (株)メディカルレビュー社, Jan. 2017, 頭頸部癌Frontier, 4(2) (2), 128 - 131, Japanese
    [Invited]
    Introduction commerce magazine

  • PHASE 2 STUDY OF LENVATINIB IN PATIENTS WITH DIFFERENTIATED, MEDULLARY AND ANAPLASTIC THYROID CANCER: FINAL ANALYSIS RESULTS
    Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, K. Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina Dutcus, Louise Young, Makoto Tahara
    Nov. 2016, ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12, 134 - 134, English
    Summary international conference

  • 食道 食道がんに対する治療戦略 頸部食道癌に対するCDDP/5-FU併用化学放射線療法の多施設共同臨床第II相試験
    全田 貞幹, 小島 隆嗣, 大幸 宏幸, 加藤 健, 泉 佐知子, 花井 信広, 堅田 親利, 清田 尚臣, 對馬 隆浩, 藤井 正人
    (一社)日本癌治療学会, Oct. 2016, 日本癌治療学会学術集会抄録集, 54回, MS20 - 4, Japanese

  • 田原 信, 清田 尚臣, 高橋 俊二, 小野田 尚佳
    (株)メディカルレビュー社, Oct. 2016, Thyroid Cancer Explore, 2(2) (2), 105 - 114, Japanese

  • 再発甲状腺癌の治療 予後とQOLを考慮したレンバチニブの使用 いつから、そしてどう使うか
    宮 章博, 清田 尚臣, 吉岡 佳奈, 小田 瞳, 笹井 久徳, 小林 薫, 藪田 智範, 舛岡 裕雄, 東山 卓也, 福島 光浩, 伊藤 康弘, 木原 実, 宮内 昭
    日本内分泌外科学会・日本甲状腺外科学会, Sep. 2016, 日本内分泌・甲状腺外科学会雑誌, 33(Suppl.2) (Suppl.2), S211 - S211, Japanese

  • 頭頸部がんに対する免疫チェックポイント阻害薬の現状 (第54回 日本癌治療学会学術集会Educational Book) -- (教育シンポジウム がん免疫療法 : 特に免疫チェックポイント阻害剤)
    清田 尚臣
    日本癌治療学会, Sep. 2016, 日本癌治療学会誌 = The journal of Japan Society of Clinical Oncology, 51(2) (2), 339 - 344, Japanese

  • 【腫瘍】 初発時は限局期で手術し、その後再発したがんのマネジメント 胃がん 標準的な治療と押さえておきたい副作用
    北尾章人, Kiyota Naomi
    Sep. 2016, Hospitalist, 4(3号) (3号), 547 - 557, Japanese
    [Invited]
    Introduction commerce magazine

  • Kiyota Naomi

    これまで放射性ヨウ素治療（RAI）に不応な転移・再発分化型甲状腺癌に対する薬物療法はドキソルビシンが治療選択肢の一つであったが，その有効性は不十分なものであった［１］。しかし，2014年にmulti-target kinase inhibitor（m-TKI）であるソラフェニブ（sorafenib：SOR）の有効性が証明され，新たな治療オプションとして日本でも使用できるようになった［２］。さらに，レンバチニブ（lenvatinib：LEN）も第Ⅲ相試験において明らかな有効性が示され［３,４］，RAI不応転移・再発分化型甲状腺癌の治療オプションがさらに充実することとなった。一方で，その使用にあたっては適応の慎重な判断と適切な管理が非常に重要な課題である。本稿では，このような分化型甲状腺癌（differentiated thyroid cancer，DTC）における分子標的薬の適正使用と今後の展望について解説する。

    Japan Association of Endocrine Surgeons･Japanese Society of Thyroid Surgery, Sep. 2016, 日本内分泌・甲状腺外科学会雑誌, 33(3号) (3号), 140 - 144, Japanese
    [Invited]
    Introduction scientific journal

  • Current Status of Lenvatinib for Thyroid Cancer
    Naomi Kiyota
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    Summary international conference

  • Pharmacokinetic study of S-1, an oral fluorouracil antitumor agent in Japanese patients with impaired renal function
    Keiko Goto, Yutaka Fujiwara, Takeshi Isobe, Yukari Tsubata, Takamasa Hotta, Naoko Chayahara, Naomi Kiyota, Toru Mukohara, Noboru Yamamoto, Hironobu Minami
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    Summary international conference

  • Relationship between Adverse Events and Efficacy of Lenvatinib for Thyroid Cancer
    Hideaki Goto, Naomi Kiyota, Naoko Chayahara, Kei Takenaka, Yoshinori Imamura, Meiko Nishimura, Masanori Toyoda, Toru Mukohara, Hironobu Minami
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    Summary international conference

  • Current status of immune check point inhibitors for solid malignancy
    Naomi Kiyota
    Jul. 2016, ANNALS OF ONCOLOGY, 27, English
    Summary international conference

  • Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
    Maura L. Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara Carmen Iglesias Docampo, Robert Haddad, Tamara Rordorf, Naomi Kiyota, Makoto Tahara, Manish Monga, Mark Lynch, William J. Geese, Mark Schactman, Justin Kopit, James W. Shaw, Robert L. Ferris
    Jul. 2016, CANCER RESEARCH, 76, English
    Summary international conference

  • 今村善宣, Kiyota Naomi
    (株)全日本病院出版会, Jul. 2016, ENTONI, (195号) (195号), 35 - 43, Japanese
    [Invited]
    Introduction commerce magazine

  • 【頭頸部がん、肺がん】 甲状腺がんに対する分子標的治療の現状と展望
    Kiyota Naomi
    科学評論社, Jun. 2016, 腫瘍内科, 17(6号) (6号), 622 - 627, Japanese
    [Invited]
    Introduction commerce magazine

  • Shunji Takahashi, Naomi Kiyota, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, Lina Inagaki, Kazuhisa Toda, Tomohiro Enokida, Hironobu Minami, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina Dutcus, Makoto Tahara
    May 2016, JOURNAL OF CLINICAL ONCOLOGY, 34(15) (15), English
    Summary international conference

  • Robert L. Ferris, George R. Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa F. Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Robert I. Haddad, Naomi Kiyota, Makoto Tahara, Manish Monga, MarkJohn Lynch, William J. Geese, Justin Kopit, James W. Shaw, Maura L. Gillison
    May 2016, JOURNAL OF CLINICAL ONCOLOGY, 34(15) (15), English
    Summary international conference

  • がんの治療薬を知る 薬剤選択のための知識 レンバチニブ
    Kiyota Naomi
    ヴァン・メディカル, May 2016, 臨床腫瘍プラクティス, 12(2号) (2号), 175 - 180, Japanese
    [Invited]
    Introduction commerce magazine

  • 【耳鼻咽喉科処方マニュアル】 がん治療副作用・疼痛緩和 神経障害
    後藤秀彰, Kiyota Naomi
    Apr. 2016, 耳鼻咽喉科・頭頸部外科, 88(5号) (5号), 340 - 342, Japanese
    [Invited]
    Introduction commerce magazine

  • 今村善宣, Kiyota Naomi
    (株)医学書院, Apr. 2016, 耳鼻咽喉科・頭頸部外科, 88(5号) (5号), 338 - 339, Japanese
    [Invited]
    Introduction commerce magazine

  • 【遺伝子解析に基づく新しい分子標的治療】 遺伝子解析に基づくがん治療 甲状腺がん
    Kiyota Naomi
    Apr. 2016, がん分子標的治療, 14(1号) (1号), 36 - 40, Japanese
    [Invited]
    Introduction commerce magazine

  • 【希少がんの治療戦略】 分化型甲状腺がんに対する新規抗がん剤と治療戦略
    Kiyota Naomi
    科学評論社, Mar. 2016, 腫瘍内科, 17(3号) (3号), 271 - 275, Japanese
    [Invited]
    Introduction commerce magazine

  • 【がん免疫療法のブレイクスルー-免疫チェックポイント阻害薬】 免疫チェックポイント阻害薬の副作用と管理法
    Kiyota Naomi
    Feb. 2016, 耳鼻咽喉科・頭頸部外科, 88(2号) (2号), 140 - 146, Japanese
    [Invited]
    Introduction scientific journal

  • EFFECT OF AGE AND LENVATINIB TREATMENT ON OVERALL SURVIVAL FOR PATIENTS WITH I-131- REFRACTORY DIFFERENTIATED THYROID CANCER IN SELECT
    Marcia Brose, Martin Schlumberger, Makoto Tahara, Lori Wirth, Bruce Robinson, Rossella Elisei, Kate Newbold, Naomi Kiyota, Ana O. Hoff, Corina Dutcus, James Song, Brett Hughes, Steven Sherman, Matthew Hiram Taylor
    Nov. 2015, Asia-Pacific Journal of Clinical Oncology, 11, 173 - 173, English
    Summary international conference

  • JCOG1008: Phase II/III Trial of postoperative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck
    Naomi Kiyota
    Nov. 2015, ANNALS OF ONCOLOGY, 26, 14 - 14, English
    Summary international conference

  • Radiation Therapy for T3/T4 Squamous Cell Carcinoma of Hypopharynx: A Retrospective Comparison Between Definitive Radiation Therapy and Surgery Followed by Postoperative Radiation Therapy
    Y. Matsuo, K. Yoshida, D. Miyawaki, Y. Ejima, T. Ishihara, R. Nishikawa, N. S. Sulaiman, Y. Inoue, H. Nishimura, N. Kiyota, M. Saito, N. Otsuki, K. Nibu, R. Sasaki
    Nov. 2015, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 93(3) (3), E341 - E342, English
    Summary international conference

  • Current status and future perspectives of molecular targeting treatment for thyroid cancer
    Naomi Kiyota
    Nov. 2015, ANNALS OF ONCOLOGY, 26, 53 - 53, English
    Summary international conference

  • 甲状腺がんに対する分子標的治療薬 適正使用と多職種連携を中心に
    Kiyota Naomi
    科学評論社, Nov. 2015, 腫瘍内科, 16(5号) (5号), 474 - 478, Japanese
    [Invited]
    Introduction scientific journal

  • CRTとBRTの使い分け CRTとBRTの使い分け セツキシマブ-RTの現状と問題点(解説)
    Kiyota Naomi
    Nov. 2015, 耳鼻と臨床, 61(suppl.1) (suppl.1), S3 - S8, Japanese
    [Invited]
    Introduction scientific journal

  • 【分子標的治療を含む併用療法】 放射線治療と分子標的治療の併用療法
    後藤秀彰, Kiyota Naomi
    Oct. 2015, がん分子標的治療, 13(3号) (3号), 328 - 332, Japanese
    [Refereed]
    Introduction commerce magazine

  • Yoshinori Imamura, Toru Mukohara, Yohei Shimono, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Shintaro Takao, Seishi Kono, Tetsuya Nakatsura, Hironobu Minami
    Aug. 2015, CANCER RESEARCH, 75, English
    Summary international conference

  • 甲状腺がんに対するlenvatinib
    後藤秀彰, Kiyota Naomi
    科学評論社, Aug. 2015, 腫瘍内科, 16(2号) (2号), 191 - 195, Japanese
    Introduction scientific journal

  • 【甲状腺癌】 レンビマ 甲状腺がんに対するレンバチニブ(レンビマ)の適正使用について
    Kiyota Naomi
    Aug. 2015, クリニシアン, 62(8号) (8号), 829 - 836, Japanese
    Introduction commerce magazine

  • 【機能温存を考慮した頭頸部癌治療-口腔癌(舌癌)・咽頭癌・喉頭癌を中心に-】 Evidence Based Medicine 各ガイドラインにおける機能温存の考え方 欧州臨床腫瘍学会ガイドライン
    後藤秀彰, 今村善宣, Kiyota Naomi
    メディカルレビュー社, Aug. 2015, 頭頸部癌Frontier, 3(1号) (1号), 56 - 59, Japanese
    [Invited]
    Introduction commerce magazine

  • 頭頸部腫瘍 甲状腺がんに対する分子標的治療薬
    Kiyota Naomi
    Jul. 2015, 癌と化学療法, 42(7号) (7号), 806 - 809, Japanese
    [Invited]
    Introduction scientific journal

  • Effect of age and lenvatinib treatment on overall survival for patients with I-131-refractory differentiated thyroid cancer in SELECT
    Marcia S. Brose, Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Rossella Elisei, Kate Newbold, Naomi Kiyota, Ana O. Hoff, Corina Dutcus, James Song, Steven I. Sherman, Matthew Hiram Taylor
    May 2015, JOURNAL OF CLINICAL ONCOLOGY, 33(15) (15), English
    Summary international conference

  • Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in I-131-refractory differentiated thyroid cancer (SELECT).
    Makoto Tahara, Martin Schlumberger, Rossella Elisei, Mouhammed Amir Habra, Naomi Kiyota, Corina Dutcus, Jianbo Xu, Junming Zhu, Taro Hihara, Shannon McGrath, Mark Matijevic, Tadashi Kadowaki, Yasuhiro Funahashi, Steven I. Sherman
    May 2015, JOURNAL OF CLINICAL ONCOLOGY, 33(15) (15), English
    Summary international conference

  • 中咽頭癌に対する化学放射線療法におけるPEGの有用性
    高橋 美貴, 小坂 奈々, 宇佐美 眞, 中川 絵美, 齋藤 幹, 大月 直樹, 佐々木 良平, 清田 尚臣, 丹生 健一
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 250 - 250, Japanese

  • 中・下咽頭後壁癌に対する放射線治療成績
    宮脇 大輔, 江島 泰生, 吉田 賢史, 石原 武明, 清田 尚臣, 斉藤 幹, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 254 - 254, Japanese

  • 食道癌同時合併中下咽頭癌に対する放射線治療の経験
    西川 遼, 吉田 賢史, 宮脇 大輔, 江島 泰生, 石原 武明, 松尾 佳朗, ノル・シャズリナ, 井上 由子, 西村 英輝, 清田 尚臣, 斎藤 幹, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 254 - 254, Japanese

  • 原発不明癌頸部リンパ節転移に対する放射線治療の経験
    井上 由子, 吉田 賢史, 江島 泰生, 宮脇 大輔, 石原 武明, ノル・シャズリナ, 西川 遼, 松尾 圭朗, 西村 英輝, 大月 直樹, 斎藤 幹, 清田 尚臣, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 262 - 262, Japanese

  • N3頸部リンパ節転移症例に対する放射線治療の経験
    吉田 賢史, 宮脇 大輔, 江島 泰生, 西村 英輝, 石原 武明, 松尾 佳朗, 西川 遼, 井上 由子, 清田 尚臣, 斎藤 幹, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2015, 頭頸部癌, 41(2) (2), 266 - 266, Japanese

  • 【甲状腺癌に対する分子標的薬治療の最前線】 甲状腺癌に対する分子標的薬の適正使用と副作用管理
    Kiyota Naomi
    Mar. 2015, 日本内分泌・甲状腺外科学会雑誌, 32(1号) (1号), 14 - 17, Japanese
    [Invited]
    Introduction scientific journal

  • 頭頸部癌に対するセツキシマブ併用放射線治療の初期経験
    下山 真介, 上薗 玄, 松尾 圭朗, ノル・シャズリナ, 松本 葉子, 宮脇 大輔, 吉田 賢史, 江島 泰生, 佐々木 良平, 清田 尚臣, 大月 直樹, 丹生 健一
    (公社)日本医学放射線学会, Feb. 2015, Japanese Journal of Radiology, 33(Suppl.) (Suppl.), 76 - 76, Japanese

  • 【抗がん剤の副作用と支持療法-より適切な抗がん剤の安全使用をめざして-】 臓器別がん腫レジメンの副作用と対策 局所進行頭頸部扁平上皮癌 CDDP RT療法
    Kiyota Naomi
    Feb. 2015, 日本臨床, 73(増刊2 抗がん剤の副作用と支持療法) (増刊2 抗がん剤の副作用と支持療法), 559 - 561, Japanese
    Introduction scientific journal

  • 再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
    西村明子, 清田尚臣, 豊田昌徳, 茶屋原菜穂子, 竹中圭, 瓜生恭章, 今村善宣, 船越洋平, 向原徹, 南博信
    2015, 日本内科学会雑誌, 104

  • Takashi Ura, Shuichi Hironaka, Yasuhiro Tsubosa, Junki Mizusawa, Kozo Kataoka, Ken Kato, Yuko Kitagawa, Takayuki Kii, Akihisa Tomori, Naomi Kiyota, Toshikatsu Taniki, Keisho Chin, Takashi Kojima, Yuichiro Doki
    Jan. 2015, JOURNAL OF CLINICAL ONCOLOGY, 33(3) (3), English
    Summary international conference

  • 【進化する頭頸部がん・食道がん・胃がんに対する個別化治療】 頭頸部がんの分子標的薬治療について
    竹中 圭, Kiyota Naomi
    科学評論社, Jan. 2015, 腫瘍内科, 15(1号) (1号), 14 - 20, Japanese
    Introduction scientific journal

  • Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study
    Yukinari Sanada, Kimikazu Yakushijin, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Naoko Chayahara, Masanori Toyoda, Yosuke Minami, Naomi Kiyota, Toru Mukohara, Shinichiro Kawamoto, Yohei Shimono, Mitsuhiro Ito, Hiroshi Matsuoka, Hironobu Minami
    Dec. 2014, BLOOD, 124(21) (21), English
    Summary international conference

  • Yukinari Sanada, Kimikazu Yakushijin, Katsuya Yamamoto, Meiko Nishimura, Yohei Funakoshi, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Hironobu Minami
    Oct. 2014, ANNALS OF ONCOLOGY, 25, English
    Summary international conference

  • Naomi Kiyota
    Oct. 2014, ANNALS OF ONCOLOGY, 25, English
    Summary international conference

  • Meiko Nishimura, Naomi Kiyota, Masanori Toyoda, Naoko Chayahara, Kei Takenaka, Kiyoaki Uryu, Yoshinori Imamura, Yohei Funakoshi, Toru Mukohara, Hironobu Minami
    Oct. 2014, ANNALS OF ONCOLOGY, 25, English
    Summary international conference

  • 【大きく変わりつつある頭頸部癌化学療法】 術後補助療法
    Kiyota Naomi
    Aug. 2014, JOHNS, 30(8号) (8号), 977 - 980, Japanese
    [Invited]
    Introduction scientific journal

  • 今村 善宣, Kiyota Naomi
    (株)メディカルレビュー社, Jul. 2014, 頭頸部癌Frontier, 2(1号) (1号), 106 - 107, Japanese
    [Invited]
    Introduction commerce magazine

  • 【頭頸部癌に対する最新治療】 セツキシマブ療法 セツキシマブの副作用 薬剤性間質性肺炎とその対策
    Kiyota Naomi
    Jul. 2014, 頭頸部癌Frontier, 2(1号) (1号), 70 - 73, Japanese
    [Invited]
    Introduction commerce magazine

  • A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-131-refractory differentiated thyroid cancer (SELECT)
    Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Elisei, Corina E. Dutcus, Begoria de las Heras, Junming Zhu, Mouhammed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew Hiram Taylor, Sung-Bae Kim, Monika K. Krzyzanowska, Steven I. Sherman
    Jun. 2014, JOURNAL OF CLINICAL ONCOLOGY, 32(18) (18), English
    Summary international conference

  • Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
    Yutaka Fujiwara, Naomi Kiyota, Masanori Toyoda, Takanobu Shimada, Yoshinori Imamura, Toru Mukohara, Hironobu Minami
    May 2014, JOURNAL OF CLINICAL ONCOLOGY, 32(15) (15), English
    Summary international conference

  • A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-134-refractory differentiated thyroid cancer (SELECT)
    Martin Schlumberger, Makoto Tahara, Lori J. Wirth, Bruce Robinson, Marcia S. Brose, Rossella Ellsel, Corina E. Dutcus, Begona de las Hares, Junming Zhu, Mouhamed Amir Habra, Kate Newbold, Manisha H. Shah, Ana O. Hoff, Andrew G. Gianoukakis, Naomi Kiyota, Matthew Hiram Taylor, Sung-Bae Kim, Monika K. Krzyranowska, Steven I. Sherman
    May 2014, JOURNAL OF CLINICAL ONCOLOGY, 32(15) (15), English
    Summary international conference

  • 【最新がん薬物療法学-がん薬物療法の最新知見-】 臓器別がんの薬物療法 頭頸部がん
    Kiyota Naomi
    Feb. 2014, 日本臨床, 72(増刊2 最新がん薬物療法学) (増刊2 最新がん薬物療法学), 324 - 327, Japanese
    [Invited]
    Introduction scientific journal

  • Koichiro Watanabe, Hironobu Minami, Satoshi Otsu, Yoshinori Hirashima, Ryotaro Morinaga, Kazuo Nishikawa, Yasushi Hisamatsu, Toru Mukohara, Naomi Kiyota, Naoko Chayahara, Masanori Toyoda, Yoshinori Imamura, Yutaka Fujiwara, Cornelia Quadt, Matthew Robson, Kazuto Natsume, Takuji Aoki, Kuniaki Shirao
    Nov. 2013, MOLECULAR CANCER THERAPEUTICS, 12(11) (11), English
    Summary international conference

  • Radiation-Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: Comparison Between Concurrent Chemoradiation Therapy and Radiation Therapy Alone
    D. Miyawaki, K. Yoshida, Y. Ejima, H. Nishimura, N. S. Sulaiman, N. Kiyota, M. Saito, N. Otsuki, K. Nibu, R. Sasaki
    Oct. 2013, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 87(2) (2), S472 - S473, English
    Summary international conference

  • Bulletin 第37回欧州臨床腫瘍学会(ESMO2012)における頭頸部癌の話題
    清田 尚臣
    メディカルレビュー社, Sep. 2013, 頭頸部癌frontier, 1(2) (2), 199 - 201, Japanese

  • 25-year experience with primary major salivary gland carcinoma at a single institution in Japan
    Y. Imamura, N. Kiyota, N. Otsuki, C. Hirai, Y. Funakoshi, T. Mukohara, D. Yamashita, T. Ito, K. Nibu, H. Minami
    Sep. 2013, EUROPEAN JOURNAL OF CANCER, 49, S753 - S753, English
    Summary international conference

  • 【分子標的治療薬の選び方、使い方】 分子標的治療薬の選び方、使い方 パニツムマブ
    今村 善宣, Kiyota Naomi
    (株)ヴァンメディカル, Aug. 2013, 臨床腫瘍プラクティス, 9(3号) (3号), 252 - 253, Japanese
    Introduction scientific journal

  • 【分子標的治療薬の選び方、使い方】 分子標的治療薬の選び方、使い方 セツキシマブ
    今村 善宣, Kiyota Naomi
    Aug. 2013, 臨床腫瘍プラクティス, 9(3号) (3号), 249 - 251, Japanese
    Introduction scientific journal

  • 【分子標的治療薬の使用手引き2013】 分子標的治療薬 抗EGFR抗体
    Kiyota Naomi
    Aug. 2013, コンセンサス癌治療, 12(3号) (3号), 128 - 131, Japanese
    Introduction scientific journal

  • 【分子標的薬時代の耳鼻咽喉科診療-処方するとき,服用患者を診るときのポイント】 頭頸部癌に対する分子標的薬治療 頭頸部癌に対する分子標的薬の将来展望 セツキシマブのほかには何があるのか
    Kiyota Naomi
    Jun. 2013, 耳鼻咽喉科・頭頸部外科, 85(7号) (7号), 488 - 492, Japanese
    Introduction scientific journal

  • Phase I/II trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (DCF) followed by concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
    Hironaga Satake, Makoto Tahara, Satoshi Mochizuki, Sadamoto Zenda, Takashi Kojima, Hideaki Bando, Tomoko Yamazaki, Ken Kato, Satoru Iwasa, Yoshitaka Honma, Hiroki Hara, Tomoya Yokota, Satoshi Hamauchi, Naomi Kiyota, Takayuki Kii, Keisho Chin, Atsushi Ohtsu
    May 2013, JOURNAL OF CLINICAL ONCOLOGY, 31(15) (15), English
    Summary international conference

  • 頭頸部扁平上皮癌に対する放射線治療後の甲状腺機能低下症に関する検討
    Miyawaki Daisuke, 吉田 賢史, Ejima Yasuo, 西村 英輝, 岡本 欣晃, Kiyota Naomi, 斉藤 幹, 大月 直樹, 丹生 健一, Sasaki Ryohei
    (一社)日本頭頸部癌学会, May 2013, 頭頸部癌, 39(2号) (2号), 262 - 262, Japanese
    Meeting report

  • 当院におけるT3喉頭癌の放射線治療の経験
    松尾 圭朗, 吉田 賢史, Miyawaki Daisuke, Ejima Yasuo, Kiyota Naomi, 斎藤 幹, 大月 直樹, 丹生 健一, Sasaki Ryohei
    (一社)日本頭頸部癌学会, May 2013, 頭頸部癌, 39(2号) (2号), 186 - 186, Japanese
    Meeting report

  • 進行舌癌に対する術後放射線治療の経験
    吉田 賢史, Miyawaki Daisuke, Ejima Yasuo, 西村 英輝, Kiyota Naomi, 南川 勉, 斉藤 幹, 大月 直樹, 丹生 健一, Sasaki Ryohei
    (一社)日本頭頸部癌学会, May 2013, 頭頸部癌, 39(2号) (2号), 250 - 250, Japanese
    Meeting report

  • 【セツキシマブのすべて】 大腸癌など頭頸部癌以外の癌腫におけるセツキシマブの効果について
    Kiyota Naomi
    May 2013, 頭頸部癌Frontier, 1(1号) (1号), 33 - 35, Japanese
    Introduction scientific journal

  • T1/2声門上癌に対する放射線治療成績の検討
    松本 葉子, 吉田 賢史, Ejima Yasuo, Miyawaki Daisuke, 西村 英輝, 斉藤 幹, 大月 直樹, 丹生 健一, Kiyota Naomi, Sasaki Ryohei
    (一社)日本頭頸部癌学会, May 2013, 頭頸部癌, 39(2号) (2号), 264 - 264, Japanese
    Meeting report

  • sunitinibを使用し腸管壊死をきたしたACTH産生神経内分泌腫瘍
    眞田幸尚, 向原徹, 今村善宣, 西村明子, 船越洋平, 富岡秀夫, 島田貴信, 豊田昌徳, 清田尚臣, 南博信
    2013, 日本臨床腫瘍学会学術集会(CD-ROM), 11th

  • 分子標的薬の適正な使用について 分子標的薬の適正な使用のために 分子標的薬の特徴を理解する
    Kiyota Naomi
    Dec. 2012, 頭頸部癌, 38(4号) (4号), 399 - 402, Japanese
    [Refereed][Invited]
    Introduction scientific journal

  • Patterns of Local Recurrence and Metachronous Malignancy Following Radiation Therapy for Stage I or II Hypopharyngeal Carcinoma: Role of Close Observation and Multidisciplinary Approach
    H. Nishimura, R. Sasaki, K. Yoshida, D. Miyawaki, Y. Okamoto, N. Kiyota, M. Saito, N. Otsuki, K. Nibu
    Nov. 2012, INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 84(3) (3), S491 - S491, English
    Summary international conference

  • A PILOT RANDOMIZED TRIAL COMPARING STANDARD PAIN CONTROL WITH OR WITHOUT GABAPENTIN FOR THE TREATMENT OF PAIN RELATED TO RADIATION-INDUCED MUCOSITIS IN HEAD AND NECK CANCER
    T. Kataoka, N. Kiyota, T. Shimada, Y. Imamura, N. Chayahara, M. Toyoda, Y. Funakoshi, H. Tomioka, Y. Fujiwara, K. Nibu, T. Komori, H. Nishimura, R. Sasaki, T. Mukohara, H. Minami
    Oct. 2012, ANNALS OF ONCOLOGY, 23, 91 - 91, English
    Summary international conference

  • DACARBAZINE MONO-THERAPY FOR UNRESECTABLE NEUROENDOCRINE TUMOR: A RETROSPECTIVE ANALYSIS
    Y. Imamura, Y. Fujiwara, M. Toyoda, N. Chyayahara, M. Nishimura, Y. Funakoshi, H. Tomioka, T. Shimada, K. Yakushijin, A. Okamura, N. Kiyota, T. Mukohara, H. Matsuoka, H. Minami
    Oct. 2012, ANNALS OF ONCOLOGY, 23, 161 - 161, English
    Summary international conference

  • 頭頸部癌に対する分子標的治療
    Nibu Ken-ichi, Ohtsuki Naoki, Kiyota Naomi
    Jul. 2012, 日本耳鼻咽喉科学会会報, 115(7号) (7号), 671 - 675, Japanese
    [Refereed][Invited]
    Introduction scientific journal

  • 当院における高齢者食道癌の内科的治療の成績と戦略について
    Okuno Tatsuya, Toyoda Masanori, Kiyota Naomi, Imanishi Tatsuya, Nakamura Tetsu, Azuma Takeshi
    Jun. 2012, 日本食道学会学術集会プログラム・抄録集66回, 283, Japanese
    [Refereed]
    Meeting report

  • Daily performance status-based target physical activity of early rehabilitation for hematologic malignancy patients after allogeneic hematopoietic stem cell transplantation.
    Inoue Junichiro, Ono Rei, Okamura Atsuo, Kiyota Naomi, Makiura Daisuke, Kashiwa Miyuki, Miura Yasushi, Kurosaka Masahiro, Saura Ryuichi
    20 May 2012, JOURNAL OF CLINICAL ONCOLOGY, 30(15) (15)
    [Refereed]

  • Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706
    Makoto Tahara, Naomi Kiyota, Junki Mizusawa, Kenichi Nakamura, Ryuichi Hayashi, Tetsuo Akimoto, Yasuhisa Hasegawa, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Hirofumi Fujii, Yusuke Onozawa, Akihiro Homma, Akira Kubota, Haruhiko Fukuda, Masato Fujii
    May 2012, JOURNAL OF CLINICAL ONCOLOGY, 30(15) (15), English
    Summary international conference

  • 頭頸部癌患者における放射線性粘膜炎による疼痛に対するガバペンチンのパイロット・ランダム化比較試験
    片岡 智子, 清田 尚臣, 島田 貴信, 今村 善宣, 茶屋原 菜穂子, 豊田 昌徳, 船越 洋平, 富岡 秀夫, 藤原 豊, 丹生 健一, 古森 孝英, 西村 英輝, 佐々木 良平, 向原 徹, 南 博信
    (一社)日本頭頸部癌学会, May 2012, 頭頸部癌, 38(2) (2), 188 - 188, Japanese

  • 当院における中咽頭扁平上皮癌に対する放射線治療成績
    宮脇 大輔, 西村 英輝, 吉田 賢史, 原田 文, 村岡 修, ノル・シャズリナ, 清田 尚臣, 斎藤 幹, 大月 直樹, 丹生 健一, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2012, 頭頸部癌, 38(2) (2), 195 - 195, Japanese

  • 頸部リンパ節転移を認めた原発不明悪性黒色腫の2例
    米澤 宏一郎, 森本 浩一, 山下 大介, 谷本 均, 斉藤 幹, 大月 直樹, 丹生 健一, 清田 尚臣, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2012, 頭頸部癌, 38(2) (2), 226 - 226, Japanese

  • 多診療科共同で集学的治療を行った頭頸部原発骨軟部肉腫の2例
    島田 貴信, 清田 尚臣, 米澤 宏一郎, 土井 清司, 長谷川 信吾, 西村 英輝, 佐々木 良平, 南川 勉, 橋川 和信, 田原 真一, 丹生 健一
    (一社)日本頭頸部癌学会, May 2012, 頭頸部癌, 38(2) (2), 231 - 231, Japanese

  • 【術前補助化学療法をめぐって】 術前補助化学療法の適応と実際 頭頸部がんに対する術前補助化学(放射線)療法 導入化学療法が適応となる症例と、期待される効果
    Kiyota Naomi
    ヴァン・メディカル, May 2012, 臨床腫瘍プラクティス, 8(2号) (2号), 105 - 110, Japanese
    [Invited]
    Introduction scientific journal

  • 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法
    Fujiwara Yutaka, Toyoda Masanori, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    Feb. 2012, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 174, Japanese
    [Refereed]
    Meeting report

  • Extra-Pulmonary Neuroendocrine Carcinoma(EP-NEC)に対する救済化学療法としてのアムルビシン(AMR)の効果
    Toyoda Masanori, Fujiwara Yutaka, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    Feb. 2012, 日本内科学会雑誌, 101(Suppl.) (Suppl.), 241, Japanese
    [Refereed]
    Meeting report

  • 造血幹細胞移植前の眼科受診の意義
    薬師神公和, 船越洋平, 垣内誠司, 今村善宣, 乾由美子, 川森有里子, 豊田昌徳, 島田貴信, 富岡秀夫, 茶屋原菜穂子, 清田尚臣, 藤原豊, 向原徹, 岡村篤夫, 山本克也, 村山徹, 村山徹, 松岡広, 南博信
    2012, 日本造血細胞移植学会総会プログラム・抄録集, 34th

  • 頭頸部癌化学放射線療法の位置づけと今後 術後補助化学放射線療法の実臨床への浸透のために
    Kiyota Naomi
    Oct. 2011, 頭頸部癌, 37巻, 3号, pp. 362-365, Japanese
    Introduction scientific journal

  • 局所進行切除不能食道癌(T4/M1LYM)に対する化学放射線療法の遡及的検討
    西村 英輝, 関井 修平, 吉田 賢史, 宮脇 大輔, 村岡 修, 奥野 達哉, 清田 尚臣, 岡本 欣晃, 副島 俊典, 佐々木 良平
    (NPO)日本食道学会, Sep. 2011, 日本食道学会学術集会プログラム・抄録集, 65回, 323 - 323, Japanese

  • 当科における喉頭機能温存手術の検討
    米澤 宏一郎, 森本 浩一, 齋藤 幹, 大月 直樹, 清田 尚臣, 西村 英輝, 佐々木 良平, 丹生 健一
    (一社)日本頭頸部癌学会, May 2011, 頭頸部癌, 37(2) (2), 249 - 249, Japanese

  • 遊離空腸再建後の高リスク頭頸部癌に対する術後放射線治療の検討
    西村 英輝, 佐々木 良平, 吉田 賢史, 宮脇 大輔, 丹生 健一, 大月 直樹, 斉藤 幹, 清田 尚臣, 岡本 欣晃, 副島 俊典
    (一社)日本頭頸部癌学会, May 2011, 頭頸部癌, 37(2) (2), 257 - 257, Japanese

  • 切除不能頭頸部癌に対するSequential therapyの安全性に関する後向き研究
    島田 貴信, 清田 尚臣, 大月 直樹, 丹生 健一, 西村 英輝, 佐々木 良平
    (一社)日本頭頸部癌学会, May 2011, 頭頸部癌, 37(2) (2), 258 - 258, Japanese

  • 局所進行外耳道扁平上皮癌に対する3剤(TPF)併用化学放射線療法の経験
    吉田 賢史, 西村 英輝, 宮脇 大輔, 村岡 修, 佐々木 良平, 清田 尚臣, 土井 清司, 長谷川 信吾, 丹生 健一
    (一社)日本頭頸部癌学会, May 2011, 頭頸部癌, 37(2) (2), 320 - 320, Japanese

  • 【抗EGFR抗体療法の展望】 頭頸部がん治療における抗EGFR抗体薬の位置づけ
    Kiyota Naomi
    Apr. 2011, がん分子標的治療, 9巻, 2号, pp. 116-124, Japanese
    Introduction scientific journal

  • 局所進行外耳道扁平上皮癌に対する3剤(TPF)併用化学放射線療法の経験
    難波 富美子, 吉田 賢史, 西村 英輝, 宮脇 大輔, 橋本 直樹, 村岡 修, 佐々木 良平, 清田 尚臣, 長谷川 信吾, 丹生 健一
    (公社)日本医学放射線学会, Feb. 2011, 日本医学放射線学会学術集会抄録集, 70回, S353 - S353, Japanese

  • 原発不明癌頸部リンパ節転移に対する治療経験
    村岡 修, 吉田 賢史, 西村 英輝, 宮脇 大輔, 清田 尚臣, 斎藤 幹, 大月 直樹, 丹生 健一, 岡本 欣晃, 佐々木 良平
    (公社)日本医学放射線学会, Feb. 2011, 日本医学放射線学会学術集会抄録集, 70回, S354 - S354, Japanese

  • 急性GVHD予防薬ミコフェノール酸モフェチル(MMF)使用下における移植後G-CSF至適投与量の検討
    岡村篤夫, 薬師神公和, 乾由美子, 船越洋平, 富岡秀夫, 島田貴信, 豊田昌徳, 茶屋原菜穂子, 清田尚臣, 藤原豊, 向原徹, 山本克也, 松岡広, 南博信
    2011, 日本造血細胞移植学会総会プログラム・抄録集, 33rd

  • 臍帯血移植前にボリコナゾール水晶体内投与が有効であった真菌性眼内炎
    船越洋平, 薬師神公和, 明石梓, 楠原仙太郎, 土井健史, 乾由美子, 豊田昌徳, 島田貴信, 茶屋原菜穂子, 富岡秀夫, 清田尚臣, 藤原豊, 向原徹, 岡村篤夫, 山本克也, 松岡広, 村山徹, 村山徹, 南博信
    2011, 日本造血細胞移植学会総会プログラム・抄録集, 33rd

  • PHASE I TRIAL OF COMBINATION CHEMOTHERAPY WITH DOCETAXEL, CISPLATIN AND S-1 IN PATIENTS WITH HEAD AND NECK CANCER
    Makoto Tahara, Kazuhiro Araki, Susumu Okano, Naomi Kiyota, Nozomu Fuse, Keiko Minashi, Takayuki Yoshino, Toshihiko Doi, Sadamoto Zenda, Mitushiko Kawashima, Takashi Ogino, Ryuichi Hayashi, Hironobu Minami, Atsushi Ohstu
    Nov. 2010, ANNALS OF ONCOLOGY, 21, 34 - 34, English
    Summary international conference

  • OLFACTORY NEUROBLASTOMA: IMPACT OF INDUCTION CHEMOTHERAPY AND PROTON BEAM THERAPY
    M. Tahara, S. Okano, T. Yamazaki, N. Kiyota, S. Zenda, M. Kawashima, T. Ogino, R. Hayashi, A. Ohtsu
    Oct. 2010, ANNALS OF ONCOLOGY, 21, 327 - 327, English
    Summary international conference

  • 本邦における頭頸部癌化学療法の展望 化学療法臨床研究の現状と対策
    Kiyota Naomi
    Oct. 2010, 頭頸部癌, 36巻, 3号, pp. 278-281, Japanese
    Introduction scientific journal

  • Cancer-Prevention and Early Detection 頭頸部がんとHPV(human papillomavirus)
    Kiyota Naomi
    Jul. 2010, がん分子標的治療, 8巻, 3号, pp. 223-227, Japanese
    Introduction scientific journal

  • 結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価
    藤原豊, 茶屋原菜穂子, 向原徹, 清田尚臣, 富岡秀夫, 船越洋平, 南博信
    2010, 日本内科学会雑誌, 99

  • Yasuhide Yamada, Hironobu Minami, Nozomu Fuse, Atsushi Ohtsu, Ken Kato, Naomi Kiyota, Yasushiro Shimada, Toshihiko Doi, Takako Nakajima, Tetsuya Hamaguchi, Yutaka Fujiwara, Yuichiro Ito, Kiyomi Mera
    Dec. 2009, MOLECULAR CANCER THERAPEUTICS, 8(12) (12), English
    Summary international conference

  • Yutaka Fujiwara, Naomi Kiyota, Naoko Chayahara, Akiyuki Suzuki, Yoshiko Umeyama, Toru Mukohara, Hironobu Minami
    Dec. 2009, MOLECULAR CANCER THERAPEUTICS, 8(12) (12), English
    Summary international conference

  • 化学放射線療法(CCRT)と頸部制御 頭頸部癌に対する化学放射線療法後の頸部郭清に関する文献的考察 Planned Neck DissectionかSalvage Neck Dissectionか
    Kiyota Naomi
    Sep. 2009, 耳鼻と臨床, 55 (044巻, Suppl.1, pp.(1) (1), S85 - S90, Japanese
    Introduction scientific journal

  • 【食道がんの治療をどう行うか】 食道がんの化学放射線療法(50.4Gyか60Gyか) 50.4GyでOK
    Kiyota Naomi
    ヴァン・メディカル, Feb. 2009, 臨床腫瘍プラクティス, 5巻, 1号, pp. 72-74(1) (1), 72 - 74, Japanese
    Introduction scientific journal

  • Feasibility study of a new percutaneous endoscopic gastrostomy (PEG) procedure, the "Direct IDEAL PEG", in patients with advanced head and neck cancer or esophageal cancer
    Tomonori Yano, Manabu Mute, Keiko Minashi, Naomi Kiyota, Takashi Kojima, Satoshi Takeuchi, Makoto Tahara, Kazuhiro Kaneko, Atsushi Ohtsu
    Apr. 2008, GASTROINTESTINAL ENDOSCOPY, 67(5) (5), AB190 - AB191, English
    Summary international conference

  • Kiyota Naomi
    (有)科学評論社, Dec. 2007, 腫瘍内科, 1巻, 6号, pp. 584-591(6) (6), 584 - 591, Japanese
    Introduction scientific journal

  • 再発消化管癌に対する治療 上部消化管 根治的化学放射線療法後遺残・再発食道癌に対するDocetaxelの治療成績
    鶴田 真也, 矢野 友規, 三梨 桂子, 武藤 学, 田原 信, 清田 尚臣, 布施 望, 土井 俊彦, 大津 敦
    (一社)日本癌治療学会, Sep. 2007, 日本癌治療学会誌, 42(2) (2), 282 - 282, Japanese

  • 頭頸部癌に対する集学的治療 頭頸部腫瘍に対する化学放射線療法前の内視鏡的胃瘻造設術(PEG)の安全性と有用性
    清田 尚臣, 田原 信, 武藤 学, 斉藤 真由子, 鶴田 真也, 江副 康正, 小島 隆嗣, 三梨 桂子, 矢野 友規, 土井 俊彦, 大津 敦
    (一社)日本癌治療学会, Sep. 2007, 日本癌治療学会誌, 42(2) (2), 308 - 308, Japanese

  • チアーパック入り半固形栄養剤と専用コネクターを用いた新しい胃瘻栄養管理の前向き検討
    服部 三太, 武藤 学, 矢野 友規, 三梨 桂子, 田原 信, 小島 隆嗣, 清田 尚臣, 竹内 啓, 江副 康正, 伊東 文生, 大津 敦, 吉田 茂昭
    (一社)日本消化器内視鏡学会, Apr. 2007, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 971 - 971, Japanese

  • 頭頸部癌に対する化学放射線療法前の予防的内視鏡的胃瘻造設術によって腹壁転移をきたした2例
    鶴田 真也, 矢野 友規, 武藤 学, 田原 信, 齊藤 真由子, 三梨 桂子, 清田 尚臣, 大津 敦, 吉田 茂昭
    (一社)日本消化器内視鏡学会, Apr. 2007, Gastroenterological Endoscopy, 49(Suppl.1) (Suppl.1), 972 - 972, Japanese

  • 【食道癌治療における放射線化学療法の位置づけと展望】 食道癌化学放射線療法の位置づけと今後の展望
    藤島 佳未, 武藤 学, 三梨 桂子, 矢野 友規, 小島 隆嗣, 清田 尚臣, 竹内 啓, 池松 弘朗, 田原 信, 土井 俊彦, 大津 敦, 吉田 茂昭
    (有)科学評論社, Apr. 2007, 消化器科, 44(4) (4), 375 - 380, Japanese

  • What's going on 消化器癌 Phase 1 Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. J Clin Oncol. 2005; 23: 6957-65. PMID: 16145066.--進行胃癌に対するS-1+CDDP併用療法の第1相薬物動態試験
    清田 尚臣, 大津 敦
    メジカルビュー社, 2006, Mebio oncology, 3(1) (1), 106 - 108, Japanese

  • 当院における切除不能・再発大腸癌に対する全身化学療法の治療成績
    清田 尚臣, 目良 清美, 土井 俊彦, 布施 望, 矢野 友規, 武藤 学, 佐野 寧, 大津 敦, 吉田 茂昭
    (一社)日本癌治療学会, Sep. 2005, 日本癌治療学会誌, 40(2) (2), 318 - 318, Japanese

  • A Case of Squamous Epithelia Simulating an Early Gastric Cancer, Type IIc of the Gastric Antrum Underwent Endoscopic Mucosal Resection
    TAKAHASHI Hajime, ASHIDA Kiyoshi, UEDA Satoshi, KIYOTA Naomi, FUKUCHI Takumi, NISHIDE Tomohiro, HAKUI Toshihiko, TOYOTA Joh, NAGAMATSU Ryousuke
    20 Jun. 2003, Gastroenterol Endosc, 45(6) (6), 1031 - 1035, Japanese

■ Books And Other Publications
  • 頭頸部がん薬物療法ハンドブック
    田原, 信, 清田, 尚臣, 藤井, 正人
    中外医学社, Nov. 2021, Japanese, ISBN: 9784498022881

  • 新臨床腫瘍学 : がん薬物療法専門医のために
    日本臨床腫瘍学会
    Contributor, 内分泌がん, 南江堂, May 2021, Japanese, ISBN: 9784524227396

  • 頭頸部がん薬物療法ガイダンス / 頭頸部がん薬物療法ガイダンス
    Kiyota Naomi
    Joint editor, 金原出版株式会社, Oct. 2018, Japanese
    Scholarly book

  • 新臨床腫瘍学 / 41 内分泌がん
    Kiyota Naomi
    Others, 南江堂, Jun. 2018, Japanese
    Textbook

  • 頭頸部癌診療ガイドライン2018年版 / 頭頸部癌診療ガイドライン2018年版
    Kiyota Naomi
    Joint editor, 金原出版株式会社, Dec. 2017, Japanese
    Scholarly book

  • 頭頸部がん薬物療法ハンドブック
    田原, 信, 清田, 尚臣, 藤井, 正人
    中外医学社, Aug. 2017, Japanese, ISBN: 9784498062696

  • 頭頸部がん薬物療法ガイダンス / 頭頸部がん薬物療法ガイダンス
    Kiyota Naomi
    Joint editor, 金原出版株式会社, Jul. 2015, Japanese
    Scholarly book

  • 頭頸部がん化学療法ハンドブック = Handbook of head & neck cancer chemotherapy
    田原, 信, 清田, 尚臣, 藤井, 正人
    中外医学社, May 2014, Japanese, ISBN: 9784498062689

  • 頭頸部がん化学療法ハンドブック
    Kiyota Naomi
    Joint editor, 中外医学社, May 2014, Japanese
    Textbook

  • 新臨床腫瘍学 / 血管新生に対する抗体薬
    Kiyota Naomi
    Others, 南江堂, Dec. 2012, Japanese
    Textbook

  • 目で見て学ぶ放射線療法の有害反応 / 化学放射線療法に伴う有害反応
    Kiyota Naomi
    Joint work, 日本看護協会出版会, Feb. 2011, Japanese
    Textbook

  • 身で見て学ぶ放射線療法の有害反応 / 放射線療法と併用される化学療法の理解
    Kiyota Naomi
    Joint work, 日本看護協会出版会, Feb. 2011, Japanese
    Textbook

  • EBM がん化学療法・分子標的治療法 / TPF療法後の化学放射線療法は標準治療とみなしうるか？
    Kiyota Naomi
    Joint work, 中外医学社, Nov. 2010, Japanese
    Scholarly book

  • EBM 耳鼻咽喉科・頭頸部外科の治療 / 放射線治療におけるPEG（内視鏡的胃瘻造設術）のEBMとは
    Kiyota Naomi
    Joint work, 中外医学社, May 2010, Japanese
    Scholarly book

  • EBM 耳鼻咽喉科・頭頸部外科の治療 / 術後化学放射線療法のエビデンスとは
    Kiyota Naomi
    Joint work, 中外医学社, May 2010, Japanese
    Scholarly book

  • 臨床腫瘍プラクティス / 食道癌の化学放射線療法（50.4Gyか60Gyか）
    Kiyota Naomi
    Joint work, ヴァンメディカル, Feb. 2009, Japanese
    Scholarly book

  • 新臨床腫瘍学 / Bevacizumab
    Kiyota Naomi
    Joint work, 南江堂, 2009, Japanese
    Textbook

  • Cancer Treatment Navigator / 抗VEGF抗体
    Kiyota Naomi
    Joint work, 株式会社メディカルレビュー社, Nov. 2008, Japanese
    Scholarly book

  • 癌の基礎から臨床へ / 塩酸イリノテカンの薬物代謝動態におけるUGT1A1遺伝子多型の臨床的意義
    Kiyota Naomi
    Joint work, 篠原出版新社, Oct. 2008, Japanese
    Scholarly book

■ Lectures, oral presentations, etc.
  • シスプラチン併用化学放射線療法の現状とこれから：術後シスプラチン併用化学放射線療法
    清田尚臣
    第47回日本頭頸部癌学会, Jun. 2023, Japanese, Domestic conference
    [Invited]
    Nominated symposium

  • Darolutamide for patients with androgen receptor positive salivary gland cancers (DISCOVARY): The results of phase 2 study of darolutamide monotherapy
    Susumu Okano, Makoto Tahara, Yoshinori Imamura, Hideoki Uryu, Tomoyuki Otsuka, Akira Ohkoshi, Daisuke Sano, Kiyoaki Tsukahara, Kazuchika Ono, Toyoyuki Hanazawa, Satoshi Kano, Naoki Nishio, Masato Nagaoka, Naomi Kiyota
    ASCO2023, Jun. 2023, English, International conference
    Poster presentation

  • A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.
    Yoshiaki Nagatani, Naomi Kiyota, Tomoko Yamazaki, Yukinori Asada, Masaaki Higashino, Masahiro Goto, Hironaga Satake, Ichiro Ota, Hirokazu Uemura, Katsunari Yane, Kaoru Tanaka, Takuma Onoe, Shigemichi Iwae, Shigeru Hirano, Yoshinori Imamura, Shiro Kimbara, Taku Nose, Taiji Koyama, Yohei Funakoshi, Hironobu Minami
    ASCO2023, Jun. 2023, English, International conference
    Poster presentation

  • A risk prediction model for cisplatin-induced acute kidney injury in head and neck cancer patients who receive chemoradiotherapy: A supplement analysis of a phase II/III trial of JCOG1008
    Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma
    ASCO2023, Jun. 2023, English, International conference
    Poster presentation

  • Impact of acute kidney injury on overall survival in postoperative patients with head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of a phase II/III trial of JCOG1008
    Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Takeshi Kodaira, Ryuichi Hayashi, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Shigemichi Iwae, Naoki Nishio, Yusuke Onozawa, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Ryo Kitabayashi, Keita Sasaki, Akihiro Homma
    ASCO2023, Jun. 2023, English, International conference
    Poster presentation

  • A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody
    Taiji Koyama, Naomi Kiyota, Yoshinori Imamura, Shogen Boku, Nobuhiro Shibata, Hironaga Satake, Kaoru Tanaka, Hidetoshi Hayashi, Shigemichi Iwae, Takuma Onoe, Yukinori Asada, Tomoko Yamazaki, Taku Nose, Shinya Ohata, Shiro Kimbara, Yoshiaki Nagatani, Hironobu Minami
    ASCO2023, Jun. 2023, English
    Poster presentation

  • Phase IV study validating the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module
    Singer S, Al-Ibraheem A, Pinto M, Iakovou I, Osthus A, Hammerid E, Locati L, Gamper E, Arraras J, Jordan S, Kiyota N, Buttner M, Canotiho R, Ioannidis G, Husson O, Gama R, Fanetti G, Inhestern J, Andry G, Sykiotis G
    JSMO2023, Mar. 2023, English, International conference, Co-authored internationally
    Oral presentation

  • Feasibility of the online-based quality of life survey in patients with head and neck cancer. A multi-center, prospective study
    Ishiki H, Kobayashi T, Doi H, Arakawa S, Amano K, Satomi E, Honma Y, Terada M, Mizusawa J, Kikawa Y, Imamura Y, Koyama T, Nakano K, Dagmara K, Singer S, Rumpold G, Hozner B, Bottomley A, Kiyota N
    JSMO2023, Mar. 2023, English, International conference, Co-authored internationally
    Oral presentation

  • Multidisciplinary Tumor Board of Recurrent or Metastatic Nasopharyngeal Cancer Case presentation and overview of treatment strategy for RM-NPC
    Naomi Kiyota
    ESMO Asia 2022, Dec. 2022, English
    [Invited]
    Nominated symposium

  • Updated Evidences and Optimal Treatment Strategy for Locally Advanced Head and Neck Cancer
    Naomi Kiyota
    5. 日本放射線腫瘍学会第35回学術大会, Nov. 2022, Japanese
    [Invited]
    Nominated symposium

  • Current Treatment Strategy and Future Perspective of Unresectable Anaplastic Thyroid Cancer in Japan
    Naomi Kiyota
    ACKSS2022, Nov. 2022, English
    [Invited]
    Nominated symposium

  • 進行甲状腺がんに対する薬物療法の進歩と将来展望
    清田尚臣
    第６５回日本甲状腺学会学術集会, Nov. 2022, Japanese
    [Invited]
    Nominated symposium

  • がんゲノム医療時代の甲状腺がんの薬物療法
    清田尚臣
    第６０回日本がん治療学会学術集会, Oct. 2022, Japanese
    [Invited]
    Nominated symposium

  • Recent Updates of Molecular Targeted Treatment for Advanced Thyroid Cancer
    Naomi Kiyota
    WFNMB2022, Sep. 2022, English
    [Invited]
    Nominated symposium

  • 甲状腺がんにおけるがんゲノム医療
    清田尚臣
    第46回日本頭頸部癌学会, Jun. 2022, Japanese
    [Invited]
    Nominated symposium

  • 進行甲状腺がんに対する薬物療法
    清田尚臣
    第13回日本頭頸部癌学会教育セミナー, Jun. 2022, Japanese
    [Invited]
    Public discourse

  • 頭頸部がんに対する薬物療法 update （免疫チェックポイント阻害薬）
    清田尚臣
    第123回日本耳鼻咽喉科・頭頸部外科学会総会・学術講演会, May 2022, Japanese
    [Invited]
    Public discourse

  • Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651
    A. Argiris, K. Harrington, M. Tahara, R.L. Ferris, M. Gillison, J. Fayette, A. Daste, P. Koralewski, R. Mesia Nin, N.F. Saba, M. Mak, M.A, Álvarez Avitia, A. Guminski, U. Müller-Richter, N. Kiyota, M. Roberts, T.A. Khan, K. Miller-Moslin, L. Wei, R. Robert Haddad
    ESMO Congress 2021, Sep. 2021, English
    Oral presentation

  • Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008).
    Naomi Kiyota, Makoto Tahara, Hirofumi Fujii, Tomoko Yamazaki, Hiroki Mitani, Shigemichi Iwae, Yasushi Fujimoto, Yusuke Onozawa, Nobuhiro Hanai, Takenori Ogawa, Hiroki Hara, Nobuya Monden, Eiji Shimura, Shujiro Minami, Takashi Fujii, Kaoru Tanaka, Takeshi Kodaira, Junki Mizusawa, Kenichi Nakamura, Ryuichi Hayashi, Head, Neck Cancer Study, Group of, Japan Clinical, Oncology Group, JCOG-HNCSG
    American Society of Clinical Oncology 2020, May 2020, English
    Oral presentation

  • 頭頸部がん診療連携プログラムについて
    KIYOTA NAOMI
    第３７回日本口腔腫瘍学会, Jan. 2019, Japanese, 日本口腔腫瘍学会, 長崎, Domestic conference
    [Invited]
    Nominated symposium

  • Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.
    Chiaki Suzuki, Naomi Kiyota, Yoshinori Imamura, Junpei Rikitake, Satoshi Sai, Taiji Koyama, Yasuko Hyogo, Yoshiaki Nagatani, Youhei Funakoshi, Masanori Toyoda, Naoki Otsuki, Ken-ichi Nibu, Hironobu Minami
    ASCO-SITC, Jan. 2019, English, サンフランシスコ, International conference
    Poster presentation

  • 肺動脈原発内膜肉腫の3例
    崔 諭司, IMAMURA YOSHINORI, KIYOTA NAOMI, TOYODA MASANORI, FUNAKOSHI YOUHEI, 茶屋原 菜穂子, 兵庫 寧子, 竹中 圭, 須藤 洋崇, 金原 史朗, 小山 泰司, MINAMI HIRONOBU
    第1回日本腫瘍循環器学会学術集会, Nov. 2018, Japanese, 日本腫瘍循環器学会, 東京, Domestic conference
    Poster presentation

  • 悪性腫瘍関連静脈血栓寒栓症に対する包括的研究：J-CAV project in progress
    IMAMURA YOSHINORI, KIYOTA NAOMI, 能勢 拓, 乙井 一典, 森 健太, 喜多川 浩一, 林 秀敏, 大幡 真也, 宮田 吉晴, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第1回日本腫瘍循環器学会学術集会, Nov. 2018, Japanese, 日本腫瘍循環器学会, 東京, Domestic conference
    Oral presentation

  • 頭頸部がんにおける免疫チェックポイント阻害薬と放射線治療
    KIYOTA NAOMI
    第31回日本放射線腫瘍学会学術大会, Oct. 2018, Japanese, 日本放射線腫瘍学会, 京都, Domestic conference
    [Invited]
    Nominated symposium

  • 甲状腺がんに対するレンバチニブ治療中の観血的処置の安全性に関する遡及的検討
    金原 史朗, KIYOTA NAOMI, 今村 善宣, OTSUKI NAOKI, NIBU KENICHI, MINAMIKAWA TSUTOMU, 原 仁美, 角谷 賢一朗, SASAKI RYOHEI, MINAMI HIRONOBU
    日本甲状腺外科学会, Oct. 2018, Japanese, 横浜, Domestic conference
    Oral presentation

  • Nutritional Support Dependence after Curative Chemoradiotherapy in Head and Neck Cancer: a Supplementary Analysis of a Phase II Trial (JCOG0706S1)
    IMAMURA YOSHINORI, KIYOTA NAOMI, T. Akimoto, G. Ogawa, J. Eba, S. Minami, Y. Hasegawa, S. Iwae, N. Monden, K. Matsuura, H. Fujii, Y. Onozawa, A. Homma, R. Hayashi, M. Tahara
    ESMO2018, Oct. 2018, English, 欧州臨床腫瘍学会, ミュンヘン, International conference
    Poster presentation

  • Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive actute myeloid leukemia.
    Kakiuchi S, Sakai R, Kawaguchi K, Higashime A, Kurata K, Ichikawa H, Nagao S, Rikitake J, KIYOTA NAOMI, YAKUSHIJIN KIMIKAZU, MATSUOKA HIROSHI, Minami H
    第80回日本血液学会学術集会, Oct. 2018, English, 日本血液学会, 大阪, Domestic conference
    Poster presentation

  • A randomized phase III study to evaluate the value of the omission of prophylactic neck dissection for stage I/II tongue cancer (RESPOND: JCOG1601)
    N. Hanai, T. Asakage, KIYOTA NAOMI, A. Homma, N. Monden, H. Fukushima, T. Fujii, T. Ogawa, K. Tanaka, J. Mizusawa, J. Eba, R. Hayashi
    ESMO2018, Oct. 2018, English, 欧州臨床腫瘍学会, ミュンヘン, International conference
    Poster presentation

  • A Phase II Trial of Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck
    IMAMURA YOSHINORI, KIYOTA NAOMI, K. Tanaka, H. Hayashi, I. Ota, K. Nario, S. Hirano, A. Arai, S. Iwae, T. Onoe, S. Minami, T. Shimada, K. Yane, T. Yamazaki, Y. Nagatani, TOYODA MASANORI, N. Otsuki, K. Nibu, MINAMI HIRONOBU
    ESMO2018, Oct. 2018, English, 欧州臨床腫瘍学会, ミュンヘン, International conference
    Poster presentation

  • 頭頸部がんと甲状腺がんに対する薬物療法のUpdate
    Naomi Kiyota
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    [Invited]
    Invited oral presentation

  • 透析中の大腸癌患者におけるオキサリプラチンのPKおよび安全性の評価
    長谷 善明, IMAMURA YOSHINORI, 中村 任, 山下 和彦, 奥野 護, 安井 裕之, 平岡 純, 新潟 里歩, 河野 圭志, 兵庫 寧子, 須藤 洋崇, 竹中 圭, FUNAKOSHI YOUHEI, TOYODA MASANORI, KIYOTA NAOMI, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 神戸大学医学部附属病院腫瘍センターにおける免疫関連有害事象の患者教育と診療支援体制の構築
    丹田 雅明, KIYOTA NAOMI, 西岡 達也, 土井 久容, 今西 優子, 田中 美香, 藤原 進, 飛松 和俊, 上田 健博, 立原 素子, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 脂肪幹細胞によるアディプシンを介したヒト乳がん細胞の増殖促進
    後藤 秀彰, 下野 洋平, FUNAKOSHI YOUHEI, IMAMURA YOSHINORI, TOYODA MASANORI, KIYOTA NAOMI, 河野 誠司, 高尾 信太郎, 向原 徹, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 局所進行頭頸部扁平上皮癌に対するTPE 導入化学療法とセツキシマブ併用放射線療法の第Ⅱ相試験
    KIYOTA NAOMI, 尾上 琢磨, 岡野 晋, 高橋 俊二, 北村 守正, 藤井 正人, 妹尾 直, 野上 尚之, 山中 竹春, 全田 貞幹, 田原 信
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • プラチナ抵抗性舌扁平上皮癌に対してニボルマブ投与後にStevens-Johson syndromeを発症した一例
    力武 隼平, 崔 諭司, 金原 史郎, 鈴木 千晶, IMAMURA YOSHINORI, 兵庫 寧子, FUNAKOSHI YOUHEI, TOYODA MASANORI, KIYOTA NAOMI, MINAMI HIRONOBU, 大場 万里恵, 濱岡 大, 田島 翔子, 錦織 千佳子
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 第16回日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Updates of chemotherapy for head and neck cancer and thyroid cancer
    Naomi Kiyota
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    [Invited]
    Invited oral presentation

  • Synchronous esophageal cancer and multiple myeloma: a report of two cases
    東目 亜湖, FUNAKOSHI YOUHEI, 力武 隼平, 兵庫 寧子, 鈴木 千晶, IMAMURA YOSHINORI, TOYODA MASANORI, YAKUSHIJIN KIMIKAZU, KIYOTA NAOMI, MATSUOKA HIROSHI, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例
    崔 諭司, IMAMURA YOSHINORI, KIYOTA NAOMI, 重岡 学, TOYODA MASANORI, FUNAKOSHI YOUHEI, 兵庫 寧子, 須藤 洋崇, 金原 史郎, 奥田 拓亮, 吉田 賢史, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Efficacy and Safety of Nivolumab for Previously Treated Non-squamous Cell Carcinoma of the Head and Neck
    鈴木 千晶, KIYOTA NAOMI, IMAMURA YOSHINORI, 力武 隼平, 崔 諭司, 金原 史郎, 兵庫 寧子, 長谷 善明, FUNAKOSHI YOUHEI, TOYODA MASANORI, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Docetaxel plus Cisplatin in Recurrent and/or Metastatic Non-squamous Cell Carcinoma of Head and Neck: a Phase II Trial
    IMAMURA YOSHINORI, KIYOTA NAOMI, 田中 薫, 林 秀俊, 太田 一郎, 平野 滋, 岩江 信法, 南 修次郎, 家根 且有, 山崎 知子, 長谷 善明, TOYODA MASANORI, 大月 直樹, 丹生 健一, MINAMI HIRONOBU
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Curent status of immune check point inhibitor for recurrent or metastatic head and neck cancer
    Naomi Kiyota
    第16回日本臨床腫瘍学会, Jul. 2018, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • A Retrospective Analysis of Extra-pulmonary Small Cell Carcinoma Treated with Chemotherapy Concurrent with or without Radiotherapy
    Shiro Kimbara, Naomi Kiyota, Junpei Rikitake, Satoshi Sai, Hideaki Goto, Hirotaka Suto, Yasuko Hyogo, Chiaki Suzuki, Yoshiaki Nagatani, Yoshinori Imamura, Youhei Funakoshi, Masanori Toyoda, Hironobu Minami
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • A Multicenter Phase ⅡＴrial of Docetaxel, Cisplatin and Cetuximab (TPE) Followed by Cetuximab with Concurrent Radiotherapy in Patients with Local Advanced Squamous Cell Carcinoma of the Head and Neck (ECRIPS study)
    Naomi Kiyota, Takuma Onoe, Susumu Okano, Shunji Takahashi, Morimasa Kitamura, Masato Fujii, Sunao Senoo, Naoyuki Nogami, Takeharu Yamanaka, Sadamoto Zenda, Makoto Tahara
    第16回日本臨床腫瘍学会, Jul. 2018, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • A Case of Stevens-Johnson Syndrome After Administration of Nivolumab for Platinum-refractory Tongue Cancer
    Junpei Rikitake, Naomi Kiyota, Yoshinori Imamura, Chiaki Suzuki, Marie Ohata, Syoko Tajima, Satoshi Sai, Shiro Kimbara, Yasuko Hyogo, Youhei Funakoshi, Masanori Toyoda, Dai Hamaoka, Chikako Nishigori, Hironobu Minami
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 第16回日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • A case of intimal sarcoma of pulmonary artery with long-term disease stabilization by pazopanib
    Satoshi Sai, Yoshinori Imamura, Naomi Kiyota, Manabu Shigeoka, Masanori Toyoda, Youhei Funakoshi, Yasuko Hyogo, Hirotaka Suto, Shiro Kimbara, Yusuke Okuda, Kenji Yoshida, Hironobu Minami
    第16回日本臨床腫瘍学会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第Ⅱ相臨床試験
    IMAMURA YOSHINORI, KIYOTA NAOMI, 田中 薫, 林 秀俊, 太田 一郎, 平野 滋, 岩江 信法, 南 修次郎, 家根 且有, 山崎 知子, 長谷 善明, 大月 直樹, 丹生 健一, MINAMI HIRONOBU
    第42回日本頭頸部癌学会, Jun. 2018, Japanese, 日本頭頸部癌学会, 東京, Domestic conference
    Oral presentation

  • 再発・転移の頭頸部非扁平上皮癌に対するドセタキセル+シスプラチン併用療法の第II相臨床試録
    今村 善宣, KIYOTA NAOMI, 田中 薫, 林 秀俊, 太田 一郎, 平野 滋, 岩江 信法, 南 修司郎, 家根 且有, 山崎 知子, 長谷 善明, 豊田 昌徳, OTSUKI NAOKI, NIBU KENICHI, MINAMI HIRONOBU
    頭頸部癌学会, Jun. 2018, Japanese, 東京, Domestic conference
    Oral presentation

  • 甲状腺癌気道浸潤例に対する放射線外照射の有効性の検討
    鈴木 千晶, KIYOTA NAOMI, OTSUKI NAOKI, 宮脇 大輔, 今村 善宣, NIBU KENICHI, SASAKI RYOHEI
    頭頸部癌学会, Jun. 2018, Japanese, 東京, Domestic conference
    Oral presentation

  • Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age.
    Nabil F. Saba, George R. Blumenschein, Joel Guigay, Lisa F. Licitra, Jerome Fayette, Kevin J. Harrington, Naomi Kiyota, Maura L. Gillison, Robert L. Ferris, Vijayvel Jayaprakash, Mark John Lynch, Li Li, Peter Brossart
    American Society of Clinical Oncology 2018 Annual Meeting, Jun. 2018, English, American Society of Clinical Oncology, シカゴ, International conference
    Poster presentation

  • Adapalene gel 0.1% vs. placebo as prophylaxis for anti-EGFR-induced acne-like rash: a randomized left-right comparative evaluation (APPEARANCE)
    Motoko Tachihara, Naoko Chayahara, Yoshimi Fujishima, Atsushi Fukunaga, Ken Washio, Masatsugu Yamamoto, Kyosuke Nakata, Kazuyuki Kobayashi, Kei Takenaka, Masanori Toyoda, Naomi Kiyota, Kazutoshi Tobimatsu, Hisayo Doi, Naomi Mizuta, Naho Marugami, Atsushi Kawaguchi, Chikako Nishigori, Yoshihiro Nishimura, Toru Mukohara, Hironobu Minami
    American Society of Clinical Oncology Annual Meeting 2018, Jun. 2018, English, Chicago, International conference
    Poster presentation

  • がんクリニカルシークエンスと遺伝性腫瘍の関係
    TOYODA MASANORI, 味木 徹夫, KIYOTA NAOMI, FUNAKOSHI YOUHEI, IMAMURA YOSHINORI, MINAMI HIRONOBU
    第115回内科学会総会, Apr. 2018, Japanese, 日本内科学会, 京都, Domestic conference
    Poster presentation

  • A comparative analysis of pathological features and molecular genetics between salivary duct carcinoma and adenocarcinoma, not otherwise specified.
    IMAMURA YOSHINORI, KIYOTA NAOMI, Nibu K, Ikeda C, Itoh T, Sasaki R, Sakai K, Nishio K, TOYODA MASANORI, MINAMI HIRONOBU, Otsuki N
    AACR Annual Meeting 2018, Apr. 2018, English, American Association for Cancer research, シカゴ, International conference
    Poster presentation

  • 乳癌センチネルリンパ節におけるprogrammed death-1発現に関する検討
    多田羅 敬, 向原 徹, Shimono Yohei, 山崎 隆, Toyoda Masanori, Kiyota Naomi, Kono Seishi, 高尾 信太郎, Kakeji Yoshihiro, Minami Hironobu
    第51回制癌剤適応研究会, Mar. 2018, Japanese, 制癌剤適応研究会, 下呂, Domestic conference
    Oral presentation

  • Pazopanibにより長期病勢安定が得られた肺動脈原発血管内膜肉腫の一例
    崔諭司, IMAMURA YOSHINORI, KIYOTA NAOMI, 豊田昌徳, 船越洋平, 兵庫寧子, 須藤洋崇, 奥田祐亮, YOSHIDA KENJI, SHIGEOKA MANABU, MINAMI HIRONOBU
    第1回日本サルコーマ治療研究学会学術集会, Feb. 2018, Japanese, Domestic conference
    Oral presentation

  • Exploratory analysis of prognostic and predictive factors of lenvatinib for radioiodine-refractory differentiated thyroid cancer
    Chiaki Suzuki, Kiyota Naomi, Yoshinori Imamura, Yoshiaki Nagatani, Hirotaka Suto, Naoko Chayahara, Toyoda Masanori, Yasuhiro Ito, Akihiro Miya, Akira Miyauchi, Naoki Otsuki, Nibu Ken-ichi, Minami Hironobu
    The 2018 Multidisciplinary Head and Neck Cancers Symposium, Feb. 2018, English, ASTRO, Arizona, USA, International conference
    Poster presentation

  • 口腔癌に対する免疫チェックポイント阻害薬の適正使用と腫瘍内科医との診療連携
    Kiyota Naomi
    第36回日本口腔腫瘍学会総会学術大会, Jan. 2018, Japanese, 日本口腔腫瘍学会, 新潟, Domestic conference
    [Invited]
    Nominated symposium

  • 頭頸部がんに対する分子標的薬及び免疫チェックポイント阻害薬の役割
    Kiyota Naomi
    第69回日本気管食道科学会総会, Nov. 2017, Japanese, 日本気管食道科学会, 大阪, Domestic conference
    [Invited]
    Nominated symposium

  • 頭頸部がんにおける免疫チェックポイント阻害薬の適正使用
    Kiyota Naomi
    第31回日本耳鼻咽喉科学会専門医講習会, Nov. 2017, Japanese, 日本耳鼻咽喉科学会, 神戸, Domestic conference
    Public discourse

  • Molecular targeted treatment for thyroid cancer
    Kiyota Naomi
    2nd Congress of Asia-Pacific Society of Thyroid Surgery, Nov. 2017, English, Asia-Pcific Society of Thyroid Surgery, 沖縄, International conference
    [Invited]
    Nominated symposium

  • 頭頸部がんのRare Cancer, 頭頸部悪性黒色腫
    Kiyota Naomi
    Japanese Society of Medical Oncology 2017, Jul. 2017, Japanese, Japanese Society of Medical Oncology, 神戸, International conference
    [Invited]
    Nominated symposium

  • Safety and efficacy of induction chemotherapy with TPF for locally advanced head and neck squamous cell carcinoma
    Yoshiaki Nagatani, Kiyota Naomi, Hirotaka Suto, Kei Takenaka, Yoshinori Imamura, Yasuko Hyogo, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    Japanese Society of Medical Oncology 2017, Jul. 2017, English, Japanese Society of Medical Oncology, 神戸, International conference
    Poster presentation

  • Remarkable response to cetuximab-containing chemotherapy for tongue cancer refractory to immune checkpoint inhibitors
    Hirotaka Suto, Kiyota Naomi, Yoshinori Imamura, Yasuko Hyogo, Kei Takenaka, Yoshiaki Nagatani, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Expression of programmed death-1 (PD-1) in sentinel lymph nodes of breast cancer
    多田羅 敬, Shimono Yohei, 山崎 隆, Toyoda Masanori, Kiyota Naomi, 高尾 信太朗, Kono Seishi, Kakeji Yoshihiro, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Efficacy and feasibility of induction chemotherapy followed by chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
    Yoshiaki Nagatani, Kiyota Naomi, Hirotaka Suto, Kei Takenaka, Yoshinori Imamura, Yasuko Hyogo, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Dose Modification in Patients with Advanced Pancreatic Cancer Treated with Nab-paclitaxel/Gemcitabine
    Kei Takenaka, Toyoda Masanori, MeikoNishimura, Kiyota Naomi, Yoshinori Imamura, Yoshiaki Nagatani, Hirotaka Suto, Yasuko Hyogo, Hideaki Goto, Toru Mukohara, Minami Hironobu
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • Bone marrow involvement and extramedullary hematopoiesis in a case of malignant melanoma after introduction of nivolumab
    Hirotaka Suto, Kiyota Naomi, Yoshiaki Nagatani, Kei Takenaka, Yoshinori Imamura, Yasuko Hyogo, Meiko Nishimura, Toyoda Masanori, Toru Mukohara, Minami Hironobu
    Japanese Society of Medical Oncology 2017, Jul. 2017, English, Japanese Society of Medical Oncology, 神戸, International conference
    Poster presentation

  • 頭頸部がんに対する免疫チェックポイント阻害薬
    Kiyota Naomi
    日本頭頸部癌学会主催第8回教育セミナー, Jun. 2017, Japanese, 日本頭頸部癌学会, Kyoto, Domestic conference
    Public discourse

  • 当院における 嗅神経芽細胞腫の検討
    Ohtsuki Naoki, Shinomiya Hirotaka, Inokuchi Gou, Kokan Norio, Kiyota Naomi, Sasaki Ryohei, Kohmura Eiji, Nibu Ken-ichi
    第41回日本頭頸部癌学会, Jun. 2017, Japanese, 京都, Domestic conference
    Oral presentation

  • 腫瘍内科医からみた頭頸部がん臨床試験におけるIMRTの重要性と課題
    Kiyota Naomi
    第41回日本頭頸部癌学会, Jun. 2017, Japanese, 日本頭頸部癌学会, Kyoto, Domestic conference
    [Invited]
    Nominated symposium

  • Nivolumab vs Investigator’s Choice for Platinum-Refractory Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (CheckMate 141): Outcomes in First-line R/M Patients and Updated Safety and Efficacy
    Maura L. Gillison, George Blumenschein Jr, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis Worden, Nabil F. Saba, Lara Carmen, Iglesias Docampo, Robert Haddad, Tamara Rordorf, Kiyota Naomi, Makoto Tahara, Mark Lynch, Justin Kopit, Robert L. Ferris
    American Society of Clinical Oncology Annual Meeting; June 2–6, 2017, Jun. 2017, English, American Society of Clinical Oncology, Chicago, USA, International conference
    Poster presentation

  • Induction chemotherapy of TPF for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) - A retrospective safety analysis at our institution -
    Yoshiaki Nagatani, Kiyota Naomi, Yoshinori Imamura, Miyawaki Daisuke, Sasaki Ryohei, Shinomiya Hirotaka, Naoki Otsuki, Kenichi Nibu
    第41回日本頭頸部癌学会, Jun. 2017, Japanese, 日本頭頸部癌学会, 京都, Domestic conference
    Oral presentation

  • A Multicenter Phase II Trial of Docetaxel, Cisplatin and Cetuximab (TPE) Followed by Cetuximab with Concurrent Radiotherapy in Patients with Local Advanced Squamous Cell Carcinoma of the Head and Neck (ECRIPS study)
    Sadamoto Zenda, Yosuke Ota, Kiyota Naomi, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara
    American Society of Clinical Oncology Annual Meeting; June 2–6, 2018, Jun. 2017, English, American Society of Clinical Oncology, Chicago, USA, International conference
    Poster presentation

  • 転移再発甲状腺がんに対する薬物療法
    Kiyota Naomi
    日本内分泌外科学会2017, May 2017, Japanese, 日本内分泌外科学会, Kobe, Domestic conference
    [Invited]
    Nominated symposium

  • 骨転移診療の現状と各診療科の意識調査 整形外科医・腫瘍内科医・放射線治療医に対するアンケート
    Akisue Toshihiro, Sakai Yoshitada, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Hara Hitomi, Kawamoto Teruya, 深瀬 直政, Kuroda Ryosuke, Kiyota Naomi, Minami Hironobu
    The 90th Annual Meetin of the Japanese Orthopaedic Association, May 2017, Japanese, The Japanese Orthopaedic Association, 仙台, Domestic conference
    Oral presentation

  • Quantitative mass spectrometry imaging of erlotinib in skin rashes of cancer patients receiving erlotinib
    Meiko Nishimura, Hiroaki Aikawa, Mitsuhiro Hayashi, Yu Mizutani, Kei Takenaka, Yoshinori Imamura, Naoko Chayahara, Toyoda Masanori, Kiyota Naomi, Toru Mukohara, Akinobu Hamada, Minami Hironobu
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Asociation for Cancer Research, Washington, DC, USA, International conference
    Poster presentation

  • 3D culture may better represent trastuzumab resistance associated with PIK3CA mutation than 2D culture.
    Takashi Tatara, Toru Mukohara, Rina Tanaka, Shimono Yohei, Toyoda Masanori, Kiyota Naomi, Hirai Midori, Kakeji Yoshihiro, Minami Hironobu
    Annual Meeting of the American Association for Cancer Research 2017, Apr. 2017, English, American Association for Cancer Research, Washington DC, USA, International conference
    Poster presentation

  • HER2陽性乳癌細胞株を用いたPIK3CA変異によるtrastuzumab耐性機構に関する2次元、3次元培養の比較
    多田羅 敬, Mukohara Toru, 田中 里奈, Shimono Yohei, Toyoda Masanori, Kiyota Naomi, Hirai Midori, Kakeji Yoshihiro, Minami Hironobu
    第50回制癌剤適応研究会, Mar. 2017, Japanese, 制癌剤適応研究会, 徳島, Domestic conference
    Public symposium

  • Patient-reported outcomes (PROs) in recurrent or metastatic(R/M) squamous cell carcinoma of the head and neck (SCCHN)treated with nivolumab (Nivo) or Investigator’s Choice (IC):CheckMate 142
    Kiyota Naomi, K. Harrington, R.L. Ferris, J.W. Shaw, F. Taylor, M. Derosa, D. Turner-Bowker, L. Morrissey, K. Cocks, M. Gillison, J. Guigay
    ESMO Asia 2016 Congress, Dec. 2016, English, European Society of Medical Oncology, Singapore, Singapore, International conference
    Oral presentation

  • Efficacy and safety of nivolumab for recurrent ormetastatic (R/M) squamous cell carcinoma of the headand neck (SCCHN) in Asia: CheckMate 141 subgroup analysis
    Y. Hasegawa, Kiyota Naomi, Takahashi Satoru, T. Yokota, C-J. Yen, S.Iwae, Y. Shimizu, R-L. Hong, M. Goto, Y. Namba, R.L. Ferris, M. Monga, M. Lynch, S. Hagihara, M. Tahara
    ESMO Asia 2016 Congress, Dec. 2016, English, European Society of Medical Oncology, Singapore, Singapore, International conference
    Oral presentation

  • Outcomes after radiation therapy for recurrent carcinoma of the oral tongue
    Miyawaki Daisuke, Ejima Yasuo, Yoshida Kenji, Ishihara Takeaki, Kiyota Naomi, Minamikawa Tsutomu, Naoki Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    The 29th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2016, Japanese, Japanese Society for Radiation Oncology, 京都, Domestic conference
    Oral presentation

  • Patient-reported outcomes (PROs) in recurrent or metastatic(R/M) squamous cell carcinoma of the head and neck (SCCHN)treated with nivolumab (Nivo) or Investigator’s Choice (IC):CheckMate 141
    K. Harrington, R.L. Ferris, J. Shaw, F. Taylor, M. Derosa, D. Turner-Bowker, L. Morrissey, K. Cocks, Kiyota Naomi, M. Gillison, J. Guigay
    ESMO 2016, Oct. 2016, English, European Society of Medical Oncology, Copenhagen, Denmark, International conference
    Oral presentation

  • FDG-PET/CTにて腹膜にびまん性の集積を認め、がん性腹膜炎との鑑別を要した腹膜結核の1例
    原田 雅也, Toyoda Masanori, 竹中 圭, 兵庫 寧子, 西村 明子, 長谷 善明, 今村 善宣, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    第213回近畿地方会, Sep. 2016, Japanese, 日本内科学会近畿支部, 大阪, Domestic conference
    Oral presentation

  • 本邦における脊椎転移患者の治療にかかる院内連携の現状の検討 -骨転移キャンサーボードが与える影響について-
    Sakai Yoshitada, Akisue Toshihiro, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Kiyota Naomi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 本邦における脊椎転移患者の治療にかかる院内連携の現状の検討 -骨転移キャンサーボードが与える影響について
    Sakai Yoshitada, Akisue Toshihiro, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Kiyota Naomi, Minami Hironobu
    2016 the Japanese Society of Medicla Oncology Annual Meeting, Jul. 2016, Japanese, The Japanese Society of Medical Oncology, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • 本邦における骨転移治療の現状についてのアンケート結果の報告
    Sakai Yoshitada, Akisue Toshihiro, 松原 伸晃, 中村 直樹, Kakutani Kenichiro, Kiyota Naomi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 腎障害時のS-1薬物動態試験
    後藤 慶子, 藤原 豊, 磯部 威, 津端 由佳里, 堀田 尚誠, 茶屋原 菜穂子, Kiyota Naomi, Mukohara Toru, 山本 昇, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 進行性甲状腺癌（放射性ヨウ素治療抵抗性分化型癌，髄様癌，未分化癌）に対する レンバチニブの第2相試験：最終報告
    高橋 俊二, Kiyota Naomi, 山崎 知子, 茶屋原 菜穂子, 仲野 兼司, 稲垣 里奈, 戸田 和寿, 榎田 智弘, Minami Hironobu, 今村 善宣, 佐々木 達哉, 鈴木 拓也, 藤野 克樹, Corina Dutcus, 田原 信
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 治癒切除不能な進行・再発結腸直腸癌患者に対するセツキシマブ隔週投与の第II相臨床試験
    茶屋原 菜穂子, Kiyota Naomi, Toyoda Masanori, Mukohara Toru, 藤島 佳未, 辻 晃仁, 佐竹 悠良, 木村 祥子, 小高 雅人, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 甲状腺がんに対するレンバチニブの有害事象と治療効果の関連について
    後藤 秀彰, Kiyota Naomi, 茶屋原 菜穂子, 竹中 圭, 今村 善宣, 西村 明子, Toyoda Masanori, Mukohara Toru, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 化学療法及び放射線化学療法に伴う口内炎に対するイブプロフェン含嗽剤の安全性と有効性を検討する非盲検非対照第I/II相試験（ポスター発表）
    青木 紫織, 五百蔵 武士, Nakagawa Tsutomu, 日比 徹, 丹田 雅明, 奥野 護, 茶屋原 菜穂子, Kiyota Naomi, Minami Hironobu, Hirai Midori
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Poster presentation

  • 化学療法及び放射線化学療法に伴う口内炎に対するイブプロフェン含嗽剤の安全性と有効性を検討する非盲検非対照第I/II相試験
    青木 紫織, 五百蔵 武士, Nakagawa Tsutomu, 日比 徹, 丹田 雅明, 奥野 護, 茶屋原 奈穂子, Kiyota Naomi, Minami Hironobu, Hirai Midori
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 悪性黒色腫で全身多発転移を伴うもNivolumabとVemurafenibにて長期生存を得た1例
    Fukumoto Takeshi, Fujiwara Susumu, 坂口 正展, 岡 昌宏, Nishigori Chikako, Kiyota Naomi, Ejima Yasuo
    第109回近畿皮膚科集談会(第456回大阪地方会・第447回京滋地方会), Jul. 2016, Japanese, 大阪地方会, 神戸, Domestic conference
    Oral presentation

  • シスプラチン投与患者におけるeGFR / CKD-EPIの検討
    船越 洋平, 藤原 豊, Kiyota Naomi, Mukohara Toru, Toyoda Masanori, 今村 善宣, 茶屋原 菜穂子, 梅津 道夫, Nibu Ken-ichi, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Next-generation sequencing provides therapeutic targets in advanced biliary tract cancer (aBTC)
    Toyoda Masanori, Ajiki Tetsuo, Naoko Chayahara, Kiyota Naomi, Mukohara Toru, Wakako Toga, Murtaza Mehdi, Alan Huang, Huaixiang Hao, Ku Yonson, Minami Hironobu
    The Japanese Society of Medical Oncology 2016 Annual Meeting, Jul. 2016, Japanese, The Japanese Society of Medical Oncology, 神戸, Domestic conference
    Public symposium

  • HLA alleles correlate with gemcitabine plus erlotinib-induced ILD in Japanese patients with advanced pancreatic cancer
    西村 明子, Toyoda Masanori, 茶屋原 菜穂子, Kiyota Naomi, Mukohara Toru, 古武 剛, 辻 晃仁, 齊藤 公亮, 斎藤 嘉朗, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • First-Line Chemotherapy for Recurrent or Metastatic Head and Neck Cancer with or without Cetuximab: A single institution experience
    今村 善宣, Kiyota Naomi, Toyoda Masanori, 茶屋原 菜穂子, 後藤 秀彰, Mukohara Toru, Nibu Ken-ichi, Sasaki Ryohei, Minami Hironobu
    第14回日本臨床腫瘍学会, Jul. 2016, English, 日本臨床腫瘍学会, 兵庫, Domestic conference
    Poster presentation

  • Comparison of 2D- and 3D-cultures in in vitro evaluation of trastuzumab in HER2-overexpressing breast cancer cell lines
    Mukohara Toru, 田中 里奈, 今村 善宣, Nakagawa Tsutomu, 山本 和宏, 茶屋原 菜穂子, Toyoda Masanori, Kiyota Naomi, Hirai Midori, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • Case Report of Two Patients with Pulmonary Artery Intimal Sarcoma Treated with Adjuvant Doxorubicin and Ifosfamide。
    竹中 圭, Kiyota Naomi, 今村 善宣, 後藤 秀彰, 久野 寧子, 西村 明子, 茶屋原 菜穂子, Toyoda Masanori, Mukohara Toru, Minami Hironobu
    第14回日本臨床腫瘍学会学術集会, Jul. 2016, English, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 同時併用化学放射線療法を施行した進行期喉頭癌,下咽頭癌症例におけるTalk Score の検討
    高橋 美貴, 松井 美緒, 涌井 絵美, Kiyota Naomi, Sasaki Ryohei, Ohtsuki Naoki, Usami Makoto, Nibu Ken-ichi
    The 40th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2016, Japanese, Japan Society for Head and Neck Cancer, Saitama, Japan, 埼玉、ソニックシティー, Domestic conference
    Oral presentation

  • 当科で放射線治療を施行した下咽頭癌T1・T2症例の検討
    古川 竜也, Ohtsuki Naoki, Shinomiya Hirotaka, 小松 弘和, Morimoto Koichi, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    The 40th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2016, Japanese, Japan Society for Head and Neck Cancer, Saitama, Japan, 埼玉、ソニックシティー, Domestic conference
    Oral presentation

  • Outcomes after radiation therapy for recurrent carcinoma of the oral tongue
    Miyawaki Daisuke, Ejima Yasuo, Yoshida Kenji, Ishihara Takeaki, 西川遼, Kiyota Naomi, Minamikawa Tsutomu, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    The 40th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2016, Japanese, 日本頭頸部癌学会, 大宮, Domestic conference
    Oral presentation

  • Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Makoto Tahara, Kiyota Naomi, Tomoya Yokota, Yasuhisa Hasegawa, Kei Muro, Shunji Takahashi, Takuma Onoe, Akihiro Homma, Jun Taguchi, Masami Suzuki, Koichi Minato, Katsunari Yane, Shinya Ueda, Hiroki Hara, Ken Saijo, Takeharu Yamanaka
    2016 ASCO Annual Meeting, Jun. 2016, English, American Society of Clinical Oncology, Chicago, United States of America, International conference
    Poster presentation

  • Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results
    Shunji Takahashi, Kiyota Naomi, Tomoko Yamazaki, Naoko Chayahara, Kenji Nakano, LINA INAGAKI, Kazuhisa Toda, Tomohiro Enokida, Minami Hironobu, Yoshinori Imamura, Tatsuya Sasaki, Takuya Suzuki, Katsuki Fujino, Corina Dutcus, Makoto Tahara
    2016 ASCO Annual Meeting, Jun. 2016, English, American Society of Clinical Oncology, Chicago, United States of America, International conference
    Poster presentation

  • Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141
    Robert L. Ferris, George R. Blumenschein, Jerome Fayette, Joel Guigay, A. Dimitrios Colevas, Lisa F. Licitra, Kevin J. Harrington, Stefan Kasper, Everett E. Vokes, Caroline Even, Francis P. Worden, Robert I. Haddad, Kiyota Naomi, Makoto Tahara, Manish Monga, Mark John Lynch, William J. Geese, Justin Kopit, James W Shaw, Maura L. Gillison
    2016 ASCO Annual Meeting, Jun. 2016, English, American Society of Clinical Oncology, Chicago, United States of America, International conference
    Oral presentation

  • First-Line treatment with Cetuximab-based Combination Therapy for Recurrent/Metastatic Head and Neck Cancer: A single institution experience
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, Morimoto Koichi, Shinomiya Hirotaka, Ejima Yasuo, Minamikawa Tsutomu, Sasaki Ryohei, Nibu Ken-ichi
    第40回日本頭頸部癌学会, Jun. 2016, English, 日本頭頸部癌学会, 埼玉, Domestic conference
    Oral presentation

  • First-line Treatment of Recurrent/Metastatic Head and Neck Cancer with or without Cetuximab
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, Morimoto Koichi, Shinomiya Hirotaka, Ejima Yasuo, Yoshida Kenji, Minamikawa Tsutomu, Sasaki Ryohei, Nibu Ken-ichi
    The 40th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2016, Japanese, Japan Society for Head and Neck Cancer, Saitama, Japan, 埼玉、ソニックシティー, Domestic conference
    Oral presentation

  • 再発転移頭頸部扁平上皮癌1st line化学療法におけるセツキシマブ併用効果。
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, Toyoda Masanori, 茶屋原 菜穂子, 後藤 秀彰, Mukohara Toru, Nibu Ken-ichi, Sasaki Ryohei, Minami Hironobu
    第113回日本内科学会総会, Apr. 2016, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • 再発・転移頭頸部扁平上皮癌におけるプラチナ耐性獲得時の血液学的予後予測因子に関する検討
    今村 善宣, Kiyota Naomi, 後藤 秀彰, 竹中 圭, 西村 明子, 茶屋原 菜穂子, Toyoda Masanori, Mukohara Toru, Nibu Ken-ichi, Minami Hironobu
    第113回日本内科学会総会, Apr. 2016, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • radiotherapy for cervical lymph node metastases of unknown primary site
    Yuko Inoue, Yoshida Kenji, Ejima Yasuo, Miyawaki Daisuke, Ishihara Takeaki, Hideki Nishimura, Ryo Nishikawa, Yoshiro Matsuo, Kiyota Naomi, Naoki Otsuki, Kenichi Nibu, Sasaki Ryohei
    The 75th Annual Meeting of the Japan Radiological Society, Apr. 2016, English, Japan Radiological Society, 横浜, Domestic conference
    Oral presentation

  • Definitive Radiotherapy for T3/T4 Hypopharyngeal Squamous Cell Carcinoma
    Yoshiro Matsuo, Yoshida Kenji, Yuko Inoue, Ryo Nishikawa, Nor Shazrina, Ishihara Takeaki, Miyawaki Daisuke, Ejima Yasuo, Hideki Nishimura, Kiyota Naomi, Miki Saito, Naoki Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    The 75th Annual Meeting of the Japan Radiological Society, Apr. 2016, Japanese, Japan Radiological Society, 横浜, Domestic conference
    Oral presentation

  • RADIOTHERAPY FOR CERVICAL LYMPH NODE METASTASES OF UNKNOWN PRIMARY SITE
    Inoue Yukako, Yoshida Kohsuke, Ejima Yasuo, Miyawaki Daisuke, Ishihara Takeaki, R.Nishikawa, Y.Matsuo, H.Nishimura, N.Otsuki, Saito Miki, Kiyota Naomi, Nibu Ken-ichi, Sasaki Ryohei
    The 28th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2015, Japanese, JASTRO, 群馬, Domestic conference
    Oral presentation

  • Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: a Dose-Volume Histogram Analysis
    Miyawaki Daisuke, N. Mukumoto, Ejima Yasuo, Yoshida Kohsuke, Ishihara Takeaki, Kiyota Naomi, Saito Miki, N. Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    The 28th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2015, Japanese, JASTRO, 群馬, Domestic conference
    Oral presentation

  • Prognostic value of FDG PET imaging in pharyngeal cancer patients treated with radiotherapy alone or chemoradiotherapy
    Ishihara Takeaki, Kazuhiro Kitajima, Yuko Suenaga, Ejima Yasuo, Saito Miki, Naoki Otsuki, Nibu Ken-ichi, Kiyota Naomi, Takahashi Satoru, Sasaki Ryohei
    The 28th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2015, Japanese, JASTRO, 群馬, Domestic conference
    Oral presentation

  • Outcomes of radiotherapy for oro- or hypopharyngeal cancer with concomitant esophageal cancer
    Ryo Nishikawa, Yoshida Kenji, Miyawaki Daisuke, Ejima Yasuo, Ishihara Takeaki, Yoshiro Matsuo, Nor Shazrina, Yuko Inoue, Hideki Nishimura, Kiyota Naomi, Saito Miki, Naoki Otsuki, Ken-ihci Nibu, Sasaki Ryohei
    The 28th Annual Meeting of the Japanese Society for Radiation Oncology, Nov. 2015, Japanese, JASTRO, 群馬, Domestic conference
    Poster presentation

  • Radiotherapy for T3/T4 squamous cell carcinoma of hypopharynx: retrospective comparison between definitive radiotherapy and surgery followed by postoperative radiotherapy
    Yoshiro Matsuo, Yoshida Kenji, Yuko Inoue, Ryo Nishikawa, Nor Shazrina, Ishihara Takeaki, Miyawaki Daisuke, Ejima Yasuo, Hideki Nishimura, Kiyota Naomi, Saito Miki, Naoki Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    57th Annual Meeting of ASTRO, Oct. 2015, English, ASTRO, San Antonio, USA, International conference
    Poster presentation

  • Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: a Dose-Volume Histogram Analysis
    Miyawaki Daisuke, N. Mukumoto, Ejima Yasuo, Yoshida Kohsuke, Ishihara Takeaki, Kiyota Naomi, Saito Miki, N. Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    57th Annual Meeting of ASTRO, Oct. 2015, English, ASTRO, San Antonio, USA, International conference
    Poster presentation

  • Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: a Dose-Volume Histogram Analysis
    Miyawaki Daisuke, N. Mukumoto, Ejima Yasuo, Yoshida Kohsuke, Ishihara Takeaki, Kiyota Naomi, Saito Miki, N. Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    European Cancer Congress 2015, Sep. 2015, English, European Cancer Congress, Vienna, Austria, Austria, International conference
    Poster presentation

  • アプレピタント併用におけるオキシコドン除法剤の薬物動態研究
    藤原 豊, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, 島田 貴信, 今村 善宣, Mukohara Toru, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • Treatment experience of rhabdomyosarcoma in adults at our institution。
    瓜生 恭章, Kiyota Naomi, 竹中 圭, 久野 寧子, 西村 明子, 乾 由美子, Chayahara Naoko, Toyoda Masanori, Mukohara Toru, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference
    Oral presentation

  • Prognostic Value of the Inflammation Markers for Platinum Refractory Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Yoshinori Imamura, Kiyota Naomi, Naoki Otsuki, Toyoda Masanori, Chayahara Naoko, Meiko Nishimura, Mukohara Toru, Nibu Ken-ichi, Sasaki Ryohei, Minami Hironobu
    第13回日本臨床腫瘍学会学術集会, Jul. 2015, English, 日本臨床腫瘍学会, 札幌, Domestic conference
    Poster presentation

  • RADIOTHERAPY FOR CERVICAL LYMPH NODE METASTASES OF UNKNOWN PRIMARY SITE
    井上由子, Yoshida Kenji, Ejima Yasuo, Miyawaki Daisuke, Ishihara Takeaki, ノルシャズリナ, 西川遼, 松尾圭朗, 西村英輝, Ohtsuki Naoki, Saito Miki, Kiyota Naomi, Nibu Ken-ichi, Sasaki Ryohei
    4th Congress of Asian Society of Head and Neck Oncology, 39th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2015, English, Japan Society for Head and Neck Cancer, 神戸, International conference
    Poster presentation

  • Oncological and Functional outcome of locally advanced (T3/T4) hypopharyngeal cancer
    Komatsu Hirokazu, Hirotaka Shinomiya, Morimoto Koichi, Saito Miki, Naoki Otsuki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    The Joint Meeting of 4th Congress of Asian Society of Head and Neck Oncology, Jun. 2015, English, Asian Society of Head and Neck Oncology, 兵庫, International conference
    Poster presentation

  • Treatment outcomes of definitive radiotherapy in patients with T3N0M0 laryngeal cancer
    Ishihara Takeaki, Yoshiro Matsuo, Miyawaki Daisuke, Yoshida Kenji, Ejima Yasuo, Morimoto Koichi, Saito Miki, Naoki Otsuki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    4th Congress of Asian Society of Head and Neck Oncology 39th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2015, Japanese, Japan Society for Head and Neck Cancer, 神戸, Domestic conference
    Poster presentation

  • Treatment outcome of parotid cancers
    四宮 瞳, Ohtsuki Naoki, Yamashita Daisuke, 今村 善宣, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    2015年6月3日～6日の4th Congress of Asian Society of Head and Neck Oncology, Jun. 2015, English, 日本頭頸部癌学会, 神戸, International conference
    Oral presentation

  • Radiotherapy for posterior pharyngeal wall cancer of oropharynx and/or hypopharynx
    Miyawaki Daisuke, Ejima Yasuo, Yoshida Kenji, Ishihara Takeaki, Kiyota Naomi, Saito Miki, Naoki Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    4th Congress of Asian Society of Head and Neck Oncology, 39th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2015, English, 神戸国際会議場, 神戸, International conference
    Poster presentation

  • Radiotherapy for Head and Neck Cancers with N3 Lymph Node Metastasis
    Yoshida Kenji, Miyawaki Daisuke, Ejima Yasuo, Yoshiro Matsuo, Ryo Nishikawa, Kiyota Naomi, Saito Miki, Naoki Otsuki, Hideki Nisimura, Kenichi Nibu, Sasaki Ryohei
    4th Congress of Asian Society of Head and Neck Oncology, 39th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2015, Japanese, 神戸国際会議場, 神戸, International conference
    Poster presentation

  • Prognostic value of the Inflammation Scores for Platinum Refractory Head and Neck cancer.
    今村善宣, Kiyota Naomi, Ohtsuki Naoki, Saito Miki, Morimoto Koichi, Komatsu Hirokazu, Ejima Yasuo, Yoshida Kenji, Miyawaki Daisuke, 上薗玄, Ishihara Takeaki, Minamikawa Tsutomu, Sasaki Ryohei, Nibu Ken-ichi
    第39回日本頭頸部癌学会学術集会, Jun. 2015, English, 日本頭頸部癌学会, 神戸, Domestic conference
    Oral presentation

  • Outcomes of radiotherapy for oro and hypopharyngeal cancer with concomitant esophageal cancer
    Ryo Nishikawa, Yoshida Kenji, Miyawaki Daisuke, Ejima Yasuo, Ishihara Takeaki, Yoshiro Matsuo, Nor Shazrina, Yuko Inoue, Hideki Nishimura, Kiyota Naomi, Saito Miki, Naoki Otsuki, Ken-ihci Nibu, Sasaki Ryohei
    4th Congress of Asian Society of Head and Neck Oncology, 39th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2015, English, Japan Society for Head and Neck Cancer, 神戸, International conference
    Poster presentation

  • Definitive radiotherapy for T3/T4 hypopharyngeal squamous cell carcinoma
    Yoshiro Matsuo, Yoshida Kenji, Yuko Inoue, Ryo Nishikawa, Nor Shazrina, Ishihara Takeaki, Miyawaki Daisuke, Ejima Yasuo, Hideki Nishimura, Kiyota Naomi, Saito Miki, Naoki Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    4th Congress of Asian Society of Head and Neck Oncology, 39th Annual Meeting of Japan Society for Head and Neck Cancer, Jun. 2015, English, Japan Society for Head and Neck Cancer, 神戸, International conference
    Poster presentation

  • Radioimmunotherapy with 90Y ibritumomab tiuxetan for low grade malignant lymphoma.
    R Nishikawa, Yoshida Kohsuke, Miyawaki Daisuke, Ejima Yasuo, Ishihara Takeaki, Y Matsuo, NS Sulaiman, Inoue Yukako, H Nishimura, Kiyota Naomi, Saito Miki, N Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    15th International Congress of Radiation Research, May 2015, English, 京都, International conference
    Poster presentation

  • Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck
    Miyawaki Daisuke, Ejima Yasuo, Yoshida Kenji, Ishihara Takeaki, Kiyota Naomi, Saito Miki, Naoki Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    15th International Congress of Radiation Research, May 2015, English, International Congress of Radiation Research, 京都, International conference
    Poster presentation

  • 再発・転移粘膜悪性黒色腫に対するダカルバジン単剤療法の後方視的検討
    西村 明子, Kiyota Naomi, Toyoda Masanori, Chayahara Naoko, 竹中 圭, 瓜生 恭章, 今村 善宜, 船越 洋平, Mukohara Toru, Minami Hironobu
    第112回日本内科学会総会, Apr. 2015, Japanese, 日本内科学会, 京都, Domestic conference
    Poster presentation

  • 化学療法中の固形腫瘍患者に対するインフルエンザワクチン2回接種法の有効性と安全性.
    眞田 幸尚, Yakushijin Kimikazu, 野村 哲彦, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Kawamoto Shinichiro, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第112回日本内科学会総会, Apr. 2015, Japanese, 日本内科学会, 京都, Domestic conference
    Oral presentation

  • Prognostic value of FDG PET imaging in patients with pharyngeal cancer and who received definitive radiotherapwith radiotherapy or without chemotherapy
    Ishihara Takeaki, Kazuhiro Kitajima, Yuko Suenaga, Ejima Yasuo, Saito Miki, Naoki Otsuki, Nibu Ken-ichi, Kiyota Naomi, Takahashi Satoru, Sasaki Ryohei
    The 74th Annual Meeting of the Japan Radiological Society, Apr. 2015, Japanese, 日本医学放射線学会, 横浜, Domestic conference
    Poster presentation

  • Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer
    Yoshinori Imamura, Mukohara Toru, Shimono Yohei, Yohei Funakoshi, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Shintaro Takao, Kono Seishi, Tetsuya Nakatsura, Minami Hironobu
    AACR Annual Meeting、2015, Apr. 2015, English, AACR, ペンシルバニア, アメリカ, International conference
    Poster presentation

  • 進行食道癌による通過障害対する緩和的放射線治療の成績
    Uezono Haruka, Ejima Yasuo, Miyawaki Daisuke, Ishihara Takeaki, ノルシャズリナ, 西川 遼, 井上由子, Ikeda Atsuki, Okuno Tatsuya, Toyoda Masanori, Kiyota Naomi, Sasaki Ryohei
    日本放射線腫瘍学会第27回学術大会, Dec. 2014, Japanese, 日本放射線腫瘍学会, 横浜、パシフィコ横浜, Domestic conference
    Oral presentation

  • Efficacy of the Two-Dose Influenza Vaccine in Cancer Patients Receiving Chemotherapy: A Prospective Study.
    Yukinari Sanada, Yakushijin Kimikazu, Tetsuhiko Nomura, Katsuya Yamamoto, Keiji Kurata, Kei Takenaka, Seiji Kakiuchi, Yoshiharu Miyata, Yoshinori Imamura, Meiko Nishimura, Yohei Funakoshi, Yuriko Iwamoto, Chayahara Naoko, Toyoda Masanori, Minami Yosuke, Kiyota Naomi, Mukohara Toru, Kawamoto Shinichiro, Shimono Yohei, Mitsuhiro Ito, Matsuoka Hiroshi, Minami Hironobu
    56th Meeting of the American Society of Hematology, Dec. 2014, English, American Society of Hematology, サンフランシスコ, International conference
    Poster presentation

  • 治療前FDG-PETによる喉頭癌の再発予測
    Kitajima Kazuhiro, 末永裕子, 神田知紀, Miyawaki Daisuke, Yoshida Kenji, Ejima Yasuo, Sasaki Ryohei, Komatsu Hirokazu, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Minamikawa Tsutomu, Kiyota Naomi, Sugimura Kazuro
    第54回日本核医学会学術総会, Nov. 2014, Japanese, The Japan Nuclear Medicine, 大阪, Domestic conference
    Oral presentation

  • Retrospective analysis of whole brain radiotherapy for brain metastases
    Uezono Haruka, Ejima Yasuo, Miyawaki Daisuke, Ishihara Takeaki, Y Imamura, H Shinomiya, Komatsu Hirokazu, H Fujio, Morimoto Koichi, Saito Miki, N Otsuki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    The 15th Asian Oceanian Congress of Radiology AOCR 2014, Sep. 2014, English, Asia Oceania Congress of Radiology, Kobe, We retrospectively reviewed 9 cases who underwent radiotherapy with Cetuximab concurrently. Primary tumor response and acute toxicity are reported. Although mucositis was the most remarkable adverse events, one patient developed grade 5 drug-induced interstitial lung disease., International conference
    Poster presentation

  • Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck
    Miyawaki Daisuke, Ejima Yasuo, Yoshida Kohsuke, H Nishimura, Kiyota Naomi, N Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    The 15th Asian Oceanian Congress of Radiology, Sep. 2014, English, Asian Oceanian Congress of Radiology, Kobe, The purpose of this study was to compare the risk of HT in squamous cell carcinoma of the head and neck undergoing treatment with CCRT or RT alone at our institution, International conference
    Poster presentation

  • Experience of radiotherapy plus cetuximab for head and neck cancer
    Uezono Haruka, Ejima Yasuo, Miyawaki Daisuke, Ishihara Takeaki, Y Imamura, H Shinomiya, Komatsu Hirokazu, H Fujio, Morimoto Koichi, Saito Miki, N Otsuki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    The 15th Asian Oceanian Congress of Radiology AOCR 2014, Sep. 2014, English, Asia Oceania Congress of Radiology, Kobe, International conference
    Poster presentation

  • A retrospective analysis of dacarbazine monotherapy for recurrent or metastatic mucosal melanoma
    西村 明子, Kiyota Naomi, Toyoda Masanori, Chayahara Naoko, 竹中 圭, 瓜生 恭章, 今村 善宣, 船越 洋平, Mukohara Toru, Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Oral presentation

  • Clinicopathological Analysis of Salivary Duct Carcinoma and Salivary Gland Adenocarcinoma, N.O.S
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, 平井 千穂子, Itoh Tomoo, 船越 洋平, Sasaki Ryohei, Nibu Ken-ichi, Mukohara Toru, Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, English, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Poster presentation

  • A prospective study of the efficacy of influenza vaccination for cancer patients receiving chemotherapy
    眞田 幸尚, Yakushijin Kimikazu, 山本 克也, 西村 明子, 船越 洋平, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    The 12th Annual Meeting of Japanese Society of Medical Oncology, Jul. 2014, Japanese, Japanese Society of Medical Oncology, 福岡, Domestic conference
    Oral presentation

  • 免疫組織化学染色による唾液腺導管癌15例の検討．
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, Yamashita Daisuke, Sasaki Ryohei, Nibu Ken-ichi
    第38回日本頭頸部癌学会, Jun. 2014, Japanese, 日本頭頸部癌学会, 東京, Domestic conference
    Oral presentation

  • 免疫組織化学染色による唾液腺導管癌15例の検討
    今村善宣, Kiyota Naomi, Ohtsuki Naoki, Yamashita Daisuke, Sasaki Ryohei, Nibu Ken-ichi
    The 38th annual meeting of the Japan Society for Head and Neck Cancer, Jun. 2014, Japanese, Japan Society for Head and Neck Cancer, 東京, Domestic conference
    Oral presentation

  • Experience of radiotherapy plus cetuximab for head and neck cancer
    Uezono Haruka, Ejima Yasuo, Miyawaki Daisuke, 今村善宣, 四宮弘隆, Komatsu Hirokazu, Fujio Kumi, Morimoto Koichi, Saito Miki, Ohtsuki Naoki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    The 38th annual meeting of the Japan Society for Head and Neck Cancer, Jun. 2014, Japanese, Japan Society for Head and Neck Cancer, 東京, Domestic conference
    Poster presentation

  • 中咽頭癌に対する化学放射線療法におけるPEG留置患者の栄養投与量と有害事象
    高橋美貴, 小坂奈々, Usami Makoto, 中川絵美, Saito Miki, Ohtsuki Naoki, Ejima Yasuo, Miyawaki Daisuke, Sasaki Ryohei, Kiyota Naomi, Nibu Ken-ichi
    The 38th annual meeting of the Japan Society for Head and Neck Cancer, Jun. 2014, Japanese, Japan Society for Head and Neck Cancer, 東京, 中咽頭癌に対する化学放射線療法におけるPEG留置患者の栄養投与量と有害事象を検討, Domestic conference
    Oral presentation

  • 進行期喉頭癌・下咽頭癌に対する治療戦略
    Ohtsuki Naoki, 四宮弘隆, Komatsu Hirokazu, Morimoto Koichi, Saito Miki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    The 38th annual meeting of the Japan Society for Head and Neck Cancer, Jun. 2014, Japanese, Japan Society for Head and Neck Cancer, 東京, Domestic conference
    Oral presentation

  • T3N0-1声門癌に対する喉頭温存を目的とした根治的化学放射線治療の検討
    Sasaki Ryohei, 松尾圭朗, Ejima Yasuo, Miyawaki Daisuke, Uezono Haruka, 今村善宣, Kiyota Naomi, 四宮弘隆, Komatsu Hirokazu, Morimoto Koichi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi
    The 38th annual meeting of the Japan Society for Head and Neck Cancer, Jun. 2014, Japanese, Japan Society for Head and Neck Cancer, 東京, Domestic conference
    Oral presentation

  • Phase II study of lenvatinib (LEN), a multi-targeted tyrosine kinase inhibitor, in patients (pts) with all histologic subtypes of advanced thyroid cancer (differentiated, medullary and anaplastic).
    Takahashi Satoru, Tahara M, Kiyota Naomi, Yamazaki T, Chayahara Naoko, Nakano K, Inagaki R, Toda K, Enokida T, Minami Hironobu, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus C
    Eur Soc Medical Oncol, May 2014, English, ESMO, Madrid, スペイン, International conference
    Poster presentation

  • Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.
    Fujiwara Y, Kiyota Naomi, Toyoda Masanori, Shimada T, Imamura Y, Mukohara Toru, Minami Hironobu
    Am Soc Clinc Oncol, May 2014, English, ASCO, シカゴ, アメリカ, International conference
    Poster presentation

  • 当院における唾液腺導管癌15例の臨床病理学的検討．
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, 平井 千浦子, Toyoda Masanori, Chayahara Naoko, 船越 洋平, Mukohara Toru, Nibu Ken-ichi, Minami Hironobu
    第111回日本内科学会総会, Apr. 2014, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • Definitive radiotherapy for T3 laryngeal cancer
    松尾圭朗, Ejima Yasuo, Miyawaki Daisuke, Uezono Haruka, 松本葉子, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    The 73rd Annual Meeting of the Japan Radiological Society, Apr. 2014, English, The Japan Radiological Society, 横浜、パシフィコ横浜, [Objective] The purpose of this study is to evaluate the results of T3 laryngeal cancer with radiotherapy in our institution.[Materials and Methods] Between 2006 and 2013, 20 patients with T3 laryngeal cancer treated with radiotherapy in our institution. Sixteen patients was diagnosed with N0, 2 patients did with N1, 1 patient did with N2, and 1 patient did with N3 disease. Sev, Domestic conference
    Oral presentation

  • Treatment outcomes of radiotherapy for T1/T2 supraglottic carcinoma
    松本葉子, Miyawaki Daisuke, Ejima Yasuo, Uezono Haruka, Yoshida Kenji, Sasaki Ryohei, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi
    The 73rd Annual Meeting of the Japan Radiological Society, Apr. 2014, Japanese, The Japan Radiological Society, 横浜、パシフィコ横浜, Domestic conference
    Poster presentation

  • Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck
    Miyawaki Daisuke, Ejima Yasuo, Uezono Haruka, Yoshida Kenji, 西村英輝, 岡本欣晃, Kiyota Naomi, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    The 73rd Annial Meeting of the Japan Radiological Society, Apr. 2014, Japanese, The Japan Radiological Society, 横浜、パシフィコ横浜, The purpose of this study was to compare the risk of HT in squamous cell carcinoma of the head and neck undergoing treatment with CCRT or RT alone at our institution., Domestic conference
    Poster presentation

  • 頭頸部癌に対するセツキシマブ併用放射線治療の初期経験
    下山真介, Uezono Haruka, 松尾圭朗, ノルシャズリナ, 松本葉子, Miyawaki Daisuke, Yoshida Kenji, Ejima Yasuo, Sasaki Ryohei, Kiyota Naomi, Ohtsuki Naoki, Nibu Ken-ichi
    第305回公益社団法人日本医学放射線学会関西地方会, Nov. 2013, Japanese, 日本医学放射線学会関西地方会, 大阪(ブリーゼプラザ), Domestic conference
    Oral presentation

  • 乳癌における新規治療標的としてのTyro3．
    Roudy Chiminch Ekyalongo, Mukohara Toru, 船越 洋平, 富岡 秀夫, 片岡 優, Toyoda Masanori, Kiyota Naomi, Minami Hironobu
    第72回日本癌学会学術総会, Oct. 2013, English, 日本癌学会, 横浜, Domestic conference
    Poster presentation

  • 中・下咽頭扁平上皮癌に対する放射線治療後の甲状腺機能低下症に関する検討
    Miyawaki Daisuke, Ejima Yasuo, Yoshida Kenji, Uezono Haruka, 西村英輝, 岡本欣晃, 酒井英郎, Kiyota Naomi, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    日本放射線腫瘍学会第26回学術大会, Oct. 2013, Japanese, 日本放射線腫瘍学会, 青森（ホテル青森、リンクステーションホール青森）, Domestic conference
    Oral presentation

  • TYRO3 as a potential therapeutic target in breast cancer.
    Roudy Chiminch Ekyalongo, Mukohara Toru, Yohei Funakoshi, Hideo Tomioka, Yu Kataoka, Shimono Yohei, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Hironobu Minam
    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 2013, English, American Association for Cancer Research, Boston, USA, International conference
    Poster presentation

  • T1／2声門上癌に対する放射線治療成績の検討
    松本葉子, Yoshida Kenji, Uezono Haruka, Miyawaki Daisuke, Ejima Yasuo, 西村英輝, Sasaki Ryohei, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi
    日本放射線腫瘍学会第26回学術大会, Oct. 2013, Japanese, 日本放射線腫瘍学会, 青森（ホテル青森、リンクステーションホール青森）, Domestic conference
    Oral presentation

  • Reversibility of acquired resistance and "addiction" to MET inhibitors.
    Yohei Funakoshi, Mukohara Toru, Hideo Tomioka, RoudyChiminch Ekyalongo, Yu Kataoka, Yohei Shimono, Chayahara Naoko, Toyoda Masanori, Kiyota Naomi, Yutaka Fujiwara, Minami Hironobu
    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 2013, English, American Association for Cancer Research, Boston, USA, International conference
    Poster presentation

  • A Phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors.
    Watanabe K, Minami Hironobu, Otsu S, Hirashima Y, Morinaga R, Nishikawa K, Hisamatsu Y, Mukohara Toru, Kiyota Naomi, Chayahara Naoko, Toyoda Masanori, Imamura Y, Fujiwara Y, Quadt C, Robson M, Natsume K, Aoki T, Shirao K
    AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Oct. 2013, English, American Association for Cancer Research, Boston, USA, International conference
    Poster presentation

  • Radiation Induced Hypothyroidism in Squamous Cell Carcinoma of the Head and Neck: Comparison between Concurrent Chemoradiotherapy and Radiation Therapy Alone
    Miyawaki Daisuke, Yoshida Kohsuke, Ejima Yasuo, H Nishimura, NS Sulaiman, Kiyota Naomi, Saito Miki, N Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    55th Annual meeting ASTRO, Sep. 2013, English, ASTRO, Atlanta, GA, USA, International conference
    Poster presentation

  • 25 year experience with primary salivary gland carcinoma at a single institution in Japan European Journal of Cancer 49,
    Yoshinori Imamura, Kiyota Naomi, Naoki Otsuki, Chihoko Hirai, Yohei Funakoshi, Mukohara Toru, Yamashita Daisuke, Itoh Tomoo, Minami Hironobu, Nibu Ken-ichi
    ECCO2013, Sep. 2013, English, European CanCer Organisation, Amsterdam, Holland, This is one of the largest clinicopathological reports of major SGC from a single institution in Japan. Prognosis and prognostic factors of SGC were in accordance to previous reports., International conference
    Poster presentation

  • ｓｕｎｉｔｉｎｉｂを使用し腸管壊死をきたしたACTH産生神経内分泌腫瘍
    眞田 幸尚, Mukohara Toru, 今村 善宣, 西村 明子, 船越 洋平, 富岡 秀夫, 島田 貴信, Toyoda Masanori, Kiyota Naomi, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Poster presentation

  • 乳癌膵転移の1例
    山下 祐司, Mukohara Toru, Toyoda Masanori, Kiyota Naomi, Kouno Seishi, Shiomi Hideyuki, Hara Shigeo, Hayakumo Takanobu, 高尾 信太郎, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Poster presentation

  • 進行胆道癌に対するGC療法が腎機能に与える影響
    Toyoda Masanori, 今村 善宣, 西村 明子, 船越 洋平, 富岡 秀夫, 島田貴信, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Oral presentation

  • A Retrospective Analysis of Renal Function for Patients with Advanced Biliary Tract Cancer Treated by GC
    島田 貴信, Kiyota Naomi, 今村 善宣, 西村 明子, 船越 洋平, 富岡 秀夫, Toyoda Masanori, Chayahara Naoko, Mukohara Toru, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, Japanese, 日本臨床腫瘍学会, 仙台, Domestic conference
    Oral presentation

  • Excessive MET signaling causes acquired resistance to and addiction to METinhibitors MET-amplifed cancer cellline
    船越 洋平, Mukohara Toru, 富岡 秀夫, エキャロンゴ ルーディ チミンチ, 片岡 優, Toyoda Masanori, Kiyota Naomi, 藤原 豊, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, English, 日本臨床腫瘍学会, 仙台, Domestic conference
    Poster presentation

  • Clinicopathologic Analysis of Salivary Duct Carcinoma in 15 Japanese Patients
    Yoshinori Imamura, Kiyota Naomi, Naoki Otsuki, Itoh Tomoo, Chihoko Hirai, Takanobu Shimada, Yamashita Daisuke, Sasaki Ryohei, Nibu Ken-ichi, Mukohara Toru, Minami Hironobu
    第11回日本臨床腫瘍学会学術集会, Aug. 2013, English, 日本臨床腫瘍学会, 仙台, We hereby reported a clinicopathologic analysis of 15 Japanese patients with SDC., Domestic conference
    Poster presentation

  • 頸部リンパ節転移を認めた原発不明悪性黒色腫の2例
    米澤宏一郎, Morimoto Koichi, Yamashita Daisuke, 谷本 均, Saito Miki, Ohtsuki Naoki, Kiyota Naomi, Sasaki Ryohei, Nibu Ken-ichi
    第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, 原発不明癌頸部リンパ節転移の約80％が扁平上皮癌であり、悪性黒色腫の頻度は0．9％と非常に稀である。今回我々は頸部リンパ節にのみ転移を認めた原発不明悪性黒色腫の2症例を経験した。症例1は72歳男性。2005年9月に左顎下部腫瘤を主訴に来院し、同部よりの穿刺吸引細胞診で悪性黒色腫の診断が得られた。原発巣は明らかでなく、左顎部敦清術を行った。転移リンパ節は1個であったが節外浸潤を認めたため、術後化学療法としてDAV（Dacarbazine, Nimustine, Vincristine)を8コース施行した。現在術後6年経過し、再発・転移を認めない。症例2は61歳男性。症例1と同様に原発不明悪性黒色腫の診断で左顎部敦清術を行った。多発リンパ節転移と節外浸潤を認めたため、術後にDAVを8コース施行した。現在術後2年経過し、再発・転移を認めない。原発不明悪性黒, Domestic conference
    Oral presentation

  • 頭頸部扁平上皮癌に対する放射線治療後の甲状腺機能低下症に関する検討
    Miyawaki Daisuke, Yoshida Kenji, Ejima Yasuo, 西村英輝, 岡本欣晃, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, Domestic conference
    Poster presentation

  • 当院における唾液腺導管癌15例の臨床病理学的特徴
    今村 善宣, Kiyota Naomi, Ohtsuki Naoki, 島田 貴信, Yamashita Daisuke, Sasaki Ryohei, Nibu Ken-ichi
    第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 東京, 当院におけるSDC 15例の臨床病理学的特徴を報告した。, Domestic conference
    Poster presentation

  • 当院におけるT3喉頭癌の放射線治療の経験
    松尾圭朗, Yoshida Kenji, Miyawaki Daisuke, Ejima Yasuo, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, Domestic conference
    Oral presentation

  • 進行舌癌に対する術後放射線治療の経験
    Yoshida Kenji, Miyawaki Daisuke, Ejima Yasuo, 西村英輝, Kiyota Naomi, Minamikawa Tsutomu, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, Domestic conference
    Poster presentation

  • 再発・転移頭頸部がんに対するドセタキセル・シスプラチン併用（DC）療法
    島田貴信, Kiyota Naomi, 今村善宣, Morimoto Koichi, Saito Miki, 西村英輝, Sasaki Ryohei, Ohtsuki Naoki, Nibu Ken-ichi
    第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, Domestic conference
    Oral presentation

  • T1／2声門上癌に対する放射線治療成績の検討
    松本葉子, Yoshida Kenji, Ejima Yasuo, Miyawaki Daisuke, 西村英輝, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Kiyota Naomi, Sasaki Ryohei
    第37回日本頭頸部癌学会, Jun. 2013, Japanese, 日本頭頸部癌学会, 新宿、東京（京王プラザホテル）, Domestic conference
    Poster presentation

  • Ten Year Experience with Combined Modality Therapy Including Radiotherapy for Squamous Cell Carcinomas of Oropharynx
    Miyawaki Daisuke, H Nishimura, Yoshida Kohsuke, Ejima Yasuo, Kiyota Naomi, Saito Miki, N Otsuki, Nibu Ken-ichi, Sugimura Kazuro, Sasaki Ryohei
    European Congress of Radiology（ECR, Mar. 2013, English, European Society of Radiology, Austria,Vienna, Purpose/Objective(s): To assess the efficacy of radiation therapy for Squamous cell carcinomas of oropharynx at Kobe University Hospital retrospectively.Materials/Methods: Between July 2000 and March 2011, 98 patients with squamous cell carcinomas of the, International conference
    Poster presentation

  • 当院における中咽頭扁平上皮癌に対する放射線治療成績
    Miyawaki Daisuke, Yoshida Kenji, 西村英輝, 原田 文, 村岡 修, ノル シャズリナ, ビンティ スライマン, Kiyota Naomi, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    日本放射線腫瘍学会第25回学術大会, Nov. 2012, Japanese, 日本放射線腫瘍学会, 東京（東京国際フォーラム）, 【目的】当院における中咽頭扁平上皮癌の放射線治療成績を遡及的に検討する。【方法】2000年7月から2011年1月までに当院にて中咽頭扁平上皮癌と診断され、放射線治療を施行した96例を対象とした。年齢の中央値は62歳（31-96歳）、男:女=80:16であった。亜部位は前壁：側壁：後壁：上壁＝24：57：3：12、進展度はT1：T2：T3：T4a：T4b＝6：54：17：10：5、N0：N1：N2a：N2b：N2c：N3＝18：14：6：32：17：9であった。手術は13例に施行され、化学療法の併用は81例（同時併用76例）、処方線量の中央値は70Gy（60-70.8Gy）であった。【結果】経過観察期間の中央値は25.5か月(3-141か月)。3年の全生存割合は76％で、無再発生存割合は66％、局所領域制御割合は70％であった。病期別の3年全生存割合は, Domestic conference
    Poster presentation

  • 上顎洞癌の治療総論
    Kiyota Naomi
    頭頸部がんに対する超選択的動注化学療法の実技, Nov. 2012, Japanese, 厚生労働省がん臨床研究事業, 札幌, 上顎洞癌の治療について, Domestic conference
    Public discourse

  • 術後ハイリスク症例に対する化学放射線療法
    Kiyota Naomi
    進行頭頸部がんに対する集学的治療としての薬物療法と放射線療法, Nov. 2012, Japanese, 厚生労働省がん臨床研究事業, 東京, 術後化学放射線療法の有用性について, Domestic conference
    Public discourse

  • Excessive MET signaling causes acquired resistance to and addiction to MET inhibitors in MKN45 gastric cancer cell line
    Funakoshi Y, Mukohara Toru, Tomioka H, Ekyalonog RC, Kataoka Y, Inui Y, Kawamori Y, Kiyota Naomi, Fujiwara Y, Minami Hironobu
    24rh EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2012, English, EORTC-NCI-AACR, Dublin, Ireland, Excessive MET signaling causes acquired resistance to and addiction to MET inhibitors in MKN45 gastric cancer cell line, International conference
    Poster presentation

  • 頭頸部がん治療の過去と未来 頭頸部がんの分子標的治療について
    Kiyota Naomi
    第50回日本癌治療学会学術集会, Oct. 2012, Japanese, 日本癌治療学会, 横浜, 頭頸部がんの分子標的薬の適正使用, Domestic conference
    [Invited]
    Nominated symposium

  • Patterns of Local Recurrence and Metachronous Malignancy Following Radiation Therapy for Stage I or II Hypopharyngeal Carcinoma: Role of Close Observation and Multidisciplinary Approach
    H Nishimura, Sasaki Ryohei, Yoshida Kohsuke, Miyawaki Daisuke, Y Okamoto, Kiyota Naomi, Saito Miki, N Otsuki, Nibu Ken-ichi
    54th ASTRO Annual Meeting, Oct. 2012, English, ASTRO, U.S.A , Boston, International conference
    Poster presentation

  • A randomized phase II trial comparing standard pain control with or witout gabapentin for the treatment of pain related radiation-induced mucositis head and neck cancer
    Kataoka Tohru, Kiyota Naomi, Shimada T, Toyoda Masanori, Fujiwara Y, Nibu Ken-ichi, Komori Takahide, Sasaki Ryohei, Mukohara Toru, Minami Hironobu
    European Society of Medical Oncology, 2012, Oct. 2012, English, European Society of Medical Oncology, Viena, A randomized phase II trial comparing standard pain control with or witout gabapentin for the treatment of pain related radiation-induced mucositis head and neck cancer, International conference
    Poster presentation

  • MCF-7乳癌細胞株における insuylin-like growth factor 1 receptor受容体阻害薬に対する獲得耐性機構
    エキャロンゴ ルーディ チミンチ, Mukohara Toru, 片岡 優, 船越 洋平, 富岡 秀夫, Kiyota Naomi, 藤原 豊, Minami Hironobu
    第71回日本癌学会学術総会, Sep. 2012, English, 日本癌学会, 札幌, MCF-7乳癌細胞株における insuylin-like growth factor 1 receptor受容体阻害薬に対する獲得耐性機構, Domestic conference
    Poster presentation

  • A RANDOMIZED PHASE II TRIAL COMPARING STANDARD PAIN CONTROL WITH OR WITHOUT GABAPENTIN FOR THE TREATMENT OF PAIN RELATED TO RADIATION-INDUCED MUCOSITIS IN HEAD AND NECK CANCER
    Tomoko Kataoka, Kiyota Naomi, Takanobu Shimada, Toyoda Masanori, Yutaka Fujiwara, Kenichi Nibu, Komori Takahide, Minami Hironobu
    37th Congress of the European-Society-for-Medical-Oncology (ESMO), Sep. 2012, English, Vienna, AUSTRIA, International conference
    Poster presentation

  • 頭頸部がん：頭頸部がん薬物療法のトピック
    Kiyota Naomi
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, 頭頸部がんの薬物療法のトピックの紹介, Domestic conference
    [Invited]
    Invited oral presentation

  • 当科における悪性腫瘍に伴う静脈血栓塞栓症（VTE）の検討
    島田 貴信, Kiyota Naomi, 西村 明子, 今村 善宣, 船越 洋平, 富岡 秀夫, Chayahara Naoko, Toyoda Masanori, Yakushijin Kimikazu, 岡村 篤夫, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, cancer related VTEの現状, Domestic conference
    Poster presentation

  • 当科においける静脈血栓塞栓症(VTE) 症例の検討
    島田 貴信, Kiyota Naomi, 藤原 豊, 西村 明子, 今村 善宣, 船越 洋平, 富岡 秀夫, Toyoda Masanori, Chayahara Naoko, Yakushijin Kimikazu, 岡村 篤夫, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, 当科においける静脈血栓塞栓症(VTE) 症例の検討, Domestic conference
    Poster presentation

  • 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析
    今村 善宣, 藤原 豊, Toyoda Masanori, Chayahara Naoko, 西村 明子, 船越 洋平, 富岡 秀夫, 島田 貴信, Yakushijin Kimikazu, 岡村 篤夫, Kiyota Naomi, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, 切除不能神経内分泌腫瘍に対するダカルバジン単剤療法：後方視的解析, Domestic conference
    Poster presentation

  • Radiotherapy for Squamous Cell Carcinomas of Oropharynx
    Miyawaki Daisuke, H Nishimura, Yoshida Kohsuke, Y Okamoto, Kiyota Naomi, Saito Miki, N Otsuki, Nibu Ken-ichi, Sasaki Ryohei
    The 6th S.Takahashi Memorial Symposium & The 6th Japan-US Cancer Therapy International Joint Symposium, Jul. 2012, English, 高橋信次記念三次元原体照射国際学会, 広島県（広島国際会議場）, Purpose: To assess the efficacy radiation therapy for Squamous cell carcinomas of oropharynx at Kobe University Hospital retrospectively.Methods: Between September 1990 and January 2011, 138 patients with Squamous cell carcinomas of the oropharynx were tr, International conference
    Poster presentation

  • Chemoradiotherapy in Patients with Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
    H Nishimura, Yoshida Kohsuke, Miyawaki Daisuke, M Oda, Okuno Tatsuya, Kiyota Naomi, A Harada, O Muraoka, NS Sulaiman, Sasaki Ryohei
    The 6th S.Takahashi Memorial Symposium & The 6th Japan-US Cancer Therapy International Joint Symposium, Jul. 2012, English, 高橋信次記念三次元原体照射国際学会, 広島県（広島国際会議場）, International conference
    Poster presentation

  • A Pilot Randomized Trial Comparing Standard Pain Control with or without Gabapentin for the Treatment of Pain Related to Radiation-induced Mucositis in Head and Neck Cancer
    Tomoko Kataoka, Kiyota Naomi, Takanobu Shimada, Meiko Nishimura, Yoshinori Imamura, Chayahara Naoko, Toyoda Masanori, Yohei Funakoshi, Hideo Tomioka, Yutaka Fujiwara, Kenichi Nibu, Takahide Komor, Hideki Nishimura, Sasaki Ryohei, Mukohara Toru, Minami Hironobu
    第10回日本臨床腫瘍学会学術集会, Jul. 2012, Japanese, 日本臨床腫瘍学会, 大阪, Domestic conference
    Oral presentation

  • 頸部リンパ節転移を認めた原発不明悪性黒色腫の2例
    米澤宏一郎, Morimoto Koichi, Yamashita Daisuke, 谷本 均, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Kiyota Naomi, Sasaki Ryohei
    第36回日本頭頸部癌学会, Jun. 2012, Japanese, 日本頭頸部癌学会, 島根県松江市（島根県民会館）, Domestic conference
    Oral presentation

  • 分子標的薬の適正な使用について 頭頸部がん領域における分子標的薬の適正な使用について
    Kiyota Naomi
    第36回日本頭頸部癌学会, Jun. 2012, Japanese, 日本頭頸部癌学会, 松江, 頭頸部がんの分子標的薬の適正使用, Domestic conference
    [Invited]
    Nominated symposium

  • 頭頸部癌患者における放射線性粘膜炎による疼痛に対するガバペンチンのパイロット・ランダム化比較試験
    片岡 智子, Kiyota Naomi, 島田 貴信, 今村 善宣, Chayahara Naoko, Toyoda Masanori, 船越 洋平, 富岡 秀夫, 藤原 豊, Nibu Ken-ichi, Komori Takahide, 西村 英輝, Sasaki Ryohei, Mukohara Toru, Minami Hironobu
    第36回日本頭頸部癌学会, Jun. 2012, Japanese, 日本頭頸部癌学会, 松江, 放射線粘膜炎に対するガバペンチンの有用性, Domestic conference
    Oral presentation

  • 当院における中咽頭扁平上皮癌に対する放射線治療成績
    Miyawaki Daisuke, 西村英輝, Yoshida Kenji, 原田 文, 村岡 修, ノル シャズリナ, ビンティ スライマン, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Sasaki Ryohei
    第36回日本頭頸部癌学会, Jun. 2012, Japanese, 日本頭頸部癌学会, 島根県松江市（島根県民会館）, 【目的】当院における中咽頭扁平上皮癌の放射線治療成績を遡及的に検討する。【方法】1990年9月から2011年1月までに当院にて中咽頭扁平上皮癌と診断され、放射線治療を施行した138例を対象とした。年齢の中央値は61歳（31-96歳）、男:女=117:21、経過観察期間の中央値は27か月(3-209か月)であった。亜部位は前壁：側壁：後壁：上壁＝39：77：4：18、進展度はT1：T2：T3：T4＝8：71：26：33、N0：N1：N2：N3＝23：21：80：14であった。手術は33例に施行され、化学療法の併用は112例（同時併用91例）、処方線量の中央値は70Gy（50-76.8Gy）であった。【結果】経過観察期間の中央値は27か月(3-209か月)。3年の全生存割合は73％で、無再発生存割合は65％、局所領域制御割合は73％であった。病期別の3年, Domestic conference
    Oral presentation

  • 当院における高齢者食道癌の内科的治療の成績と戦略について
    池田 篤紀, Okuno Tatsuya, Toyoda Masanori, Kiyota Naomi, Imanishi Tatsuya, Nakamura Tetsu, 西村 英輝, 黒田 大介, Azuma Takeshi
    第66回日本食道学会学術集会, Jun. 2012, Japanese, 日本食道学会, 軽井沢, Domestic conference
    Poster presentation

  • 多診療科共同で集学的治療を行った頭頸部原発骨軟部肉腫の2例
    島田貴信, Kiyota Naomi, 米澤宏一郎, Doi Kiyoshi, Hasegawa Shingo, 西村英輝, Sasaki Ryohei, Minamikawa Tsutomu, 橋川和信, 田原真一, Nibu Ken-ichi
    第36回日本頭頸部癌学会, Jun. 2012, Japanese, 日本頭頸部癌学会, 松江, 多診療科連携にて治療した頭頸部肉腫の検討, Domestic conference
    Poster presentation

  • Phase II trial of chemoradiotherapy concurrent with S-1 plus cisplatin in patients with unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Results of the Japan Clinical Oncology Group study, JCOG 0706
    Makoto Tahara, Kiyota Naomi, Junki Mizusawa, Kenichi Nakamura, Ryuichi Hayashi, Tetsuo Akimoto, Yasuhisa Hasegawa, Shigemichi Iwae, Nobuya Monden, Kazuto Matsuura, Hirofumi Fujii, Yusuke Onozawa, Akihiro Homma, Akira Kubota, Haruhiko Fukuda, Masato Fujii
    2012 ASCO Annual Meeting, Jun. 2012, English, ASCO, Chicago, International conference
    Poster presentation

  • 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法
    今村 善宣, 藤原 豊, Toyoda Masanori, Chayahara Naoko, 富岡 秀夫, 船越 洋平, Kiyota Naomi, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第109回日本内科学会講演会, Apr. 2012, Japanese, 日本内科学会, 京都, 切除不能高分化神経内分泌腫瘍に対するダカルバジン療法, Domestic conference
    Poster presentation

  • 抗がん薬投与におけるeGFRの有用性の検討
    船越 洋平, 藤原 豊, Toyoda Masanori, 島田 貴信, Chayahara Naoko, 富岡 秀夫, Kiyota Naomi, Umezu Michio, Mukohara Toru, Minami Hironobu
    第109回日本内科学会講演会, Apr. 2012, Japanese, 日本内科学会, 京都, 抗がん薬投与におけるeGFRの有用性の検討, Domestic conference
    Poster presentation

  • Extra-pulmonary neuroendocrine carcinoma (EP-NEC) に対する救済化学療法としてのアムルビシン（AMR）の効果
    Toyoda Masanori, 藤原 豊, 垣内 誠司, 今村 善宣, 船越 洋平, 富岡 秀夫, Chayahara Naoko, Kiyota Naomi, Mukohara Toru, Minami Hironobu
    第109回日本内科学会講演会, Apr. 2012, Japanese, 日本内科学会, 京都, Extra-pulmonary neuroendocrine carcinoma (EP-NEC) に対する救済化学療法としてのアムルビシン（AMR）の効果, Domestic conference
    Poster presentation

  • 再建遊離空腸に対する術後(化学)放射線療法の検討
    西村英輝, Yoshida Kenji, Miyawaki Daisuke, Nibu Ken-ichi, Ohtsuki Naoki, Saito Miki, Kiyota Naomi, 副島俊典, 岡本欣晃, Sasaki Ryohei
    第24回日本放射線腫瘍学会, Nov. 2011, Japanese, 日本放射線腫瘍学会, 神戸ポートピアホテル（神戸市）, Domestic conference
    Oral presentation

  • 遊離空腸再建後の高リスク頭頸部癌に対する術後放射線治療の検討
    西村英輝, Sasaki Ryohei, Yoshida Kenji, Miyawaki Daisuke, Nibu Ken-ichi, Ohtsuki Naoki, Saito Miki, Kiyota Naomi, 岡本欣晃, 副島俊典
    第35回日本頭頸部癌学会, Jun. 2011, Japanese, 日本頭頸部癌学会, ウインク愛知（名古屋市）, Domestic conference
    Oral presentation

  • 当科における喉頭機能温存手術の検討
    米澤宏一郎, Morimoto Koichi, Saito Miki, Ohtsuki Naoki, Kiyota Naomi, 西村英輝, Sasaki Ryohei, Nibu Ken-ichi
    第35回日本頭頸部癌学会, Jun. 2011, Japanese, 日本頭頸部癌学会, ウインク愛知（名古屋市）, Domestic conference
    Oral presentation

  • 切除不能頭頸部癌に対するSequential therapyの安全性に関する後向き研究
    島田貴信, Kiyota Naomi, Ohtsuki Naoki, Nibu Ken-ichi, 西村英輝, Sasaki Ryohei
    第35回日本頭頸部癌学会, Jun. 2011, Japanese, 日本頭頸部癌学会, ウインク愛知（名古屋市）, Domestic conference
    Oral presentation

  • 局所進行外耳道扁平上皮癌に対する3剤(TPF)併用化学放射線療法の経験
    Yoshida Kenji, 西村英輝, Miyawaki Daisuke, 村岡 修, Sasaki Ryohei, Kiyota Naomi, Doi Kiyoshi, Hasegawa Shingo, Nibu Ken-ichi
    第35回日本頭頸部癌学会, Jun. 2011, Japanese, 日本頭頸部癌学会, ウインク愛知（名古屋市）, Domestic conference
    Oral presentation

  • 原発不明頸部リンパ節転移に対する治療経験
    村岡修, Yoshida Kenji, 西村英輝, Miyawaki Daisuke, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, 岡本欣晃, Sasaki Ryohei
    第70回日本医学放射線学会総会, May 2011, Japanese, 日本医学放射線学会, 震災の影響によりWEB開催, Domestic conference
    Oral presentation

  • 局所進行外耳道扁平上皮癌に対する3剤（TPF）併用化学放射線療法の経験
    難波富美子, Yoshida Kenji, 西村英輝, Miyawaki Daisuke, 橋本直樹, 村岡修, Sasaki Ryohei, Kiyota Naomi, Hasegawa Shingo, Nibu Ken-ichi
    第70回日本医学放射線学会総会, May 2011, Japanese, 日本医学放射線学会, 震災の影響によりWEB開催, Domestic conference
    Oral presentation

  • Successful treatment with intravitreal injection of voricanazole in a patient with fungal endophthalmitis before cord blood transplantation
    船越 洋平, Yakushijin Kimikazu, 明石 梓, Kusuhara Sentaro, 土井 健史, 乾 由美子, Toyoda Masanori, 島田 貴信, Chayahara Naoko, 富岡 秀夫, Kiyota Naomi, 藤原 豊, Mukohara Toru, 岡村 篤夫, 山本 克己, Matsuoka Hiroshi, 村山 徹, Minami Hironobu
    第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 松山, Domestic conference
    Poster presentation

  • Optimal use of G-CSF after allogeneic hematopoietic stem cell transplantation under MMF dosing for GVHD prophylaxis
    岡村 篤夫, Yakushijin Kimikazu, 乾 由美子, 船越 洋平, 富岡 秀夫, 島田 貴信, Toyoda Masanori, Chayahara Naoko, Kiyota Naomi, 藤原 豊, Mukohara Toru, 山本 克也, Matsuoka Hiroshi, Minami Hironobu
    第33回日本造血細胞移植学会総会, Mar. 2011, Japanese, 日本造血細胞移植学会, 松山, Domestic conference
    Poster presentation

  • 局所進行頭頸部癌に対する化学放射線療法の実践的管理
    Kiyota Naomi
    シンポジウム「頭頸部がんに対する化学放射線療法の適応と実践」, Dec. 2010, Japanese, 日本対がん協会「がん医療水準均てん化推進事業」, 東京, Domestic conference
    Invited oral presentation

  • 局所進行外自動扁平上皮癌に対する3剤（TPF）併用化学放射線療法の経験
    Yoshida Kenji, 西村英輝, Miyawaki Daisuke, 村岡修, 橋本直樹, Sasaki Ryohei, Hasegawa Shingo, Kiyota Naomi, Nibu Ken-ichi
    日本放射線腫瘍学会第23回学術大会, Nov. 2010, Japanese, 東京, Domestic conference
    Oral presentation

  • Foretinib (GSK1363089) inhibits growth of gastric cancer cell lines through blockade of inter-receptor tyrosine kinases networks.
    Mukohara Toru, Kataoka Yu, Tomioka Hideo, Kiyota Naomi, Fujiwara Yutaka, Yashiro Masakazu, Hirai Midori, Minami Hironobu
    22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics 2010, Nov. 2010, English, EORTC, NCI, AACR, ベルリン, ドイツ, International conference
    Poster presentation

  • Therapy-related pure erythroid leukemia with hemophagocytic syndrome
    Yohei Funakoshi, Katsuya Yamamoto, Yumiko Inui, Hideo Tomioka, Chayahara Naoko, Yakushijin Kimikazu, Kiyota Naomi, Yutaka Fujiwara, Atsuo Okamura, Mukohara Toru, Matsuoka Hiroshi, Minami Hironobu
    第72回日本血液学会総会, Sep. 2010, Japanese, 日本血液学会, 横浜, Domestic conference
    Poster presentation

  • 原発不明癌頸部リンパ節転移に対する治療経験
    村岡修, Yoshida Kenji, 西村英輝, Miyawaki Daisuke, Sasaki Ryohei, 河辺哲也, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi
    第35回 神戸放射線腫瘍懇話会, Aug. 2010, Japanese, 神戸, Domestic conference
    Oral presentation

  • 本邦における頭頸部癌化学療法の展望 化学療法臨床研究の現状での問題点と対策
    Kiyota Naomi
    第34回日本頭頸部癌学会, Jun. 2010, Japanese, 日本頭頸部癌学会, 東京, Domestic conference
    Invited oral presentation

  • 原発不明癌頚部リンパ節転移に対する治療経験
    Yoshida Kenji, 西村英輝, Miyawaki Daisuke, 河辺哲也, Sasaki Ryohei, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi, Kiyota Naomi, 岡本欣晃
    第34回頭頚部癌学会, Jun. 2010, Japanese, 東京（新宿）, Domestic conference
    Oral presentation

  • 局所進行頭頸部扁平上皮癌術後再発High-Risk群に対するHigh-dose CDDP+RTの実施可能性試験
    Kiyota Naomi, 田原 信, 門脇 重憲, 岡野 晋, 河島 光彦, 松浦 一登, 小野澤 祐輔, Nibu Ken-ichi, 林 隆一
    第34回日本頭頸部癌学会, Jun. 2010, Japanese, 日本頭頸部癌学会, 東京, Domestic conference
    Oral presentation

  • 下咽頭癌に対する術後放射線治療の遡及的検討
    西村英輝, Yoshida Kenji, 河辺哲也, Miyawaki Daisuke, Nibu Ken-ichi, Saito Miki, Ohtsuki Naoki, Kiyota Naomi, 副島俊典, Sasaki Ryohei
    第34回頭頚部癌学会, Jun. 2010, Japanese, 東京（新宿）, Domestic conference
    Oral presentation

  • 結腸直腸がんに対するmFOLFOX6/FOLFIRI±Bevacizumab療法における甲状腺機能の評価
    藤原 豊, Chayahara Naoko, Mukohara Toru, Kiyota Naomi, 富岡 秀夫, 船越 洋平, Minami Hironobu
    第107回日本内科学会講演会, Apr. 2010, Japanese, 日本内科学会, 東京, Domestic conference
    Poster presentation

  • Effect of axitinib (AG-013736) on thyroid function and biomarkers in Japanese patients with advanced solid tumors.
    Yutaka Fujiwara, Kiyota Naomi, Chayahara Naoko, Akiyuki Suzuki, Yoshiko Umeyama, Mukohara Toru, Minami Hironobu
    臨床腫瘍学会, Mar. 2010, English, 日本臨床腫瘍学会, 東京, Domestic conference
    Poster presentation

  • Effect of axitinib (AG-013736) on thyroid function and biomarkers: results form phase I studies in Japanese patients.
    Fujiwara Y, Kiyota Naomi, Chayahara Naoko, Suzuki A, Umemura Y, Mukohara Toru, Minami Hironobu
    21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2009, English, AACR, Boston, 米国, International conference
    Poster presentation

  • A phase I study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
    Yamada Yuko, Minami Hironobu, Fuse N, Ohtsu A, kato K, Kiyota Naomi, Shimada Y, Doi T, Nakajima T, Hamaguchi T, Fujiwara Y, Itoh Y, Mera K
    21st EORTH-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Nov. 2009, English, AACR, Boston, 米国, International conference
    Poster presentation

  • 頭頚部癌に対する集学的治療の取り組み中での放射線生物学の役割
    Sasaki Ryohei, 西村 英輝, Yoshida Kenji, 河邊 哲也, Miyawaki Daisuke, Sugimura Kazuro, Kiyota Naomi, Okuno Tatsuya, Minamikawa Tsutomu, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi
    第48回日本医学放射線学会生物部会学術大会, Jul. 2009, Japanese, 日本医学放射線学会生物部会, 富山, Domestic conference
    Oral presentation

  • 頭頸部癌患者に対する化学放射線療法に嚥下リハビリテーションを導入した症例の検討
    常行美貴, Kiyota Naomi, Saito Miki, Ohtsuki Naoki, Nibu Ken-ichi
    第33回日本頭頸部癌学会, Jun. 2009, Japanese, 日本頭頸部癌学会, 東京, Domestic conference
    Oral presentation

  • 頭頸部がん治療における多職種医療普及のためのサテライト講演会 その成果と課題
    全田貞幹, 大田洋二郎, 本間明宏, Nibu Ken-ichi, 神田亨, 妻木浩美, Kiyota Naomi, 浅井昌大
    第33回日本頭頸部癌学会, Jun. 2009, Japanese, 日本頭頸部癌学会, 東京, Domestic conference
    Poster presentation

  • Final results of a phase I trial of chemotherapy combination with docetaxel, cisplatin ,and S-1 (TPS) in patients with locally advanced or recurrent metastatic head and neck cancer.
    Tahara M, Araki K, Kiyota Naomi, Okano S, Fuse N, Minashi K, Yoshino T, Doi T, Minami Hironobu, Ohtsu A
    Am Soc Clin Oncol, Jun. 2009, English, 米国臨床腫瘍学会, Orland, 米国, International conference
    Poster presentation

  • 根治切除不能局所進行頭頸部扁平上皮癌(LASCCHN)に対する5-FU、Cisplatin同時併用化学放射線療法の有用性に関する後ろ向き検討
    Kiyota Naomi, Minami Hironobu
    第5回日本臨床腫瘍学会学術総会, Mar. 2007, Japanese, 日本臨床腫瘍学会, 札幌, Domestic conference
    Poster presentation

  • 1. Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.

■ Research Themes
  • 難聴発症および重症化に関わる遺伝的素因と後天的要因の解明研究
    和佐野 浩一郎, 清田 尚臣, 古平 毅, 内田 育恵, 吉田 忠雄
    日本学術振興会, 科学研究費助成事業, 基盤研究(B), 東海大学, 01 Apr. 2024 - 31 Mar. 2028

  • B細胞を軸とした免疫チェックポイント阻害の有害事象の包括的機序解明と効果の推定
    南 博信, 清田 尚臣, 船越 洋平
    日本学術振興会, 科学研究費助成事業, 基盤研究(B), 神戸大学, 01 Apr. 2023 - 31 Mar. 2027

  • 唾液腺癌における免疫微小環境の特徴と免疫関連バイオマーカーの探索
    清田 尚臣
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2023 - 31 Mar. 2026

  • Genetic alterations and expressions of immune check point molecules in sinonasal neuroendocrine carcinoma
    清田 尚臣
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2020 - 31 Mar. 2023
    令和２年度の検討において、当院における鼻副鼻腔悪性腫瘍データベースの137例中、鼻副鼻腔神経内分泌悪性腫瘍の60例を抽出し、主たる組織型は嗅神経芽細胞腫（ONB）が利用可能な組織検体を有する症例に絞り込みを行った。その結果、本研究の中心である腫瘍の体細胞遺伝子変異の程度と免疫多重染色による腫瘍内及び腫瘍周囲免疫細胞の関係を検討する上で十分な症例数を確保できるのはONB 27例であった。組織型別に進行期及び転帰は、Kadish A/B/C/D/unkown（2/3/17/1/4）であり、ONB全症例における観察期間中央値は4.9年で全体での5年生存割合は92%であった。本研究に十分利用可能な組織検体については、ONB 27例中26例で手術検体が利用可能であり、病理診断科の協力の下に組織型の再レビューを行った。また、次世代シーケンサー（NGS）を用いた遺伝子変異解析及び、免疫多重染色については、研究協力者である近畿大学医学部ゲノム生物学教室及びがん研究会有明病院先端医療センターと検討を重ねた。この結果、免疫多重染色を行う上で重要な腫瘍細胞を標識する抗体を決定することができた。また、組織検体の研究協力機関への移送には本研究に関するプロトコール作成と倫理審査（神戸大学での一括審査）が必要であり、プロトコール作成を行い神戸大学大学院医学研究科等医学倫理委員会に提出した。NGS及び免疫多重染色を行うために必要な腫瘍組織標本の作製は、耳鼻咽喉・頭頸部外科の協力の下に行うことが決定した。

  • Clinical research in the development of patient reported outcome measures for cancer patients
    Naomi Kiyota
    国立研究開発法人日本医療研究開発機構, 革新的がん医療実用化研究事業, 国立大学法人神戸大学, Apr. 2019 - Mar. 2023, Principal investigator

  • Kiyota Naomi
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2017 - 31 Mar. 2020, Principal investigator
    Total of 35 cases with salivary gland cancer were analyzed. The pathological types of these cases are mucoepidermoid carcinoma(MEC) low-grade, high-grade, salivary duct carcinoma(SDC), adenocarcinoma (ANOS) and adenoid cystic carcinoma (ACC) and 7 cases in each. Genetic analyses were performed with Oncomine Tumor Mutation Load Assay and multiplex immunohistochemistry was performed with CD3/CD4/CD8/CD204/FOXP3/PD-L1/PD-L2. Tumor mutational load appeared to be higher in MEC-high, SDC and ANOS. From the multiplex immunohistochemistry analysis, intra-tumor Treg and PD-L1 positive cell were suggested to be poor prognostic factors for disease-free survival irrespective of pathological subtypes.
    Competitive research funding

  • Kiyota Naomi, Otsuki Naoki, ITOH Tomoo, Hirai Chihoko, NISHIO Kazuto, SAKAI Kazuko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2014 - 31 Mar. 2017, Principal investigator
    Salivary adenocarcinoma was divided into two categories. One is androgen recepotor positive adenocarcinoma (APA) and the other is androgen receptor negative adenocarcinoma (ANA). Immunohistochemistry and genetic analysis revealed that APA was almost similar to salivary duct carcinoma (SDC) and ANA was quite different from both of ANA and SDC. Moreover, APA often harbored HER2 ampfilication similar to SDC. Thus, the development of therapeutic drugs for APA and SDC should be done simultaneously.And we found flt-3 mutation and RET mutation in salivary gland cancer. We already have targeting agents correspond to these mutations.So we will confirm this result in a larger cohort and investigate the clinical applicability of these novel mutation in salivary gland cancer.
    Competitive research funding

  • （AMED）進行頭頸部がんに対する術後補助療法の標準治療確立のための多施設共同研究/頭頸部癌に対する新たな術後補助療法の開発
    清田 尚臣
    国立研究開発法人国立がん研究センター, 革新的がん医療実用化研究事業, 2017, Principal investigator
    Competitive research funding

  • （AMED）進行上顎洞癌に対する超選択的動注化学療法を併用した放射線治療による新規治療法開発に関する研究
    清田 尚臣
    国立大学法人北海道大学, 革新的がん医療実用化研究事業, 2017, Principal investigator
    Competitive research funding

  • （AMED）甲状腺未分化癌の標準的治療法の開発に向けた全国的組織を用いた医師主導臨床試験の企画/（４） 術前化学療法臨床試験のプロトコール作成（５） 化学放射線療法のプロトコール作成
    清田 尚臣
    公立大学法人大阪市立大学, 革新的がん医療実用化研究事業, 2017, Principal investigator
    Competitive research funding

  • （AMED）HER2陽性再発転移の唾液癌に対する個別化治療の開発
    清田 尚臣
    国立大学法人北海道大学, 臨床研究・治験推進研究事業(CRT事業）, 2017, Principal investigator
    Competitive research funding

  • （AMED）頭頸部腫瘍に対する強度変調放射線治療の確立と標準化のための臨床研究/頭頸部癌に対するIMRTの有用性に関する研究
    清田 尚臣
    革新的がん医療実用化研究事業, 2016, Principal investigator
    Competitive research funding

  • （AMED）進行頭頸部がんに対する術後補助療法の標準治療確立のための多施設共同研究/頭頸部癌に対する術後補助療法の開発
    清田 尚臣
    革新的がん医療実用化研究事業, 2016, Principal investigator
    Competitive research funding

  • （AMED）進行上顎洞癌に対する超選択的動注化学療法を併用した放射線治療による新規治療法開発に関する研究
    清田 尚臣
    革新的がん医療実用化研究事業, 2016, Principal investigator
    Competitive research funding

  • （AMED）新規医薬品・医療機器等の創出、難治性疾患の治療法の開発および最適な治療法の確立に関する研究/HER2過剰発現・遺伝子増幅腫瘍あるいはHER2遺伝子変異陽性腫瘍に
    清田 尚臣
    革新的医療技術創出拠点プロジェクト（早期探索的・国際水準臨床研究事業）, 2016, Principal investigator
    Competitive research funding

  • 成人固形がんに対する標準治療確立のための基盤研究/頭頸部がんに対する標準治療確立のための多施設共同研究
    清田 尚臣
    国立がん研究センター研究開発費, 2016, Principal investigator
    Competitive research funding

  • 厚生科研「進行頭頸部がんに対する科学放射線療法を中心とした集学的治療の開発に関する研究」
    清田 尚臣
    2010, Principal investigator
    Competitive research funding

TOP